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Abstract 
Background  
One fifth of primary care attendees report chronic non-cancer pain (CNCP) most of 
which is related to musculoskeletal conditions, 12% of these are prescribed strong 
opioid analgesics. Evidence suggests long-term opioid use causes hypogonadism in 
men (including sexual reproductive dysfunction), but in women, the relationship is not 
known.  
Aim 
To investigate the relationship between opioid use and reproductive and sexual 
dysfunction in women aged 18-55 years old.  
Methods 
A systematic review summarised existing evidence for sexual and reproductive 
dysfunction in women prescribed opioids (>1 month) for CNCP. Two further original 
studies investigated women prescribed opioids for musculoskeletal pain. A clinical 
practice research datalink (a UK primary care database) cohort study compared the 
risk of four outcomes (irregular/absent menstrual cycles, menopausal symptoms, low 
libido and infertility) for long-term (≥3 months) and short-term opioid users. A cross-
sectional study investigated the risk of female sexual dysfunction (FSD) dependent 
on daily oral morphine equivalent dose (MED).  
Results 
 iii 
 
The systematic review identified 12 small papers, mainly from secondary care. 
Opioid use was associated with irregular menstruation, decreased libido and 
decreased sex hormone levels. In the cohort study (n=44260) there was an 
increased risk of abnormal menstruation (Hazard ratio (HR) 1.13; 95% CI 1.05, 1.21) 
and menopause (HR 1.16; 95% CI 1.10, 1.23) in long-term opioid users when 
compared to short-term users, but no association with infertility or low libido. The 
cross-sectional survey (n=153) found FSD in 50% of those receiving ≥20mg MED 
daily, falling to 31.7% in those not currently using opioids (OR 2.29; 95% CI 0.94, 
5.55).  
Conclusion 
This thesis highlights that there is an increased risk of menstrual disturbances and 
menopausal symptoms with opioids and these should be considered when opioids 
are prescribed for CNCP. These findings may help management decisions in CNCP 
when discussing treatment options with patients.  
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1 Introduction 
This thesis focuses on the study of opioid use for chronic non cancer pain (CNCP) in 
women, and sexual and reproductive adverse effects of those opioids. This chapter 
will introduce the subject of interest, and discuss the rationale for the thesis. The 
aims and objectives of the thesis will then be presented and finally this chapter will 
provide an overview of the remaining chapters of the thesis. 
CNCP can be defined as any painful condition lasting for three months or more and 
not associated with cancer (Chapman et al., 2010). CNCP affects women more 
commonly than men and has been shown to affect 22% of those attending primary 
care, with musculoskeletal conditions as the leading cause of CNCP (Breivik et al., 
2006; Gureje et al., 1998). A previous self-report survey of the general population 
(aged 25 years and over) in Scotland found that 50.4% of those who completed the 
survey reported chronic pain, this survey found women were more likely to be 
affected than men (Odds Ratio (OR) 1.24, 95% confidence interval (CI 1.07,1.43) 
(Elliott et al., 1999). Most patients with CNCP are managed in primary care (70%) 
with only a proportion (23%) being referred to a pain specialist (Breivik et al 2006). 
Recommendations for treating CNCP include self-care, physiotherapy, psychological 
approaches, medicine, surgery and alternative medicines (Turk et al., 2011). Opioids 
are often recommended as second line therapy for CNCP, and 62-63% of UK 
patients with CNCP were prescribed an opioid in a survey of CNCP in Europe 
(Breivik et al., 2006; Cheung et al., 2014; Chou et al., 2009b; Gureje et al., 1998; 
National Institute for Health and Care Excellence, 2014a). Opioids are analgesics 
used for treatment of moderate to severe pain (BNF, 2018a). The use of opioids for 
CNCP has increased over the past two decades with one study finding a 38% 
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increase in the incidence of prescribed opioids between 2002 and 2009 (Bedson et 
al., 2016). The evidence to show that opioids are effective in CNCP is weak, and 
adverse effects are a growing concern, with up to 80% of those treated with opioids 
experiencing at least one adverse effect, such as constipation, itching, dependency 
or tolerance (Els et al., 2017a; Eriksen et al., 2006; Kissin, 2013; Noble et al., 2010; 
The British Pain Society, 2010). With the increasing numbers of patients receiving 
opioids, previous authors have noted that even with low rates of adverse effects, 
large numbers within the population can be affected (Campbell et al., 2010; Sullivan 
et al., 2008).  
The focus of the thesis is sexual and reproductive dysfunction and the relationship 
with opioid use, which has been highlighted previously as an area requiring further 
research by the American and British pain societies (Chou et al., 2009a; The British 
Pain Society, 2010). Endocrine dysfunction (particularly sexual and reproductive 
dysfunction) associated with opioid use has recently become an area of concern, 
This is thought to be related to a disruption of either the hypothalamic-pituitary-
gonadal (HPG) axis and/or the hypothalamic-pituitary-adrenal (HPA) axis, which can 
lead to symptoms such as erectile dysfunction in men and amenorrhoea (absent 
menstruation), female sexual dysfunction (FSD), infertility and depression in women. 
Previous research has found good evidence that men taking long-term opioids (either 
prescribed or illegal) are affected by sexual dysfunction often associated with low 
testosterone; the primary mechanism for this effect in men is thought to be through 
suppression of the HPG axis (Abs et al., 2000; Aloisi et al., 2009; Benyamin et al., 
2008; Daniell, 2002; Katz and Mazer, 2009; Smith and Elliott, 2012). This adverse 
effect in men is also known as opioid induced androgen deficiency (OPIAD), and has 
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been shown to affect up to 92% of men treated with long-term opioids (Abs et al., 
2000; Aloisi, 2003; Benyamin et al., 2008; Daniell, 2002; Katz and Mazer, 2009; 
Rubinstein et al., 2013; Smith and Elliott, 2012). OPIAD in men appears to be linked 
more closely to the use of long-acting opioids rather than morphine equivalent daily 
dose (all opioid doses can be converted into a morphine equivalent dose, which is 
discussed in section 2.3), with one study finding 53% of male opioid users were 
affected overall, compared with 74% who used long-acting preparations (Rubinstein 
et al., 2013). Sexual and reproductive dysfunction have not been investigated so 
thoroughly in women. However, previous work in women taking illegal opioids (for 
instance heroin) has shown that women can be affected by amenorrhoea, 
galactorrhoea (inappropriate production of milk) and infertility, although hormone 
levels were often still within normal limits (Afrasiabi et al., 1979; Ballantyne and Mao, 
2003; Bawor et al., 2015; Brennan, 2013; Brook and Marshall, 2001; Brown and 
Zueldorff, 2007; Colameco and Coren, 2009; Katz and Mazer, 2009; Pelosi et al., 
1974; Smith and Asch, 1987; Stoffer, 1968; Williams et al., 2013). Symptoms of 
sexual and reproductive dysfunction, appear to improve when opioid dependency is 
treated with regular maintenance therapy (methadone and buprenorphine), and this 
relationship does appear to be dose related (Brown and Zueldorff, 2007; Schmittner 
et al., 2005). There is little published evidence relating to sexual and reproductive 
dysfunction when opioids are used legally to treat CNCP in women.  
1.1 Thesis rationale  
This thesis focuses on the use of opioids for women with CNCP in primary care, and 
sexual and reproductive dysfunction. Opioid use is increasing for CNCP, and the 
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majority of patients are treated in primary care (including ongoing prescribing of 
opioids if these have been recommended by secondary care), it is therefore 
important that this research is undertaken in primary care (Breivik et al., 2006). There 
has been limited previous research on sexual and reproductive dysfunction in women 
receiving legal opioids for CNCP. However, as discussed previously, there is 
evidence for sexual dysfunction in men receiving prescribed opioids, and also in 
women taking illegal opioids (Abs et al., 2000; Afrasiabi et al., 1979; Bawor et al., 
2015; Brennan, 2013; Brown and Zueldorff, 2007; Daniell, 2002; Katz and Mazer, 
2009; Pelosi et al., 1974; Rubinstein et al., 2013; Smith and Elliott, 2012; Stoffer, 
1968). CNCP represents a significant burden on the NHS, and opioids are prescribed 
in a large proportion of these patients (Belsey, 2002; Breivik et al., 2006). Given the 
evidence of the relationship between opioid use and reproductive and sexual 
dysfunction in males using either illegal or prescribed opioids and in women receiving 
illegal opioids, it is reasonable to investigate this further in women receiving 
prescribed opioids for CNCP. It is important to determine if potential adverse effects 
exist because there would therefore be a need to discuss these with women prior to 
commencing opioids, and during any review of long-term opioid use. Given the above 
evidence, there is a strong case for investigating this further in women receiving 
opioids for CNCP in primary care. 
1.2 Thesis aims and objectives 
The overall aim of this thesis is to investigate the relationship between opioid use and 
reproductive and sexual dysfunction in women aged 18-55 years old.  
The specific objectives are as follows: 
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1. To conduct a systematic review of the literature to identify and summarise the 
currently available evidence for reproductive and sexual dysfunction in women 
aged 18-55 years old receiving opioids for CNCP. 
2. To investigate the relationship between opioid use for musculoskeletal pain 
and reproductive dysfunction. Reproductive dysfunction is defined based on 
symptoms and includes abnormal menstruation to less frequent or absent 
menstruation, menopausal symptoms/menopause and infertility. 
3. To investigate the relationship between opioid use for musculoskeletal pain 
and female sexual dysfunction (FSD).  
1.3 Outline of subsequent chapters  
• Chapter 2 background information relating to the thesis. This chapter 
includes the definitions and epidemiology of pain. A definition of opioids and 
their pharmacology will be discussed, and the epidemiology of opioid use 
including effectiveness and adverse events are described. It also gives an 
overview of the endocrine system and a description of reproductive 
dysfunction that can occur. Finally the chapter explains FSD and the 
classification systems currently in use for diagnosing FSD.  
• Chapter 3 systematic review. This chapter presents the findings of a 
systematic review of studies investigating sexual and reproductive dysfunction 
in women receiving long-term opioids for CNCP.  
• Chapter 4 methodology. This chapter provides the background to the 
methods used within the remainder of the thesis and the underlying 
epidemiological concepts.  
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• Chapter 5 cohort study methods. This chapter provides the methods for the 
cohort study undertaken as part of this thesis within the clinical practice 
research datalink (CPRD).  
• Chapter 6 cohort study results. This chapter provides the results from the 
cohort study, including a description of the population and a comparison of risk 
for four outcomes (abnormal menstruation, menopause/menopausal 
symptoms, low libido and infertility) using Cox regression. The two comparison 
groups within this study are long-term opioid users (90 days or more of opioid 
use) and short-term opioid users. 
• Chapter 7 cohort study discussion. This chapter discusses the cohort 
study, with a summary of the main findings, comparison with other studies, the 
strengths and limitations of the study, the meaning of the study and any 
unanswered questions. 
• Chapter 8 cross-sectional study methods. This chapter provides the 
methods for the cross-sectional study undertaken for the thesis. This study 
was a postal survey and the chapter includes information about the 
construction of the questionnaire. 
• Chapter 9 cross-sectional study results. This chapter presents the results 
of the cross-sectional study. It includes the demographics of the study 
population and the results of logistic regression comparing groups based on 
daily morphine equivalent dose for a single outcome (FSD). 
• Chapter 10 cross-sectional study discussion. This chapter discusses the 
cross-sectional study including a summary of the findings, comparison with 
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other studies, the strengths and limitations of the study, the meaning of the 
study, generalisability and any unanswered questions. 
• Chapter 11 overall discussion. This chapter summarises the main findings 
from the studies included with the thesis, the strengths and limitations of the 
thesis overall, the implications for future research and suggests potential 
future relevant areas of research. It provides a conclusion for the thesis.  
1.4 Summary  
Prior research has demonstrated that reproductive and sexual dysfunction are 
common in men receiving prescribed opioids and in women taking illegal opioids, but 
few studies have investigated this in women taking prescribed opioids. Identifying 
whether a relationship is present in women taking prescribed opioids is important as 
it will help to shape discussions around the risks and benefits associated with opioid 
use for CNCP. This thesis will investigate the association between opioid use for 
CNCP and reproductive and sexual dysfunction.  
This chapter has presented the outline of the remainder of the thesis. The next 
chapter provides a more in depth explanation of the core concepts important for the 
thesis including pain, opioids and the HPG axis.   
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2 Background 
2.1 Introduction 
Opioid use is recommended in guidelines for treatment of patients with chronic non 
cancer pain (CNCP) (Cheung et al., 2014; Chou et al., 2009a). However, evidence 
for the effectiveness of opioids in CNCP is poor (Noble et al., 2010), and adverse 
effects are common, affecting up to 80% of those receiving them (The British Pain 
Society, 2010). Recently, concerns have been raised around possible endocrine 
adverse effects from opioids and this thesis aims to investigate this area more fully, 
specifically investigating reproductive and sexual function in women.   
2.2 Pain 
Pain is defined by the International Association for the Study of Pain (IASP) as “An 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”, and chronic pain as pain that 
continues after the normal time of healing (defined as three to six months) (Merskey 
& Bogduk 1994: p210). CNCP can be defined as any painful condition lasting for 
greater than or equal to three months and not associated with neoplastic disease 
(cancer) (Chapman et al., 2010). The most commonly reported cause for CNCP in a 
European study was arthritis/osteoarthritis (34% of respondents) and the most 
common location for CNCP was the lower back (24% of respondents) (Breivik et al., 
2006). CNCP causes not just physical suffering but also associated disability and 
socioeconomic losses (through loss of working days), both for the person suffering 
and for society as a whole (Rhodin et al., 2010). The economic cost can be split into 
direct health care related costs (e.g. medicine costs, cost of appointments with 
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healthcare professionals) and indirect costs (e.g. loss of work days and productivity 
and benefit payments). A study in 1998 looking at chronic back pain within the United 
Kingdom (UK) found the direct costs to be £1632 million per year and indirect costs 
of £10668 million per year (making the cost of the provision of health care for the 
condition seem small); one of the key contributors to indirect costs was lost days of 
work and production (116 million lost work days in 1994-1995 due to back pain) 
(Maniadakis and Gray, 2000). In a chronic pain survey in Europe, one in four people 
with chronic pain, reported that pain had negatively impacted on their ability to work, 
with a mean loss of 7.8 days of work in six months (Breivik et al., 2006).  
2.2.1 Epidemiology of CNCP  
CNCP affects many people across the globe. A World Health Organisation (WHO) 15 
centre study (5447 participants) showed that 22% of those attending primary care 
suffered from persistent pain, and women were more commonly affected than men 
(Gureje et al., 1998). The global burden of disease study 2010 found that 
musculoskeletal conditions were the second largest contributor of years lived with 
disabilities (YLD’s) across nearly all world regions (Vos et al., 2012). A European 
study showed that 19% of adult Europeans suffer from chronic pain of moderate to 
severe intensity, and of these 40% consider their pain relief to be inadequate. The 
majority (70%) of these patients were managed in primary care by general 
practitioners, with 23% being seen by a “pain specialist” during the course of their 
condition. This study also showed that, in the UK, the median duration of pain was 
5.9 years, and 37% of sufferers were not happy with their pain control (Breivik et al., 
2006). In 2002, a study showed that Primary care workload for CNCP in the UK 
accounted for 4.6 million General Practitioner (GP) appointments which is the 
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equivalent of 793 full time GP’s and a cost of £69 million to the National Health 
Service (NHS) (Belsey, 2002).  
2.2.2 Women and pain  
Women are affected significantly more by pain syndromes when compared to men 
(migraine in a ratio of around 4 to 1, fibromyalgia in a ratio of 3:1 and 
Temporomandibular Joint Dysfunction in a ratio of around 2:1), have a lower 
threshold for pain, greater pain related distress and are more likely to seek treatment 
for their painful condition (Bailey, 2013; Craft, 2007; Leresche, 1997; Lipton and 
Bigal, 2005; Paller et al., 2009; Queiroz, 2013). The reasons that women experience 
more pain than men are multifactorial and include physiological, psychological and 
cultural factors. When considering the question of women and how they experience 
pain, it is important to remember that the biological differences between women and 
men (their sex based on genetic differences determined at conception) are not the 
same as the gender differences (created through social expectations, and their 
influence during a child’s development) (Greenspan et al., 2007). Women would 
traditionally (in terms of their gender) be expected to report symptoms of their pain 
earlier than when compared with men (Bailey, 2013). Women are also more likely to 
experience catastrophising, an abnormal psychological response to pain 
characterised by rumination, magnification and helplessness related to the pain; 
catastrophising has been shown to mediate the difference between responses to 
chronic pain by men and women (Paller et al., 2009). A systematic review in 2009 
showed greater pain sensitivity in women compared to men in most pain modalities. 
Women were more likely to report musculoskeletal pain than men and osteoarthritis 
pain has been shown to be of a greater intensity in women (Fillingim et al., 2009). 
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Women have also been shown to have a higher likelihood of being affected by CNCP 
compared with men, and this includes the majority of musculoskeletal conditions. 
Pain in women tends to be more widespread, of greater intensity and longer duration 
than in men (Breivik et al., 2006; Campbell et al., 2010; Gureje et al., 1998). 
Musculoskeletal pain syndromes have been found to be up to 10 times more likely in 
women than men, and women are also more likely than men to develop a pain 
related disability (Bailey, 2013; Craft, 2007; Jordan et al., 2010; Unruh, 1996). A 
further systematic review in 2014 found that there was increasing prevalence of 
CNCP conditions in women during reproductive years and also found that 
musculoskeletal pain was worse during periods of low oestrogen within each monthly 
cycle (Hassan, Muere and Einstein, 2014). 
Several reviews have looked at the biological differences in pain between women 
and men (rather than differences due to gender) and looked at the role of gonadal 
hormones (hormones produced in the ovaries and testes such as oestrogen, 
progestogen and testosterone) in pain (Greenspan et al., 2007; Hassan et al., 2014; 
Paller et al., 2009). These reviews found that females and males differ greatly in their 
response to pain and discuss the reasons for this difference between the sexes. It is 
thought to be partly due to the influence of gonadal hormones (e.g. oestrogen and 
progesterone in women and testosterone in men) which are likely to play an 
important role in abnormal pain states. The actual mechanism that links ovarian 
hormones (particularly oestrogen) with pain is unknown, but oestrogen is known to 
play a key role at several points in the pain pathway; at the afferent (sensing) nerves 
where the pain signal may be altered, in the spinal cord and in the brain where 
oestrogen receptors are found in key areas for pain, and also have effects on 
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neurotransmitters such as serotonin and dopamine (Hassan et al., 2014). Craft 
(2007) found that oestrogen was a key moderator in adult pain, but that this was a 
complex relationship and depended on changes in oestrogen levels and the type and 
duration of pain, and oestrogen could both improve and worsen pain depending on 
the mechanism in action. For instance pain in osteoarthritis has been shown to 
improve in high oestrogen states (e.g. pregnancy and post-menopausal women on 
hormone replacement therapy), whereas pain in lupus and temporomandibular 
disorders appears to worsen in high oestrogen states (and they also appear to 
worsen during peaks of oestrogen during the monthly menstrual cycle). Finally 
fibromyalgia has been shown to worsen when oestrogen levels are low (during the 
menopause and during menstruation) (Aloisi and Bonifazi, 2006; Craft, 2007; Paller 
et al., 2009). The difference between pain syndromes and how oestrogen levels 
change these is not fully understood, but is thought to be related to the mechanisms 
involved in the pain syndrome itself and how oestrogen interacts with these (Aloisi 
and Bonifazi, 2006). The link between gonadal hormones and pain is also supported 
by the presence of chronic pain conditions such as migraine that can be linked to the 
female menstrual cycle (Hassan et al., 2014). For instance, 80% of women with 
migraines have been shown to have complete relief of symptoms when pregnant (a 
high oestrogen state), and CNCP conditions increase in prevalence during 
childbearing years between menarche and menopause. This again shows that this is 
a complex relationship and oestrogen levels do not directly correlate with pain level 
and are dependent on multiple other factors, including the underlying pain condition 
itself (Aloisi, 2003; Aloisi and Bonifazi, 2006; Craft, 2007; Hassan et al., 2014).  
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2.3 Opioids 
The British National Formulary (BNF) states that “Opioid analgesics are usually used 
to relieve moderate to severe pain particularly of visceral origin” (BNF, 2018a). 
Opioids are amongst the oldest painkillers known to man. Morphine, one of the 
strongest opioids, was originally produced from opium an extract of the “opium 
poppy” (Minami and Satoh, 1995; Vuong et al., 2010). Opioid drugs bind to opioid 
receptors (found in the brain, spinal cord and peripheral tissues) to produce their 
analgesic effect, and comprise of natural opioids (such as morphine), and synthetic 
opiates (such as diamorphine). The term opioids can be used to refer to all opioid 
analgesics regardless of source (Freynhagen et al., 2013; Reddy et al., 2010; Vuong 
et al., 2010).   
Several opioid receptors exist including mu(µ), delta (δ) and kappa (κ), which can be 
found in the brain, spinal cord and afferent neurons (sensory receptors in the 
peripheral nervous system that send signals to the central nervous system). Opioids, 
either physiological (endogenous opioids) or pharmacological (exogenous opioids), 
bind to opioid receptors in order to exert their effect (Freynhagen et al., 2013; Grady 
et al., 2002; Minami and Satoh, 1995; Vuong et al., 2010), which is mediated both 
centrally (within the brain) and peripherally (within the nerves and spinal cord) 
(Minami and Satoh, 1995; Satoh and Minami, 1995; Stannard et al., 2013; Vuong et 
al., 2010). The action of opioids is dependent on the opioid receptor they bind to, the 
location of this receptor and the type of cell involved. Presynaptic opioid receptors 
inhibit the release of neurotransmitters, and post-synaptically they decrease the 
excitability of the neurone. Both of these actions decrease the transmission of pain 
signals and therefore the sensation of pain (Stannard et al., 2013).  
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Opioids are traditionally separated into weak or strong opioids based on relative 
effectiveness when compared to morphine. For instance, 100mg of oral codeine is 
equivalent to 10mg of oral morphine (relative potency of 0.1). There is wide variation 
of conversion values for opioids to morphine equivalent doses in the literature, and 
these can alter based on the route of administration and metabolism of medicines 
(altered by liver and renal function), meaning the conversion may be different in 
different patients (BNF, 2018b; Pereira et al., 2001). Throughout the thesis 
conversion factors used by Von Korff et al (2008) will be employed (Von Korff et al., 
2008). A model for categorising analgesics including opioids into six groups has been 
developed by UK primary care physicians; in this model, opioids are split into four 
different potency categories including weak, moderate, strong and very strong and 
this will be used to categorise opioids throughout the thesis see Figure 2-1 (Bedson 
et al., 2013). 
Opioids can also be separated by duration of action into either immediate or modified 
release. Short acting/immediate release preparations release all active ingredients on 
administration, giving a rapid onset and short duration of pain relief; these types of 
opioids are useful during dose titration (Fallon et al., 2006). Modified release 
preparations are designed to release the active ingredient at a predetermined rate to 
maintain a constant drug level over a specific period of time, normally once (24 hour 
slow release) or twice per day (12 hours slow release) preparations (Excellence, 
2012; Fallon et al., 2006). See Table 2-1 summarising some of the commonly used 
opioids and their different formulations, split by strength and mode of action (Grady et 
al., 2002; The British Pain Society, 2010). However, Buprenorphine is 
pharmacologically different to other opioids. Buprenorphine is a mixed opioid agonist-
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antagonist, it binds strongly to opioid receptors and is not easily displaced, meaning 
other opioids either physiological or pharmacological will have more difficulty binding 
to receptors (Walsh and Eissenberg, 2003). 
Table 2-1 Summary of opioids (BNF, 2018a; The British Pain Society, 
2010)  
 
Opioid Name 
(generic) 
Short acting 
preparations 
(examples) 
Long acting 
preparations 
(examples) 
STRONG Buprenorphine Temgesic (S/L) BuTrans, Hapoctasin, 
Transtec (T/D) 
Diamorphine Oral or IV diamorphine  
Fentanyl Abstral, Effentora,  Fentanyl (T/D) 
Hydromorphone Palladone (oral) Palladone SR (oral) 
Morphine Morphine Solutions 
(oral) 
MST continus 
Oxycodone Oxycodone Dolocodon PR 
Pentazocine Pentazocine (oral)  
Pethidine Pethidine (oral, IM)  
Tramadol Tramadol, Zydol (oral) Tramadol M/R 
WEAK Codeine 
Phosphate 
Codeine Phosphate 
(oral) 
 
Dihydrocodeine 
tartate 
Dihydrocodone tartate DHC continus 
Mepatazinol Meptid (oral)  
Key: S/L sublingual, T/D transdermal, IV intravenous, SR slow release, PR prolonged 
release, M/R modified release, IM Intramuscular 
 37 
 
 
Figure 2-1 Analgesic categories reproduced from (Bedson et al., 2013). Key: NSAIDs non-steroidal anti-
inflammatory drugs, COX2 cyclooxygenase-2, n number.   
 38 
 
2.3.1 Opioids and effectiveness in CNCP 
A Cochrane review on the use of long-term opioids (defined as > six months via oral, 
transdermal or intrathecal route) for CNCP in adults from 2010, identified 27 papers 
(open label case series and one controlled trial) (Noble et al., 2010). The authors of 
the review concluded that there was weak evidence for pain relief with oral opioids. 
The results were not generalisable to the whole population due to the lack of 
controls, and the studies being based around specific patient groups. The studies 
showed statistical heterogeneity, indicating variability between the studies combined 
for the meta-analysis. Heterogeneity can be reported using the I2 statistic, and if the I2 
statistic is more than 50% it may represent significant heterogeneity, therefore the 
results of the meta-analysis may not be a true reflection of the actual effect (Higgins 
and Green, 2011). Studies of oral opioids showed a 63.4% mean decrease in pain 
score (Standard Mean Deviation 1.99, 95% CI 1.17, 2.8, I2 = 51.3%), but there was a 
high dropout rate of study participants. 11.9% (95% CI, 7.8%, 17.7%) of subjects 
discontinued opioid use due to insufficient pain relief and 32.5% due to adverse 
events (95% CI 26.1%, 39.6%) (Noble et al., 2010). A further review in 2013 by a 
different author found no randomised controlled trial’s (RCT’s) that evaluated the 
long-term use of opioids (more than six months) and agreed with the Cochrane 
review that there was an absence of high quality evidence that might substantiate 
any recommendations in guidelines for the use of opioids (Kissin, 2013). A more 
recent trial in patients with low back pain and hip and knee osteoarthritis has found 
that opioid analgesics were no more effective than non-opioid analgesics for pain 
related function over 12 months of use, however the non-opioid analgesics group 
included tramadol on the third step of treatment, which in the definition of opioids 
used for this thesis would mean that opioid use was present in both comparison 
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groups (Krebs et al., 2018). In contrast, a systematic review in 2004 (18 RCT’s 
follow-up was short ranging from four days to eight weeks with open label follow-up 
for up to two years) found a mean decrease in pain of 30%, but low dose opioids 
were ineffective and higher doses were of limited benefit due to adverse effects 
(Kalso et al., 2004). A recent Cochrane review that evaluated effectiveness of high 
dose opioids (>200mg morphine equivalent per day) found no evidence to support 
the use of opioids at this dose in CNCP (Els et al., 2017a). A review of guidelines 
developed for use of opioids in CNCP from 2004-2013 (seven national guidelines 
were identified), all discussed the limited evidence for long-term use of opioids, and 
recommended a discussion of risk and benefits prior to commencing opioids, and a 
trial of treatment to identify patient response and the dose required with tailored 
follow-up (Cheung et al., 2014). Despite the lack of evidence for use of opioids in 
CNCP, a postal survey of GP’s showed that 83% (35% response rate) felt that 
opioids were effective for CNCP (McCracken et al., 2008). There is some evidence 
from a systematic review of open-label studies that some patients can benefit from 
long-term opioids, but opioids should only continue if there is clinically meaningful 
pain reduction, and if this is not evident a drug holiday should be considered (Hauser 
et al., 2015). Opioids continue to be recommended by experts as part of multi-
disciplinary treatment of CNCP, patients should be monitored regularly and the dose 
should not be escalated above 120mg/day morphine equivalent dose without 
specialist input (O’Brien et al., 2017). 
Several studies have found a relationship between treatment with opioids and poor 
patient outcomes. A population based cohort study set in Sweden found that rather 
than opioids being associated with improved pain scores, use of strong opioids was 
associated with poor health related quality of life (QoL) and were a risk factor for 
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mortality (Sjøgren et al., 2010). The authors commented that they could not be sure 
the opioids caused increased mortality and decreased QoL since the causes may 
well be multifactorial. Another cross-sectional study based in Denmark also showed 
that those with CNCP on opioids, when compared to those not taking an opioid failed 
to achieve similar functional status, QoL and pain control, but as a cross-sectional 
study and there is no way to establish causality in these relationships (Eriksen et al., 
2006). Patients with back pain who were prescribed opioids early in their 
management, had worse self-reported disability at six month follow-up, even when 
confounders such as CNCP were adjusted for; findings were statistically significant 
but the actual increase in disability score was small and unlikely to be clinically 
important (Ashworth et al., 2013).  
2.3.2 Trends in opioid use 
In 2013 the NHS in England prescribed 21,710,300 items classified as an opioid in 
the BNF, at a cost of £13.35/item. This was an increase of 5.3% in the total number 
of items from 2012 (Prescribing and Primary Care team, 2012, 2013). Several 
studies in the UK have shown increases in opioid usage; Zin et al (2014) found an 
increase in women taking strong opioids (four specific opioids were included in the 
study morphine, oxycodone, buprenorphine and fentanyl) for non-cancer pain of 
575.3% between 2000 and 2010 using data from the Clinical Practice Research 
Datalink (CPRD), Ruscitto et al (2015) found an 18 fold increase in strong opioid 
prescribing between 1995 and 2010 in a region of Scotland (Tayside), Foy et al 
(2016) found prescribing of strong opioids (e.g. diamorphine, morphine, oxycodone, 
fentanyl, and buprenorphine) increased by more than six times between 2005 and 
2012 in Leeds and Bradford, and Bedson et al (2016) found a 38% increase in 
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incidence of prescribed opioids between 2002 and 2009 in a CPRD database study 
(Bedson et al., 2016; Foy et al., 2016; Ruscitto et al., 2015; Zin et al., 2014). This 
trend of increasing opioid use has also been seen in the United States (US) where 
two large studies, TROUP (trends and risks of opioid use for pain) and CONSORT 
(consortium to study opioid risks and trends), showed year on year increases in 
opioid prescribing (Von Korff et al., 2008; Sullivan et al., 2008). Denmark has also 
seen a 600% increase in opioid prescribing over the past 20 years (Eriksen et al., 
2006). These increases are despite poor evidence for the effectiveness of opioid 
therapy, which was discussed in depth in section 2.3.1 (Els et al., 2017a; Kalso et al., 
2004; Kissin, 2013; Noble et al., 2010). These increases reflect a trend of increased 
opioid prescribing for CNCP since the early 1980’s, when there was a change in 
perceptions and attitudes towards use of opioids. Patient advocacy groups and 
professional health organisations began to promote effective pain control for patients 
with CNCP through the use of opioids if necessary. An important aspect of this was 
to moderate the fear surrounding their use, and consequently this led to drug 
companies marketing their opioids more aggressively (Freynhagen et al., 2013; 
Sjøgren et al., 2010). This change in perceptions is reflected in a postal survey of UK 
GP’s in 2008; 83% of those surveyed reported believing that opioids were effective 
for CNCP, but there were concerns about adverse effects, monitoring of patients and 
addiction (McCracken et al., 2008). The acceptance of opioids into mainstream care 
was facilitated by the introduction of the WHO analgesic ladder for cancer pain in 
1986, which has three steps. The first step involves the prescribing of non-opioids 
such as paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs). Step two 
involves the addition of an opioid for mild to moderate pain if pain remained 
uncontrolled, and in step three opioids for moderate to severe pain are 
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recommended for pain that failed to respond to step one and two (World Health 
Organisation, 1990). The WHO analgesic ladder was initially proposed for cancer 
pain, but it is often now applied more generally for CNCP despite not being validated 
in this setting (British Medical Association, 2017). A review of seven national 
guidelines (including two from the US and one from the UK) showed that opioids 
were widely recommended as second line therapy for CNCP, as part of an 
individualised approach to care, in line with the WHO analgesic ladder (Cheung et 
al., 2014; Chou et al., 2009b). The National Institute for Clinical Excellence (NICE) 
recommends the use of codeine for pain relief as second line (following paracetamol 
with or without topical NSAIDs) for osteoarthritis, one of the commonest 
musculoskeletal conditions (National Institute for Health and Care Excellence, 
2014a).  
WHO uses opioid consumption as an indicator of progress in pain relief within each 
country (Zin et al., 2014). Epidemiological studies looking at opioid use in the US and 
The Netherlands indicate that predictors for opioid use include: female sex, older 
age, already receiving an NSAID, living alone, shorter education history, poor self-
rated health and being unemployed (Eriksen et al., 2006; Parsells et al., 2008). A 
study within Scotland found that women when compared to men had a higher odds of 
receiving opioids, odds ratio 1.44 (95% CI 1.38, 1.50) and these odds increased with 
escalating polypharmacy (0-4 other medicines vs. 15 or more medicines odds ratio of 
20.7 (95% CI 18.9, 22.6)) (Ruscitto et al., 2015). 
2.3.3 Opioids and adverse events 
An adverse event is defined by the Medicines and Healthcare products Regulatory 
Agency (MHRA): “An adverse drug reaction (ADR) is a response to a medicinal 
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product which is noxious and unintended.” (MHRA, 2014). Up to 80% of patients 
taking opioids will experience at least one adverse event, so these should be 
discussed with patients prior to commencing treatment (The British Pain Society, 
2010). A recent Cochrane review found the absolute event rate for any adverse event 
when taking medium to long-term opioids was 78% and 7.5% for serious adverse 
events (Els et al., 2017b).  
Acute adverse effects of opioids include sedation, nausea, dizziness, itching, 
constipation (40-45% of patients) and pupillary constriction (The British Pain Society, 
2010). Tolerance to the majority of these adverse effects occurs within a few days 
but itching and constipation often persist. Respiratory depression is also a problem 
with acute therapy, but does not tend to occur in those using opioids long-term 
unless there is a major dose, formulation, or route of administration change (Baldini 
et al., 2012; Grady et al., 2002; The British Pain Society, 2010). A systematic review 
showed specific adverse effects such as constipation, somnolence, nausea, 
vomiting, dizziness and itching were significantly more likely to occur in those 
receiving oral opioids when compared to placebo (Kalso et al., 2004).  
Chronic adverse effects include persisting acute adverse effects, but also 
dependency, tolerance, addiction, endocrine adverse effects (e.g. opioid induced 
endocrinopathy leading to sexual and reproductive dysfunction for which the 
evidence is unclear and is the focus of this thesis), immunological effects (some 
opioids have direct immunosuppressive effects, this area is little studied and the 
clinical impact of this is unclear), sleep disordered breathing and opioid induced 
hyperalgesia (Baldini et al., 2012; Grady et al., 2002; The British Pain Society, 2010). 
Tolerance is a loss of analgesic potency with the patient requiring ever increasing 
doses due to decreasing efficacy over time. This is not to be confused with opioid 
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induced hyperalgesia which is worsening sensitivity to pain due to increasing doses 
of opioids (Manchikanti et al., 2010). Some opioids for instance tramadol and 
methadone have also been shown to increase the risk of serotonin syndrome when 
used in combination with other serotonin releasing agents (e.g. antidepressants) 
(Rastogi et al., 2011). Opioids have also been shown to increase morbidity and 
mortality of those taking them. Adults over 60 years old taking long-term opioids at a 
dose of more than 50mg/day have a twofold increased risk of fracture, and patients 
taking high dose opioids (more than 100mg/day) are also at higher risk of overdose 
(Bedson et al., 2019a; Dunn et al., 2010; Saunders et al., 2009). All-cause mortality 
has also been shown to be higher in opioid users when compared to non-opioid 
analgesic use (anticonvulsants and low-dose tricyclic antidepressants) with a hazard 
ratio of 1.64 (95% CI 1.26, 2.12) within the first 180 days of therapy and this was 
even higher in the first 30 days with a hazard ratio of 4.16 (95% CI 2.27, 7.63) (Ray 
et al., 2016). 
Authors of the CONSORT study in the US, which investigated opioid prescribing 
trends from 1997 to 2005, highlighted that even with low rates of adverse effects, 
there could potentially be a large effect on morbidity and mortality in the population 
due to the high rates of opioid use (Campbell et al., 2010; Sullivan et al., 2008). It is 
important to note that the reported rate of adverse effects from opioids is up to 80%, 
and in many trials there is a high drop-out rate secondary to these adverse effects 
(Kalso et al., 2004; Noble et al., 2008, 2010; The British Pain Society, 2010). A 
systematic review in 2004 of 14 randomised control trials (follow-up of up to eight 
weeks and then open label follow-up for up to two years in eight studies) found that 
with opioid treatment, compared to placebo, the number needed to harm was 4.2 (CI 
3.1-6.4). This means that for every four people treated with opioids, one experienced 
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an adverse event that they wouldn’t have experienced if treated with a placebo 
(Kalso et al., 2004). A systematic review found a discontinuation rate in those taking 
oral opioids due to adverse effects of 22.9% (95% CI 15.3, 32.8%), but there was a 
high level of heterogeneity in the group (I2 = 95.8%) so the results should be 
interpreted cautiously (Noble et al., 2010).  
In summary, opioids are associated with high rates of adverse effects ranging from 
simple problems such as constipation to much more serious consequences such as 
increased fracture rate, risk of overdose particularly in older patients, and increased 
mortality.  
2.4 The endocrine system 
The endocrine system consists of blood borne chemical messengers called 
hormones released from endocrine tissues, which circulate throughout the body and 
influence target tissues where they have a regulatory effect. The effects of the 
endocrine system are wide ranging and help co-ordinate the body’s internal 
physiology including controlling growth, development, metabolism, thyroid functions 
and reproductive functions. The release of hormones within the endocrine system is 
most often controlled by a process of negative feedback, where a signal causes a 
response which then acts to reduce the amount of signal being sent, (Figure 2-2) and 
occasionally will have positive feedback loops (e.g. during childbirth and breast 
feeding) (Brook and Marshall, 2001; Pocock et al., 2013). Central to the endocrine 
system is the hypothalamic-pituitary axis. The hypothalamus is located in the brain 
and has complex neural inputs from virtually all areas of the brain and is regulated by 
higher centres within the brain, but also has autonomy in release of hormones, which 
enter the pituitary blood supply and exert an action on the pituitary’s cells stimulating 
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them to produce and release further appropriate hormones. The pituitary is made up 
of the anterior and the posterior pituitary and is connected to the brain by the pituitary 
stalk, through which the connecting blood supply runs. These hormones released 
from the pituitary then act on a target organ, which in turn itself will release a 
hormone which has a physiological purpose and will affect the release of further 
hormones from the pituitary (direct feedback) and the hypothalamus (indirect 
feedback) (Figure 2-2) (Brook and Marshall, 2001).  
The area of hormonal regulation that this thesis will focus on is that of female sex 
steroid production. This is mainly via the hypothalamic-pituitary-gonadal (HPG) axis, 
with particular interest in the ovaries. The hypothalamus releases gonadotrophin 
releasing hormone (GnRH) which acts on the pituitary, where luteinising hormone 
(LH) and follicle stimulating hormone (FSH) are secreted from gonadotrophs (10-15% 
of cells in the anterior pituitary). These exert an action on the ovaries causing the 
release of gonadal hormones including oestrodiol, progesterone and inhibin (Figure 
2-3), which support normal sexual and reproductive behaviour (Table 2-2) (Brook and 
Marshall, 2001; Katz and Mazer, 2009; Pocock et al., 2013).  
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Table 2-2 Summary of action of LH and FSH in women 
Hormone Affect in Women 
Luteinising hormone Induce ovulation 
Maintain secretory function of corpus luteum (a 
hormone secreting structure formed from the 
ovum (egg) following ovulation that disappears if 
fertilization does not occur) and therefore 
production of progesterone. 
Follicle stimulating 
hormone 
Stimulate development of ovarian follicles (the 
process during the first half of the month that 
surrounds the ovum with cells prior to ovulation) 
leading to secretion of oestrodiol  
Production of inhibin (prevents production of FSH 
by the pituitary) 
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Figure 2-2 Hypothalamic, pituitary, target organ axis. Adapted from Fig 3.3 
Page 40 Essential Endocrinology 4th Edition (Brook and Marshall, 2001).  
 
Figure 2-3 Hypothalamic, pituitary, gonadal (HPG) axis. Adapted from Fig 
33.24 Page 677 Human Physiology 4th edition (Pocock et al., 2013).  
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2.4.1 Opioid induced endocrine adverse effects and their possible causes. 
The possible endocrine implications of opioids in women are altered menstrual 
cycles, menopausal symptoms, female sexual dysfunction (FSD), infertility and 
possibly galactorrhoea as discussed in Chapter 1. Each of these has many potential 
causes and these will be discussed in the remainder of this section (Ballantyne and 
Mao, 2003; Brennan, 2013; Brown and Zueldorff, 2007; Colameco and Coren, 2009; 
Katz and Mazer, 2009; The British Pain Society, 2010). The mechanism for 
reproductive and sexual dysfunction is thought to be due to opioids creating a 
negative feedback effect on the hypothalamus, causing decreased GnRH release 
and subsequent decrease in gonadotrophin release, there may also be peripheral 
effects (see section 2.4 for more information on how the HPG system functions) 
(Smith and Elliott, 2012). 
Amenorrhoea and oligomenorrhoea are associated with hypogonadism and are 
forms of menstrual cycle disorders. Amenorrhoea is a failure to menstruate; it may be 
primary (complete absence of menstruation) or secondary, which is defined as lack 
of menstruation for six months or more in a women or girl who has previously had 
normal menstruation (Brook and Marshall, 2001; Ojeda, 2011). Oligomenorrhoea can 
be defined as either an abnormally long period of time (35 days to six months) 
between regular menstruation, or less than nine menstrual cycles in a year (Impey 
and Child, 2012; Norwitz and Schorge, 2013; The Practice Committee of the 
American Society for Reproductive Medicine, 2008). The prevalence of amenorrhoea 
in the general population (not due to pregnancy, menopause or lactation) is between 
3 and 4% (The Practice Committee of the American Society for Reproductive 
Medicine, 2008). The four main causes for secondary amenorrhoea are hypothalamic 
amenorrhoea, polycystic ovary syndrome (PCOS), hyperprolactinaemia and 
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premature ovarian failure (POF) (The Practice Committee of the American Society for 
Reproductive Medicine, 2008). There are however many more causes of 
amenorrhoea such as endocrine disorders (adrenal disease, thyroid disease 
including subclinical hypothyroidism and ovarian tumours), anatomical disorders and 
inflammatory/infective conditions can all cause irregular periods (Dickerson et al., 
2009; Impey and Child, 2012; The Practice Committee of the American Society for 
Reproductive Medicine, 2008).  
Hypothalamic amenorrhoea is due to an alteration in hypothalamic regulation of the 
HPG axis, due to a number of reasons including psychological stress, excessive 
exercise, nutritional changes and decreased weight which all lead to suppression of 
GnRH (The Practice Committee of the American Society for Reproductive Medicine, 
2008). Hyperprolactinaemia can also cause amenorrhoea through suppression of 
GnRH production and is most commonly secondary to pituitary disease (usually 
benign) or prescribed medicines (Impey and Child, 2012; Melmed et al., 2011). 
PCOS affects around 5% of the population and accounts for nearly 80% of cases 
infertility due to anovulation (Impey and Child, 2012).  
Alcohol intake can be related to the chances of achieving conception. One study 
found that Danish couples who consumed 10 or more alcoholic drinks per week were 
less likely to conceive a pregnancy than when compared with those drinking five or 
less drinks per week (Jensen et al., 1998). Smoking was found to be significantly 
associated in one study with premature ovarian failure (POF). (Chang et al., 2007; 
Luborsky et al., 2003).   
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2.5 Female sexual dysfunction  
Female sexual dysfunction (FSD) covers a wide range of disorders with the common 
outcome that a person is unable to respond sexually or experience sexual pleasure 
(American Psychiatric Society, 2013). In women the normal stages of sexual function 
are arousal, the sexual act itself and orgasm (Bhugra and Colombini, 2013). Sexual 
function however is not purely a biological process it is complex and has personal, 
interpersonal and cultural influences (American Psychiatric Society, 2013). FSD can 
happen during any of the stages of normal sexual function, and a woman may be 
affected in more than one way. Sexual health is multidimensional, influenced and 
affected by the biological, psychological, medical conditions (including prescription 
medicines) and social factors including current relationship status. (Basson et al., 
2001; Dalpiaz et al., 2008).  
Corona et al (2006) state that “Sexuality is an integral part of being human, love, 
affection and sexual intimacy contribute to healthy relationships and a person’s 
happiness and self-esteem” (Corona et al., 2006). FSD affects a high proportion of 
women, but FSD is often ignored in health care settings. An example of this is a 
study by Read et al. (1997) where consecutive patients leaving a GP consultation 
were surveyed revealing that 42% of women attending in this primary care setting 
reported sexual dysfunction, a sexual problem was only coded in 2% of these 
patients’ notes (Read et al., 1997). A further study of older patients aged 40-80 years 
old, across 29 countries, found that 26-48% of women reported lack of interest in 
sex, but only 9% had been asked about sexual health during their routine health care 
visits in the previous three years (Laumann et al., 2005). A postal survey of the 
general population in 1998 (44% response rate) found that 41% of women reported a 
current sexual problem (median age 49 years old); in a subset of women 30-59 years 
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old the rate was 28% (Dunn, Croft et al. 1998). Improving sexual health has been 
shown to have an effect on quality of life overall. It is also important because sexual 
health problems can potentially be an early sign of other underlying systemic health 
conditions (Clegg et al., 2012). There are many barriers to discussion about sexual 
health and these come from both the clinician and the patient, for example limited 
time, embarrassment and the lack of treatment options (Bachmann, 2006; 
Montgomery, 2008).  
Sexual function in women is complicated and varies significantly through life. It is 
clear that several factors can influence sexual function such as systemic conditions 
including anaemia, hypothyroidism, autoimmune disease, chronic pain, age, 
menopausal status, medicine, alcohol intake and also low mood/depression 
(Arunakumari and Walker, 2009; Katz and Mazer, 2009). A longitudinal study of 
women in the peri-menopause and early menopausal phase showed a statistically 
significant decrease in sexual desire amongst this group compared to before this 
period of time began. Additionally, women who suffered worse menopausal 
symptoms, or had higher stress levels, were also more likely to have decreased 
sexual function (Woods et al., 2010). A strength of this study was that diaries for 
sexual activity and desire were filled in contemporaneously from the 1990’s so this 
limited recall bias. Sexual desire has also been shown to decrease with age in a 
cross sectional population study in Australia with each decade from 20 to 70 years 
old showing a decrease in sexual desire within the cohort (Hayes et al., 2008). The 
same study showed that sexual distress was positively associated with depression 
(Hayes et al., 2008). The following commonly used drugs have been associated with 
a FSD: alcohol, hormonal contraceptives, antidepressants and anti-hypertensives 
(Arunakumari and Walker, 2009). This situation becomes even more complex when 
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considering chronic pain. It is often the case that these patients are treated with 
opioids, and therefore it may be difficult to ascertain whether the FSD is secondary to 
the chronic painful condition, the opioid treatment for it, or both.  
2.5.1 Classification systems for FSD 
Definitions of FSD are evolving continually. Currently there are five main 
classification systems in use. These are the Diagnostic and Statistical Manual of 
Mental Disorders (DSM) V, the International Classification of Diseases (ICD-10), 
International Conference on Women’s Sexual Dysfunction, the Fourth International 
Consultation on Sexual Dysfunctions and the American Foundation of Urologic 
disease (American Psychiatric Society, 2013; Basson et al., 2001; Hatzimouratidis 
and Hatzichristou, 2007; McCabe et al., 2016; World Health Organisation, 2012). It is 
important when undertaking research to use a widely recognised definition for the 
condition being studied, because without this the results are not easily understood in 
a clinical context. ICD-10 and DSM V are the most widely used systems 
internationally (McCabe et al., 2016). The fact that there are several widely 
recognised classification systems and no single gold standard has made the 
research in the area relatively confused, with research using different definitions for 
the same condition. DSM V is mainly a psychiatric disorders classification system, 
but it has been adapted to define organic conditions, whereas ICD-10 splits disorders 
into organic and non-organic (American Psychiatric Society, 2013; McCabe et al., 
2016; World Health Organisation, 2012). There are also several expert consensus 
definitions for FSD from conferences that are in use. These have taken ICD-10 and 
DSM V and expanded the definitions (Basson et al., 2001; McCabe et al., 2016). All 
the classification systems split sexual dysfunction into four main groups of problems 
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which include desire, arousal, orgasm and sexual pain. A summary of the conditions 
defined within each system can be seen in Table 2-3. 
The most common form of FSD is loss of desire. This occurs when a woman suffers 
from either persistent or recurrent deficiency of sexual fantasies and desire for sexual 
activity which thereby causes the woman either personal or interpersonal distress 
(American Psychiatric Society, 2013; Basson et al., 2001; McCabe et al., 2016; Quirk 
et al., 2002; Rosen et al., 2000; World Health Organisation, 2012). Low desire 
conditions are described in slightly different ways by each of the classification 
systems (see Table 2-4). The common parts of the definitions are that the symptoms 
are required to cause personal distress, be persistent or recurrent (at least three- or 
six-months dependent on definition) and affect the woman on over 75% of occasions. 
Sexual arousal disorders do not preclude a woman from experiencing sexual 
enjoyment or arousal, but this must be absent on more than 75% of occasions.  
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Table 2-3 Summary of classification systems for female sexual dysfunction  
 
 Desire Arousal Orgasmic Sexual pain Other Further Info 
ICD-10 (World 
Health 
Organisation, 
2012) 
Lack or loss 
of sexual 
desire  
Sexual 
aversion  
Lack of sexual 
enjoyment 
Failure of 
sexual 
response  
 
Orgasmic 
dysfunction 
 
Non-organic 
vaginismus 
Dyspareunia 
 
Excessive sexual 
drive  
 
 
DSM-V 
(American 
Psychiatric 
Society, 2013) 
Female sexual interest-
arousal disorder 
Female 
orgasmic 
disorder 
 
Genito-pelvic 
pain- 
penetration 
disorder 
 
Substance or 
medicine induced 
disorder  
 
Symptoms for 6 
months on >75% 
of occasions 
causing clinically 
significant distress  
4th international 
consultation on 
sexual 
dysfunction 
(McCabe et al., 
2016) 
Hypoactive 
sexual 
desire 
dysfunction 
Female sexual 
arousal 
dysfunction 
Female 
orgasmic 
dysfunction 
 
Female 
genital-pelvic 
dysfunction 
Painful 
orgasm  
 
Persistent genital 
arousal disorder 
Postcoital syndrome  
Hypohedonic 
orgasm  
Present for three 
months, leads to 
distress occur in 
>75% of occasions  
International 
consensus 
development 
conference on 
women’s sexual 
dysfunction 
(Basson et al., 
2001) 
Hypoactive 
sexual 
desire 
disorder 
Sexual 
aversion 
disorder 
Sexual arousal 
disorder 
Orgasmic 
disorder 
Dyspareunia 
Vaginismus 
Noncoital 
sexual pain 
disorder 
 Requires personal 
distress 
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 Table 2-4 Desire disorder definitions from each classification system for 
FSD 
 
 
Grading system Desire 
condition 
Description 
Fourth 
international 
consultation on 
sexual dysfunction 
(McCabe et al., 
2016)   
Hypoactive 
sexual desire 
dysfunction 
Persistent or recurrent deficiency of 
absence of sexual or erotic thoughts 
or fantasies and desire for sexual 
activity. In order to diagnose must 
cause distress.  
 
International 
consensus 
conference on 
women’s sexual 
dysfunction 
(Basson et al., 
2001) 
 
Hypoactive 
sexual desire 
disorder  
 
Persistent or recurrent deficiency (or 
absence) of sexual 
fantasies/thoughts, and/or desire for 
or receptivity to sexual activity which 
causes personal distress. Sub 
grouped into lifelong vs acquired, 
generalised vs situational, aetiology 
(organic, psychogenic, mixed, 
unknown) 
DSM V (American 
Psychiatric 
Society, 2013) 
Female sexual 
interest-arousal 
disorder 
Lack of or significantly decreased 
sexual interest or arousal is 
manifested by at least three of the 
following characteristics i) absent or 
decreased interest in sexual activities 
ii) absent or decreased sexual or 
erotic thoughts or fantasies iii) no or 
decreased initiation of sexual activity 
and typically unreceptive to a partners 
attempts to initiate iv) absent or 
decreased sexual excited or pleasure 
during sexual activity in almost all or 
all sexual encounters, v) absent or 
decreased sexual interest or arousal 
in response to any internal or external 
sexual or erotic cues vi) absent or 
decreased genital or non-genital 
sensations during activity in almost all 
or all sexual encounters 
ICD-10 (World 
Health 
Organisation, 
2012) 
Lack or loss of 
sexual desire   
Loss of sexual desire is the principal 
problem and is not secondary to other 
sexual difficulties. Lack of sexual 
desire does not preclude sexual 
enjoyment or arousal but makes the 
initiation of sexual activity less likely 
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2.6 Summary 
This chapter has presented an overview of the core concepts that are important for 
the remainder of the thesis. The epidemiology of CNCP and opioid use has been 
discussed and the scale of the problem explored. Adverse effects of opioids have 
been discussed in general terms and the more specific sexual and reproductive 
effects and relevant physiology. This chapter provides the context for the remainder 
of the thesis. 
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3 Systematic review 
3.1 Introduction 
Reproductive and sexual dysfunction secondary to hypogonadism are recognised 
adverse events in men receiving opioids, and in women receiving illegal opioids, this 
has been discussed in depth in section 2.4.1 (Abs et al., 2000; Aloisi et al., 2009; 
Benyamin et al., 2008; Brown and Zueldorff, 2007; Daniell, 2002; Genazzani et al., 
1993; Rubinstein et al., 2013; Schmittner et al., 2005; Smith and Elliott, 2012). This 
has been highlighted as an area for further research by both the British Pain Society 
and in a paper for the American Pain Society and American Academy of Pain 
Medicine highlighting research gaps (Chou et al., 2009b; Williams et al., 2013). The 
most appropriate initial step for investigating this potential link is to assess the current 
evidence available through a comprehensive systematic review of the literature. This 
chapter will present the methods and results of a systematic review investigating 
women aged 18-55 years old receiving long-term opioids for CNCP and potentially 
associated sexual and reproductive dysfunction. The results of the review will be 
used to determine relevant outcomes to be used in subsequent studies within the 
thesis. 
3.2 Aims 
To conduct a comprehensive systematic review of the published literature in relation 
to long-term opioid use for CNCP and potentially related endocrine adverse effects in 
women aged 18-55 years old, with a specific focus on reproductive and sexual 
dysfunction relating to hypogonadism (biochemical or clinical).  
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3.3 Methods 
To undertake the systematic review, a search of the relevant databases was 
undertaken using a predefined search strategy. The papers included were selected 
based on inclusion and exclusion criteria defined in a systematic review protocol 
developed prior to starting the review, and these were applied to the title, abstract 
and full text (see Appendix 1). Papers included were reference checked, as were any 
literature reviews for relevant papers, to ensure that no potential papers that might be 
included were missed. Papers that met the inclusion criteria were assessed for 
quality using critical appraisal skills programme (CASP) checklists (Critical Appraisal 
Skills Programme (CASP), 2014). Data was extracted using a standardised proforma 
(see Appendix 2). The collected data was synthesised by the author (ER Emily 
Richardson).  
3.3.1 Search strategy 
A Search of the following databases was undertaken in October 2014: 
1. MEDLINE – General Medical Database 1946 to present. Contains over 5,600 
worldwide journals. MEDLINE includes a broad range of resources focusing 
on biomedicine and health (U S National Library of Medicine, 2014). Accessed 
via Ovid. 
2. Embase – Excerpta Medica Database 1974 to present (strong in its coverage 
of drug and pharmaceutical research [Drug therapy and research, including 
pharmaceutics, pharmacology and toxicology] with over 22 million records, 
7500 journals, 90 countries) (Elsevier, 2014). Research into use of databases 
for drug adverse effects has shown that Embase performs well, and uncovers 
 60 
 
references that would not be found through MEDLINE alone (Biarez et al., 
1991). The database was limited to exclude MEDLINE results. Accessed via 
Ovid. 
3. TOXLINE – Toxicology Data Network 1965 to present. Specialised database 
that provides bibliographic information covering the effects (biochemical, 
pharmacological, physiological, and toxicological) of drugs and other 
chemicals, with over 4 million bibliographic citations (U S National Library of 
Medicine, 2013). The search excluded PubMed as these references will have 
been found through the Medline search. TOXLINE is accessed through its 
own internet interface.  
4. PsychINFO – Psychology and allied fields 1806 to present. The scope of this 
database is mental health and behavioural science, and it contains over three 
million peer-reviewed articles, it was accessed via Ovid (American 
Psychological Association, 2014).  
5. CINAHL – Cumulative Index to Nursing and Allied Health Literature 1981 to 
present. CINAHL is a database specific to nursing but also covers 17 other 
allied health professions (National Institute for Health and Care Excellence, 
2014b). Accessed via Healthcare databases advanced search from NICE 
(HDAS NICE).  
6. AMED – Allied and Complementary Medicine produced by the Health Care 
Information Service on the British Library. The scope of the database is 
journals in allied professions to medicine, complementary medicine and 
palliative care. 1985 to present (National Institute for Health and Care 
Excellence, 2014c). Accessed via Ovid.  
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7. Web of Science, a collection of databases allowing searching not only for 
publications, but for citations as well, which is accessed via its own internet 
interface (Keele University, 2014).  
The search strategy was developed in partnership with other primary care clinicians, 
systematic reviewers and medical librarians. Appendix 3 presents the detailed search 
strategy for each database. This consisted of three search strands. Strand one 
searched for different types of opioid analgesics using generic terms such as 
narcotic/opioid analgesics and narrow drug name terms; this was adapted from a 
Cochrane review on the use of opioids in CNCP (Noble et al., 2010). Strand two 
searched for adverse effects as a generic term using a search strategy taken from a 
paper by Golder et al (2006), which developed adverse effects search filters for 
MEDLINE (~100% sensitivity) and Embase (~83% sensitivity). This was then 
adapted for use in the other databases searched. The final search strand looked at 
specific female reproductive and sexual adverse effects. These included conditions 
identified from a preliminary literature search, such as opioid induced hypogonadism, 
opioid induced androgen deficiency (OPIAD) and a wide range of female 
reproductive health related endocrine disorders.  
There were limitations as to the length and type of search that could be done with 
some of the databases, and this led to differences between searches. The search in 
PsychINFO did not include the search strand for generic adverse effects as this 
decreased the search results significantly. There were papers known to the author 
(ER) that were not included in the search results, but when this strand was removed 
the papers appeared in the search results. Additionally, the search strand for adverse 
effects was developed and validated for MEDLINE and Embase not PsychINFO. The 
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search of AMED did not yield many results as this is not a database that focuses on 
conventional pharmacological treatments but rather alternative treatments. TOXLINE 
is a less sophisticated search engine allowing only a single search line, consequently 
the search strategy had to be considerably simplified.  
Citation tracking 
References from relevant papers were tracked, and the papers examined for whether 
they met the inclusion criteria. Any review papers that were revealed through the 
literature search were not included in the systematic review, but their references 
were searched for any relevant literature that had not already been identified through 
the database searches. The reference lists from full texts that were included in the 
systematic review, were also searched for any papers that were not found from the 
initial search. No extra papers were included following citation tracking. 
3.3.2 Study selection 
Papers identified through the database search and additional methods were then 
reviewed to see if they met pre-defined inclusion and exclusion criteria. These were 
applied to the title, abstract and then full text. Titles were assessed by a single 
reviewer (ER) and the abstracts and full texts were reviewed by two reviewers (ER 
and John Bedson (JB) or Ying Chen (YC)), with a third reviewer arbitrating on any 
conflicts of opinion (Kate M Dunn (KD)). 
3.3.3 Inclusion criteria 
Articles selected for inclusion in the systematic review fulfilled the following criteria: 
• Population: Human females, aged 18-55 years old. 
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o If studies included males or females outside the age range the paper 
was included if stratified data was available. 
• The age range was chosen to include women up to and including those going 
through the menopause. A preliminary literature search revealed that 
menopausal symptoms may be one of the potential reproductive adverse 
effects in women associated with long-term opioids (Daniell, 2008). 
• Opioid use for CNCP defined as use for longer than one month. 
o There is no specific definition of long-term opioid use. Previous 
epidemiological studies have used a definition of long-term opioids as 
use for “longer than 90 days and associated with a total supply of at 
least 120 days, or with 10 or more opioid prescriptions of any type 
dispensed” (Campbell et al., 2010; Von Korff et al., 2008). It was shown 
that people who fulfilled these criteria were more likely to continue 
opioids for a year (Campbell et al., 2010; Von Korff et al., 2008). 
However, in a preliminary literature search, it was found that there was 
limited relevant literature available. Some of the literature that appeared 
relevant had taken one month of opioid treatment as their definition for 
long-term use. Consequently, a pragmatic decision was made to define 
chronic use as ‘one month or more’ to allow inclusion of as many 
potentially relevant papers as possible.  
3.3.4 Exclusion criteria 
The following criteria were used to exclude studies identified through the search. 
• Non-human studies 
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• Methadone use for rehabilitation from illegal drug use with no chronic pain 
• Illegal opioid users 
• Cancer pain 
• Non-pain conditions 
• Non-English papers, where no translation was available 
• Full text unavailable 
• Systematic reviews/Review papers 
• Editorials 
All other study types were included.  
3.3.5 Data extraction 
Following selection of full texts to be included, a single reviewer (ER) extracted data 
using a standardised word proforma (appendix 2). The proforma was developed prior 
to identifying the papers with guidance from Keele University’s Research Institute for 
Primary Care and Health Sciences systematic review team, and was based on other 
extraction forms developed from within the primary care research centre. Prior to 
completing the review, it was expected that there would be a wide variety of study 
designs included. Consequently, since the data extraction form needed to 
encompass all study types, not all of the information would be found for each 
included study. The form also included a section to record the study design. Data 
was extracted on the number of people included in each arm of studies, the types of 
outcomes recorded, results, quality assessment, authors’ conclusions, and reviewers’ 
comments on the papers included.  
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3.3.6 Quality assessment 
Prior to starting the literature review and developing the protocol it was decided that it 
was important to include a wide variety of studies to ensure full representation of the 
evidence available. Consequently, it would be important to have a consistent way of 
assessing quality. There is no gold standard for quality assessment of observational 
studies included in systematic reviews and when quality assessment is undertaken, a 
tool developed by the reviewer is often used (Mallen et al., 2006). The centre for 
reviews and dissemination (CRD) at York University produce guidelines on 
undertaking systematic reviews. These suggest that there is no perfect instrument to 
assess quality in reviews on adverse effects, as these often include different study 
designs and no single assessment checklist will be appropriate for all the included 
studies. The CRD recommend using validated assessment criterion, and the reason 
for quality assessment should be clear to the author prior to commencing (Centre for 
Reviews and Dissemination, 2009). CASP checklists were used to assess the quality 
of the papers included as they offer tools for different study types, but as they are all 
developed by the same team, they follow a similar format (Critical Appraisal Skills 
Programme (CASP), 2014). A checklist was completed for each of the papers apart 
from the single case reports for which there is no CASP quality assessment tool. 
Case studies provide low quality evidence and the Oxford Centre for Evidence Based 
Medicine does not include them in their grading system for level of evidence 
(Glasziou et al., 2003; Howick et al., 2011). Case reports are not, however, to be 
completely ignored; they provide evidence on previously un-investigated areas, and 
generate hypotheses for rare adverse effects from common treatments. In addition, a 
systematic review of case reports can provide appropriate evidence for rare harms. 
Case reports are subject to publication bias, as a case report with negative findings 
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would never be written (Centre for Reviews and Dissemination, 2009). CASP 
checklists do not give a grade of evidence once completed but do provide an idea of 
whether the results presented are reasonable and highlight limitations in the studies. 
3.4 Results 
3.4.1 Studies identified 
The search returned 10694 papers (Embase 4088, Web of Science 3120, MEDLINE 
1664, TOXNET 1432, PsychINFO 270, CINAHL 110, and AMED 10), after excluding 
duplicates this reduced to 9706 and the titles of these were screened by a single 
reviewer (ER). 361 titles appeared to meet the inclusion criteria and these abstracts 
were included for review. Abstracts were reviewed by ER and one other (JB or YC) to 
assess whether they met inclusion/exclusion criteria. Any disagreements were 
decided by a third reviewer (KD) and 22 papers were identified for inclusion. The full 
texts were then screened by a single reviewer, and 12 papers were included in the 
final review (See Figure 3-1). An updated search in April 2016 identified 241 
additional papers (253 prior to excluding duplicates), of which 225 were excluded 
based on title; the remaining 16 abstracts were reviewed and no full texts were 
included (one paper men only, one discussed no adverse effects, one did not 
mention endocrine adverse effects, 12 review articles and one conference abstract). 
A further update was undertaken in December 2018 and this identified a further 189 
titles (180 after removal of duplicates), 22 abstracts were reviewed (three 
replacement opioid therapy, two not long-term opioids, one no specific adverse 
effects, seven review articles, one risks during pregnancy, one editorial, three 
treatment of OPIAD, one non reproductive adverse effects, two were publications of 
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work from this thesis), two full texts were reviewed. Neither full text was included in 
the review since one did not separate results by sex and age, and the other full text 
did not describe duration of opioid use. 
 68 
 
Figure 3-1 Flow chart showing results of systematic search and 
selection of included studies. Numbers in brackets are those for each 
category from the updated search; the first number is the 2014-16 
search and the second 2016-18. 
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3.4.2 Quality assessment 
The main limitations of the papers were small numbers of participants, and 
subsequently the subgroups of interest were not powered for statistical analysis. 
Recruitment was on the whole well described, but in the case of Daniell (2008) 
recruitment was not systematic and controls were paid. Data was collected for the 
most part using validated questionnaires or laboratory measurements of 
hormones. There were some drawbacks to hormone measurements as they were 
not synchronised with the menstrual cycle, this will affect the results due to the 
natural variation in hormones throughout the cycle. The results of the CASP 
checklist highlighting strengths and limitations of each paper is summarised in 
Table 3.1. 
3.4.3 Study characteristics 
The studies included considered a variety of methods of opioid delivery, including 
oral (six studies), intrathecal (five studies) and transdermal (one study). Oral 
opioids are tablets or liquids taken by mouth. Intrathecal opioids are given long-
term through use of a pump with a catheter (tube) inserted into the spinal canal. 
Intrathecal opioids are delivered directly to central opioid receptors and avoid the 
blood brain barrier, which means much lower doses of opioids are required. 
Transdermal opioids are delivered via a patch placed on the skin and provide a 
constant amount of opioid throughout the day through absorption into the capillary 
system.  
One cohort study, four case control studies, four cross-sectional studies, one case 
series and two single case reports were included. The studies all had small 
numbers of participants with a maximum of 41 patients in the case arm of one of 
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the papers. These small numbers were partly due to the narrow range of this 
review, as only women under 55 years old could be included (often the studies 
had larger numbers but this included males and older women). In total there were 
only 165 patients included in all the studies (including 35 controls). The length of 
time that patients were followed-up for after commencing opioids was variable, 
ranging from a minimum of one month up to 12 years. The outcomes observed 
were either clinical (menstrual abnormalities and decreased libido), or biochemical 
(measurements of sex hormones LH, FSH, oestrodiol, progesterone, 
dehydroepiandrosterone sulphate (DHEAS), free testosterone (fT), total 
testosterone (TT), prolactin (PRL), sex hormone binding globulin (SHBG) and a 
GnRH stimulation test measuring subsequent levels of LH and FSH). In the 
majority of papers, both clinical and biochemical aspects were investigated. A 
proportion of the results were not stratified for age or gender and therefore were 
not included in the review. A summary of the papers and their main findings can 
be found in Table 3-1.
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Table 3-1 Summary of papers included within the systematic review (age presented in years) 
Author, Year, 
Location 
(reference) 
Design Authors summary of findings Quality assessment from CASP 
checklists. 
Intrathecal opioids 
Abs et al., 2000 
Belgium (Abs et 
al., 2000) 
Case-control study.  
Setting: Pain clinic.  
Duration of treatment: 26.6 
+/- 16.3 months.  
Sample Size: Cases N = 21 
and controls N = 3 
Opioid: Morphine or 
Hydromorphone 
Age: 49.2 (± 11.7), 21 
premenopausal women 
included 
Neuroendocrine dysfunction 
(clinically and biochemically) 
following opioid use. Obvious 
difference in hormonal levels 
between case and control in 
premenopausal women but did 
not reach significance due to 
small numbers within the 
subgroup.  
Positives: matched for chronic pain. 
Validated questionnaire and 
hormone levels.                         
Negatives: Selection criteria not 
described. Larger numbers needed 
for statistical analysis, no power 
calculation performed. Missing data 
reasons not described. 
Finch et al., 
2000 
Australia (Finch 
et al., 2000)  
Case-control study (No 
controls for women < 45 
years old so considered as 
cross-sectional).  
Setting: Pain clinic. Duration 
of treatment: 0.02-8 years 
(median 2.5). 
Sample Size: N = 7 
Opioid: Morphine 
Age: 38.3 (±1.5) (mean ± 
SEM) 
Small doses of intrathecal 
morphine have a profound effect 
on the HPG axis so patients 
should be monitored. 
Positives: selection of 30 sequential 
patients from pain clinic. 
Negatives: No control for women < 
45 years old so no longer case-
control. One time hormone 
measures. 
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Author, Year, 
Location 
(reference) 
Design Authors summary of findings Quality assessment from CASP 
checklists. 
Roberts et 
al.,2001 
Australia 
(Roberts et al., 
2001)  
Cross-sectional study.  
Setting: Pain clinic. 
Duration of treatment:  
minimum 6 months. 
Sample Size: N = 15 
Opioid: Morphine, 
hydromorphone, sufentanil 
Age: 53.4 (±1.4, range 28-
88), 15 premenopausal 
women 
HPG axis affected but requires 
further detailed assessment. 
This should be discussed with 
patients. 
Positives: 80% response rate. 
Questionnaire validated.   
Negatives: Retrospective data 
collection. Scant data for 
premenopausal females. Missing 
data not explained (in reported data 
for women <50 years old, one 
reports 14 women included and 
another 15). 
Njee et al., 2004 
France (Njee et 
al., 2004) 
Cross-sectional study.  
Setting: Pain clinic. 
Duration of treatment: 54 +/- 
39.8 months (4-144). 
Sample Size: N = 10 
Opioid: Morphine 
Age: 43.8 
No evidence of permanent HPG 
suppression. Transient 
amenorrhoea, not accompanied 
by hormonal assays supportive 
of HPG suppression. 
Negatives: retrospective data 
collection. Only minor focus on 
endocrine adverse effects and 
collected via a questionnaire which 
was not described and may not 
have been validated.  
Kim et al., 2014 
United States 
(Kim et al., 
2014)  
Case series. Setting: Pain 
clinic. Duration of treatment: 
12 months and 24 months. 
Sample Size: N = 2 
Opioid: Morphine 
Age: 43 and 46 
 
Two female patients < 55 years 
old were both androgen 
deficient on hormone assays. 
Androgen deficiency is common 
in patients treated with 
intrathecal opioids for CNCP. 
Positives: consecutive patients 
recruited         
Negatives: Only two patients in age 
range, was undertaken as a cohort 
study, but assessed as a case 
series. Questionnaire used was not 
described and may not have been 
validated. 
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Author, Year, 
Location 
(reference) 
Design Authors summary of findings Quality assessment from CASP 
checklists. 
Oral opioids 
Mussig et al.,  
2007 
Germany 
(Mussig et al., 
2007) 
Case report.  
Setting: Endocrine clinic. 
Duration of treatment: 4 
months. 
Sample Size: N = 1 
Opioid: hydromorphone 
Age: 32 
Hypogonadism when receiving 
hydromorphone which resolved 
when changed onto tramadol 
Negative: Single case reported 
because of positive effect of 
treatment change. 
Daniell, 2008 
United States 
(Daniell, 2008) 
Case-control study.  
Setting: Primary care 
Duration of treatment: 
Minimum 1 month. 
Sample Size: Case N = 21, 
Control N = 16 
Opioid: methadone, 
morphine sulphate, 
oxycodone, transdermal 
fentanyl (in two cases) 
Age: Cases 39.3 (±4.9 S.D.) 
Controls 42.7 (±3.5) 
Hormonal assays were 48-57% 
lower in opioid treated women 
(fT, TT, oestrodiol, LH, FSH, 
DHEAS) compared to controls. 
Statistically significant for TT, fT, 
oestrodiol and DHEAS. 
Amenorrhoea cases: 52%, 
controls: 20%, p <0.05. 
Positives: No drop outs as one time 
measurement.        
Negatives: Controls not well 
matched (chronic pain, statistically 
different for BMI (body mass index), 
smoking status and age). Results 
not split for oral or transdermal 
opioid delivery. 
Fraser et al., 
2009 
Canada (Fraser 
et al., 2009) 
Cross-sectional study.   
Setting: Pain clinic.  
Duration of treatment: 5.5 
years (+/- 3 years) 
Sample Size: N = 14 
Opioid: daily morphine-
Lower rate of hypogonadism 
than expected. 21% of women 
had hypogonadism. 
Positives: interviews by a single 
interviewer with a set method.                      
Negatives: hormone assays not 
timed to cycle. Single measurement. 
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Author, Year, 
Location 
(reference) 
Design Authors summary of findings Quality assessment from CASP 
checklists. 
equivalent dose 679 ± 
620mg 
Age: 38.6 (± 7.2)  
Reddy et al., 
2010  
England (Reddy 
et al., 2010) 
Case report.  
Setting: Endocrine clinic. 
Duration of treatment: 7 
years 
Sample Size: N = 1 
Opioid: Morphine 
Age: 37 
Hypogonadism clinically and 
biochemically. 
Negative: Single case reported 
because of clinical findings. 
 
Rhodin et al.,  
2010 
Sweden 
(Rhodin et al., 
2010) 
Case-control.  
Setting: Pain clinic. 
Duration of treatment: at 
least 1 year. 
Sample Size: Case N = 16, 
controls N = 6 
Opioid: methadone, 
morphine, oxycodone 
Age: 48 (32-63), split into 
women < 50 but no average 
age given 
HPG axis disruption with sexual 
disturbance and menstrual 
irregularities. 
Positives: Validated questionnaire. 
Clinical and biochemical results 
correlate. Control group had chronic 
pain. Enough power to show 
statistical significance.   
Negatives: small numbers, 3 women 
receiving opioids on HRT, 0 in 
control group. 
Wong et al.,  
2011 
Canada (Wong 
et al., 2011) 
Case-control.  
Setting: Pain Clinic. Defined 
chronic pain as pain for > 
6months.               
Duration of treatment: No 
A significant decrease in fT in 
patients with low libido and a 
non-significant decrease in 
DHEAS but not correlated with 
symptoms of hypogonadism. 
Positives: Matched for chronic pain               
Negatives: Data only partly stratified 
for pre-menopausal women. Exact 
length of time on opiates not 
reported. Recall bias asked to 
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Author, Year, 
Location 
(reference) 
Design Authors summary of findings Quality assessment from CASP 
checklists. 
minimum stated.      
Sample Size: Cases N = 30, 
controls N = 10 
Opioid: not described 
Age: 53 (28-83), included 30 
premenopausal women 
compare current sexual desire to 
that before opiates. 
 
Transdermal opioids 
Aurilio et al.,  
2011 Italy 
(Aurilio et al., 
2011) 
Open prospective cohort 
study. 
Setting: pain clinic.  
Duration of treatment: 6 
months 
Sample Size: N = 8  
Opioid: Buprenorphine  
Premenopausal women. 
Mean age 39.5 (26-50) 
No strong endocrine 
impairment. No changes in 
menstrual cycle reported and 
hormone levels were stable or 
increasing. 
Positives: hormone levels used as 
outcomes and six month follow-up, 
repeated measures from same 
patient at four time points.                        
Negatives: small numbers, 
demographics of group not 
described. Hormone sampling not 
timed to cycle. 
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3.5 Study results  
The following section will discuss the evidence found for disruption of the HPG 
axis, in the form of sexual and reproductive dysfunction. Clinical and biochemical 
outcomes have been reported within the papers, and as such the results have 
been presented split into these two groups. 
3.5.1 Clinical outcomes 
The clinical outcomes that were included in the studies were alteration in 
menstrual cycle and libido. The findings are summarised in Table 3-2. 
Menstrual Cycle 
Ten studies looked for changes in menstrual cycle as a marker for hypogonadism, 
and defined any changes as either amenorrhoea or oligomenorrhoea which were 
explained in section 2.4.1. Daniell (2008) undertook a case-control study, which 
was the only paper included in the review that showed a statistically significant 
difference in the menstrual cycle between those taking oral opioids (52% who 
developed non-surgical amenorrhoea) and controls (20%, probability (p) <0.05). 
The rate of amenorrhoea found in controls (20%) was higher than would be 
expected for the general population (3-4%) suggesting the controls may not be a 
representative of the general population (The Practice Committee of the American 
Society for Reproductive Medicine, 2008). Controls were not well matched to 
those taking opioids, with statistically significant differences in age (controls older), 
smoking status (controls smoked less), BMI (controls had a lower BMI) and they 
were not matched for chronic pain. The other oral studies that reported data on 
menstrual cycles were Fraser et al (2009) which was a cross-sectional study and 
found 23% (3/13) of women developed oligo/amenorrhoea following commencing 
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opioids. Rhodin et al (2010) undertook a case-control study, and found 
amenorrhoea in 81% (13/16) of cases and 0% (0/6) of controls (no statistical 
analysis given). There were two case studies both reporting amenorrhoea whilst 
taking long-term oral opioids, and one showing resolution of amenorrhoea with 
decreasing dose of hydromorphone with conversion to tramadol (a less potent 
opioid).  
Four of the papers on intrathecal opioids reported on menstrual status, showing 
oligo/amenorrhoea in 67% (14/21) (Abs et al., 2000), 71% (5/7) (Finch et al., 
2000), 31% (4/13) (Njee et al., 2004) and 47% (7/15) (Roberts et al., 2001) of 
those treated with opioids. In one study, the menstrual cycle irregularities that 
were present at the start of treatment resolved by 4-8 months of treatment (it was 
unclear if this was an issue preceding treatment or following treatment) (Njee et 
al., 2004). Abs et al (2000) also looked at the menstrual cycle in three control 
patients and each of these continued to have a regular cycle, but no statistical 
analysis was made due to the small number of subjects. One study examined 
eight premenopausal women using transdermal opioids and found no reported 
alteration in menstruation (Aurilio et al., 2011). The data across the studies 
suggest that 23% to 71% of women taking oral or intrathecal opioids may be 
affected by oligo/amenorrhoea. However, those taking transdermal opioids did not 
appear to suffer with this particular adverse effect (Abs et al., 2000; Finch et al., 
2000; Njee et al., 2004; Roberts et al., 2001).  
Libido 
Three papers reported on the status of libido for premenopausal women. Wong et 
al (2011) found no statistical difference in decreased libido, with 61% (19/31) of 
cases taking oral opioids reporting decreased libido and 70% (7/10) of controls (p 
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= 0.62). However, Roberts et al (2001) found low libido in 71% (10/14) of those 
receiving intrathecal opioids, and Finch et al (2000) found low libido in 100% (7/7) 
of those commencing treatment. Other studies did provide information on libido but 
this was not stratified for age or gender so could not be included in the review.  
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Table 3-2 Summary of clinical effects within the systematic review. 
Sign/Symptom Study Result 
Amenorrhoea 
Intrathecal Studies Abs (2000) 67% (14/21) cases amenorrhoea, 0% (0/3) controls  
Finch (2000) 71% (5/7) amenorrhoea 
Njee (2004) 31% (4/13) amenorrhoea resolving by 4-8 months of treatment 
Roberts (2001) 47% (7/15) oligo/amenorrhoea 
Oral Studies Daniell (2009) 52% cases non-surgical amenorrhoea, 20% of controls, p<0.05 
Fraser (2009) 23% (3/13) oligo/amenorrhoea 
Mussig (2007) 1/1 amenorrhoea, at 3 months on opioids resolution of amenorrhoea on 
removal of opioid 
Rhodin (2010) 81% (13/16) cases amenorrhoea, 0% (0/6) controls 
Reddy (2010) 1/1 amenorrhoea for 7 years on opioids 
Transdermal 
Studies 
Aurilio (2011) 0/8 reported altered menstruation 
Decreased Libido/Sexual Desire 
Intrathecal Studies Roberts (2001) 71% (10/14)  
Finch (2000) 100% (7/7) 
Oral Studies Wong (2011) 61% cases, 70% controls p=0.62 
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3.5.2 Hormonal 
This section will report the results of the hormonal assays completed within the 
studies, it will be divided by route of administration of opioids. 10 studies reported 
on hormonal assays, they include three intrathecal opioid studies (Abs et al., 2000; 
Finch et al., 2000; Kim et al., 2014), six oral studies (Daniell, 2008; Fraser et al., 
2009; Mussig et al., 2007; Reddy et al., 2010; Rhodin et al., 2010; Wong et al., 
2011) and one transdermal opioid study (Aurilio et al., 2011) and are summarised 
in Table 3-3. 
Intrathecal Opioids 
Abs et al (2000) performed a case-control study that showed levels of LH, FSH 
and oestrodiol that were at the low end of normal in current opioid users and 
normal levels in controls, this difference was not statistically significant. Low levels 
of progesterone were found in the opioid treated group, which were lower than in 
the control group, the difference was not statistically significant. Finch et al (2000) 
looked at the hormone levels (oestrodiol, FSH and LH) of seven premenopausal 
women and found levels of oestrodiol and FSH that were at the bottom end of 
normal and low levels of LH. Kim et al (2014) focused on measuring TT, fT and 
DHEAS levels and had two cases with low hormone levels, the author labelled 
them as androgen deficient. Finch et al (2000) found that the subjects treated with 
opioids in the majority of cases had hormone levels in the low end of normal which 
were lower than in controls.  
Oral Opioids 
Daniell (2009), Rhodin et al (2010) and Wong et al (2011) all undertook case-
control studies giving a statistical analysis of their results. Daniell (2009) found a 
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statistically significant (p<0.01) decrease in TT, fT, oestrodiol and DHEAS in opioid 
users, however even though there was a difference in these hormones between 
cases and controls, those treated with opioids still had levels within the normal 
range. Rhodin et al (2010) also showed lower hormone levels in the treatment 
group (oestrodiol, FSH, LH and post GnRH stimulation LH and FSH) which were 
statistically significant for oestrodiol (p = 0.05) and LH peak post GnRH stimulation 
(p=0.01). Contrary to this, Wong et al (2011) found no statistically significant 
difference in hormone levels between treatment and control groups in 
premenopausal women, but they focused on different hormones including fT, TT, 
PRL, DHEAS and SHBG. Fraser et al (2009) undertook a cross-sectional study 
and showed low normal levels of all the hormones tested for (TSH (thyroid 
stimulating hormone, a hormone that is not related to the HPG axis), LH, FSH, 
SHBG, Oestrodiol and Progesterone). The final two studies were case reports 
both showing low or low normal levels of FSH, LH and oestrodiol; Mussig et al 
(2007) showed negative correlation of oestrodiol level to morphine plasma levels (r 
= -0.6, p = 0.03) as they withdrew hydromorphone and replaced it with tramadol (a 
weaker opioid) (Mussig et al., 2007; Reddy et al., 2010).  
Transdermal Opioids 
Aurilio et al (2011) measured hormones at baseline and throughout treatment of 
up to six months with transdermal buprenorphine. They found no statistically 
significant change in hormone levels (LH, FSH, TT and fT) during this period.
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Table 3-3 Summary of hormonal effects within the systematic review. 
Sign/Symptom Study Result 
Hormone Effects 
Intrathecal 
Studies 
Abs (2000) 21 cases 3 controls. Low normal levels of LH, FSH and oestrodiol and low 
progesterone in cases compared with normal in controls. Did not reach 
significance. Small numbers.  
Finch (2000) 7 cases no control. Low normal levels of oestrodiol and FSH, low LH. 
Kim (2014) 2 cases with low levels of testosterone, free testosterone or DHEAS author 
describes them as androgen deficient. 
Oral Studies Daniell (2009) 21 cases, 16 controls statistically significant decrease in TT, fT, oestrodiol, 
DHEAS. The mean values for all hormones were still within normal limits. 
Fraser (2009) 14 cases. Normal levels of TSH, LH, FSH, SHBG, oestrodiol and 
progesterone.  
Mussig (2007) 1 case. LH, FSH and oestrodiol all increased with decreasing opioid dose. 
Oestrodiol showed a negative correlation with morphine plasma levels r= -
0.6, P=0.03. 
Reddy (2010) 1 case. Low levels of LH, oestrodiol, PRL, low normal FSH. 
Rhodin (2010) 16 cases, 6 controls. Statistically significant decrease in oestrodiol and LH 
peak after GnRH stimulation. FSH, LH and FSH peak post GnRH lower than 
in control but do not approach statistical significance. Levels within normal 
range. 
Wong (2011) 29 cases, 9 controls. No statistically significant difference overall for any 
hormone levels in premenopausal women. (fT, TT, PRL, DHEAS, SHBG). In 
those with low libido cases had a statistically significant decrease in TT (p = 
0.04) 
Transdermal 
Studies 
Aurilio(2011) N=8. No statistically significant change in hormone levels (LH, FSH, TT, fT) 
from baseline to 6months. 
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3.5.3 Sensitivity analysis  
A sensitivity analysis was undertaken comparing the results for women aged 18-55 
years old and those aged 18-45 years old, in order to remove women in the peri-
menopause from the analysis. When women were split into pre and post-menopausal 
within the data this was used as the cut off. The results were similar in the different 
age groups and menopausal states. The results of the sensitivity analysis can be 
seen in Appendix 4. 
3.6 Discussion 
3.6.1 Summary of main findings 
The systematic review identified 12 studies in total. Of the studies included, five were 
case-control, three cross-sectional, two case reports, one case series and one cohort 
study. The papers looked at three different methods of opioid delivery; oral (five 
studies), intrathecal (six studies) and one study with topical buprenorphine. The 
outcomes reported were changes in hormone levels, menstrual cycle and libido. 
Clinical and biochemical changes were found in women taking oral or intrathecal 
opioids but these were not replicated in those women receiving transdermal 
buprenorphine.  
Hormone levels in the case-control studies for oral (three studies) and intrathecal 
(one study) opioids were found to be lower in cases than in controls and statistically 
significant in two studies, however the hormone levels were still within normal 
laboratory range in some cases (Abs et al., 2000; Daniell, 2008; Rhodin et al., 2010; 
Wong et al., 2011). The studies that showed hormone levels within normal range still 
often found these levels were associated with clinical symptoms (Abs et al., 2000). 
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This contrasted with those in the transdermal study who showed no statistically 
significant change in hormone level when compared with baseline (Aurilio et al., 
2011).  
Oligo/amenorrhoea was observed in 23-81% of patients taking oral or intrathecal 
opioids (six studies) with Daniell (2008) showing a statistically significant difference 
between those taking opioids and controls (Abs et al., 2000; Daniell, 2008; Finch et 
al., 2000; Fraser et al., 2009; Njee et al., 2004; Rhodin et al., 2010; Roberts et al., 
2001). These results again were found to be different to those receiving transdermal 
buprenorphine in whom none of the exposed women reported altered menstruation 
(Aurilio et al., 2011). Three studies reported data for libido and found low libido in 61-
100% of women with one study comparing libido with controls finding no statistically 
significant difference (Finch et al., 2000; Roberts et al., 2001; Wong et al., 2011). 
3.6.2 Strengths and limitations 
Systematic review 
The strengths of the review are that it was undertaken systematically with a 
predefined search strategy, inclusion/exclusion criteria and data extraction form. 
Firstly, the search protocol will be discussed, this was developed in conjunction with 
systematic review specialists. The search was developed based on a search protocol 
for an opioid Cochrane review and a search for adverse effects (Golder et al., 2006; 
Noble et al., 2010). The literature was also searched to ensure that the most 
appropriate databases were used, which led to the inclusion of the database 
TOXLINE as this is a specific database for adverse drug effects. The search strategy 
was comprehensive and produced a large number of results. No further papers were 
found through citation checking. Inclusion and exclusion criteria were developed a 
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priori then applied to abstracts and full texts by two independent reviewers. Any 
disagreements were referred to a third reviewer helping to prevent inconsistencies in 
how the criteria were applied and improving reproducibility.  
Including case studies in the systematic review is a limitation since with this type of 
report there is the potential for publication bias. A decision prior to starting the review 
was taken to include all publication types except for review papers, conference 
abstracts and editorials. A preliminary search had shown low numbers of papers in 
the area of interest, and it was felt that it was important to include as many potential 
papers as possible in the review. Publication bias with case reports occurs because 
case reports often report a link in clinical findings and therapy. These can act as a 
stimulus for further research; however negative findings are not published because 
this would not justify the case report in the first instance. One of the studies was a 
case series, but due to the study inclusion criteria only two of eight patients were 
included in the review. However, this evidence is more reliable than from a case 
report, as the patients were selected systematically from a sample attending a pain 
clinic (Kim et al., 2014).  
A meta-analysis was not undertaken due to the wide variation in studies included. In 
the systematic review protocol it stated that a meta-analysis would be undertaken if 
possible, primarily with the laboratory hormonal assays. Unfortunately, due to the 
variety of hormonal markers used and the different routes of administration, there 
were only two papers in the intrathecal and oral arms of the review that included 
some of the same hormone assays (excluding case studies). This would not have 
been appropriate for a meta-analysis. 
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Papers included in the study 
All the studies included in the review have their limitations; this is partly due to the 
practicalities of undertaking a study in analgesia, as it would be unethical to withhold 
analgesics from a patient in chronic pain, in order to use them as a control subject. 
The review had a narrow remit and therefore included only a small subset of the 
subjects (women aged 18-55 years old) from papers that had small numbers to begin 
with. In total across all the papers included there were less than 200 cases and only 
35 controls that could be included in the review. These small numbers lead to some 
difficulties with the analysis for the authors of the papers, particularly when trying to 
show statistical significance. For instance Abs et al (2000) found a difference in 
hormone levels between cases and controls, but probably due to the small numbers 
involved (21 cases, three controls) this was not statistically significant.  
The studies were on the whole set within secondary care pain clinics (or from cases 
presenting to secondary care endocrinology clinics, one of 12 studies was set in 
primary care). This decreases the generalisability of the findings of these studies to 
the general population. A study within Europe showed that only 23% of patients with 
chronic pain were seen by a “pain specialist”, and the rest were managed in primary 
care. Consequently the participants in the majority of the studies represent a subset 
of chronic pain patients and they are likely to have had pain for longer than those 
presenting to general practice (Breivik et al., 2006). A study in Germany showed a 
median time of 12 years from pain onset to being seen in a specialist pain clinic 
(Schulte et al., 2010). Given the demographics of those attending pain clinic there is 
a potential for them to be systematically different from the general population of pain 
patients attending primary care.  
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Matching of cases and controls was an area with the potential to introduce bias, and 
often did not account for possible confounding factors such as chronic pain. Daniell 
(2008) recruited the cases and controls through public solicitation, and from the 
private practice of other medical practitioners. The sample is therefore drawn from 
the local general population; however the recruitment does not seem to have been 
systematic and those taking part as controls were offered a monetary reward and 
copies of their endocrine blood results. This raises the possibility of whether or not 
the controls had their own reasons to want hormonal investigation, perhaps financial 
or clinical, and if so, this becomes a potential confounding factor. The reliability of this 
study is limited as the controls were not well matched to those taking opioids, with 
statistically significant differences in age (controls older), smoking status (controls 
smoked less), BMI (controls had a lower BMI) and controls were not matched for 
chronic pain. All of these are confounding factors, which could potentially affect 
menstrual cycle and therefore the reliability of the results of this study (Daniell, 2008).  
Another limitation affecting generalisability to a UK primary care population is that 
five of the studies were based on intrathecal opioids. UK national guidance suggests 
in the case of CNCP that this treatment should be administered in secondary care, 
under the supervision of a multidisciplinary pain team (The British Pain Society, 
2008). This management strategy is not one that is deliverable in primary care, 
however patients do continue to live and function in the community where any 
potential adverse effects will manifest themselves, and if significant are likely to be 
brought to the attention of their GP.  
Those studies that used questionnaire data collected this retrospectively introducing 
the possibility of recall bias, which is unlikely to be significant in terms of the 
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menstrual cycle but in terms of libido may be affected. It is often recommended that 
questions should not be asked about a period of time more than six months 
previously unless about significant life events e.g. deaths, and in several of the 
papers the follow-up time after commencing opioids was much longer, in one case up 
to 14 years (Abs et al., 2000; Bowling, 2004; Daniell, 2008; Finch et al., 2000; Fraser 
et al., 2009; Kim et al., 2014; Njee et al., 2004; Rhodin et al., 2010; Roberts et al., 
2001; Wong et al., 2011).  
Consistency in measuring hormone levels in premenopausal women can be 
problematic, because of the fluctuation in hormone levels that occurs during the 
menstrual cycle (Brook and Marshall, 2001). The majority of the studies included did 
not measure hormones at specific times in the cycle. Aurilio et al (2011) attempted to 
ensure that hormonal assays were taken within the same phase of the cycle. Despite 
this, however, large variations in oestrodiol levels were found between follow-up 
tests, indicating that this technique did not fully account for natural variations in 
hormones throughout the cycle. Several studies (including the two case studies) 
recognised the importance of timing hormone measurements to menstrual cycle, but 
because their patients were either oligo/amenorrhoeic or were expected to have 
hypogonadism, samples that had no relation to the menstrual cycle were used 
(Daniell, 2008; Fraser et al., 2009; Mussig et al., 2007; Reddy et al., 2010; Rhodin et 
al., 2010). Other studies tried to account for hormone (LH and FSH) variability in 
different ways, either through serial samples 15 minutes apart, GnRH stimulation 
tests, or samples taken at a specific times of the day (Abs et al., 2000; Rhodin et al., 
2010; Wong et al., 2011). Kim,C. et al (2014) and Finch et al (2000) do not discuss 
this so it is likely their sampling method was unsystematic (Finch et al., 2000; Wong 
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et al., 2011). Various methods were undertaken to try to account for hormonal 
variation within the cycle, but none of these are completely satisfactory and 
limitations still exist. 
3.6.3 Confounding factors 
As mentioned in chapter two, the symptoms of HPG axis disruption can be caused by 
a variety of other conditions and medicines as well as potentially by long-term opioid 
use. CNCP is a potential cause for some of the symptoms reported such as 
decreased libido, and a significant issue with the studies examined was the way in 
which they accounted for the effect of chronic pain. CNCP can have a wide ranging 
impact on a patient’s life, both physically and emotionally. In this case, confounding 
by indication is the primary issue, since it might be that not only the opioids 
prescribed for the painful condition cause potential adverse effects, but the painful 
condition they were prescribed for in the first instance might cause them as well, 
such as decreased libido (Katz and Mazer, 2009). For example the cross-sectional 
studies did not account for the CNCP as a causative factor, having only measured 
hormone levels once whilst on treatment (except Aurilio et al 2001 who took serial 
assays at baseline and up to six months). The studies could have partially accounted 
for the effect of CNCP by taking pre and post treatment hormonal assays and using 
the subject as their own control. The data shows that the patients included in the 
studies did indeed have decreased libido, but it is likely that this may be related not 
just to opioids but to the presence of CNCP. For example, in the case of Wong et al 
(2001) there was a non-significant difference when compared to the control group 
who were receiving non-opioid analgesics for pain. 
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One way to overcome confounding by indication is to use control subjects that are as 
closely matched as possible. Five case-control studies attempted to address this 
through the use of matched controls, however one of these had no controls in the 
age group of the systematic review, and therefore was included as a cross-sectional 
study (Finch et al., 2000). Out of the remaining four, three were matched for CNCP. 
None described this in detail but Rhodin et al (2010) said they matched for a 
comparable pain syndrome, Wong et al (2001) chose consecutive patients attending 
pain clinic, and Abs et al (2000) pain of similar duration and character. However, they 
did not match the subgroups for other factors. Abs et al (2000) did present data 
showing no statistically significant difference between cases and controls (Abs et al., 
2000; Rhodin et al., 2010; Wong et al., 2011). Daniell (2008) selected controls that 
did not necessarily suffer from chronic pain, since patients were selected from the 
general population and their inclusion or exclusion was not dependent on them 
having CNCP. There were statistically significant differences between the case and 
control groups with the controls being older (p <0.002), less likely to smoke (p 
<0.001) and have a lower BMI (p<0.002) than those taking opioids within the study. 
The author acknowledged these differences and provided evidence as to why he did 
not believe this influenced the results. 
3.6.4 Clinical implications 
The evidence reviewed appears to indicate that there is a potential relationship 
between long-term opioid use and reproductive and sexual dysfunction in women. 
The studies are limited, but show that clinically women may report amenorrhoea and 
loss of libido, both of which could potentially be associated with infertility. The 
implications of the findings from this systematic review are important for shared 
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decision making, and these potential adverse effects should be included when 
discussing long-term opioids with premenopausal women. This is also clinically 
important in the follow-up of patients on long-term opioids, as clinicians might need to 
include questions relating specifically to potential sexual and reproductive adverse 
effects. Patients may also be more likely to volunteer this information if they are 
aware there is a possible link with their medicine. It may also be important to discuss 
contraception with these women as opioids are not recommended during pregnancy 
unless the benefits outweigh the potential risks.  
Aurilio et al (2011) studied transdermal opioids and found that hormonal 
measurements did not decrease with their use. This was reflected in their clinical 
findings, with no patients reporting menstrual disorders. This compares with the other 
studies of oral and intrathecal opioids, which showed decreased hormone levels that 
in some cases were statistically significant. It is important to remember that topical 
buprenorphine is not only different to the other opioids administered due to the route 
but also in the way buprenorphine works as it is a mixed agonist-antagonist which is 
explained further in section 2.3 (Walsh and Eissenberg, 2003). Another possible 
reason for this difference in adverse effects could be the equivalent dose of 
morphine/day prescribed for which there is no data from the systematic review. This 
potential difference will need investigating further because if this difference is 
reproducible, it would provide a safe means of treating premenopausal women with 
opioids, without altering their HPG axis clinically or biochemically.  
The link to HPG axis disruption does appear to be strongest in patients commencing 
on intrathecal opioids. If use of this route of administration increases in the future, it 
may be necessary to introduce pre-treatment, and sequential in-treatment hormonal 
 92 
 
assays to prevent clinically adverse effects that might be heralded by changes in the 
hormonal assays. This is also a consideration for when designing future studies so 
that patients might act as their own controls and offer a time varying covariate by 
which clinical changes might be assessed. 
3.6.5 Comparison with existing literature 
This literature review has found similar results to the current literature for men and 
illegal opioid use in women. A systematic review in men receiving regular opioids 
regardless of type found low testosterone in regular users when compared to controls 
(Bawor et al., 2015). Research in women taking illegal opioids and receiving opioids 
for treatment of heroin addiction have previously found menstrual disturbances, 
decreased sexual desire, infertility and reductions in LH and FSH levels (Afrasiabi et 
al., 1979; Pelosi et al., 1974; Smith and Asch, 1987; Stoffer, 1968). The systematic 
review undertaken for this thesis has found that women treated with prescribed long-
term opioids appear to be affected by symptoms of reproductive sexual dysfunction 
which is also related to decreases in hormone levels. Hormone levels are often still 
within the normal range so cannot truly be thought of as hypogonadism, in 
comparison with men where low testosterone levels are an established adverse 
effect through suppression of the HPG axis (Ballantyne and Mao, 2003; Brennan, 
2013; Brown and Zueldorff, 2007; Colameco and Coren, 2009; Katz and Mazer, 
2009; Williams et al., 2013).  
3.7 Conclusion  
This is the first comprehensive systematic review of the literature, specifically 
examining the effects of long-term prescribed opioids on the HPG axis in women 
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aged 18-55 years old. This review supports the view that long-term use of opioids 
might have a negative effect on women’s HPG axis, leading potentially to sexual and 
reproductive dysfunction. There is weak evidence that this may not be a class effect, 
and certain types of opioid or methods of delivery may have a different magnitude of 
effect, or none at all. The evidence found appears to show women treated with 
opioids have low-normal, or low levels of sex hormones, and that there are clinically 
significant changes including decreased libido and irregular menstrual cycle. Further 
work needs to be undertaken to account for CNCP, and whether this is a contributing 
factor to the changes noticed. The route of opioid administration, as well as type of 
drug and morphine equivalent dose, also needs to be investigated and whether this 
has any effect on the likelihood of developing hypogonadism. It might be that 
transdermal opioids do not cause this adverse effect, and therefore may potentially 
be a safer mode of opioid delivery in premenopausal women. The key to further 
research will be larger numbers of patients and controls who are matched for CNCP 
and longer follow-up periods.  
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4 Methodology 
4.1 Introduction 
This focus of this thesis is the epidemiological study of reproductive and sexual 
dysfunction in women who have been prescribed opioids for CNCP. This chapter 
describes the underpinning research methods and the study designs used to 
investigate the specific objectives of the thesis.  
The chapter initially defines epidemiology, its uses within medical research, and its 
core concepts and measurements. The chapter then gives an overview of the 
approaches that were used to investigate opioid use, and any associated 
reproductive and sexual dysfunction. The strengths and weaknesses of the two core 
methods (cross-sectional postal survey and primary care database cohort study) 
used within the thesis are discussed. This chapter will also discuss some of the 
underlying concepts, and where problems can arise with epidemiological research 
(including bias, validity, reliability and confounding). The issue of health literacy will 
be introduced as this has a direct impact on the use of postal survey methods.  
4.2 Epidemiology 
Epidemiology is a word developed from Greek and when translated literally, it means 
“studies upon people” (Blumenthal et al., 2001, p135). Epidemiology has been 
defined as “the study of distribution and determinants of illness and disease in 
populations” (Croft et al. 2010, p3). Epidemiological research can provide 
descriptions of a particular disease profile within a population, or look at possible 
causes for certain conditions by comparing different population groups (Blumenthal 
et al., 2001; Bowling, 2014a; Coggon et al., 2003). Epidemiological research studies 
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what is already happening in a population and provides evidence that relates to 
populations rather than individuals. The key for all epidemiological research, is to 
have a robust way of identifying those with and without the outcome or disease under 
investigation, and if necessary the exposure of interest. Epidemiology can be divided 
into descriptive epidemiology and analytical epidemiology. Descriptive epidemiology 
measures disease frequency and develops hypotheses. Analytical epidemiology 
investigates hypotheses and evaluates causal relationships through comparisons 
between different populations. This thesis focuses on the pharmacoepidemiology of 
opioid analgesics. Pharmacoepidemiology is specifically focused on studying the 
effects of medicines in populations, and is useful for investigating possible harms of 
medicines already in use, in particular where there is little evidence available already 
(Evans, 2012). Pharmacoepidemiological research into long-term opioid use is 
important, as there is evidence for significant risk of adverse effects with opioids, and 
little evidence for effectiveness of long-term opioid use in CNCP (Bedson et al., 
2019a; Els et al., 2017b, 2017a). A recent overview of Cochrane reviews of adverse 
effects in medium and long-term opioids found no previous Cochrane reviews 
investigating hypogonadism as a potential adverse effect in women receiving long-
term opioids for CNCP, and this has been highlighted as an area that needs further 
research (see the results of the systematic review discussed in Chapter 3 and 
background in Chapter 2 for further information) (Els et al., 2017b). Further 
investigation in this area will enhance the evidence base for long-term opioid use, 
and subsequently help to guide management decisions for long-term analgesia. 
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4.3 Descriptive epidemiology 
Descriptive epidemiology can be defined as “the study of variations in measures of 
population health by time, person and place” (Bruce, Pope and Stanistreet, 2008, 
p38). Studies undertaking descriptive epidemiology often use routinely collected data 
(e.g. primary care databases and disease registers), in order to understand the 
distribution of disease within a population and to develop hypotheses for further 
investigation. The main methods for descriptive epidemiological studies are case 
reports, case series, cross-sectional studies and ecological studies. One of the 
studies in this thesis is a cross-sectional survey and its main aim is to describe the 
prevalence of sexual dysfunction in opioid users. Therefore, this method is discussed 
in more detail in section 4.4. The cohort study undertaken within this thesis uses a 
primary care database as its data source, and the cohort will initially be evaluated 
using descriptive epidemiology.  
4.3.1 Measures of the frequency of reproductive dysfunction in opioid users 
It is important to measure the frequency of reproductive dysfunction in opioid users in 
different groups, (e.g. by dose, current (vs previous) usage or duration of usage) and 
their data can then help to develop hypotheses regarding the potential relationship 
between opioids and sexual and reproductive dysfunction to be developed. The two 
main measures of disease frequency used in epidemiology are incidence and 
prevalence (the formulas for calculating these are shown in Figure 4-1). Incidence is 
defined as the number of new cases within a population during a specified time 
period (Coggon et al., 2003). Prevalence can either be the proportion of current 
cases at a specific point in time (point prevalence) or during a specified time period 
(period prevalence) within a population (Bowling, 2014a; Coggon et al., 2003). 
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Figure 4-1 Incidence and prevalence equations (Stewart, 2010) 
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The gold standard for calculating an incidence rate uses person-years at risk to 
calculate the total population at risk during a specific time period (this takes into 
account the differing amounts of time that individuals contribute to a study) (Stewart, 
2010). Within the cohort study undertaken within this thesis, incidence rate will be 
calculated as cases per person-years, this is possible as there is data for each 
participant from entry to the cohort until the participant leaves the cohort. The cross-
sectional study will report prevalence rather than incidence as it provides data on a 
cross-section in time (the tools within the questionnaire refer to a period of time up to 
six months).  
4.4 Cross-sectional studies 
Cross-sectional studies are observational studies that collect data on exposure and 
outcomes of interest at a single time point (or time period), and provide descriptive 
data (Blumenthal et al., 2001; Bowling, 2014b). They are an efficient way to estimate 
prevalence in a population. Cross-sectional studies can either be done through 
collecting new data (often in the form of a postal questionnaire), or through accessing 
already available data, for instance from a primary care database (Berger et al., 
2009). In this thesis, a cross-sectional postal survey was chosen to investigate the 
relationship between opioids and sexual dysfunction since it allowed women to be 
directly questioned with regards to their sexual function, and additionally this is an 
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area where using existing records may not be appropriate (Montgomery, 2008). 
Existing medical records may be incomplete concerning sexual dysfunction. Both 
clinicians and patients can find sexual function a difficult area to discuss, and there is 
evidence that patients will not disclose sexual problems unless they are explicitly 
asked due to their private and potentially embarrassing nature (Humphery and 
Nazareth, 2001; Montgomery, 2008) 
Information from cross-sectional studies is only analysed at a single time point (or 
period of time), therefore temporal relationships are difficult to establish. Any 
relationship found is considered an association or correlation, and results must be 
interpreted with caution (Berger et al., 2009; Bowling, 2014b; Coggon et al., 2003; 
Sedgwick, 2014). If it is important to establish a temporal relationship then other 
study designs should be considered, for example longitudinal studies (Berger et al., 
2009; Stewart, 2010). When designing a cross-sectional study it is important to take 
into account the need to collect sufficient data on confounding factors (see 4.7.3 for 
further information on confounding) so that they can be included in any statistical 
analysis (Blumenthal et al., 2001).  
4.4.1 Measures of association in cross-sectional studies 
As well as providing descriptive results, cross-sectional studies can be used to 
produce measures of association using odds ratios (OR) or relative risks (RR) 
(Reichenheim and Coutinho, 2010). OR are closely related to and often confused 
with RR. RR is the ratio of the disease rate in exposed participants compared to 
unexposed participants, RR will be discussed fully in section 4.5.1 (see Figure 4-2 for 
the equation which derives an odds ratio). An OR is the ratio of the odds of disease 
in exposed participants divided by the odds in unexposed participants, so in the case 
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of this thesis the odds of reproductive and sexual dysfunction in different types of 
opioid users (Coggon et al., 2003). The higher the denominator and the less frequent 
the outcome, the closer the OR approximates to RR. However, the OR overestimates 
the RR, particularly with small sample sizes (Coggon et al., 2003; Knol et al., 2012; 
Nemes et al., 2009).  
Figure 4-2 2 x 2 table and equations for odds ratio 
Risk Factor Disease No 
Disease 
Total 
Present a b a + b 
Absent c  d c + d 
Total a + c b + d a + b + c + 
d 
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Logistic regression can be used to model a relationship between an exposure and 
outcome and produces an odds ratio. This describes the relationship between an 
independent variable and a dichotomous outcome (such as in this study where 
reproductive dysfunction is either present or absent). Logistic regression can either 
be univariate or multivariate (Tripepi et al., 2008). When using logistic regression to 
model odds ratios in cross-sectional studies, certain assumptions should be met in 
the data if the aim is to investigate any causal relationship. First, the population 
should be steady (in cross-sectional studies there is a population at a single 
point/period in time so it will not change, but in other studies the population should be 
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the same at the start as at the end of the study period). Second, there should be no 
reverse causality (sexual dysfunction would never be an indication for opioid use). 
Third, exposure must precede the outcome, and finally, duration of the outcome must 
be the same across groups. If these are all met, then logistic regression is an 
appropriate measure for cross-sectional studies (Reichenheim and Coutinho, 2010).  
Univariate logistic regression takes the likelihood (probability of the outcome 
occurring/1-probability of the outcome occurring) of a dichotomous outcome based 
on a descriptive factor (in the case of the cross-sectional study sexual dysfunction 
and opioid use respectively) and then transforms this using a natural logarithm. This 
logarithmic transformation produces a linear relationship, which is then used in 
regression analysis in order to predict how the log (odds) of the outcome changes 
based on independent variables. Figure 4-1 shows how univariate logistic regression 
is calculated, logit y is the natural logarithm of the likelihood, 	  is the value of logit y 
when the independent variable is 0, ! represents the independent variable and 	" is 
the estimated regression coefficient for the independent variable. This regression 
coefficient indicates the expected change in the log of the odds for a single unit 
increase of ! (for instance the increase of the log of the odds of sexual dysfunction 
for an increase for one year in age). To get the final OR from univariate logistic 
regression, the value for 	" is exponentiated using the natural logarithm. The OR is 
the odds of the outcome occurring or not based on a single unit increase in the 
descriptive factors (Sullivan, 2013; Tripepi et al., 2008).  
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Figure 4-3 Equations for univariate and multivariate logistic regression.  
Univariate analysis  
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Multivariate analysis  
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Key: 	  represents the value for logit y when the independent variable is 0, X represents the 
independent variable, 	"represents the regression coefficient and e represents the value for 
the natural logarithm (2.1783). Adapted from (Tripepi et al., 2008). 
Multivariate logistic regression is possible due to the conversion of the dichotomous 
outcome to a linear relationship, and therefore multiple independent risk factors can 
be included in a single model. This means that the effect of the independent factor, in 
this case opioid use, can be adjusted for multiple other factors including confounders, 
for instance in the cross-sectional study age and pain status. The equation for 
multiple logistic regression is shown in Figure 4-3 as it is an extension of univariate 
analysis, where multiple independent variables (!0) are included in the model to 
predict the likelihood of the outcome. When undertaking multiple logistic 
regression,	0 represent the changes in the expected odds with a one unit change of 
!0, when all other variables are held constant. In multiple logistic regression it is 
important that independent variables are only included within the model if there is 
clinical reasoning to suspect that they can affect the dependent outcome.  
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OR and multiple logistic regression will be used within the cross-sectional element of 
the thesis to assess the measure of association between opioid use and sexual 
dysfunction and this will allow for adjustment for confounding factors.  
4.4.2 Cross-sectional postal surveys 
Cross-sectional postal surveys are considered quick and relatively inexpensive to 
undertake. Additionally, it is possible to cover a widely distributed population (Kelley 
et al., 2003; Mann, 2003). If an appropriate sampling frame for the population is 
selected, then it is reasonably easy to select a representative sample, and providing 
non-response is not an issue (either very good response rate or no difference 
between responders and non-responders) the results can be generalisable to the 
population of interest (Kelley et al., 2003). The sampling frame for the cross-sectional 
study within this thesis will be GP patient lists within the West Midlands Clinical 
Research Network (WM:CRN) (WM:CRN, 2019). The cross-sectional study 
investigates women prescribed opioids, of whom all should be registered at a GP 
practice as otherwise they would be unable to access prescribed medicines. It is 
therefore an appropriate sampling frame (Herrett et al., 2015). The information 
gained from a postal survey, has the advantage that it can be tailored in order that 
the investigator can ask everything they believe will be required for analysis, but this 
may not be the case for secondary data (Stewart, 2010). Bias can occur with survey 
research if there are problems during data collection (Delgado-Rodriguez and Llorca, 
2004). There are many different types of bias including misclassification bias, 
observer/interviewer bias, social desirability bias and recall bias. Misclassification 
bias is when cases or those exposed can be misclassified as being controls or 
unexposed or vice versa. Most studies have an element of misclassification bias, and 
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it is particularly important when this bias is not independent of the identification 
exposure and outcome and therefore different between comparison groups as this 
can then affect any association seen during analysis (Delgado-Rodriguez and Llorca, 
2004). Postal questionnaires, when compared to face to face interviews, minimise 
social desirability bias (the phenomenon where the person answering questions does 
so based on what they assume is the correct answer, or on what they feel will make 
them appear in the best light). However social desirability remains an important issue 
for all self-report measures (Bowling, 2005, 2014c). There are several ways to 
combat social desirability bias within a postal questionnaire, one of the most common 
methods is the use of scales with several questions rather than single items. These 
tools can then be analysed for internal consistency (see section 4.4.4 for further 
details). Postal questionnaires offer more anonymity than face-to-face or telephone 
interviews, so are useful when investigating sensitive subjects. This is particularly 
important for this thesis as the main outcome for the cross-sectional study is sexual 
dysfunction, which may be considered a sensitive subject (Stewart, 2010; 
Tourangeau and Yan, 2007). Postal surveys are not subject to observer/interviewer 
bias (where the knowledge of the disease or exposure status can influence the data 
being recorded) (Delgado-Rodriguez and Llorca, 2004; Stewart, 2010). Recall bias is 
a particular type of information bias where those taking part in the study with either 
the disease or the exposure of interest, are more prone to recall either the 
consequences of a possible exposure or the exposure itself (Blumenthal et al., 2001; 
Stewart, 2010). 
One of the disadvantages of postal surveys is non-response, this needs to be taken 
into account following a sample size calculation in order to ensure enough 
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questionnaires are disseminated to achieve the required sample size (Kelley et al., 
2003). Non-response decreases the effective sample size and can introduce non-
response bias, if those who do not respond are systematically different from those 
who do respond, and this systematic difference is related to the factors of interest for 
the study. This is discussed fully in 4.7.1 (Bowling, 2014b; Delgado-Rodriguez and 
Llorca, 2004). Investigating sensitive subjects can mean that there is higher non-
response (of the entire questionnaire and of individual questions considered to be 
sensitive), and measurement error through participant misreporting (answering 
untruthfully either consciously or subconsciously) than with non-sensitive questions 
(Stewart, 2010; Tourangeau and Yan, 2007).  
When postal surveys are sent, they rely on the study population being literate and 
able to speak a common language, and they are only suitable if the questions are 
straight forward and easy to understand (Bowling, 2014c). Survey research is 
complex and it is often difficult to perfect question wording, form and order, all of 
which can affect the responses obtained, as well as the overall formatting of the 
survey (Bowling, 2014c). As postal surveys rely on structured questionnaires, a 
respondent may feel that their answer does not fully fit one of the responses and this 
may lead to either item non-response, or the respondent selecting more than one 
answer (Bowling, 2014d). Additionally, as surveys often do not allow free text 
responses, this can mean there can be a lack of depth in information. However, this 
is not necessarily a problem if this information is not required for analysis (Kelley et 
al., 2003). As postal surveys arrive at a household there is no way to control who 
actually completes the survey, or be sure that there have been no external influences 
on the respondent completing it (Bowling, 2014c).  
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Information bias is when important information is either collected, interpreted or 
measured incorrectly and results in misclassification of the participant either for the 
exposure or outcome. Information bias can occur when the respondent is trying to 
complete a questionnaire quickly or has little interest in the subject. This can affect 
responses in several ways, for instance the participant may neither agree nor 
disagree with a statement, choose the same answer for all the questions, or mentally 
flip a coin in order to pick an answer, this is known as satisficing (Streiner et al., 
2014). Methods to avoid satisficing include ensuring questions are as simple and 
relevant as possible in order to maintain the respondents motivation (Streiner et al., 
2014).  
Protopathic bias is another form bias, where the exposure is related to early signs of 
the disease under investigation, and so results may reflect the natural course of the 
disease. Pain is often an early sign of many conditions and quite naturally, 
analgesics are therefore often prescribed or purchased over the counter. The 
disease of interest will progress over its natural course, and the analgesics could 
then be considered a risk factor, when in fact they were prescribed for the early 
stages of the condition. However this is unlikely to be the case in the cohort study, as 
pain is not considered an early symptom of any of the outcomes included within the 
study, although it is possible that CNCP may be related to symptoms of low libido 
(Ambler et al., 2001; Delgado-Rodriguez and Llorca, 2004; Signorello et al., 2002). 
See Table 4-1 for a summary of the advantages and disadvantages of postal cross-
sectional surveys. 
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Table 4-1 Advantages and disadvantages of postal and cross-sectional 
surveys 
Postal cross-sectional surveys 
Advantages Disadvantages 
Postal surveys 
 
1. Quick and low-cost  
2. Avoids interviewer bias 
3. Minimises social desirability bias 
4. Useful for investigating sensitive 
subjects 
5. Investigation of multiple exposures 
and outcomes possible 
 
 
1. Respondent may misunderstand a 
question and there is no way to 
know whether this has occurred 
2. Non-response bias 
a. Unit non-response 
b. Item non-response 
3. Reliance on closed questions 
4. Must be as short as possible 
5. No control over who completes 
survey 
6. Population of interest must be 
literate and speak a common 
language 
7. Recall bias 
 
Cross-sectional studies 
1. No loss to follow-up 2. Single time point 
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4.4.3 Validity and postal surveys 
Validity is the extent to which a concept is accurately measured and how well the 
conclusion drawn reflects the real situation in the population studied (Heale and 
Twycross, 2015). Validity can be split into two core concepts: external and internal 
validity. External validity is the ability to generalise the study findings to the 
population of interest. Internal validity is both the ability of the study to accurately 
identify the outcome of interest and classify the exposure, and then to correctly 
characterise the relationship between the exposure and outcome (Bowling, 2014e; 
Campbell, 1957; Coggon et al., 2003; Delgado-Rodriguez and Llorca, 2004). These 
concepts are important in all epidemiological research and need to be considered 
during the design phase of any study.  
External validity 
External validity can be threatened by selection bias, where the characteristics of the 
sample included in the study differ from those of the population of interest, and 
therefore the sample does not represent the target population (Bowling, 2014e; 
Delgado-Rodriguez and Llorca, 2004). Selection bias can occur for many reasons 
including ascertainment bias where the cases selected do not represent the cases in 
the population, sampling bias where the way the population is sampled introduces 
bias, and bias introduced through loss to follow-up or non-response (see section 
4.7.1 for further detail) (Delgado-Rodriguez and Llorca, 2004). Another way in which 
selection bias can be introduced is when the initial identification of those included in 
the study is related to the factor being studied (Blumenthal et al., 2001; Delgado-
Rodriguez and Llorca, 2004; Kelley et al., 2003).  
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The initial sampling frame is important in order to ensure the population of interest for 
the study is represented. GP registers are a comprehensive sampling frame within 
the UK, and they provide almost universal coverage (over 98%) of the population and 
GPs provide the vast majority (over 90%) of patient contacts within the NHS 
(Gregory, 2009; Herrett et al., 2015). However, it is important to remember that in the 
case of the cross-sectional study, only those practices that wish to take part will be 
included, and this may not be representative of the whole UK population, but will be 
representative of the local population. However, there are certain groups that are 
more likely to be absent from these lists: prisoners, asylum seekers, travellers and 
the homeless (Hall et al., 2012). In the case of the cross-sectional study described in 
this thesis, the population of interest is women 18-45 years of age receiving 
prescribed opioids for CNCP, so using a primary care sampling frame is likely to 
accurately represent this population. There are many types of sampling but the two 
main types are random sampling and non-random sampling (Kelley et al., 2003). 
Sampling error is the probability that a sample is not representative of the population 
from which it has been drawn. Simple random sampling will give the closest estimate 
of the population than any other sampling methods (Berg, 2005; Kelley et al., 2003). 
Selection bias due to sampling bias can occur when non random sampling is 
undertaken and this may mean that the comparison groups are systematically 
different to one another (Delgado-Rodriguez and Llorca, 2004; Stewart, 2010). Both 
the studies within this thesis use primary care lists as sampling frames. The cohort 
study uses the clinical practice research datalink (CPRD) and the cross-sectional 
study uses GP registers from within the WM:CRN. Any woman identified through 
initial searches as meeting the inclusion criteria will be included in the study, so no 
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sampling bias will occur following identification based on the inclusion and exclusion 
criteria (which will be described in detail in the relevant methods sections).  
Loss to follow-up is a form of selection bias in longitudinal studies where those that 
start the study do not contribute data until the end because they have, for whatever 
reason, stopped responding (Kristman et al., 2016). Loss to follow-up in the cohort 
study undertaken for the thesis only occurs if the patient dies or leaves the 
contributing general practice. These two groups may be older (the cohort only 
included 18-55 year olds) or have moved location more often than other patients and 
this could potentially affect the results. Selection bias is minimised in both studies 
undertaken within the thesis, as they each take complete samples identified through 
primary care registers, which are appropriate sampling frames for the populations of 
interest. Loss to follow-up should not occur in either study as the cross-sectional 
study is only examining a single point in time and the cohort study uses retrospective 
data.  
Internal validity 
Internal validity was defined previously within this section. It describes whether the 
study accurately identifies the outcome of interest and the relationship between the 
exposure and outcome (Bowling, 2014e; Campbell, 1957; Coggon et al., 2003; 
Delgado-Rodriguez and Llorca, 2004). This is particularly important in studies using 
surveys to identify the outcomes of interest, so in this thesis is relevant to the cross-
sectional postal survey. Face validity is where the study investigator makes an 
assessment at face value about whether the questions appear to be relevant, 
reasonable, unambiguous and clear (Bowling, 2014e). A more systematic way of 
measuring this is to assess content validity, which is similar to face validity, but 
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usually involves a panel making judgments about whether the full spectrum of a 
condition is covered by the tool (Bowling, 2014e; Heale and Twycross, 2015). 
Construct validity assesses whether the instrument measures the intended concept 
and can be split into convergent validity where the tool should correlate with similar 
variables, and discriminant validity where the results should not correlate with 
dissimilar tools (Bowling, 2014e; Heale and Twycross, 2015). Criterion validity is the 
extent to which a research instrument is comparable to other instruments that 
measure the same variable and ideally any new instrument would be compared to 
the gold standard or the closest alternative if this is not available (Bowling, 2014e; 
Heale and Twycross, 2015). The cross-sectional study will use previously validated 
items where possible. This is particularly important for the identification of the 
exposure and outcomes, as identifying these correctly is important for internal 
validity.  
4.4.4 Reliability and postal surveys 
Reliability is the accuracy and consistency of a research instrument (Heale and 
Twycross, 2015; Tavakol and Dennick, 2011). Reliability is important for postal 
surveys as it helps to ensure that the results are reproducible, and that all the items 
are measuring the same concept. There are many ways to test reliability; the most 
common way of doing this is through the use of Cronbach’s alpha, a test to 
determine the internal consistency of an instrument. Internal consistency is the extent 
to which all the items within a tool measure the same concept or construct. 
Cronbach’s alpha can only be used if there are more than two items in a tool and it 
produces a result between zero and one. The higher the result the more reliable the 
test is. An acceptable reliability score is ≥ 0.7. However values >0.9 may indicate that 
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some questions could be removed as there may be some redundant items (for 
instance where more than one item is measuring the same aspect and a single item 
would provide the same level of information) and this could decrease the length of 
the tool (Heale and Twycross, 2015; Tavakol and Dennick, 2011). It is important to 
remember that if a tool includes sections for different constructs or conditions, then 
Cronbach’s alpha should be calculated for each section individually. Cronbach’s 
alpha will also be affected by the length of the tool and the longer the tool is, the 
higher the alpha result will be (likely due to similar questions causing redundant items 
as explained above). Cronbach’s alpha is a measurement of reliability for the whole 
tool (Tavakol and Dennick, 2011). When selecting tools for inclusion in the postal 
survey the reported reliability will be considered during the assessment process.  
4.4.5 Health literacy and postal surveys 
Health literacy has been defined as “the cognitive and social skills which determine 
the motivation and ability of individuals to gain access to, understand, and use 
information in ways which promote and maintain good health” (Nutbeam et al. 1998, 
p357). Health literacy is a particularly important concept for the cross-sectional 
survey as it directly influences the participants’ ability to understand and answer the 
questions. For instance, the questionnaire for the cross-sectional study relies on 
patients understanding which medicines they are using for pain relief. There are 
different skills that contribute to health literacy. These are functional health literacy, 
interactive health literacy and critical health literacy (Rowlands et al., 2014). In the 
context of a postal survey the most important skill is functional health literacy, which 
is the ability of a person to read and understand information in front of them since if 
the question is not understood, it may lead to item non-response (Paz et al., 2009; 
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Rowlands et al., 2014, 2015). The validity of data collected from self-report is 
dependent on the respondents ability to understand each survey item, which is a 
direct reflection of their functional health literacy (Paz et al., 2009). The more difficult 
a question is to understand the higher the likelihood of non-response (Paz et al., 
2009). Interactive health literacy and critical health literacy are less important for the 
study, as these revolve around discussions with health professionals and patients 
taking control of their own health (including asking questions when discussing new 
medicines leading to better shared decision making and taking positive action to 
change their environment and how this can affect their overall health) (Rowlands et 
al., 2014).  
The Organisation for Economic Co-operation and Development (OECD) studied adult 
skills (to assess skill levels to see how these match with the demands of the 
workplace) and found that 16.4% of adults (aged 16-65 years old) in the UK had a 
literacy level at or below level one (the equivalent to a D-G grade at GCSE (General 
Certificate of Secondary Education), the grade range for GCSE’s is A-F, indicating 
these adults would achieve a low level pass at GCSE) (OECD, 2012). Adults reading 
at level one, would typically be able to understand information about familiar topics, 
and be able to find a single piece of information from the text, the level expected from 
eight to ten year olds (OECD, 2012). Low literacy is associated with lower 
socioeconomic status and poor health (OECD, 2012; Paz et al., 2009). A study 
specifically looking at health literacy in the UK, found that 43% of those studied fell 
below the competency threshold for understanding text in 64 patient information 
leaflets (for various conditions and treatments) (Rowlands et al., 2015). Health 
literature is an area where there appears to be a great discrepancy between the 
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reading level of those it is aimed at, and the complexity of the writing (Meade and 
Smith, 1991; Rowlands et al., 2015). It is therefore prudent when designing self-
completion surveys to aim for a reading level of around 8-10 years old, or five years 
of formal education. This needs to include patient information leaflets and consent 
forms which are particularly important since they are only valid if the participant has 
been fully informed, and was therefore able to make a decision to participate based 
on this information (Health Research Authority, 2017). 
Tools for assessing reading level of texts  
There are several commonly used tools for assessing the readability of a text, some 
of the most commonly used are the Flesch-Kincaid, The Simple Measure of 
Gobbledygook (SMOG) and Flesch reading ease tools (Calderón et al., 2006; 
McLaughlin, 1969; Meade and Smith, 1991; Paz et al., 2009; Wang et al., 2013). 
These tools use formulas including factors, such as the number of syllables per word 
and words per sentence to calculate a reading grade, the formulas for each tool are 
shown in Table 4-2 (Wang et al., 2013). However, these tools do not take into 
account the structure of the sentence or context and therefore are a slightly simplistic 
way of assessing the reading ease of a passage of text (Meade and Smith, 1991). 
The tools also do not assess whether words are easily misunderstood in the context, 
for instance the word chronic which is commonly used by health care professionals to 
mean a long-term illness but may be understood by patients to mean a severe illness 
(Rowlands et al., 2014). The tools can be very variable and will often give very 
different reading ages to each other. This is due to the fact that the tests are looking 
for a different level of comprehension, with SMOG aiming for people to understand 
100% of the text compared with only 35% understanding for Flesch-Kincaid (Meade 
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and Smith, 1991; Wang et al., 2013). Flesch and Flesch-Kincaid are commonly used, 
as they are included as part of Microsoft Word packages, and this facilitates their 
ease of use (Microsoft, 2013a). These tools integrated into Word will be used to 
assess the patient facing materials used within the cross-sectional study and where 
possible steps will be taken to reduce the reading age. 
Table 4-2 Commonly used readability tools (Calderón et al., 2006) 
Tool Formula Outcome Comprehe
nsion 
Flesch-
Kincaid 
= (0.39	 3 4		5
	6
ℎ)
− (84.6	
3 4							)
Grade levels 
5th to College 
graduate 
35% 
SMOG = 3	
+	9			
ℎ	 : 3		
3	 30		
 
Grade levels 100% 
Flesch = 206.835	 − (1.015	
3 			
	
ℎ	
− (84.6	
3 								))
0-100. Higher 
score indicates 
easier 
readability 
75% 
 
4.5 Analytical epidemiology 
Analytic epidemiology involves investigating hypotheses in order to understand 
possible causal relationships (Bruce et al., 2008). Analytical epidemiology is most 
often undertaken in case-control studies and cohort studies. One of the focuses of 
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this thesis will be to investigate the relationship between opioid use and reproductive 
dysfunction through a retrospective primary care database cohort study. One of the 
most important steps during the design stage of any study is a sample size 
calculation. Sample size calculations are based on the power (the probability of 
detecting an effect, given that the effect is really there) required (usually greater than 
0.8), the significance level that will be used (usually a P value of 0.05) and the 
predicted difference between the two groups (Bowling, 2014a).   
4.5.1 Measures of association in analytical epidemiology 
Prior to undertaking an analytical study and tests of statistical significance, it is 
important for the researcher to have developed a research question and an 
associated null hypothesis. A null hypothesis is the assumption that there will be no 
association or effect (an effect size equal to zero) and when it is rejected an 
association or effect is shown to be possible (Greenland et al., 2016). In the case of 
the cohort study within this thesis, the null hypothesis is: 
There is no difference in reproductive dysfunction between those prescribed opioids 
dependent on duration of use (long-term vs short-term). 
The null hypothesis is used as the basis for testing the data and if it is rejected the 
alternative hypothesis is accepted - in this case, that there is a relationship between 
opioid use and reproductive dysfunction. In epidemiological work it is important to 
assess the probability that any observed relationship has occurred by chance, or is 
due to other factors (such as other exposures or confounding factors) (Wassertheil-
Smoller, 2004). Statistical tests can be either one or two sided. Two-sided tests, test 
for both directions of change (either an increase or decrease in the study population 
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compared with controls) whereas a one sided test will only test one direction (either 
that the exposure is more or less likely to cause the outcome). In this thesis, two 
sided tests will be used as the null hypothesis expects no difference between groups. 
Analytical tests return probabilities (P values); the lower the P value the more likely 
the null hypothesis is incorrect. The level at which the null hypothesis is rejected is 
conventionally taken to be (and throughout this thesis) as ≤0.05. The level at which 
the P value is considered significant (alpha α) should be decided during the design 
phase (Greenland et al., 2016). It is important to remember that the calculation of 
probability relies on all the assumptions underlying the model being true, in order to 
test the null hypothesis (for instance random sampling of those included) (Greenland 
et al., 2016).  
Confidence Intervals (CI) are useful for interpreting statistical significance of a test. 
The benefit is that they provide a range for the likely value, whereas a P value 
indicates the probability of the observed value occurring by chance. P values and CI 
(most commonly a 95% CI is used) are however closely interlinked, and it is 
recommended that P values are not interpreted in isolation (Greenland et al., 2016). 
The 95% CI indicates that if the same investigation was undertaken and sampled in 
the same way, 95% of times the true value for the population mean will be found 
within this range. As such the 95% CI reflects how precise the results are (see Figure 
4-4 for the equation for a 95% CI ) (Blumenthal et al., 2001; Greenland et al., 2016; 
Stewart, 2010). The larger the sample size, the narrower the 95% CI is likely to be 
and, as long as the sample was appropriate, the closer the sample mean is likely to 
be to the population mean (Stewart, 2010). 95% CI will be used throughout the thesis 
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where appropriate to indicate the precision of the estimate, and whether it might be 
considered a significant result. 
Figure 4-4 How to calculate 95% confidence interval (Stewart, 2010) 
95%	=	
	 = 5				 ± (1.96	 3 
			) 
5
			 = 5
			?	
 ÷ (9		A) 
As discussed previously with OR in section 4.4, epidemiologists can also undertake 
calculations to estimate risk and whether there is a link between an exposure of 
interest and the incidence or prevalence of a disease (measures of association) 
(Wassertheil-Smoller, 2004). There are many ways to calculate the risk of an 
outcome (dependent on the study design), these include relative risk, attributable risk 
(the risk difference between exposed and unexposed people) and population 
attributable risk (the risk difference between the total population and the exposed 
population and indicates the reduction in incidence if the exposure was completely 
removed) (Stewart, 2010; Wassertheil-Smoller, 2004). Relative Risk (RR) is the ratio 
of the disease rate in exposed participants when compared to unexposed 
participants (see Figure 4-5 for the equation to calculate relative risk). A RR of one 
indicates no risk associated with the exposure of interest, a RR greater than one 
indicates an increased risk and less than one a decreased risk (Coggon et al., 2003; 
Stewart, 2010). RR will not be used during this thesis. OR is more appropriate for the 
cross-sectional study, as it can be adjusted for confounding factors using multiple 
logistic regression within the available statistical software packages, and Cox 
regression which estimates hazard ratios (discussed fully later in this section) is more 
appropriate for the cohort study.  
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Figure 4-5 Equations for calculating relative risk based on a 2 x 2 table 
	
	 = 		/(	 + )/( + ) 
Chi-squared analysis is used to compare observed categorical variables to those 
expected in the population based on 2x2 tables see Figure 4-2. Expected values are 
calculated and compared to the actual values by the chi-squared calculation (in 
normal practice a Yates correction is used on the formula) (Figure 4-6), the chi-
squared value is compared with the known distribution of chi-squared to give the 
likelihood of the difference occurring by chance (Wassertheil-Smoller, 2004). Chi-
squared analysis is used during the thesis to compare distributions of descriptive and 
explanatory variables between the different exposure groups. 
Figure 4-6 Chi-squared formula and chi-squared with Yates correction. 
O=observed, E=expected and lower case letters indicate boxes in a 2x2 
table. Taken from (Wassertheil-Smoller, 2004). 
=ℎ − B	 = 	 (	 − C	)
.
C	 +	
( − C).
C +	
( − C).
C +	
( − C).
C 	 
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ℎ	D	
	
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.
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The cohort study undertaken for this thesis will use survival analysis, as it is able to 
examine the effect of an exposure, taking time into account (Bradburn et al., 2003a). 
The most common way of undertaking multivariable analysis of survival time is the 
Cox proportional hazards model (Bradburn et al., 2003a). The Cox proportional 
hazards model is semi-parametric, and it models the effect of predictors and 
covariates on the hazard rate but leaves the baseline hazard rate unspecified. It does 
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not assume knowledge of absolute risk estimates, but does rely on the assumption of 
proportional hazards (where the factors included in the model have a constant effect 
over time) (Cox, 1972). Hazard is the probability that an individual within the study at 
time (t) will have an event at that time (Clark et al., 2003). Analysis accommodates 
for censored subjects (a participant is censored if an outcome of interest occurs, an 
unrelated death occurs, or the patient is lost to follow-up). This is important when 
undertaking database research, as participants may leave a contributing practice at 
any time. In Cox regression, the dependent variable is the hazard function at any 
given time, it does not assume that survival follows a particular distribution which is 
an advantage when compared with other forms of survival analysis (Bradburn et al., 
2003a). For survival analysis to be valid, there needs to be a minimum of 10 events 
for each covariate included in the model. Less than this and results should be 
interpreted with caution (Peduzzi et al., 1995). Multivariable models are useful when 
a single exposure or risk factor is being studied but several other risk factors exist 
and these need to be adjusted for during analysis, when building a model it is 
important to consider both the statistical and clinical importance of possible 
covariates and confounders (Bradburn et al., 2003b). Cox regression relies on the 
assumption of a constant relationship between the dependent variable and the 
explanatory variable. This assumption can and should be tested through use of 
Kaplan-Meier graphs, log-log plots and Schoenfeld residuals (a statistical test for the 
association between residuals and time; if p <0.05 it indicates that the proportional 
hazards assumption does not hold), and this assumption is more likely to be violated 
if follow-up periods are long (Bellera et al., 2010; Bradburn et al., 2003b). If the 
proportional hazards assumption is violated for certain covariates, they may still be 
included within the model but as time varying covariates (tvc). This takes into account 
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the covariate interacting with log (time), so they are modelled as covariates that alter 
over time (Bradburn et al., 2003b). All variables to be included in the models within 
this thesis will be tested prior to inclusion, and if they violate the proportional hazards 
assumption then they will be included as time varying covariates as described above.  
4.6 Cohort studies 
Cohort studies follow two or more groups (exposed group compared to a non-
exposed group) from exposure (or prior to exposure) to outcome (Blumenthal et al., 
2001; Stewart, 2010). Cohort studies can either be prospective (where participants 
are followed from exposure forwards through time) or retrospective (where the 
groups are identified in the past then followed through to the present) (Stewart, 
2010). It is important that the comparison groups are as similar as possible in all 
ways except for the exposure of interest, to decrease confounding (Grimes and 
Schulz, 2002). Cohort studies are useful when temporal relationships between 
exposure and outcomes are being studied (Berger et al., 2009). Loss to follow-up is a 
problem in prospective cohort studies, as they can run for very long periods of time, 
and loss to follow-up needs to be taken into account during the design process. 
Retrospective cohort studies do not suffer from loss to follow-up but missing data can 
be a problem, as data was initially collected for a different purpose (Stewart, 2010). 
Using RR is the preferred method of assessing the likelihood of exposed people 
developing the disease when compared to the unexposed participants, however this 
does not take into account the role of time. If it is important to include time within the 
analysis then Cox regression can be used, this produces a hazard ratio and was 
used for the cohort study undertaken for this thesis (see section 4.5.1 for further 
details) (Cox, 1972; Stewart, 2010). 
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A database cohort study was chosen as the method for the first study included in this 
thesis. It provides an efficient way to examine a large number of women to assess for 
a possible relationship between opioid use and reproductive and sexual dysfunction.  
4.6.1 GP consultation database research 
Database research uses routinely collected data in order to answer research 
questions. These types of databases are often known as multi-purpose databases 
(Hall et al., 2012). Within the UK there are many longitudinal primary care databases 
that can provide anonymised patient records for research. These include 
ResearchOne, CALIBER (Clinical research using LInked Bespoke studies and 
Electronic health Records), The Health Improvement Network (THIN), QResearch 
and Clinical Practice Research Datalink (CPRD) (Vezyridis and Timmons, 2016). UK 
healthcare is uniquely positioned to provide almost complete population coverage 
through primary care databases, thanks to the NHS providing almost universal 
healthcare. There are more than 9000 general practices in the UK and each 
database receives data from only a small fraction of these (NHS Information Centre 
for Health and Social Care, 2012). Research using primary care databases has 
grown considerably over the last decade. A systematic review of publications using 
CPRD, THIN and QResearch found an increase from seven papers published in 
1995 to 171 in 2015 (Vezyridis and Timmons, 2016). The same review found that a 
strong focus of research within databases, seems to be drug safety research and the 
journal with the most publications was Pharmacoepidemiology and Drug Safety 
(Vezyridis and Timmons, 2016). RCTs are the gold standard for investigating the 
efficacy of a new medicine, however there is also a place for observational studies to 
investigate these medicines in everyday clinical practice (Berger et al., 2009). Based 
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on the recent research undertaken using primary care databases, it appears that this 
would be an appropriate method to investigate the pharmacoepidemiology of opioids 
(Vezyridis and Timmons, 2016). 
Factors to consider when selecting a database include population covered, 
geographical location, latency of data (the delay between an event occurring and this 
information being included in the database), data linkage, quality and validation of 
data (Berger et al., 2009; Hall et al., 2012). UK databases should provide good 
population coverage but as discussed in section 4.4.3 they may miss some specific 
populations including prisoners. If these populations were required then another 
method with primary data collection might be more appropriate (Hall et al., 2012). 
Prior to accessing data, it is important to define exposure, outcome, confounders, 
and inclusion and exclusion criteria. The database should be checked to see if the 
required information is present, easily accessible and contains the appropriate level 
of detail, for instance antenatal care may be missing and if you are studying this 
particular area it may not be appropriate to use a primary care database (Hall et al., 
2012). It is important to consider whether there is any bias built into the system, for 
instance recording of abnormal investigation results but not normal results (Hall et al., 
2012). Another consideration is whether the database provides long enough follow-
up after an exposure in order to observe the outcome of interest. This requires 
having an idea of the period of time between exposure and outcome (Hall et al., 
2012).  
CPRD is funded by the National Institute for Health Research (NIHR), and the MHRA 
and owned by the UK Department of Health. CPRD contains the records of 11 million 
patients (4.4 million active) from 674 general practices (Herrett et al., 2015). CPRD is 
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the only database accessible online, and it extracts data from multiple clinical 
systems, which means that any GP can contribute data (there are three main clinical 
systems currently in use in the UK by GPs EMIS, Vision and SystemOne). It also has 
permanent data linkage to secondary care through Hospital Episode Statistics (HES) 
(Vezyridis and Timmons, 2016; Williams et al., 2012). THIN contains data from 
around 600 GPs that use the Vision clinical system and has health records for 3.7 
million active patients. THIN has to be accessed at source and is not available online 
(IMS Health Incorporated, 2015). QResearch contains health records for 18 million 
patients from 1000 GPs and collects data from practices that use EMIS. Access is 
restricted to academics employed by UK universities and this is limited to sample 
data sets of maximum 100000 patients (Nottingham, 2012). CPRD was chosen as it 
contains linked data, which was important for the cohort study, which this cohort is a 
secondary analysis of due to the outcomes of interest (Bedson et al., 2019a). It is 
also not restricted to just one GP records system. CPRD has been shown to be 
broadly representative of the UK population and the sub set of practices that have 
HES linkage are also representative. This will be discussed fully in Chapter 5 (Herrett 
et al., 2010, 2015; Williams et al., 2012). 
Primary care database research  
The advantages of primary care database research are that it allows for large sample 
sizes that are broadly representative of the UK population, and also provides long-
term follow-up data. Primary care databases contain information on all aspects of 
patient care including conditions, prescriptions, lifestyle factors and secondary care 
contacts (Herrett et al., 2015). Data within primary care databases are recorded for 
clinical care, and even though this means it is not specifically collected for research, 
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it does mean there is a need for the primary care clinician to record quality 
information, as this directly affects patient care at practice level (Gnani and Majeed, 
2006). Information in primary care databases is constantly updated, and this means it 
can be ideal for monitoring treatments and their possible adverse effects in a real 
world setting (Herrett et al., 2015). It is important to remember when using databases 
for pharmacoepidemiological research, that results can be limited by bias and 
confounding, and this should be taken into account when drawing conclusions. 
However, this is a very cost effective way to investigate prescribed medicine, and can 
provide a long period of follow-up in comparison with RCTs (Gnani and Majeed, 
2006). 
One of the disadvantages of using routinely collected primary care data is (as 
discussed above), that information is extracted from systems that are designed for 
patient care (not for research). This means it may not provide the detail or 
information required for the study (Gnani and Majeed, 2006). Primary care databases 
can have issues with missing data, for instance ethnicity and social status. Some 
data (e.g. BMI, Blood pressure (BP) and smoking) may be recorded more frequently 
in those with certain conditions (e.g. cardiovascular disease and women receiving 
oral contraception), as these measurements are required by the quality outcomes 
framework (QoF) (this is a national voluntary scheme for GPs where certain targets 
are set and if met the GP receives an annual reward) (National Health Service, 
2017). This means that the data may be more likely to be missing not at random 
(MNAR, this will be explained further in section 4.7.2) (Herrett et al., 2015). Medical 
records may also include more information on participants who have the exposure of 
interest when compared to unexposed participants and this is known as recorder 
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bias. This may affect the cohort study, as those receiving long-term opioids 
compared to short-term opioids are likely to see their GP more often, and therefore 
potentially have more information in their records (Delgado-Rodriguez and Llorca, 
2004; Stewart, 2010). Missing data can also be introduced, where conditions are self-
managed at home (this could include with the use of over-the-counter medicine), or 
where the patient does not consider them sufficiently important or serious to discuss 
with their GP. This is known as the ‘clinical iceberg’ and only the tip of the iceberg is 
seen within primary care constituting the conditions that the GP is aware of (as the 
patient has consulted) and have been coded within the database and only prescribed 
medicines are included in the database (Herrett et al., 2015; Last, 1963). Missing 
data may also be due to the use of free text (adding information without coding), and 
in the majority of cases free text has not been utilised in database research in the 
past. Consequently some diagnoses, in particular early symptoms and signs, could 
be missed and potentially bias results (Price et al., 2016; Williams et al., 2012). 
Primary care databases are made up of GP practices that have volunteered to be 
included and there is evidence that these volunteer practices are often larger and 
provide above average quality of care, so they therefore may not be representative of 
all GPs (Gnani and Majeed, 2006). For a summary of the advantages and 
disadvantages of research using CPRD see Table 4-3. 
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Table 4-3 Advantages and disadvantages of CPRD database research 
Primary care database research using CPRD 
Advantages Disadvantages 
1. Large sample size available 
2. Anonymised records 
3. Information on all aspects of 
medical care 
4. Linkage to HES and ONS  
5. Cost-effective as data collected as 
part of routine care 
6. Longitudinal studies can be 
undertaken in a timely and cost-
effective manner 
7.  Low level of biases as data is 
collected for routine medical care 
8. Not subject to recall bias 
 
1. Routinely collected data so 
database may not contain all the 
information required to answer the 
specific research question 
2. Missing data, for instance BMI, 
and if information is recorded in 
the free text rather than coded 
3. No data on self-managed 
conditions (clinical iceberg), 
including no information on over 
the counter medicine 
4. Specific populations missing e.g. 
homeless 
5. Diagnostic labels may reflect 
variations in individual clinician 
practice rather than adhering to 
set diagnostic criteria  
 
4.7 Bias 
Bias can be defined as “systematic error that results in an incorrect estimate of the 
association between exposure and disease” (Blumenthal et al., 2001, p140). Bias 
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can be particularly important in epidemiological research and can affect the 
conclusions that are drawn, so it should always be considered during both design 
and interpretation of studies. Selection bias and information bias have been 
discussed previously (see Sections 4.4.2 and 4.4.3). In this section the focus will be 
non-response bias (a form of information bias) and the effect that this can have, 
including the impact of missing data. 
4.7.1 Non-response bias 
Non-response bias is caused when those who respond are systematically different 
from those who do not respond (Delgado-Rodriguez and Llorca, 2004). Non-
response bias can happen in one of several ways: loss to follow-up (if this is different 
between the groups under study), missing information about certain variables that is 
different between groups under study, and non-response to the survey (Delgado-
Rodriguez and Llorca, 2004). However, it is important to note that the presence of 
these factors does not automatically mean that bias is introduced. Non-response can 
be either unit or item non-response. Unit non-response occurs when the subject does 
not respond at all, despite being included in the study. Item non-response is where 
certain parts of the information requested are missing (Berg, 2005). Response rates 
tend to be lower for postal surveys than face-to-face or telephone interviews and 
when sensitive questions are included within the questionnaire (Edwards et al., 
2009). Non-response is therefore particularly important for the cross-sectional survey 
undertaken for this thesis.  
First, considering unit non-response, the amount of bias introduced by unit non-
response is dependent on the level of non-response but also the difference between 
responders and non-responders (Fowler, 2014). There is no agreed minimum for 
 128 
 
acceptable response rates, but it is important to try to maximise response rates and if 
possible it is important to have information about how responders and non-
responders may differ (Berg, 2005; Fowler, 2014). Responders may not represent 
the study population and therefore may not be generalisable to the population of 
interest (Kelley et al., 2003). As part of the cross-sectional study, age and registered 
GP (which will give an estimation of deprivation) of responders and non-responders 
will be able to be compared, and this will be useful in understanding whether the two 
groups differ systematically. 
Item non-response is where a respondent answers some, but not all of the questions 
in the survey (Berg, 2005). There can be many reasons for item non-response 
including accidentally missing a question, turning two pages at a time, and not 
knowing the answer or not wanting to respond because the question is considered to 
be too personal or sensitive (Brick and Kalton, 1996). When dealing with item non-
response it is important to understand in what sense the data is missing (missing at 
random (MAR) or missing not at random (MNAR)) and this will be discussed section 
4.7.2. In the cross-sectional study item non-response may be a problem; how much 
of an issue this creates during analysis depends on which items are missing. For 
instance, if the items relating to the outcome of interest are missing, it will create 
more issues than if data on ethnicity is missing. 
Improving response rates  
A Cochrane review identified 481 trials, evaluating 110 different strategies for 
improving response rates (75 strategies were evaluated on more than 1000 
participants) (Edwards et al., 2009). The strategies that were found to increase 
response rate included: providing monetary incentives, personalising invitations to 
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participants, using a first class stamp rather than franking, including a second 
questionnaire with reminders, having University sponsorship, the topic being of 
interest to participants, pre-notification prior to receiving the questionnaire and also 
shorter questionnaires, see Table 4-4 (Edwards et al., 2009). The information from 
the systematic review was taken into account during the development of the 
questionnaire for the cross-sectional study. The covering letter used to introduce the 
study is also important in securing responses to a questionnaire and it is important to 
explain how the participant was identified, outline study aims, confidentiality and the 
importance of the participants response (Bowling, 2014c). 
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Table 4-4 Methods for increasing response rate in postal questionnaires information from Edwards et al 2009. 
Significant results are indicated by a * 
Method Odds Ratio (95% CI) Final 
Response 
P value  Heterogeneity (I2 Statistic) 
Monetary incentive* 1.87 (1.73, 2.04) P<0.00001  I2 = 84% 
Recorded delivery* 1.76 (1.43, 2.18) P<0.00001  I2 = 71% 
Teaser on the envelope * 3.08 (1.27, 7.44) P = 0.013 Single Study 
Interesting topic* 2.00 (1.32, 3.04) P = 0.0012  I2 = 80% 
Pre-notification* 1.45 (1.29, 1.63) P < 0.00001  I2 = 89% 
F/U contact* 1.35 (1.18, 1.55) P = 0.000015  I2 = 76% 
Unconditional incentives* 1.61 (1.36, 1.89) P < 0.00001  I2=88% 
Shorter questionnaires* 1.64 (1.43, 1.87) P < 0.00001  I2=91% 
Second copy of questionnaire at f/u* 1.46 (1.13, 1.90) P = 0.0040  I2=82% 
Mentioning an obligation to respond 1.61 (1.16, 2.22) P = 0.95  I2=0% 
University sponsorship* 1.32 (1.13, 1.54) P = 0.00043  I2 = 83% 
Non-monetary incentive* 1.15 (1.08, 1.22) P < 0.00001  I2 = 79% 
Personalised questionnaires* 1.14 (1.07, 1.22) P = 0.000075  I2 = 63% 
Hand-written addresses* 1.25 (1.08, 1.45) P = 0.0023  I2 =14% 
Stamped returned envelope vs franked* 1.24 (1.14, 1.35) P < 0.00001  I2 = 69% 
Stamped outward envelope vs franked 0.95 (0.88, 1.03) P = 0.20  I2 = 0.0% 
Assurance of confidentiality* 1.35 (1.24, 1.42) P < 0.00001  Single Study 
Anonymous vs Non Anonymous 0.96 (0.66, 1.39) P = 0.06  I2 = 72% 
First class outward mailing* 1.11 (1.02, 1.21) P = 0.015  I2 = 0% 
Sensitive questions * 0.94 (0.88, 1.00) P = 0.035  I2 = 0% 
Mention obligation to respond vs none 1.61 (1.16, 2.22) P = 0.0042  I2 = 0.0% 
Veiled threat in letter vs none* 2.09 (1.49, 2.93) P = 0.0000021  Single Study 
Response deadline given vs no deadline 1.00 (0.84, 1.19) P = 0.98  I2 = 48% 
Sent by GP vs by research group 1.52 (0.73, 3.15) P = 0.26  I2 = 84% 
Hand written vs non handwritten signature* 1.23 (1.08, 1.41) P = 0.0017  I2 = 62% 
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Method Odds Ratio (95% CI) Final 
Response 
P value  Heterogeneity (I2 Statistic) 
Open vs closed questions 0.31 (0.09, 1.04) P = 0.057  I2 = 96% 
Easy question first vs last* 1.61 (1.14, 2.26) P = 0.0068  I2 = 0.0% 
Demographics first vs last 1.08 (0.94, 1.25) P = 0.26  I2 = 7% 
More relevant questions first vs last* 1.23 (1.10, 1.37) P = 0.00037  Single Study 
High quality vs standard quality paper 0.8 (0.6, 1.06)  P = 0.12  I2 =0.0% 
Folder or booklet vs stapled 1.10 (0.99, 1.23) P =0 .079  I2 = 0.0% 
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4.7.2 Missing data 
Missing data is an issue in most research with populations of people. It can be 
categorised into three types: missing completely at random (MCAR), missing at 
random (MAR) or missing not at random (MNAR). It is important when confronted 
with missing data to know which type of missingness applies as this affects the way it 
can be dealt with. This will be important in the cross-sectional study as by its very 
nature there is likely to be both unit and item non-response, contributing to missing 
data. Data that is MCAR has no relation to any variables in the analysis (including 
exposure, outcome or confounders), this causes loss of statistical power but 
estimates are not biased (Kristman et al., 2016). Data that is MAR is where the 
likelihood of that data being missing is not related to the missing factor, but it is 
related to the other variables. The missing data can be assumed to be split evenly 
between the groups of interest and will have a similar lack of effect on the results of 
the study as MCAR (Kristman et al., 2016). Data that is MNAR is directly related to 
the variable of interest, for instance those with depression who may be less likely to 
report mental health conditions than those without depression. The missing data is 
related directly to the outcome of interest and cannot be explained by other factors, 
so it is important that this is taken into account during analysis (Kristman et al., 
2016). This is the most important type of missing data and even small amounts can 
cause significant bias (Kristman et al., 2016). When data is MNAR, groups can self-
select (either to respond or not respond) and you can end up with narrow 95% CI 
around results which can lead to overconfidence that they represent the true results 
(Kristman et al., 2016). 
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Dealing with missing data 
The most important step when dealing with missing data is to decrease its 
occurrence in the first place and this should be considered at all stages of the study 
design process (Brick and Kalton, 1996). One method for dealing with missing data is 
through imputation, which essentially allows the missing values to be replaced. The 
crudest way to do this is with the average result for the sample but it can be done 
with prediction equations (Berg, 2005; Brick and Kalton, 1996). The major drawback 
to imputation is that the precision of results will be better than expected as most 
imputation methods are computed by averaging other observations and this means 
observations included are more similar than if all the results were true observations 
(Berg, 2005). When imputed data are used in traditional statistical methods, the 
sample size will use imputed values as well as true values which will create tighter 
standard errors and inflated significance tests (Berg, 2005). Weighting is another way 
to deal with missing data by discarding partial observations and assigning a weight to 
each complete observation in order to balance the sample; for instance if a certain 
characteristic is present in equal amounts in the population but the sample has a 2:1 
split, the underrepresented characteristic would be weighted to make the sample 
more representative of the population of interest (Berg, 2005). A further approach is 
the maximum-likelihood approach which uses probability distribution. This makes an 
assumption of the distribution of the sample and then this is used to calculate missing 
data values. Maximum-likelihood makes a strong assumption about the probability 
distribution generating random survey responses (Berg, 2005).  
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4.7.3 Confounding 
Confounding occurs when exposure and outcome are both related to a third factor 
that is not on the causal pathway under investigation but may affect any association 
seen (see Figure 4-7). The confounder will interact with the independent 
variable/exposure and the outcome (Bowling, 2014a; Delgado-Rodriguez and Llorca, 
2004; Jager et al., 2008). Confounding can lead to the level of risk associated with an 
exposure of interest being either over or underestimated, and affects the validity of 
any investigation into cause and effect (Blumenthal et al., 2001; Signorello et al., 
2002). During the design phase of any epidemiological study it is important to 
consider possible confounding factors. These can either be controlled for during 
matching or information can be collected on these specific factors and then they can 
be included in statistical analysis (e.g. through multiple logistic regression). 
Confounding factors can be anything, for instance the environment, medicine, diet, 
genetics and medical conditions, which means it can be difficult to account for all 
possible confounders. In a perfect world research could be undertaken by just 
altering a single factor at once and seeing what effect it has. However this is not 
possible in epidemiological research as most studies are purely observational 
(Blumenthal et al., 2001; Coggon et al., 2003). In the case of this thesis the 
independent exposure is the use of opioids (either split by duration or daily morphine 
equivalent dose), and the dependent outcome of interest is symptomatic HPG axis 
disruption (reproductive and sexual dysfunction). Covariates need to be considered, 
and these are factors that can cause the outcome of interest but do not lie on the 
direct causal pathway under investigation, they are unrelated to the exposure. 
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Figure 4-7 Confounders and their relationship with independent and 
dependent variables adapted from (Bowling, 2014a) 
 
 
Confounding by indication is common in epidemiological studies of interventions 
(Signorello et al., 2002) and is introduced when the indication for the exposure is also 
a risk factor for the outcome of interest. This type of bias occurs mainly in 
retrospective observational studies, so it is an important issue for the cohort study 
undertaken as part of this thesis (Delgado-Rodriguez and Llorca, 2004). As a 
treatment is being prescribed (opioids) there will always be an indication for this 
treatment and the choice to offer treatment can be complex. Factors that can affect 
whether a treatment is provided are: disease severity, stage, symptoms, current 
treatment, previous failed treatments, individual preferences and clinician treatment 
preferences (Signorello et al., 2002). It is often the case that dependent on the 
severity of a disease, different treatments may be recommended. This is the case 
with musculoskeletal conditions where guidelines recommend simple analgesia 
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(paracetamol and topical NSAIDs) as a first line treatment, then oral NSAIDs, and 
then opioids only if simple analgesics have failed (National Institute for Health and 
Care Excellence, 2014a; Signorello et al., 2002). Confounding by indication can be 
difficult to deal with in observational studies but careful statistical analysis can go 
some way to balancing the effect (Signorello et al., 2002).  
Methods to control confounding  
Confounding should be taken into account during the design of studies (through 
randomization, matching and restriction) and during analysis (through multiple 
regression, stratification or standardization) (Jager et al., 2008). Within observational 
studies, it is possible to use matching and restriction during the design phase, 
whereas randomization of patients to treatment groups is only possible within 
interventional studies (Jager et al., 2008). It is important that confounding is 
considered during the design phase, as it is not always possible to fully account for 
confounding during analysis and this can lead to residual confounding (Smith and 
Phillips, 1992). Residual confounding is where the design or analysis is unable to 
fully account for confounding factors (because for instance a confounder was not 
considered, data were not complete or it was not possible to measure a particular 
confounder), and this still has an effect on the results of the study (Jager et al., 
2008). 
As mentioned above, matching for characteristics that may be confounders (e.g. age, 
sex) can decrease the potential for confounding. Another way is to restrict those 
selected to participate through inclusion or exclusion criteria (Jager et al., 2008). For 
instance, it may be predetermined that only patients aged 20-40 years are included, 
or any patients with pre-existing cancer excluded. This decreases differences 
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between study groups but may mean that the results are less generalisable (Jager et 
al., 2008). The cohort study will be matched for year and age at the start of opioid 
use (split by opioid duration), practice and having a coded musculoskeletal condition 
in order to make the two groups similar without over matching and restricting those 
that can be included within the cohort. It will ensure that all those included have no 
contraindications to opioid use.  
During the analysis phase of a study, confounding can be dealt with using several 
different methods including multiple logistic regression (within the cross-sectional 
study logistic regression will be used as this allows analysis of a binary outcome), 
stratification and standardisation. Stratification divides a study population into 
subgroups based on a specific confounder, following which relative risks are 
calculated per subgroup. Stratification is useful when there are only a small number 
of confounders to adjust for. However with continuous variables, residual 
confounding is likely to remain, for instance if age is dichotomised at 50 years, there 
is likely to be difference remaining in the two subgroups (Jager et al., 2008). 
Standardisation takes account of confounding factors by creating weighted averages 
for different groups (e.g. age groups) and then calculating an overall adjusted effect 
size (Jager et al., 2008; Stewart, 2010). Standardisation can account for confounders 
including age and sex, in order to eliminate the effect of the confounding factor on the 
analysis (Coggon et al., 2003). Statistical analysis using regression models can also 
be used to adjust for confounders, as it holds all other factors constant whilst 
assessing the independent variable of interest (Bowling, 2014a; Smith and Phillips, 
1992). Multivariable logistic regression will be used in the analysis of the postal 
survey (see section 4.4.2 for further details) and Cox regression models will be used 
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in analysis of the CPRD cohort study (see section 4.5.1); these will be used to 
understand associations and adjust for potential confounding factors.  
4.8 Summary 
Epidemiology can be used to study the distribution of disease in different populations, 
and the differences between population groups. There are many different techniques 
used in epidemiological research. In this thesis the two methods that will be used are 
a cohort study utilising primary care consultation data collected routinely and a cross-
sectional postal survey collecting new data specifically for this research project. The 
issues when designing these types of research have been discussed above and will 
be taken into account during the design phase of each study.  
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5 Cohort study methods 
5.1 Introduction 
As previously discussed in chapter one, long-term opioid use in men is associated 
with hypogonadotrophic hypogonadism known as OPIAD (Abs et al., 2000; Aloisi et 
al., 2009; Benyamin et al., 2008; Daniell, 2002; Smith and Elliott, 2012). The 
systematic review in chapter three has shown limited evidence for this in women, but 
it has highlighted that there is a potential link requiring further investigation.  
5.2 Aim 
To assess if long-term opioid use for musculoskeletal pain is associated with 
reproductive and sexual dysfunction when compared with short-term opioid use, 
specifically symptomatic disruption of the hypothalamic-pituitary-gonadal axis in 
women, 18-55 years old. 
5.3 Objectives 
1. To investigate the prevalence of reproductive and sexual dysfunction among 
women 18 to 55 years old receiving opioids (long-term and short-term) for 
musculoskeletal pain, through a matched cohort from CPRD with linked HES 
data. 
2. To determine if women aged 18 to 55 years old prescribed long-term opioids for 
musculoskeletal pain, when compared to women receiving short-term opioids, are 
more at risk of developing reproductive and sexual dysfunction. Reproductive and 
sexual dysfunction within this cohort study specifically refers to menstrual 
irregularities, menopause (and symptoms of menopause), low libido and infertility. 
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5.4 Clinical practice research datalink (CPRD) 
CPRD is a large UK primary care database which contains high-quality, anonymised 
information on over 11 million patients from over 600 general practices. There are 
currently between 4 and 5 million active patients (alive and currently registered with a 
CPRD practice). The data available from CPRD includes demographics, 
investigations, diagnoses, symptoms, referrals and prescribed medicines (Herrett et 
al., 2015). Prior to 2012 CPRD was known as the General Practice Research 
Database (GPRD). CPRD can also be linked to access information from HES data 
(which uses ICD-10 clinical coding for recording secondary care contacts) and Office 
for National Statistics (ONS) for death registries. These linked databases will be used 
for outcomes and information on deaths (Database, 2015; Health and Social Care 
Information Centre, 2015a; Herrett et al., 2015). The structure of healthcare within 
the UK means that primary care databases provide almost complete coverage; over 
98% of the population are registered with GP’s who act as gatekeepers to secondary 
care and record the outcome of any such care (Garcia Rodriguez and Perez 
Gutthann, 1997; Herrett et al., 2015; Williams et al., 2012). CPRD has been 
compared with data from the UK census (age, ethnicity and sex) and found to be 
broadly representative of the UK population (Herrett et al., 2010). CPRD provides 
high quality data as practices are required to reach a set standard in recording quality 
prior to contributing data. There are specific rules for coding data in CPRD, for 
example, diagnoses need only be coded on first presentation, if there is a treatment 
change or if another significant event occurs (Jordan et al., 2006). There are ongoing 
quality checks following the inclusion of a practice in CPRD to ensure that the data 
continues to meet the required standard for individual patients and the practice 
(Herrett et al., 2010). This cohort included only practices with HES and ONS linkage 
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(n=350). Practices with linkage have been shown to be similar to practices without 
linkage when comparing follow-up, prescribed medicine and demographics 
(Gallagher et al., 2011). 
5.4.1 Validity of CPRD 
CPRD has been externally validated in previous studies. A systematic review in 2009 
found that estimates for validity were high, but the reporting of the methods was often 
unclear; the median proportion of confirmed diagnoses was 89% over 357 validation 
studies (Herrett et al., 2010). Other studies have evaluated the completeness of data 
in musculoskeletal disorders which is pertinent to the identification of patients 
included in the cohort study undertaken for this thesis (Jordan et al., 2006). This 
study compared the forerunner of CPRD which was known as GPRD with three other 
databases, two national and one local to estimate prevalence of rheumatoid arthritis, 
osteoarthritis and arthralgia. GPRD estimated a lower prevalence of all conditions in 
comparison with the other databases. This was thought to be due to the difference in 
coding instructions, with GPRD allowing symptom codes if the diagnosis is uncertain, 
whereas the other databases encourage diagnostic coding. As discussed above, 
GPRD also only requires coding of diagnosis at first presentation and significant 
events, which means there is potential for missing data, as patients with stable 
chronic conditions may not have presented to the healthcare practitioner during the 
study period (Jordan et al., 2006). Additionally, patients with new conditions may not 
present to primary care, but may self-manage their condition in the community, 
although this issue affects all primary care databases (Last, 1963).  
Prescriptions are generated electronically and recorded automatically by UK primary 
care systems, so the only medicines not included in the database will be those that 
 142 
 
can be purchased from pharmacists without a prescription (“over the counter” 
medicines, of which the only “over the counter” opioids available are low dose co-
codamol and dihydrocodeine for a maximum of 3 days/32 tablets for acute pain), and 
handwritten prescriptions or medicines prescribed from secondary care (although 
there is a facility to record these prescriptions within GP computer systems) (Garcia 
Rodriguez and Perez Gutthann, 1997; Herrett et al., 2010; Jordan et al., 2006; 
Medicines and Healthcare products Regulatory Agency, 2009). 
5.4.2 Advantages 
One advantage of using CPRD is that it is a large database. This was important for 
this study as the outcomes of interest have low rates in the general population 
(premature ovarian failure has a prevalence of 1%). Therefore, in order to have 
enough power for statistical analysis, a large number of subjects was required 
(Luborsky et al., 2003). As well as having a substantial population of subjects, CPRD 
has over 79 million person years of follow-up and individual patients have a median 
follow-up period of 9.4 years (IQR 3.4-13.9) (Herrett et al., 2010). 
5.4.3 Limitations 
Use of databases for research can mean that there is the potential for missing data 
and there are a few specific considerations related to the use of databases with this 
study. The nature of missing data in databases can be a complex issue because the 
data may be missing in different proportions in different groups. For instance, with 
blood pressure (BP) measurements, the quality outcomes framework (QoF, a 
voluntary annual rewards scheme with certain indicators for UK GPs) asks for yearly 
BP measurements in patients with hypertension and every five years in healthy 
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patients over 45 years old, but there is no requirements for BP in well patients under 
45 years old. QoF requirements can change year on year (National Health Service, 
2017; NHS, 2015). 
CPRD does not have the facility to identify whether prescriptions are specifically for a 
particular condition, however it does require coding of a condition when changing 
treatment regimen so there should be a temporal relationship between a prescription 
and a coded condition (Jordan et al., 2006). 
5.5 Hospital episode statistics database 
HES contains information on hospital admissions, outpatient appointments and 
Accident and Emergency attendances in England. Every year HES processes 125 
million patient records. The primary function of HES data is to ensure that the 
hospitals are paid for the work that they do, but the database is also available for 
research. HES was conceived in 1987 to provide national data on all episodes of 
hospital care delivered in England (Health and Social Care Information Centre, 
2015a). Not all CPRD data is linked to HES; only 58% of CPRD practices have 
consented to data linkage, but, as mentioned above, this subset of practices is 
comparable to the whole of CPRD (Herrett et al., 2015). 
5.6 Study population 
This cohort study used a subset of participants from a previously defined population 
used in a similar cohort study examining the use of long-term opioid prescribing and 
adverse effects (Bedson et al., 2016, 2019a). Subjects were included in the original 
cohort if they: 
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1. Started long-term use of opioids between 2002 and 2013. Long-term opioid use 
was defined as the issue of three opioid prescriptions within 90 days from and 
including the first date of a new prescription for opioids (provided there was no 
opioid prescription in the preceding six months). A period of opioid use ended if 
there was a gap of more than six months from last use of opioids (28 days after 
the issue of the last prescription since prescribing guidelines from the NHS 
Business Services Authority for prescription of controlled drugs state that no more 
than a 28 day supply should be given except in exceptional circumstances) (NHS 
Business Services Authority, 2014). This is in line with definitions used in previous 
epidemiological studies (Dunn et al., 2010; Von Korff et al., 2008). A new episode 
of opioid use occurs if there was no opioid use in the preceding six months. 
Opioids were defined as analgesics for moderate and severe pain and were 
identified from sections 4.7.1 and 4.7.2 of the British National Formulary (BNF) 
(BNF, 2018a). This includes weak to very strong opioids and both short and long-
acting opioids (these were defined in Section 1.3).  
2. Participants must have had a recorded non-inflammatory musculoskeletal 
problem in primary care in the period 14 days before the index opioid prescription 
to 90 days following this. Musculoskeletal pain was chosen as the indication for 
opioids rather than all cause CNCP in order to provide a more homogenous group 
of study participants, and to partly address the issue of confounding by indication 
(see Section 4.7.3 for definition and further information). Musculoskeletal 
conditions have been identified as the underlying cause for CNCP in 40% of UK 
CNCP patients, and one in seven primary care consultations are for a 
musculoskeletal condition, so this represent a significant proportion of patients 
attending UK primary care (Breivik et al., 2006; Jordan et al., 2010). The time 
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period for the musculoskeletal condition being coded and the opioid being 
prescribed ensured that there was a temporal relationship between the 
musculoskeletal problem and index opioid prescription, particularly due to the 
need to code a condition when changing treatment regimen in CPRD (Jordan et 
al., 2006). 
3. Aged 18 years or over at initial prescription. 
4. At least 12 months of records in the CPRD database prior to the initial opioid 
prescription. 
5. No record of cancer prior to prescription or within six months following the index 
opioid prescription. Patients were censored if they had a cancer diagnosis 
following inclusion in the cohort. 
6. Registered at a CPRD general practice that consented to linkage to other 
datasets (as outcomes for the original cohort were partially identified from the 
integrated HES data and office of national statistics (ONS) data for patient 
deaths).  
The cohort was prepared based on the above criteria for the larger study (Bedson et 
al., 2016, 2019a). A short-term opioid group was matched for year of birth (± five 
years), sex, practice and first year of opioid use (± two years). Short-term opioid 
users had not used long-term opioids but had been prescribed opioids that did not fit 
the criteria described above for the subject to be considered a long-term opioid user. 
The study carried out for this thesis included a subgroup of patients fulfilling the 
above criteria, who additionally were women and aged between 18 and 55 years old 
at first opioid prescription; the inclusion and exclusion criteria are summarised in 
Table 5-1. The cohort was developed for the larger study and the database was 
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received by the author (ER) for analysis, prepared, and limited to women 18 to 55 
years old (undertaken by YC).  
Table 5-1 Cohort inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Women 
Age 18-55 years old at initial opioid 
prescription 
Starting a period of long-term opioid use 
Coded musculoskeletal condition from 
14 days before to 90 days after initial 
opioid prescription 
Linked HES and ONS data 
Cancer diagnosis at any time prior to 
study or within the first six months of 
opioid prescription 
Less than 12 months of records within 
CPRD prior to first day of opioid 
prescription 
5.7 Study outcomes 
The outcomes of interest were defined following the systematic review reported in 
Chapter 3. The outcomes of interest were abnormal menstruation (amenorrhoea or 
oligomenorrhoea), decreased libido (female sexual dysfunction), menopause and 
infertility. Despite infertility not being a condition highlighted from the systematic 
review, it has been included as an outcome as it is a significant clinical feature of 
women with hypogonadotrophic hypogonadism (Messinis, 2005). Premature ovarian 
failure was not identified separately from menopause in the review as an outcome, 
but it is also a potential outcome if opioids interfere with the HPG axis and is also a 
reason that women may present to the GP. Following identifying the outcomes of 
interest, these conditions were then identified from CPRD using Read Codes. Read 
Codes are a “coded thesaurus of clinical terms and have been used in the NHS since 
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1985… they provide the standard vocabulary by which clinicians can record patient 
findings and procedures in health and social care IT (information technology) 
systems across primary and secondary care” (Health and Social Care Information 
Centre 2015b, Read Codes). Reasons for consultation, investigations and diagnoses, 
are coded using Read Codes in CPRD.  
ER performed a search in the clinical terminology browser to develop an initial list of 
Read Codes. The clinical terminology browser was the 5 byte version 2 (2014-10-01) 
and it uses ReadEngine which is a copyrighted browser. Using the Read Code 
browser, Read Codes relevant to the outcomes of interest were identified (the full list 
can be found in Appendix 6). Relevant Read Codes were exported to Microsoft 
Excel, and reviewed for relevance by ER and refined with input from another primary 
care clinician (JB) (Microsoft, 2013b). Data on outcomes was collected from day 90 
of opioid use up to five years of follow-up. The same conditions were identified from 
one year before opioid prescription and used in statistical analysis as pre-existing 
conditions. This information was searched for in CPRD and added to the study 
database by the study statistical advisor (YC). 
5.8 Covariate data 
The systematic review, a search for literature regarding the outcomes of interests, 
and professional knowledge had revealed a wide range of possible confounding 
factors and covariates that needed to be taken into account during the design of the 
study.  
Data on comorbidities was collected from between 12 months before and three 
months after initial opioid prescription, comorbidity was identified using three different 
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methods. Comorbidity is defined on the basic premise that a patient has two or more 
simultaneous clinical conditions (Valderas et al., 2008). Firstly, the outcomes of 
interest were considered as comorbidities if they occurred prior to the start of follow-
up, and they were identified in the same way as described above for identifying 
outcomes. Secondly, the following specific covariate conditions were also identified: 
thyroid conditions, low BMI (<18), adrenal conditions (e.g. adrenocortical 
insufficiency), obesity (as a coded condition), structural gynaecology conditions (e.g. 
PCOS), illegal opioid misuse and BMI (categorised as <25 kg/m2, ≥25 kg/m2 
(overweight) or missing, where multiple values were recorded the value closest to the 
start of follow-up was used). Depression and anxiety were not included as specific 
covariates and treatments including antidepressants were not included separately 
from total number of prescriptions, as it was not considered during the development 
of the cohort. The limitations of this will be discussed in Chapter 7. Finally the total 
number of prescriptions was mapped to BNF sections and the number of sections 
prescribed from was used as a surrogate for the number of comorbid conditions 
(Perkins et al., 2004). NSAID use was also assessed since research looking at use of 
NSAIDs in chronic back pain has found that women using short-term NSAIDs for ten 
days had failed to ovulate (6.5% of those taking naproxen and 27.3% eterocoxib) 
compared to women receiving placebo who ovulated (Salman et al., 2015). Data was 
collected on NSAID use for four months prior to the start of follow-up, see Figure 5-1 
for a GANT chart showing the timeline of data collection for the study.  
Data on smoking and alcohol use was identified in the year prior to first opioid 
prescription and up to the start of follow-up. They were both categorised as ever, 
never or missing.  
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5.9 Preparing the database 
A matched cohort was already available for patients taking long-term opioids 
compared to those who had taken short-term opioids as defined previously. This 
cohort was limited to include women between 18 and 55 years of age.  
The Read Codes for associated conditions and outcomes were initially identified 
through the clinical terminology browser by ER and when a code was found, the sub 
codes and parent codes were reviewed to see if they should be included by two 
reviewers (ER and JB). The Read Codes are not compatible with the CPRD 
database so needed to be converted to medcodes (which are numerical codes that 
are unique to CPRD and have equivalent alphanumerical Read Codes) that could be 
searched for within the database (Watson et al., 2017). The Read Codes were also 
converted to ICD-10 codes for searching data from HES. The search within CPRD 
was undertaken by YC based on Read Codes provided by ER (see Appendix 6).  
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Figure 5-1 Gant chart showing cohort study timeline. Solid line shows day 
of initial opioid prescription, Dotted line shows the start of follow-up. 
 
5.10 Statistics 
The sample size (198000) of the initial cohort (from which this study sample was 
taken) was calculated to have a power of 80% to detect a hazard ratio of 1.2 for the 
rarest adverse event being studied which was opioid overdose with an adverse rate 
 151 
 
of 50/10,000 persons. The rate of the rarest outcomes in the sub study reported here 
is premature ovarian failure, which affects 1% of the population (Luborsky et al., 
2003) and amenorrhoea affecting 3-4% of the population. The population included in 
this study was 44260 (22130 long-term and short-term users) (The Practice 
Committee of the American Society for Reproductive Medicine, 2008). A 
retrospective power calculation for each outcome using a 5% type 1 error rate and 
the actual data from each outcome shows that the power for the outcomes 
menstruation (power = 0.82) and menopause (power = 0.99) was sufficient, but for 
low libido (power = 0.10) and infertility (power = 0.09) was not. It is important to note 
that retrospective power calculations should not be used to help interpret results, as 
they are based on the assumption that the observed results are equal to the true 
values within the population (Hoenig and Heisey, 2001). 
Statistical analysis of the data was performed using STATA 14.0 (StataCorp, 2017). 
When statistical tests were undertaken <0.05 (for two-tailed tests) was used as the 
level for statistical significance. 
5.10.1 Demographics 
The demographics of the women receiving long-term opioids and the women 
receiving short-term opioids were described using means and standard deviations if 
normally distributed and medians and interquartile ranges (IQR) if non–parametric. 
The demographics were compared using descriptive statistical tests, where two 
categorical variables were compared a chi-squared test was used, if the comparison 
included continuous variables a student’s t test was used if the data was parametric, 
and a Wilcoxon-Mann-Whitney test for non-parametric data.  
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The cohort was split into age categories (18-25 years old, 26-35 years old, 36-45 
years old and 46-55 years old) in order to describe the age distribution of the 
subjects within the study and for use in some of further analysis (as certain outcomes 
might be expected to occur more frequently in different age groups, for instance 
menopause would not be expected in 18-25 year olds). The age groups were not 
used as a covariate in Cox regression modelling, and age was included as a 
continuous variable. These categories were chosen based initially on the normal age 
for menopause, with those 45 years old and younger being considered early 
menopause (Chang et al., 2007). The age groups were evenly split (as far as 
possible) and 46 years and over included only women having a menopause at a 
“normal” age and then split at further 10-year gaps.  
5.10.2 Covariates 
Covariate conditions (defined above in section 5.8) were described using the number 
affected in long-term and short-term opioid groups and women across the entire 
cohort. Proportions in both groups and the entire database were calculated. 
Comparison of the proportions between long-term and short-term opioid users was 
undertaken using chi-squared statistics.  
5.10.3 Outcomes 
Basic descriptive statistics were performed for each outcome detailing the number of 
subjects affected in the whole cohort, the short-term and long-term opioid users. The 
proportions for those affected were calculated and presented with the 95% CI. 
 Analysis one calculated the incidence per 10,000-person years at risk. The 
incidence per 10,000-person years was calculated for the whole group, long-term 
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opioid users and short-term opioid users. Following this, the incidence per 10,000-
person years was calculated for each age group.  
Analysis two compared the level of risk dependent on duration of opioid use for the 
four outcomes of interest using survival analysis. 
5.10.4 Survival analysis 
Survival analysis was undertaken using the Cox proportional hazards model, 
described fully in section 4.5 (Cox, 1972). Cox proportional hazards models were 
chosen because they take into account time as a factor and estimate the risk over 
the whole time period rather than just the end point of the study. The proportional 
hazards assumption was tested through log-log plots and Schoenfeld residuals. 
Subjects within the analysis were censored if they had an outcome, left a CPRD 
registered practice, died, or the practice stopped contributing to CPRD. It was 
assumed that censored patients did not differ systematically from those that 
remained uncensored. Cox proportional hazards models assessed the differential 
risk of reproductive and sexual dysfunction between different groups of opioid users.  
The initial Cox regression models were univariate looking at each of the four 
outcomes. This was done over the full five-year follow-up but also looked separately 
at year one, year two and years three to five, in order to assess if hazard differed with 
time. The Cox regression adjusted for associated factors including NSAID use, 
ethnicity, age, BMI (dichotomised at 25 representing those overweight and those of 
normal weight), smoking and the associated conditions identified above dependent 
on the numbers that were found in the earlier descriptive analysis of each associated 
condition (thyroid disease, pituitary conditions, hypothalamic conditions, adrenal 
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conditions, low BMI, structural gynaecological conditions and illegal opioid use). A 
Cox regression was undertaken for each covariate individually for each outcome and 
where the proportional hazards assumption was violated, those covariates were 
included as time-varying covariates (Bellera et al., 2010). All of the above were run 
over the full five-year follow-up and year one, year two and years three to five. Based 
on the age groups calculated earlier, if there were large differences in numbers with 
outcomes in each age group, the Cox regression was also run split by age but as this 
decreased the numbers for analysis it was dependent on the number with each 
outcome, as to whether it was appropriate to undertake this analysis. 
Sensitivity analyses were undertaken using first a complete-case approach (where 
cases with missing data are removed from analysis), secondly removing those with 
pre-existing outcome conditions, and finally removing women with a coded diagnosis 
of menopause as a proxy for HRT use. An online convenience sampled survey on 
the website menopause matters found that 60% of respondents had used or were 
currently using HRT, so using a diagnosis of menopause as a proxy for HRT use 
does mean that more women were removed than necessary but it should have 
excluded all women who are currently receiving HRT (Cumming et al., 2015).  
5.11 Summary 
In this chapter the methods for the cohort study have been outlined. This chapter 
also discusses the important advantages and disadvantages that need to be 
considered when undertaking a database cohort study. In the following chapter the 
results of the cohort study will be discussed.  
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6 Cohort study results 
This chapter presents the results of the CPRD cohort study undertaken for this 
thesis, the methods of which were presented in chapter 5. The cohort study 
investigated women aged 18-55 years old with a painful musculoskeletal condition 
and a prescribed opioid for possible sexual and reproductive dysfunction. There were 
four outcomes of interest within this study: abnormal menstruation, menopause, low 
libido and infertility. First the cohort is described and then the incidence rate and Cox 
regression for each outcome is presented. 
6.1 Demographics 
The cohort contained 44260 women in total. There were 22130 short-term opioid 
users and 22130 long-term opioid users. Table 6-1 shows comparisons between the 
two groups. No statistically significant difference was found between long-term and 
short-term opioid users for age or region which were matched for in the study design, 
but there were statistically significant differences when comparing ethnicity, NSAID 
use, BMI, smoking status, alcohol use and number of comorbidities. 
6.1.1 Comorbidity and NSAID use 
The median number of comorbidities in long-term opioid users was 8 (IQR 6, 12) 
compared with a median of 6 (IQR 4, 9) in short-term opioid users; the difference 
between the two groups was statistically significant (p<0.01). NSAIDs were 
prescribed to 57.5% (95% CI 56.8, 58.1) of long-term opioid users compared with 
short-term opioid users where 39.2% (95% CI 38.6, 39.9) were prescribed NSAIDs, 
this was a statistically significant difference (p<0.01) (Table 6-1). 
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Table 6-1 Study participant demographics split by duration of opioid use. 
Figures are number in each group, percentage (95% CI) except in categories marked with a 
star where figures are Median (IQR). ~ p value indicated is calculated using Wilcoxon-Mann-
Whitney for non-normally distributed data. Other p values are Chi-squared.   
 Short-term opioids Long-term opioids P value 
Number 22130 22130  
Ethnicity    
1 (White) 13,445, 60.8%  15,576, 70.4 %  <0.01 
 
 
2 (Other) 1,226, 5.5%  1,158, 5.2%  
3 (Unknown) 7,459, 33.7%  5,396, 24.4%  
 
Region 
   
1 (North) 2,020, 9.1%  2,020, 9.1%  Matched 
2 (Midlands and 
East England) 7,509, 33.9%  7,509, 33.9%  
3 (London) 5,905, 26.7%  5,905, 26.7%  
4 (South) 6,695, 30.3%  6,695, 30.3%  
 
Age* 43 (36, 49) 43 (35, 49) 
 
Matched 
 
NSAID   
 
0 (no 
prescription) 13446, 60.8%  9,407, 42.5%  
<0.01 
1 (NSAIDs 
prescribed) 8,684, 39.2%  12,723, 57.5%  
    
BMI* 26.3 (23.1, 30.7) 27.8 (23.9, 32.9) <0.01~ 
Comorbidities* 6 (4, 9) 8 (6, 12) <0.01 
Smoking status   
Never Smoked 11,504, 52.0%  9,944, 44.9%  <0.01 
Ever Smoked 9,824, 44.4%  11,414, 51.6%  
Missing data 802, 3.6%  772, 3.5%  
Alcohol status    
Never Alcohol 2,721, 12.3%  3,070, 13.9%  <0.01 
Ever Alcohol 17,531, 79.2%  17,154, 77.5%  
Missing data 1,878, 8.5%  1,906, 8.6%  
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6.1.2 Age 
The age range for those included within the study was 18-55 years old. The median 
age was 43 years (IQR 36, 49) in long-term opioid users and 43 years (IQR 35, 49) in 
short-term opioid users. This study uses a maximum age of 55 years, the age was 
not normally distributed and reached a peak in the 46-55 year-old age group (see 
Figure 6-1). The subjects had been split into age groups to be used in later analysis 
and the number in each group is shown in Table 6-2.  
Figure 6-1 Histogram showing age of study participants split by duration of 
opioid use 
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Table 6-2 Age groups split by duration of opioid use. Figures are number 
in each group, percentage  
Age Number of subjects 
 Short-term opioids Long-term opioids Total 
18-55 22130 22130 44260 
18-25 1,410, 6.4% 1,426, 6.4%  2,838, 6.4%  
26-35 4,121, 18.6%  4,109, 18.6%  8,232, 18.6%  
36-45 7,623, 34.4%  7,631, 34.5%  15,254, 34.5%  
46-55 8,976, 40.6%  8,964, 40.6%  17,940, 40.5%  
 
6.1.3 BMI 
The median BMI in women receiving long-term opioids was 27.8 (IQR 23.9, 32.9), 
whereas in women who received short-term opioids the median was 26.3 (IQR 23.1, 
30.7), the BMI was similar in both groups but the difference was statistically 
significant. BMI was not normally distributed within the cohort and data is skewed to 
the left (see Figure 6-2). BMI data was split into two groups for use in further 
analysis, using BMI’s of < 25, and those ≥ 25 which represents the cut off between 
those women who are overweight and those considered of normal weight or 
underweight (see Table 6-3 for distribution). Table 6-3 also shows a cut off at BMI ≥ 
30, this will not be used in further analysis but shows the number of obese women 
(defined by BMI ≥ 30) in each group. The number of women in each weight group is 
statistically significantly different between the long-term and short-term opioid users. 
Table 6-3 BMI groups split by duration of opioid use. Figures are number 
in each group, percentage (95% CI) 
 Short-term opioids Long-term opioids Total 
BMI < 25 8,409, 38.0% 6,815, 30.8% 15,224, 34.4% 
BMI ≥ 25 and <30 12,555, 56.7% 14,235, 64.3%  26,790, 60.5% 
BMI ≥ 30 5,952, 28.4% 7,957, 37.8% 13,909, 33.1% 
Missing data 1,166, 5.3% 1,080, 4.9% 2,246, 5.1% 
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Figure 6-2 Histogram showing BMI for participants split by duration of 
opioid use with line of normal distribution overlay.  
 
 
 
 
 
 
 
 
6.2 Outcomes 
6.2.1 Outcome counts and follow-up time 
The outcomes of interest were: altered menstruation (less frequent or absent 
menstruation), decrease in libido, infertility and menopause/menopausal symptoms. 
The commonest outcome was menopause, affecting 10.6% of women across the 
whole cohort. Infertility affected the least number of subjects, identified in only 0.6% 
of women. The full distribution of the outcomes can be seen in Table 6-4. 27909 
(63.1%) of women did not complete full five year follow-up due to reasons other than 
a recorded outcome and were censored; 27,521 women (62.2%) left a CPRD 
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practice before the full five year follow-up was completed and 388 (0.88%) women 
within the cohort died (see Table 6-5 for follow-up time). 
Table 6-4 Distribution of outcomes of interest split by duration of opioid 
use. Figures are number with problem, percentage with problem (95% CI) 
 Short-term opioids Long-term opioids Total 
Altered 
Menstruation 
1290, 5.8 (5.5, 6.1) 1432, 6.5 (6.2, 6.8) 2722, 6.2 (5.9, 6.4) 
Libido 161, 0.7 (0.6, 0.8) 195, 0.9 (0.7, 1.0) 356, 0.8 (0.7, 0.9) 
Infertility 135, 0.6 (0.5, 0.7) 116, 0.5 (0.4, 0.6) 251, 0.6 (0.6, 0.6) 
Menopause 2245, 10.1  
(9.8, 10.5) 
2566, 11.6  
(11.2, 12.0) 
4811, 10.9  
(10.6, 11.2) 
 
Table 6-5 Follow-up time for each outcome of interest 
Outcome Median Follow-up time 
(days) 
Interquartile Range 
Menstruation 1193 552, 1825 
Libido 1263 595, 1825 
Infertility 1268 597, 1825 
Menopause 1144 536, 1825 
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6.2.2 Rate of outcomes/10,000 person-years 
Menstrual Cycle 
Outcome number one was altered menstruation to less frequent or absent 
menstruation. This affected 2722 (44260) subjects, with a rate of 186.2/10,000 
person-years (95% CI 176.4, 196.7) in short-term opioid users, and 209.5/10,000 
person-years (95% CI 199.0, 220.7) in long-term opioid users (see Table 6-6). The 
rate of altered menstruation was found to be highest in younger age groups with a 
rate of 550.1/10,000 person-years (95% C.I. 479.7, 630.8) in 18-25 year olds 
receiving long-term opioids. The older the age group, the lower the rate, and in the 
46-55 year old age group the rate fell below the rate for the group overall to 
91.1/10,000 person-years (95% CI 83.7, 99.3), long-term users had higher rates 
across all age groups than short-term opioid users see Table 6-6.  
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Table 6-6 Rate of menstrual disturbance/10,000 person-years at risk 
Age Exposure Status Menstrual 
Disturbance 
Rate/10,000 
person-years 
(95% CI) 
Follow-up time 
person-years  
18-55 
years 
Short-term opioids 1290 186.2  
(176.4, 196.7) 
69,264  
Long-term opioids 1432 209.5  
(199.0, 220.7) 
68,342  
 Total 2722 197.8  
(190.5, 205.4) 
137,606 
 
18-25 
years 
Short-term opioids 150 380.3  
(324.0, 446.2) 
3945 
 
 Long-term opioids 205 550.1  
(479.7, 630.8) 
3727 
 
 Total 355 
 
462.8  
(417.0, 513.5) 
7671 
 
26-35 
years 
Short-term opioids 326 267.1  
(239.6, 297.7) 
12,205  
 Long-term opioids 368 302.6  
(273.2, 335.2) 
12,161 
 Total 694 
 
284.8  
(264.4, 306.8) 
24,365 
36-45 
years 
Short-term opioids 540 224.2  
(206.0, 243.9) 
24,090 
 Long-term opioids 607 255.4  
(235.8, 276.5) 
23,769 
 Total 1147 239.7  
(226.2, 253.9) 
47,859 
46-55 
years 
Short-term opioids 274 94.4  
(83.9, 106.2) 
29,025 
 Long-term opioids 252 87.8  
(77.6, 99.4) 
28,686 
 Total 526 91.1  
(83.7, 99.3) 
57,710 
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Libido 
Outcome number two examined low libido. The rate of low libido in the whole cohort 
was 25.1/10,000 person-years (95% CI 22.7, 27.9), and the rate in long-term opioid 
users was 27.7/10,000 person-years (95% CI 24.0, 31.8), which is higher than the 
rate in those receiving short-term opioids of 22.6/10,000 person-years (95% CI 19.4, 
26.4). In 36-45 year olds the difference in levels of low libido is more marked with 
long-term users at a rate of 34.1/10,000 person-years (95% CI 27.6, 42.3) and short-
term users 20.2/10,000 person-years (95% CI 15.3, 26.6) and the CI does not cross, 
which indicates a statistically significant difference in this age group. It is important to 
note that even though the results were non-significant there is a consistent 
relationship with long-term opioid users having a higher rate of low libido than short-
term users across all age groups apart from the oldest women (46-55 year olds). See 
Table 6-7 for a full summary. 
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Table 6-7 Rate of low libido/10,000 person-years at risk  
Age Exposure Status Low 
libido 
Rate/10,000 person-
years (95% CI) 
Follow-up time 
person-years 
18-55 Short-term opioids 161 22.6 (19.4, 26.4) 71,095 
Long-term opioids 195 27.7 (24.0, 31.8) 70,470  
 Total 356 25.1 (22.7, 27.9) 141,566  
18-25 Short-term opioids 8 19.3 (9.7, 38.7) 4138  
Long-term opioids 9 22.1 (11.5, 42.5) 4065  
 Total 17 20.7 (12.9, 33.3) 8203  
26-35 Short-term opioids 31 24.4 (17.2, 34.7) 12,699  
Long-term opioids 36 28.2 (20.4, 39.1) 12,754  
 Total 67 26.3 (20.7, 33.4) 25,453  
36-45 Short-term opioids 50 20.2 (15.3, 26.6) 24,809  
Long-term opioids 84 34.1 (27.6, 42.3) 24,613  
 Total 138 27.1 (22.9, 32.1) 49,722  
46-55 Short-term opioids 72 24.4 (19.4, 30.8) 29,450  
Long-term opioids 66 22.7 (17.9, 28.9) 29,038  
 Total 138 23.6 (20.0, 27.9) 58,655  
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Infertility 
Outcome number three is concerned with infertility. The overall rate of infertility was 
17.7/10,000 person-years (95% CI 15.6, 20.0). The rates were highest in 18-35 year 
olds with the rates decreasing in those over 36 years old. The results are 
summarised in Table 6-8. There was no clear difference in rates between long-term 
and short-term opioid users with the 95% CI overlapping (except in over 45 year olds 
where there were only three outcomes in total) and the rate/10,000 person-years 
being higher sometimes in short-term users and sometimes in long-term users.  
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Table 6-8 Rate of infertility/10,000 person-years at risk 
Age Exposure Status Infertility Rate/10,000 person-
years (95% CI) 
Follow-up time 
person-years 
18-55 Short-term opioids 135 19.0 (16.0, 22.5) 71,177 
Long-term opioids 116 16.4 (13.7, 19.7) 70,642  
 Total 249 17.7 (15.6, 20.0) 141,819  
18-25 Short-term opioids 15 36.4 (22.0, 60.5) 4,116  
Long-term opioids 21 51.7 (33.7, 79.3) 4,059  
 Total 36 44.0 (31.8, 61.1) 8,175  
26-35 Short-term opioids 69 54.5 (43.1, 69.0) 12,653  
Long-term opioids 61 47.9 (37.3, 61.6) 12,726  
 Total 130 51.2 (43.1, 60.8) 25,379  
36-45 Short-term opioids 51 20.5 (15.6, 27.0) 24,819  
Long-term opioids 31 12.5 (8.8, 17.8) 24,712  
 Total 82 16.6 (13.3, 20.6) 49,531  
46-55 Short-term opioids 0 0.00 29,589  
Long-term opioids 3 1.0 (0.3, 3.2) 29,145  
 Total 3 0.5 (0.2, 1.6) 58,734  
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Menopause 
Outcome four looked at menopause and menopausal symptoms. Over the whole 
group, a rate of menopause of 357.1/10,000 person-years (95% CI 347.2, 367.4) was 
found; long-term opioid users had a higher rate of 383.7/10,000 person-years (95% 
CI 369.1, 398.8) compared to short-term opioid users whose rate was 330.9/10,000 
person-years (95% CI 317.5, 344.8). Table 6-9 summarises the results over the 
different age groups. The number of woman affected under 36 years old is small with 
only three women affected in the 18-25 age group and 71 women in the 26-35 age 
group. The highest rates were seen in 45-55 year olds with a rate of 674.2/10,000 
person-years (95% CI 643.5, 706.4) in long-term opioid users and 618.9/10,000 
person-years (95% CI 589.9, 649.5) in short-term opioid users. A similar change is 
seen in the 35-45 year old age group but the rates are lower than in the 45-55 year 
olds. It is important again to note that the relationship is consistent across all age 
groups and there is a higher rate of menopause in long-term users when compared 
to short-term users.  
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Table 6-9 Rate of menopause/10,000 person-years at risk 
Age Exposure Status Menopause Rate/10,000 person-
years (95% CI) 
Follow-up 
time person-
years 
18-55 Short-term opioids  2245 330.9 (317.5, 344.8) 67,840  
Long-term opioids 2566 383.7 (369.1, 398.8) 66,875  
 Total 4811 357.1 (347.2, 367.4) 134,715  
18-25 Short-term opioids 0 0 4,144  
Long-term opioids 3 7.4 (2.4, 22.8) 4,081  
 Total 3 3.6 (1.2, 11.3) 8,225  
26-35 Short-term opioids 23 18.0 (12.0, 27.2) 12,744  
Long-term opioids 48 37.6 (28.3, 49.9) 12,760  
 Total 71 27.8 (22.1, 35.1) 25,504  
36-45 Short-term opioids 563 233.2 (214.7, 253.2) 24,147  
Long-term opioids 745 313.3 (291.6, 336.6) 23,782  
 Total 1308 272.9 (258.5, 288.1) 47,930  
46-55 Short-term opioids 1659 618.9 (589.9, 649.5) 26,804  
Long-term opioids 1770 674.2 (643.5, 706.4) 26,252  
 Total 3429 646.3 (625.0, 668.3) 53,056  
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6.3 Covariates 
This section describes the conditions that were adjusted for if appropriate during Cox 
regression. The number of subjects with each condition is shown in Table 6-10 and in 
all cases the proportion in the long-term opioids group was higher or the same as 
that in the short-term opioids group. Of the eight conditions, three had no statistically 
significant difference (general thyroid conditions, low BMI conditions and adrenal 
conditions) and the remaining five had a statistically significant difference in the 
proportion affected between long-term opioid users and short-term opioid users 
(hypothyroid, hyperthyroid, obesity, structural gynaecology conditions and opioid 
misuse), with long-term users affected more often. 
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Table 6-10 Associated conditions split by duration of opioid use. Figures are number with problem, percentage with 
problem (95% CI) 
 Short-term opioids Long-term opioids Total p  
Non-specific thyroid conditions 52, 0.2 (0.2, 0.3) 58, 0.3 (0.2, 0.3) 110, 0.2 (0.2, 0.3) 0.57 
Hypothyroid 353, 1.6 (1.4, 1.8) 551, 2.5 (2.3, 2.7) 904, 2.0 (1.9, 2.2) <0.001 
Hyperthyroid 45, 0.2 (0.2, 0.3) 76, 0.3 (0.3, 0.4)  121, 0.3 (0.2, 0.3) 0.01 
Pituitary conditions 0, 0 (0, 0) 0, 0 (0, 0) 0, 0 (0, 0)   
Adrenal conditions 0, 0 (0, 0) 1, 0 (0, 0) 1,0 (0, 0) 0.32 
Hypothalamic conditions 0, 0 (0, 0) 0, 0 (0, 0) 0, 0 (0, 0)  
Obesity 417, 1.9 (1.7, 2.1) 768, 3.5 (3.2, 3.7) 1185, 2.7 (2.5, 2.8) 0.00 
Low BMI condition 27, 0.1 (0.1, 0.2) 36, 0.2 (0.1, 0.2) 63, 0.1 (0.1, 0.2) 0.26 
Structural Gynaecology 
conditions 
100, 0.5 (0.4, 0.5) 180, 0.8 (0.7, 0.9) 280, 0.6 (0.6, 0.7) 0.00 
Illegal opioid use 6, 0.0 (0.0, 0.1) 44, 0.2 (0.2, 0.3) 50, 0.1 (0.1, 0.2) 0.00 
 
P value calculated using Chi-squared comparison
 171 
 
6.4 Cox regression 
The primary analysis of the outcomes was the Cox regression comparing long-term 
opioid users and short-term opioid users. The Cox regression was adjusted for the 
confounding factors identified (including associated conditions described in section 
6.3 and demographic factors described in section 6.1).  
Prior to undertaking Cox regression, the number of subjects with a coded 
confounding condition per group was calculated to guide whether they should be 
included in the Cox regression (see Table 6-10). No subjects had a recorded 
diagnosis of pituitary or hypothalamic conditions, and only one subject had a 
recorded adrenal condition so these were not included in the Cox regression model. 
6.4.1 Menstruation 
The proportional hazards assumption was tested using a Schoenfeld residual test 
which returned a non-significant p (0.38) value so the assumption was upheld for the 
unadjusted Cox regression comparing long-term and short-term opioid users for the 
outcome abnormal menstruation. A log-log plot and Kaplan-Meier graph were also 
produced (Figure 6-3 and Figure 6-4). The log-log plot was not parallel as you would 
expect if the proportional hazards assumption holds, it starts with a wide gap and the 
plots become closer and then cross. Consequently it was decided to run the Cox 
regressions over shorter periods of time as well as over the whole follow-up period 
(with time-varying covariates). Schoenfeld residuals were also calculated for each 
covariate included in the adjusted Cox regression model, and where the proportional 
hazards assumption was violated these covariates were included in the model for the 
full follow-up period as time varying covariates. The time varying covariates were 
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age, NSAID use, pre-existing menstrual disorders, hypothyroidism and structural 
gynaecological conditions (see Table 6-11). The issue of time varying covariates was 
also addressed by undertaking Cox regression using three different time periods: 
year one, year two and years three to five, this was an alternative to time varying 
covariates that were used over the full follow-up period. The median follow-up was 
1193 days (Interquartile range (IQR) 552, 1825).  
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Figure 6-3 Log log plot for menstruation comparing duration of opioid use 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4 Kaplan-Meier curve for menstruation outcome comparing 
duration of opioid use  
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Table 6-11 Schoenfeld residuals for menstruation to test proportional 
hazards assumption prior to Cox regression for duration of opioid use 
Variable HR (95% CI) Rho$ P value 
Duration of opioid use  1.13 (1.05, 1.22) 0.02 0.43 
Pre-existing menstrual 
disorders 
2.34 (2.00, 2.73) 0.08 <0.001* 
Thyroid conditions (not 
specified) 
0.80 (0.33, 1.92) 0.01 0.62 
Hypothyroid 0.97 (0.73, 1.29) 0.04 0.04* 
Hyperthyroid 1.17 (0.58, 2.35) 0.01 0.74 
Alcohol use ever Reference   
Alcohol use never 0.86 (0.77, 0.96) 
 
-0.03 
 
0.20 
 
Alcohol use not known 0.85 (0.72, 1.00) -0.01 0.68 
Smoker ever Reference   
Smoker never 0.92 (0.85, 0.99) -0.02 0.20 
Smoking not known 0.97 (0.78, 1.23) 0.02 0.12 
BMI <25 Reference   
BMI>= 25 1.05 (0.97, 1.14) 0.00 0.87 
BMI missing 0.69 (0.56, 0.86) 0.02 0.40 
Low BMI conditions 1.42 (0.71, 2.87) 0.04 0.03 
Structural gynaecology 
conditions 
1.31 (0.90, 1.89) -0.05 0.01* 
Illegal opioid use 2.22 (1.00, 4.96) -0.01 0.48 
No NSAID use Reference   
Non-specific NSAID use 1.00 (0.92, 1.08) 0.01 0.73 
COX2 NSAIDs 0.80 (0.66, 0.98) -0.04 0.05* 
Age 0.95 (0.94, 0.95) -0.06 0.01* 
Global test   <0.001 
* indicates which variables were included as time-varying covariates based on the 
Schoenfeld residuals test $ indicates the Pearson product-moment correlation between the 
scaled Schoenfeld residuals and log(time) for each covariate.  
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The unadjusted Cox regression shown in Table 6-12 found a hazard ratio over the 
full five-year follow-up period of 1.13 (95% CI 1.05, 1.22), and 1.25 (95% CI 1.09, 
1.42) in the first year; both were statistically significant. In the remaining time periods 
the hazard ratio was consistently more than 1 but the results were not statistically 
significant. Cox regression was adjusted for thyroid conditions, illegal opioid use, 
BMI, smoking status, alcohol use, NSAID use and the following time varying 
covariates (pre-existing menstrual disorders, hypothyroid conditions, low BMI, 
structural gynaecological conditions and age) over the full five year follow-up (Table 
6-12). The result remained statistically significant over the full follow-up (1.13 (95% 
CI 1.05, 1.21) p < 0.001) and year one (1.23 (95% CI 1.07, 1.41) p <0.001).  
Table 6-12 Cox regression comparing duration of opioid use for the 
outcome altered menstrual cycle 
Follow-up Hazard ratio (95% CI) 
unadjusted 
P Hazard ratio (95% CI) 
adjusted 
P 
5 years 1.13 (1.05, 1.22) < 0.001 1.13 (1.05, 1.21) <0.001 
< 1 year 1.25 (1.09, 1.42) < 0.001 1.23 (1.07, 1.41) <0.001 
1-2 years 1.06 (0.92, 1.24) 0.42 1.06 (0.91, 1.24) 0.45 
3-5 years 1.08 (0.96, 1.21) 0.18 1.10 (0.99, 1.26) 0.08 
 
The Cox regression for different age groups showed statistically significant hazard 
ratios in 18-45 year-olds see Table 6-13. Those women 46 years old and over had a 
hazard ratio that crossed 1 and did not show any increased risk of menstrual 
disturbances in women in the long-term opioid group compared with short-term 
opioid users. The largest hazard ratio was seen in 18-25 year olds, 1.37 (95% CI 
1.13, 1.67) p <0.001. When adjusted for the covariate factors (thyroid conditions, 
illegal opioid use, BMI, smoking status, alcohol use, NSAID use and time varying 
covariates for pre-existing menstrual disturbance, hypothyroid, structural 
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gynaecological conditions, age and low BMI conditions) this was significant in all 
women less than 46 years old (Table 6-13).  
Table 6-13 Cox Regression for menstrual disturbance and duration of 
opioid use split by age group for 5 year follow-up 
Age Range 
(years) 
Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
18-25 1.37 (1.13, 1.67) <0.001 1.31 (1.07, 1.60) 0.01 
26-35 1.15 (1.01, 1.32) 0.03 1.17 (1.02, 1.34) 0.02 
36-45 1.13 (1.02, 1.25) 0.02 1.13 (1.02, 1.26) 0.02 
46-55 0.93 (0.79, 1.10) 0.39 1.00 (0.85, 1.19) 0.96 
 
Disturbance of menstruation had a higher hazard of occurring in women taking long-
term opioids with this effect being statistically significant over the entire five year 
follow-up and the first year individually but not in year two or years three to five 
separately. The hazard ratio also remained above 1 after adjustment in women less 
than 46 years old. The relationship was statistically significant and showed the 
hazard of abnormal menstruation for women taking long-term opioids is higher than 
for women who received short-term opioids.   
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6.4.2 Libido 
The proportional hazard assumption for unadjusted Cox regression was upheld with 
a non significant Schoenfeld residual (p=0.58). The asumption was also supported by 
the log log plot (Figure 6-5) which did not show the two plots crossing and the 
kaplan-meier graph (Figure 6-6) where again the plots did not cross. The plots 
diverge as time passes which supported the use of shorter time periods rather than 
just the five year follow-up. The Shoenfeld residuals checked prior to fitting the model 
for adjusted Cox regression showed that age should be included as a time varying 
covariate (see Table 6-14). The median follow-up time was 1263 days (IQR 595, 
1825 days).  
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Figure 6-5 Log log plot for libido comparing duration of opioid use 
 
Figure 6-6 Kaplan-Meier curve for libido outcome comparing duration of 
opioid use 
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Table 6-14 Schoenfeld residuals testing the proportional hazards 
assumption for adjusted Cox regression for libido comparing duration of 
opioid use 
Variable HR (95% CI) Rho P value 
Duration of opioid use 1.19 (0.96, 1.49) 0.005 0.93 
Pre-existing libido 
disorders 
14.11 (7.9, 25.1) -0.09 0.10 
Thyroid conditions (not 
specified hypo/hyper) 
2.63 (0.65, 10.6) -0.38 0.47 
Hypothyroid 0.50 (0.18, 1.33) 0.068 0.20 
Hyperthyroid 2.27 (0.56, 9.20) -0.01 0.79 
Alcohol use ever Reference 
 
  
Alcohol use never 1.47 (1.03, 2.11) 
 
-0.01 
 
0.91 
 
Alcohol use not known 1.11 (0.63, 1.98) 0.07 0.19 
Smoker ever Reference   
Smoker never 0.97 (0.78, 1.20) -0.03 0.60 
Smoking not known 1.20 (0.68, 2.11) 0.09 0.08 
BMI <25 Reference   
BMI>= 25 0.99 (0.79, 1.23) -0.02 0.74 
BMI missing 0.33 (0.13, 0.83) -0.01 0.91 
Low BMI conditions - - - 
Structural gynaecology 
conditions 
1.53 (0.49, 4.77) 0.04 0.47 
Illegal opioid use 4.04 (0.56, 28.94) -0.01 0.85 
No NSAID use Reference   
Non-selective NSAID use 1.19 (0.96, 1.48) 0.05 0.37 
COX2 NSAIDs 0.95 (0.56, 1.59) -0.01 0.82 
Age 0.99 (0.98, 1.01) 0.11854 0.03* 
Global test   0.31 
* indicates which variables were included as time-varying covariates based on the 
Schoenfeld residuals test $ indicates the Pearson product-moment correlation between the 
scaled Schoenfeld residuals and log(time) for each covariate.  
 180 
 
The unadjusted Cox regression for low libido is shown in Table 6-15. There appeared 
to be a relationship where long-term opioids were associated with a higher hazard of 
low libido as the hazard ratios were greater than 1 in all groups. However, the 
confidence intervals crossed through 1 and the results were not statistically 
significant. The Cox regression with adjustment (for pre-existing low libido, thyroid 
conditions, BMI, structural gynaecological conditions, illegal opioid use, smoking 
status, alcohol use, NSAID use and age as a time varying covariate) did not show a 
statistically significant relationship between opioid use and low libido, but the hazard 
ratio remained greater than one in all time periods except 1-2 years (see Table 6-15).  
Table 6-15 Cox Regression adjusted and unadjusted for libido comparing 
duration of opioid use 
Follow-up Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
5 years 1.22 (0.99, 1.51) 0.06 1.19 (0.96, 1.48) 0.11 
< 1 year 1.38 (0.94, 2.02) 0.10 1.35 (0.91, 2.01) 0.14 
1-2 years 1.00 (0.66, 1.52) 0.99 0.89 (0.58, 1.37) 0.56 
3-5 years 1.26 (0.92, 1.72) 0.15 1.18 (0.85, 1.62) 0.32 
 
Cox regression was split for age over the five-year period and the hazard ratio was 
found to be statistically significant in 36-45 year olds with women who took long-term 
opioids having a higher hazard of being affected by low libido (Table 6-16). When the 
Cox regression over different age groups was adjusted (as described above) the 
hazard ratio remained significant in women 36-45 year-old (Table 6-16). The 
remaining age groups except in 46-55 year olds all had a hazard ratio over 1 but 
these were not statistically significant. This age group was then analysed over the 
three time periods and only remained statistically significant over the full five year 
follow-up and years three to five. The hazard ratios remained above 1 but the CI 
were wide, and following adjustment (as described above) the hazard ratio remained 
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statistically significant only over the whole five year follow-up (Table 6-16 and Table 
6-17).  
Table 6-16 Results of Cox regression for the outcome low libido and 
duration of opioid use comparing opioid duration split by age groups. 
Age Range 
(years) 
Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
18-25 1.14 (0.44, 2.96) 0.78 1.28 (0.47, 3.43) 0.63 
26-35 1.16 (0.72, 1.87) 0.55 1.16 (0.71, 1.91) 0.56 
36-45 1.69 (1.19, 2.40) <0.001 1.64 (1.15, 2.35) 0.01 
46-55 0.93 (0.67, 1.30) 0.67 0.89 (0.63, 1.26) 0.51 
 
Table 6-17 Cox regression for low libido comparing opioid duration for 36-
45 year olds unadjusted and adjusted 
Follow-up Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
5 years 1.69 (1.19, 2.40) <0.001 1.64 (1.15, 2.35) 0.01 
< 1 year 1.69 (0.91, 3.13) 0.10 1.76 (0.93, 3.32) 0.08 
1-2 years 1.38 (0.68, 2.82) 0.37 1.27 (0.61, 2.64) 0.53 
3-5 years 1.89 (1.11, 3.21) 0.02 1.78 (1.03, 3.07) 0.04 
 
Overall the results for libido showed a relationship where the hazard of low libido 
seemed to be higher in women who took long-term opioids compared with women 
who took short-term opioids, however this difference did not reach statistical 
significance. The only age group with a statistically significant difference were women 
aged 36-45 years old and this relationship remained significant over the full five year 
follow-up period and in years 3-5 of follow-up.    
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6.4.3 Infertility 
The proportional hazards assumption was tested using Schoenfeld residual test for 
the unadjusted Cox regression, the p value was 0.80 so the assumption was upheld. 
A log-log plot was also produced (Figure 6-7) the plots were very close together and 
appear to cross. A Kaplan-Meier curve (Figure 6-8) showed the two plots crossing 
early on and then the difference becoming wider with those not taking long-term 
opioids having a higher probability of infertility. The proportional hazards assumption 
was also checked for the adjusted Cox regression and this determined that NSAID 
use should be included in the model as a time varying covariate (see Table 6-18). 
The median follow-up time was 1268 days (IQR 597, 1825 days). 
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Figure 6-7 Log Log plot for infertility comparing duration of opioid use 
Figure 6-8 Kaplan-Meier curve for infertility comparing duration of opioid 
use 
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Table 6-18 Schoenfeld residuals testing the proportional hazards 
assumption for adjusted Cox regression for infertility and duration of opioid 
use  
Variable HR (95% CI) Rho P  
Duration of opioid use 0.84 (0.65, 1.08) -0.03 0.69 
Pre-existing infertility disorders 23.16 (14.80, 36.23) -0.09 0.13 
Thyroid conditions (not specified 
hypo/hyper) 
1.66 (0.23, 11.89) 0.05 0.42 
Hypothyroid 0.59 (0.19, 1.85) 0.05 0.43 
Hyperthyroid - - - 
Alcohol use ever Reference   
Alcohol use never 1.04 (0.80, 1.34) 0.04 0.48 
Alcohol use not known 0.66 (0.38, 1.13) 0.08 0.18 
Smoker ever Reference   
Smoker never 1.04 (0.80, 1.34) -0.08 0.23 
Smoking not known 1.31 (0.61, 2.81) -0.00 1.0 
BMI <25 Reference   
BMI>= 25 0.87 (0.67, 1.13) -0.10 0.13 
BMI missing 1.01 (0.58, 1.77) -0.06 0.35 
Low BMI conditions - - - 
Structural gynaecology conditions 2.35 (1.14, 4.84) 0.02 0.70 
Illegal opioid use - - - 
No NSAID use Reference   
Non-selective NSAID use 1.07 (0.83, 1.38) 0.13 0.04* 
COX2 NSAIDs 1.21 (0.63, 2.33) 0.01 0.49 
Age 0.91 (0.89, 0.92) -0.07 0.46 
Global test   0.46 
* indicates which variables were included as time-varying covariates based on the 
Schoenfeld residuals test $ indicates the Pearson product-moment correlation between the 
scaled Schoenfeld residuals and log(time) for each covariate.  
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The Cox regression did not show any statistically significant difference between long-
term and short-term opioid users and there was no uniform direction of change seen 
(see Table 6-19). When the results were adjusted for covariates (age, pre-existing 
infertility, thyroid conditions, BMI, structural gynaecological conditions, illegal opioid 
use, smoking status, alcohol use and NSAID use as a time varying covariate), the 
results of the Cox regression remained similar. 
Table 6-19 Infertility Cox regression for duration of opioid use unadjusted 
and adjusted   
Follow-up Hazard ratio (95% CI) 
unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
5 years 0.86 (0.67, 1.11) 0.25 0.84 (0.65, 1.08) 0.17 
< 1 year 0.95 (0.61, 1.48) 0.82 0.94 (0.59, 1.48) 0.77 
1-2 years 0.78 (0.49, 1.24) 0.29 0.76 (0.47, 1.23) 0.26 
3-5 years 0.87 (0.59, 1.28) 0.47 0.82 (0.55, 1.23) 0.33 
 
The Cox regression was then undertaken for each age group. This showed a hazard 
ratio of 0.61 (95% CI 0.39, 0.95) in the 36-45 year old age group which was 
statistically significant. The adjusted (as described above) Cox regression still found 
a statistically significant hazard ratio of less than 1 in women aged 36-45 years old, 
indicating a decreased risk of infertility in long-term opioid users see Table 6-20 for 
full results. 
Table 6-20 Infertility Cox regression for duration of opioid use split for age 
categories unadjusted and adjusted 
Age Range 
(years) 
Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
18-25 1.42 (0.73, 2.75) 0.30 1.25 (0.61, 2.54) 0.54 
26-35 0.88 (0.62, 1.24) 0.46 0.85 (0.60, 1.21) 0.36 
36-45 0.61 (0.39, 0.95) 0.03 0.61 (0.38, 0.97) 0.04 
46-55 No result   No result  
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For this outcome there was no statistically significant difference seen between 
women taking long-term opioids and short-term opioids except in the 36-45 year old 
age group, which showed those women taking long-term opioids had a lower hazard 
of infertility than short-term opioid users. The hazard ratio was less than 1 in 36-45 
year-olds over the full five year follow-up and this was statistically significant (Table 
6-21). 
Table 6-21 Cox regression infertility and duration of opioid use for age 
range 36-45 years unadjusted and adjusted 
Follow-up Hazard ratio (95% CI) 
unadjusted 
P Hazard ratio (95% 
CI) adjusted 
P 
5 years 0.61 (0.39, 0.95) <0.05 0.58 (0.37, 0.92) <0.05 
< 1 year 0.55 (0.26, 1.20) 0.14 0.64 (0.29, 1.45) 0.29 
1-2 years 0.81 (0.34, 1.97) 0.65 0.77 (0.31, 1.93) 0.57 
3-5 years 0.55 (0.27, 1.11) 0.10 0.50 (0.24, 1.05) 0.07 
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6.4.4 Menopause 
The proportional hazards assumption was tested using Schoenfeld residual test for 
the unadjusted Cox regression and p value (0.45) was not statistically significant, so 
the proportional hazards assumption was upheld for non-adjusted Cox regression. A 
log-log plot was also produced (Figure 6-10). The median follow-up time was 1144 
days (IQR 536, 1825 days). A Kaplan-Meier curve is shown in figure 6-9 and this 
clearly indicated an increased number of events in the long-term opioid group. Each 
covariate to be included in the model was then tested individually and a Schoenfeld 
residual was undertaken on the entire model, a p value of 0.0 was found with four 
covariates contributing to this (pre-existing menopause symptoms, structural 
gynaecological disorders, age and NSAID use), these covariates were then included 
in the adjusted model as time varying covariates (see Table 6-22).  
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Figure 6-9 Kaplan-Meier curve for menopause comparing duration of 
opioid use  
Figure 6-10 Log Log plot for menopause outcome comparing duration of 
opioid use 
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Table 6-22 Schoenfeld residuals testing the proportional hazards 
assumption for adjusted Cox regression for menopausal symptoms 
comparing duration of opioid use  
Variable HR (95% CI) Rho P value 
Duration of opioid use 1.16 (1.10, 1.23) -0.01 0.41 
Pre-existing menopause disorders 2.09 (1.89, 2.31) -0.08 0.00* 
Thyroid conditions (not specified 
hypo/hyper) 
0.95 (0.55, 1.64) -0.02 0.10 
Hypothyroid 1.01 0.85, 1.21) -0.01 0.37 
Hyperthyroid 0.57 (0.30, 1.10) 0.01 0.58 
Alcohol use ever Reference   
Alcohol use never 1.03 (0.94, 1.12) -0.01 0.61 
Alcohol use not known 0.92 (0.81, 1.11) -0.01 0.54 
Smoking ever Reference   
Smoking never 1.09 (1.03, 1.16) -0.02 0.20 
Smoking not known 0.95 (0.81, 1.11) 0.02 0.12 
BMI <25 Reference   
BMI>= 25 0.98 (0.93, 1.05) 0.01 0.56 
BMI missing 0.77 (0.64, 0.92) -0.01 0.33 
Low BMI conditions 0.26 (0.04, 1.87) -0.02 0.23 
Structural gynaecology conditions 1.06 (0.66, 1.71) -0.04 0.01* 
Illegal opioid use 2.32 (0.96, 5.59) 0.02 0.20 
No NSAID use Reference   
Non-specific NSAID use 0.99 (0.74, 1.06) 0.26 0.07 
COX2 NSAIDs 0.90 (0.79, 1.02) -0.03 0.05* 
Age 1.10 (1.09, 1.10) -0.14 0.00* 
Global test   0.00 
* indicates which variables were included as time-varying covariates based on the 
Schoenfeld residuals test $ indicates the Pearson product-moment correlation between the 
scaled Schoenfeld residuals and log(time) for each covariate.  
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Cox regression for menopause consistently showed hazard ratios of 1.14 or more 
across the whole follow-up period and all of the time periods showed a statistically 
significant increased risk in long-term opioid users. The highest hazard ratio was 
seen in year two with a value of 1.19 (95% CI 1.06, 1.34) see Table 6-23 for full 
results. The Cox regression was adjusted (for thyroid conditions, BMI, illegal opioid 
use, smoking status, alcohol use and time varying covariates for NSAID use, pre-
existing menopausal conditions, age and structural gynaecological conditions) and all 
time periods remained statistically significant see Table 6-23 for full results.  
Table 6-23 Unadjusted and adjusted menopause Cox regression 
comparing duration of opioid use 
Follow-up Hazard ratio (95% CI) 
unadjusted 
P Hazard ratio (95% CI) 
adjusted 
P 
5 years 1.16 (1.10, 1.23) <0.001 1.16 (1.10, 1.23) <0.001 
< 1 year 1.16 (1.04, 1.30) 0.01 1.16 (1.03, 1.30) 0.01 
1-2 years 1.19 (1.06, 1.34) <0.001 1.17 (1.04, 1.32) 0.01 
3-5 years 1.14 (1.06, 1.24) <0.001 1.16 (1.06, 1.25) <0.001 
 
The Cox regression was repeated for each individual age group (except those 25 
years old and less where there were too few outcomes to undertake Cox regression). 
The hazard ratio was greater than 1 across all age groups and was statistically 
significant. The hazard ratio after adjustment (adjusted for thyroid condition, illegal 
opioid use, BMI, smoking status, alcohol use and the following time varying 
covariates age, NSAID use, pre-existing menopausal symptoms and structural 
gynaecological conditions) remained statistically significant in all age groups, see 
Table 6-24 for full results. 
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Table 6-24 Non adjusted and adjusted menopause Cox regression split for 
age categories comparing duration of opioid use 
Age Range 
(years) 
Hazard ratio (95% 
CI) unadjusted 
P Hazard ratio (95% 
CI) adjusted 
 
18-25 No results  No results  
26-35 2.09 (1.27, 3.43) <0.001 2.00 (1.19, 3.34) <0.001 
36-45 1.35 (1.21, 1.50) <0.001 1.32 (1.18, 1.48) <0.001 
46-55 1.09 (1.02, 1.17) 0.01 1.10 (1.02, 1.17) 0.01 
 
Overall the results for menopause the hazard of reporting menopausal symptoms 
was higher in women taking long-term opioids than those receiving short-term 
opioids, this was a statistically significant change across the full five year follow-up 
and in all age groups.  
6.4.5 Sensitivity analysis 
Sensitivity analysis was undertaken using two methods. The first sensitivity analysis 
included only complete cases (cases with no missing data) and the second included 
only those without pre-existing reproductive dysfunction (defined in section 5.7). The 
results were similar with no change in statistical significance when the original 
analysis was compared with the sensitivity analyses, see Table 6-25 for the full 
results. 
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Table 6-25 Adjusted hazard ratios for complete cohort and sensitivity 
analysis including only complete cases and only those without pre-existing 
conditions comparing duration of opioid use (analyses including time 
varying covariates as described previously shown) 
 All cases Sensitivity 
Analysis 
(complete cases) 
Sensitivity analysis (removed 
if pre-existing outcome 
condition) 
Menstruation 1.14 (1.06, 1.22) 1.11 (1.01, 1.22) 1.12 (1.04, 1.20) 
Libido 1.19 (0.96, 1.48) 1.26 (0.95, 1.68) 1.20 (0.97, 1.50) 
Infertility 0.82 (0.64, 1.06) 0.80 (0.57, 1.12) 0.87 (0.67, 1.14) 
Menopause 1.16 (1.10, 1.23) 1.15 (1.07, 1.22) 1.20 (1.13, 1.28) 
 
6.5 Conclusion 
This chapter has presented the results of the CPRD cohort study undertaken for this 
thesis. There was a significant increased hazard of both menopausal symptoms and 
abnormal menstruation in long-term opioid users when compared to short-term opioid 
users. The strengths and limitations of the cohort study will be discussed in the next 
chapter.  
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7 Cohort study discussion 
The aim of the cohort study was to investigate the incidence of reproductive and 
sexual dysfunction in women prescribed opioids for potentially painful 
musculoskeletal conditions and the association between duration of opioid use and 
reproductive and sexual dysfunction. This chapter will summarise the findings of the 
cohort study, compare these results to what is already known and then discuss the 
strengths and limitations of the study. The chapter will then discuss the meaning of 
these results and how they might apply to the population of interest and the key 
messages from the study. 
7.1 Summary of main findings 
The cohort study described in chapters 5 and 6 found a statistically significant 
increased risk of menopausal symptoms and abnormal menstruation in women 
prescribed long-term opioids compared to those prescribed short-term opioids. This 
is the first study of its size to investigate this area and adds to an area where there 
has been previously little research (as seen in the systematic review in chapter 3). 
However, there was no increased risk of low libido or infertility found, although the 
number of women affected by low libido was much lower than that expected based 
on population estimates.  
These results support the original hypothesis that long-term opioid use is associated 
with symptomatic disruption of the HPG axis.  
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7.2 Comparison with other studies 
As discussed in Chapter 3, which reports the results of the systematic review, there 
were 12 papers (with 165 subjects investigated in total) investigating reproductive 
dysfunction in women aged 18-55 years old receiving long-term opioids. To the 
author’s knowledge, there are no other studies that have used a large primary care 
cohort, or had the length of follow-up, as in the cohort study undertaken as part of 
this thesis. Previous papers all had small numbers, but they did show a trend towards 
an increased risk of HPG disruption in long-term opioid users, which agrees with the 
findings reported in Chapter 6. The results of the cohort study also fit with previous 
animal studies that have shown that long-term opioids are associated with decreased 
LH levels through several mechanisms which can lead to low levels of sex hormones 
(Vuong et al., 2010). 
The cohort study found a statistically significant increased risk of abnormal 
menstruation in long-term opioid users. This is in agreement with the findings from 
the systematic review (section 3.5.1) and builds the evidence further, as only one of 
the studies in the systematic review found a statistically significant increased risk in 
opioid users in a small study. The studies in the review found a higher proportion of 
opioid users affected by abnormal menstruation (23-81%) in comparison with this 
cohort study (6.2%, 95% CI 5.9, 6.4%); this is likely due to the difference between 
database research (relying on medical records) and primary data collection research 
(Last, 1963). Medical records research only contains information if the patient has 
presented with a certain condition for medical care (this is known as the clinical 
iceberg and is discussed fully in section 4.6.1). The cohort study undertaken for this 
thesis also found an increased risk of menopausal symptoms in women prescribed 
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long-term opioids. This was not an outcome described in any of the studies in the 
systematic review, although it does fit with the hypothesis that long-term opioids 
disrupt the HPG axis (Daniell, 2008). A greater proportion of participants within the 
systematic review (61-100%) suffered with low libido compared with the cohort study 
(0.8% 95% CI 0.7, 0.9). Additionally, the number of women with a coded diagnosis of 
low libido was low in contrast to population estimates (25-41%) (Dunn et al., 1998; 
Laumann et al., 2005). This difference is likely due to the clinical iceberg and women 
not consulting their GP about problems with libido (due to a variety of reasons 
previously discussed), whereas they may reveal the condition on direct questioning 
(Last, 1963; Montgomery, 2008). 
The cohort study was undertaken within a primary care setting which contrasts with 
the currently available literature mainly undertaken within secondary care (11/12 
papers within the systematic review took place in secondary care clinics). This 
means that the study undertaken for this thesis is generalisable to the typical 
population using opioids in the UK for musculoskeletal pain (the majority of patients 
with chronic pain are treated in the community rather than in specialist clinics), 
whereas previous research may not be generalisable to a UK primary care 
population and as the numbers included were so limited may also not have been 
generalisable to patients with chronic pain treated with opioids in secondary care 
(Breivik et al., 2006).  
The cohort study undertaken for this thesis adds to the previous research in this area 
as it was the first large scale cohort study to investigate reproductive and sexual 
dysfunction. The study is the first to find both an increased hazard of 
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menopause/menopausal symptoms and abnormal menstruation in women prescribed 
long-term opioids when compared to short-term opioids.  
7.3 Strengths and limitations of the study 
One of the major challenges during the design of the cohort study was addressing 
the issue of confounding by indication, which was discussed previously in section 
4.7.3. A strength of the study was how confounding by indication was dealt with 
including matching during the recruitment stage. The two groups within the cohort 
were matched for date of opioid use and presence of a coded painful 
musculoskeletal condition. This meant all the participants across both short-term and 
long-term opioid groups were prescribed opioids and had a potentially painful 
musculoskeletal condition which the opioids were likely prescribed for, addressing 
important aspects of confounding by indication. Painful musculoskeletal conditions 
rather than CNCP were matched for, as they provided a more homogenous group of 
participants. However, this does mean that the results may not be generalisable to all 
CNCP patients. This method was unable to address confounding by severity (a 
subset of confounding by indication) or the longevity of the condition, which may then 
affect the duration of opioid use (Joffe and Rosenbaum, 1999). Long-term opioid 
users are more likely to have severe disease and this may mean they are prescribed 
opioids at a higher dose than short-term users. This could affect the results as daily 
morphine equivalent opioid dose was not taken into account within the cohort study 
and previous studies on adverse events have found increased risk of adverse events 
associated with increasing daily opioid dose (Bedson et al., 2019a; Saunders et al., 
2009). There is evidence however, that the majority of long-term opioid users in the 
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UK are receiving less potent opioids, for example codeine 15mg and this is likely to 
be reflected in the cohort (Bedson et al., 2016).  
The cohort study also considered all opioids as one so did not take into account 
different opioid types and this may potentially be a limitation. Some opioids may not 
have the same risk of adverse events as others, for instance buprenorphine seemed 
to have a fewer endocrine adverse effects than other opioids, which was highlighted 
by the systematic review in Chapter 3 and one study has also shown that tramadol 
has a lower risk of fractures when compared to hydrocodone (Solomon et al., 2010a). 
The nature of database research means that it cannot be guaranteed that the opioid 
was prescribed for the musculoskeletal condition (as the musculoskeletal condition 
and opioid were linked through a temporal association rather than a direct link in the 
database as this is not possible within CPRD) and this may introduce further 
confounding, as the indication for the opioid may be a different condition and this will 
affect the matching that was undertaken to build the cohort, however CPRD does ask 
for a code to be recorded when changing treatment regimen so this should help to 
link the opioid to a musculoskeletal condition (Jordan et al., 2006). Matching the 
cohort for opioid use ensured that all the women included were considered suitable 
for an opioid prescription and had no contraindications, which removed further 
potential systematic differences. The women in the short-term opioid group did not 
progress to long-term opioids and this may be due to many things including 
intolerance to the medicine, improvement in their condition or perception of increased 
risk associated with the opioid in some way. Consequently, systematic differences 
between the two groups may still remain, but compared to previous studies 
undertaken in this area this has been addressed as fully as possible. 
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One particular issue for this study is that CNCP is more likely to be present in the 
long-term opioid users as they are using long-term analgesics. CNCP can be 
conceptualized as chronic inescapable stress on the HPA (hypothalamic-pituitary-
adrenal) axis, and stress can be a cause of HPG dysfunction and amenorrhoea 
(Blackburn-Munro 2001; The Practice Committee of the American Society for 
Reproductive Medicine 2008). CNCP can therefore be associated with the outcomes 
of interest and could not be matched for within the cohort study, which means there 
is likely to be residual confounding by indication. CNCP has been associated with low 
libido in previous work, with one questionnaire from chronic pain clinics showing 73% 
of patients (both sexes) reporting current sexual difficulties, compared with a survey 
of the general population which found 41% of women reporting sexual difficulties 
(Ambler et al., 2001; Dunn et al., 1998).  
The comparison groups were matched for year of birth and this was important as age 
has a direct impact on two of the primary outcomes of the study (menopause and 
libido). Menopause becomes more likely as a woman gets older (the average age of 
the menopause is 52 years old in the UK) (Hardy and Kuh, 2005). Age has a direct 
link with menopause and it was important that this was taken into account during 
matching of the cohort (Hardy and Kuh, 2005). Age and menopausal status also 
have an effect on libido as both increasing age and being in the peri-menopause 
have been shown to be associated with low libido (Hayes et al., 2008). It was not 
possible to match for menopause as it was an outcome of interest but the cohort was 
matched for age by year of birth.  
The category of opioid use was identified at the start of follow-up, whereby if a patient 
met the criteria for long-term opioid use at any point they were included as a long-
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term user and if not as a short-term user. A long-term user may have stopped using 
opioids at any point during follow-up. Once assigned to a group, participants did not 
change groups, and this could be a potential limitation since in real life the opioid 
exposure would be time-varying, and this may have had an impact on the 
generalisability of the results. The identification of opioid users was based on 
prescriptions, but it cannot be established how or if the women were using the 
prescribed opioids. Identifying women purely as long-term or short-term users is also 
a potential limitation, as this is a binary measure and does not take into account 
different strengths, delivery methods and type of opioids that may be being used. In 
previous studies into adverse effects, the daily morphine equivalent dose has been 
measured, and in one particular study looking at fractures the increase in risk was 
only statistically significant in those that received 50mg or more of morphine 
equivalent per day (Saunders et al., 2009). Consequently, adverse effects may be 
dose dependent as well, but this was not part of the analysis within the cohort study 
(Bedson et al., 2019a; Saunders et al., 2009).  
Type of opioid was also not considered and some opioids have different mechanisms 
of action when compared with other opioids; for example, buprenorphine, (previously 
discussed in section 2.3). This may have an effect on the risk of adverse effects 
associated with buprenorphine, since a previous review found that adverse effects 
occur at a lower rate with buprenorphine at therapeutic dose when compared with 
other opioids (Aloisi et al., 2009; Kress, 2009). Buprenorphine within therapeutic 
range appears to have a ceiling effect for adverse effects (including respiratory 
depression) and this may also be the case for endocrine adverse effects (Kress, 
2009). Buprenorphine has been compared to morphine (equipotent doses in animal 
 200 
 
studies) for immunosuppressive effects, however buprenorphine did not have an 
effect on the HPA axis whereas morphine caused an effect. There may be a similar 
effect for the HPG axis which is the area of interest to this thesis (Kress, 2009). 
Another study found that for fractures tramadol appeared to have a lower risk when 
compared to hydrocodone and all-cause mortality was higher for oxycodone and 
codeine compared to hydrocodone, so there may be variability between opioids for 
other adverse effects (Solomon et al., 2010a). All opioids were considered together 
for the purpose of the cohort study so this did not take into account the differences 
between opioids. Buprenorphine forms only a small proportion of opioid prescribing 
(<5%) based on the available evidence (Zin et al., 2014), therefore the inclusion of 
buprenorphine if it had a decreased risk of causing adverse effects may have only 
slightly weakened any association seen, whereas if the risk is lower for instance in 
those using tramadol this could have altered results more significantly as more 
patients will be taking this than buprenorphine (Kress, 2009; Zin et al., 2014). 
Buprenorphine can also be prescribed as a patch and the mode of delivery may also 
affect potential adverse events.  
The setting of the study was important as it has both strengths and limitations. The 
cohort study was undertaken in CPRD a large primary care database within the UK 
(see section 4.61 and section 5.4). Using a database allowed investigation of the 
question in a large cohort with complete follow-up, allowing enough statistical power 
to undertake appropriate analysis. The sample should be representative of the 
population of interest and have good external validity, and CPRD has been shown to 
be broadly representative of the UK population when compared with census data 
(Herrett et al., 2010). This study is able to accurately represent the population using 
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opioids within the UK as it includes primary care patients (where the ongoing 
responsibility for prescribing most medicines within the UK lies), rather than just 
those seen in secondary care (where the majority of the current research has been 
undertaken) (NHS England, 2018; Wersocki et al., 2017). Only 23% of pain patients 
are seen by a pain specialist within the UK and these may represent a subset of 
patients with more severe pain (Breivik et al., 2006). CPRD has been validated for 
musculoskeletal conditions previously, one of the criteria for identifying the cohort. All 
prescriptions are recorded automatically within GP systems.  
The identification of the cohort is unlikely to have missing or misleading data as both 
medicine and musculoskeletal pain are well documented in CPRD (Jordan et al., 
2006; Lawson et al., 1998; Medicines and Healthcare products Regulatory Agency, 
2009). In the UK, the only opioids available legally without prescription are low dose 
codeine and dihydrocodeine for a maximum of three days for acute injuries, so 
opioids used legally for any longer than this should be recorded within CPRD 
(Medicines and Healthcare products Regulatory Agency, 2009). All practices that 
contribute to CPRD have to meet data quality conditions and are regularly monitored, 
therefore the quality of data is high and this is reflected by the large number of 
validation studies that have been undertaken (Herrett et al., 2010, 2015). CPRD data 
is entered into medical systems contemporaneously for medical care and this means 
that it is not affected by recall or reporting bias. This is important for research into 
sensitive areas where social desirability may affect results (as in this case where 
sexual and reproductive function are being investigated) (Delgado-Rodriguez and 
Llorca, 2004). The participants were matched by general practice and this helps to 
limit the differences between practices and coding and inter-rater reliability should be 
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improved. This should mean that from each GP practice patients for both the short-
term and long-term groups will have been identified in the same manner. Another 
advantage of using CPRD is that it allows the researcher access to information on 
relevant factors in the participants’ past medical history and this can then be used in 
analysis of the data. Inevitably the data recorded within CPRD may not include 
factors which might be relevant to the analysis for this study. 
Additionally, there are overall limitations that apply to all database research. As 
discussed previously, a lack of a coded diagnosis is considered as the absence of a 
disease but this is not necessarily the case (Herrett et al., 2015). Research in CPRD 
tends to have a high specificity but low sensitivity for identifying conditions so it is 
likely that all the participants identified as having a condition actually do have the 
condition, but there is a group of patients who represent false negatives (Herrett et 
al., 2010; Parikh et al., 2008). This inability to identify patients that do not present, but 
may still have a condition can be explained by a phenomenon described by Last 
(1963), who describes it as the clinical iceberg. The clinical iceberg is where only a 
small proportion of cases are actually seen by clinicians, and the rest remain hidden 
and medical services are not aware that they exist (Last, 1963). This means that a 
proportion of conditions are not recorded, but those that are, are clinically significant 
as patients have sought medical attention for them. It is important to consider that 
with sexual health conditions, this may also reflect that patients do not feel confident 
discussing these conditions with their doctor since they may be considered private, or 
patients may feel awkward discussing these issues, and consequently a larger 
proportion may not be reported (Delgado-Rodriguez and Llorca, 2004; Montgomery, 
2008). This effect can be seen in the difference in low libido rates reported within the 
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cohort (less than 1%) and those expected in the general population from previous 
self-report studies (25-50%) (Dunn et al., 1998; Laumann et al., 2005). There is no 
reason to suspect that the effect of the clinical iceberg is different in the two arms of 
the cohort study. However, due to the low numbers of women reporting low libido 
there was not enough statistical power to show a significant difference even though 
long-term opioid users appeared to be affected more often.  
Practices that contribute to CPRD do so on a voluntary basis and they tend to be 
larger practices. They may reflect a specific subset of high achieving practices, rather 
than be truly representative of all general practices, so when interpreting the results 
this needs to be considered (Campbell et al., 2013). It is also important to consider 
the limitation of recording (or ascertainment) bias where the patient may present with 
a condition, but this may not be Read Coded in the notes. There is evidence that only 
85% of the issues discussed in consultations are recorded and only 37% of what is 
discussed is Read Coded (Salisbury et al., 2013). This does mean that patients may 
be presenting with conditions that they consider important but that these are then not 
recorded in the notes in a way that is accessible if using Read Codes to identify 
potential outcomes, so there is a possibility of missing further outcomes due to 
differences in recording between clinicians. Finally, it is important to note that CPRD 
has not been validated in previous studies for the outcomes of interest in this cohort 
study, so there is no evidence to suggest that CPRD is an appropriate method to 
investigate these conditions, although it does represent the best method available 
presently. 
The cohort study took into account many important covariates during statistical 
analysis. NSAID use was included as a confounder within analysis as there is 
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evidence that short-term NSAID use is associated with a failure to ovulate. Although 
only prescribed NSAIDs were analysed, many NSAIDs (e.g. ibuprofen, aspirin) can 
be purchased over the counter in the UK and these would not be routinely recorded 
in the medical notes and consequently there effect could not be considered in this 
study (Salman et al., 2015). The cohort study was unable to take into account 
hormonal contraception (including intrauterine devices). Contraception can be 
obtained from family planning clinics in the UK, and this is information that is not 
recorded in CPRD. In the period from April 2012 to March 2013 1.2 million women 
attended family planning clinic for contraception and 47% received oral contraception 
which would not have been recorded in the GP records and accordingly would not be 
found in CPRD, there is no clear data regarding the number of times women 
consulted with GPs for oral contraception, but 7.7 million prescriptions were issued in 
2012 for free of charge contraception (this would include prescriptions from both 
family planning clinics and GP) (Health and Social Care Information Centre, 2013; 
Prescribing and Medicines Team and Health and Social Care Information Centre, 
2016)(Health & Social Care Information Centre 2013). Contraceptives can affect 
menstruation either through causing a withdrawal bleed each month (combined oral 
contraceptives), making menstruation heavier (copper coils) or potentially causing 
amenorrhoea (progesterone only pill, implants, progesterone intrauterine devices and 
depot injections). The combined oral contraceptive pill has been associated with 
decreased risk of premature ovarian failure and decreased sexual function (Chang et 
al., 2007; Davison et al., 2008). Contraceptive use could have affected the outcomes 
of interest, although there is no reason to suspect that contraception use would be 
different between the two groups.  
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Certain associated conditions were taken into account as they can cause several of 
the outcomes of interest. PCOS was included within the search for covariates, 
because PCOS accounts for 80% of cases of infertility due to anovulation. Patients 
with PCOS will often present with irregular or absent menstruation and this will be 
coded prior to a diagnosis. The number of comorbidities patients had was included in 
the analysis. This was calculated as a proxy measure as described previously based 
on the number of prescribed medicines, and it may over or underestimate the 
number of conditions. In the long-term opioid users there was a statistically 
significant increase in prescribed NSAIDs, compared with short-term users; this will 
have contributed to the number of comorbidities in this group of patients, as this was 
calculated based on number and type of medicines as described above (see section 
5.8).  
BMI is an important confounder, as it is a factor in both musculoskeletal conditions 
and menstrual disorders. Higher BMI has been directly associated with an increase in 
musculoskeletal disorders and worse recovery from these conditions which is linked 
to analgesics prescribing. BMI can also affect menstruation in women (if it is either 
high or low) (The Practice Committee of the American Society for Reproductive 
Medicine, 2008; Viester et al., 2013). There was BMI data available for 94.9% of the 
women within the cohort and this meant that it could be included in the statistical 
analysis, and a sensitivity analysis excluding those with missing data found similar 
results for each outcome in the cohort study. The cohort could also be adjusted for 
smoking and alcohol as the data was more complete than expected with over 90% of 
the participants having data available.  
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There is likely to be some residual confounding of which one aspect is that 
depression was not taken into account during the analysis. Depression and low mood 
are associated with worse pain, opioid use and also with low libido so this would be 
important to include in future studies, this was not included in the analysis of the 
cohort study so it is unclear whether this would have affected the results (Blackburn-
Munro, 2001; Scherrer et al., 2014; The Practice Committee of the American Society 
for Reproductive Medicine, 2008). 
Overall the strengths of the cohort study undertaken for this thesis, are that it is a 
large, longitudinal, cohort study with both matching and statistical analysis to control 
for confounding, which is an improvement on previous studies included within the 
systematic review. The main limitation of the study is that opioid use is considered at 
a single time point and did not take into account either dose or particular type of 
opioid used which may be important factors.  
7.4 Meaning of the study and generalisability 
To the authors knowledge this study is the first large scale cohort study to find that 
long-term opioids are associated with abnormal menstruation and menopausal 
symptoms in women aged 18-55 years old with musculoskeletal pain. These results 
are consistent with the previous limited evidence in this area, and build further on this 
as the first study to show an increased hazard of menopausal symptoms in long-term 
opioid users when compared with short-term opioid users. These findings are 
important for helping decision making surrounding opioid use and adds to the 
growing body of evidence surrounding the adverse effects of opioids (Els et al., 
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2017b). The results of this study are important given the background of increasing 
opioid use for CNCP (Bedson et al., 2016).  
This study is generalisable to women receiving long-term opioids in primary care for 
painful musculoskeletal problems, as CPRD is broadly representative of the UK 
population (Herrett et al., 2010). This is important as a large proportion of CNCP 
patients are treated in primary care and previous research has tended to focus on 
patients in secondary care (Breivik et al., 2006; Wersocki et al., 2017). This study 
focused on musculoskeletal pain, which is the commonest cause of CNCP in the UK, 
and the results are likely to be applicable to other causes of CNCP although further 
studies would be required to confirm this.  
Opioid use should also be considered in the context of the patients’ other problems, 
such as depression which can be independently related to opioid use, and the 
potential to become dependent on opioids as in those with a history of drug abuse.  
The findings of this study should be considered when clinicians are prescribing and 
reviewing long-term opioids, and discussed with patients to improve shared decision 
making; discussing the risks and benefits prior to treatment with opioids is highlighted 
as important for good practice (Williams et al., 2013). Regular reviews of long-term 
opioids are recommended and clinicians should address potential sexual and 
reproductive dysfunction during these, as often patients may not raise these without 
the clinician asking directly (Montgomery, 2008; Williams et al., 2013). 
7.5 Unanswered questions 
There are a number of unanswered questions remaining following this study. The first 
set of questions are related to the opioid. Could the relationship observed in this 
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study be affected by opioid dose, type, or mode of delivery (patches or oral therapy)? 
Is there a safe daily dose of opioids in order to minimise the risk of associated 
reproductive dysfunction? This could be addressed by adjusting or stratifying for daily 
morphine equivalent dose in further studies, and taking into account the route of 
opioid, or type of opioid used (e.g. buprenorphine vs. morphine). This could help to 
improve decision making related to the level of risk associated with using opioids, 
and what dose and mode of delivery may carry the lowest risk. Another question that 
needs to be addressed is whether the symptoms of reproductive and sexual 
dysfunction resolve on withdrawal of the opioid, this would need to be examined as a 
longitudinal study where patients were followed up after stopping opioids 
The study did not include depression as a possible confounder and it would be 
important to look at the role that depression may play, as there is clearly a complex 
relationship as depression can be related to CNCP (in this case pain secondary to 
musculoskeletal conditions), opioid use itself, and sexual dysfunction.  
The cohort study found a lower prevalence of low libido compared to the prevalence 
expected in the general population, and this discrepancy deserves further 
investigation. It is important to understand whether this reflects the actual levels of 
low libido in this population or if it is due to the nature of database research. One way 
to address this question would be to undertake a self-report study of women and ask 
about sexual function directly.  
Another area where future research may focus is examining the use of hormonal 
assays for investigating how levels of hormones may be affected by opioids. This 
information could be used to identify early problems in reproductive function.  
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It may also be important in the future to understand how women feel about 
reproductive dysfunction as a potential opioid adverse effect and where their 
priorities might lie during treatment. If a woman experienced adverse effects but was 
achieving good pain relief with their opioid analgesic, what would be a priority in 
terms of ongoing treatment? Qualitative research in this area would help us to better 
understand patients and doctors priorities. 
7.6 Key messages  
• Long-term opioid use is associated with a higher risk of menopause and 
abnormal menstruation than short-term opioid use. This is important to 
consider when initiating the prescription of opioids and also when undertaking 
medicine reviews. 
• Risk is higher in younger women receiving long-term opioids compared with 
short-term users but the actual numbers affected are low. 
• The prevalence of low libido was lower in the cohort than expected and this 
requires further investigation. 
7.7 Conclusion 
This cohort study supports the hypothesis that women taking long-term opioids are at 
higher risk of developing symptoms of HPG axis disruption than those who have 
taken short-term opioids. This substantially extends the body of evidence that show 
opioids are linked to reproductive and sexual dysfunction. This is an important 
possible adverse effect with opioid treatment and it should be discussed with women 
commencing long-term opioids as it may affect their decision making process. It will 
be important during initiation of opioids that these possible adverse effects are 
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discussed and then screened for at medicine reviews. The study found low numbers 
of women with low libido recorded in their electronic records; if women were informed 
that this was a potential adverse effect, they may be more likely to report it. The 
results of the cohort study add to the growing body of evidence that opioids carry 
significant potential adverse effects and this should be balanced with the lack of 
evidence for their effectiveness in CNCP. 
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8 Cross-sectional study methods 
This cross-sectional study was undertaken to investigate the potential relationship 
between opioid use and female sexual dysfunction (FSD) further. A cross-sectional 
study was chosen, as the CPRD cohort study found less than 1% of the cohort had a 
coded diagnosis of low libido, whereas population estimates are much higher, with 
previous studies finding 73% of patients with chronic pain and 41% of women in the 
general population reporting sexual dysfunction when surveyed, the systematic 
review also found 61-100% of those studies reported sexual dysfunction (Ambler et 
al., 2001; Dunn et al., 1998; McCool et al., 2016). A cross-sectional study can 
investigate this area more directly than the cohort study and gain information from 
women that they may not necessarily have discussed with their GP and therefore 
would not be recorded in the database (Last, 1963; Montgomery, 2008). Self-report 
cross-sectional studies have been found to be useful for investigating sensitive 
subjects and this was discussed in section 4.4.2. This chapter will discuss the 
methods for the cross-sectional study undertaken for this thesis. 
8.1 Summary 
This study was undertaken as a cross-sectional postal survey of women aged 18-45 
years old with a potentially painful musculoskeletal condition and a prescribed opioid. 
Quantitative data was collected using a single self-report postal questionnaire, and if 
the participant consented, from a review of the medical records. The main outcome 
of interest was FSD and this was assessed via the cross-sectional questionnaire.  
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8.2 Aim 
The primary aim of this study was to investigate associations between opioid use and 
FSD in women with musculoskeletal conditions using a cross-sectional study.  
8.2.1 Objectives 
1) To investigate the prevalence of FSD in women aged 18-45 years old 
receiving opioids for musculoskeletal pain. 
2) To compare the prevalence of FSD in women currently using opioids with the 
prevalence of FSD in women who have used opioids in the past but are no 
longer using opioids. 
3) To compare the number of women with FSD according to total morphine 
equivalent daily dose.  
4) To compare self-reported rates of FSD with those recorded in the medical 
records. 
8.3 Ethical Approval 
This study was approved by the West of Scotland research ethics service (reference 
number 17/WS/0182). The approval letter is included as Appendix 15. The study was 
also approved by the Health Research Authority. A single minor amendment was 
approved to increase the number of General Practices included from 20 to 30. The 
ethical approval application was undertaken by ER.  
8.4 Setting 
Participants were recruited from 30 General Practices within the NIHR West 
Midlands Clinical Research Network (WM:CRN). 
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8.5 Sample size 
The sample size calculation was based on unpublished data, from a postal 
questionnaire by Dunn et al (1998, unpublished data available from the author on 
request). This data showed an odds ratio for sexual dysfunction of 2.2, when 
comparing those taking opioids to those without opioids (31% of those receiving 
opioids reported sexual dysfunction compared with 17% of those not using opioids). 
A two-sided 95% significance level, a power of 80%, and a ratio of 1:1 for 
comparison groups were used. The calculation estimated a sample size of 316 
women. The study described above, had a response rate of 49% in women of all 
ages, but the response rate in those less than 57 years of age was 43% (Dunn et al., 
1998). Sensitive topics are widely believed to cause a lower response rate; a 
Cochrane review found an odds ratio for response of 0.94 (95% CI 0.88, 1.0) when 
sensitive questions were included compared with non-sensitive questions (Edwards 
et al., 2009). Based on the sample size calculation of 316 and an expected response 
rate of 43%, 735 women would need to be invited. However, it was felt that it was 
likely that the response rate would be lower, due to decreasing participation rates in 
postal surveys, the sensitive nature of the study and the age range of participants 
being lower than the sample returning a 43% response rate (Galea and Tracy, 2007). 
The national census, which has excellent response rates, had a response rate of 
88% in women aged 20-24 years old which is 10% less than the response rate of 
98% in women aged 60-64 years old; if this 10% decrease in response rate is taken 
into account the study required 957 women to be invited, which was adjusted to 1000 
(Office for National Statistics, 2015). Therefore, an estimated 1000 women were 
invited to participate in order to achieve a sample size of 316. 
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8.6 Study population 
Participants were women aged 18-45 years old who were registered with a GP and 
had a coded potentially painful musculoskeletal condition who had recently been 
prescribed opioids.  
8.6.1 Inclusion Criteria 
• Women 
• Aged 18-45 years old at the time of prescription. This age range was chosen 
based on previous studies which have shown the average age of the natural 
menopause in the UK to be 52 years and 11 months, with initial symptoms 
noticed at 50 years and 10 month (Hardy and Kuh, 2005). Sexual dysfunction 
has been shown to increase through the peri-menopause so the age was 
restricted in order to decrease the chance of women with menopausal 
symptoms being included in the study (Gracia et al., 2004). 
• Prescription of an opioid from group three (e.g. codeine 15mg), group four 
(e.g. codeine 30mg) or group five (e.g. oxycodone, morphine) within the six 
months prior to records search. These groups represent moderate to very 
strong opioids, based on a previously developed consensus model of 
hierarchically arranged equipotent analgesics including opioids (Bedson et al., 
2010). This was discussed in section 2.3 and the model is shown in figure 2.1. 
• A potentially painful musculoskeletal condition coded within the six months 
prior to medical records search 
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8.6.2 Exclusion Criteria 
• Symptoms and signs which indicated a serious pathology (cancer diagnosis) 
or red flag conditions that required urgent medical attention (e.g. fractures, 
cauda equina, and septic arthritis). 
• Inflammatory joint condition (e.g. rheumatoid arthritis or gout) 
• Inability to read and speak English 
• Vulnerable patients (assessed by GP), including patients on the QoF mental 
health or learning disabilities register  
• Pregnant 
• Current hormone replacement therapy (HRT) use  
• Menopause 
8.6.3 Identification of study population  
The study population was identified through Read Code searches at each 
participating practice. The Read Codes for the search were developed in partnership 
with the WM:CRN who have extensive experience of searching primary care records. 
The search was adapted from previous searches used for studies within the 
Research Institute for Primary Care and Health Sciences at Keele University. The 
opioid analgesic search was taken from the Keele University’s STAMP study 
(Smartphone and Tablet Application for Medicines and Pain) (Bedson et al., 2019b). 
The musculoskeletal search terms were a combination of codes used in STAMP and 
in KAPS (Keele Aches and Pains Study also undertaken by Keele University) 
(Campbell et al., 2016) which were used to identify potentially painful 
musculoskeletal conditions, with any codes relating to menopause or traumatic 
injuries removed. The WM:CRN have pre-made code lists for certain exclusion 
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criteria including identifying vulnerable patients, these were reviewed by ER prior to 
use in the search. The majority of the exclusion criteria were identified on an as ‘ever’ 
occurred basis, except fractures where exclusion only occurred if the fracture was 
within the 12 months prior to the search to identify participants. The average healing 
time for fractures is between two and four months depending on the location and type 
of fracture, allowing an exclusion period of 12 months meant that participants should 
have recovered from any fractures prior to the start of six month identification period 
(Solomon et al., 2010b). An example of the codes used for the search can be found 
in Appendix 12. 
8.7 Questionnaire construction 
Where possible validated measures were identified and used.  
8.7.1 Assessing female sexual dysfunction (FSD) 
A literature review was undertaken to find an appropriate tool to use in order to 
identify women with FSD. Identification of FSD is complicated through the use of 
multiple classification systems as described previously (section 2.5.1), and 
depending on the classification system used, the tools assess slightly different things. 
Over 40 tools were identified. The most relevant tools are shown in Table 8-1. The 
most widely used and validated tool is the female sexual function index (FSFI); 
however this was developed for assessing severity of FSD that had previously been 
diagnosed, not for the initial identification of FSD (Rosen et al., 2000). Several tools 
have been validated against the FSFI for identification of women with sexual 
dysfunction. One of these tools is the STEFFI (full version), which has shorter 
versions the STEFFI-1, STEFFI-2 and STEFFI-5 (STEFFI is not an acronym, the tool 
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is named after the common German girls name), originally validated in the German 
language against the FSFI. The STEFFI-5 had 83.1% sensitivity and 81.2% 
specificity for identifying FSD when compared with the FSFI, and this tool has been 
translated into English (Kriston et al., 2010). The STEFFI tool does not require the 
woman to be in a sexual relationship; this was important since the tool needed to be 
applicable to women who might not currently be in such a relationship. The 
percentage of women identifying themselves as single in the most recent UK census 
was 34.6% of those aged over 16 years old, with this percentage decreasing with 
age. However, identifying as single does not mean that a person is not sexually 
active (Office for National Statistics, 2016). STEFFI also includes an important 
question regarding whether the participant is satisfied with their sex life because 
definitions for FSD now include the woman being distressed due to symptoms rather 
than symptoms in isolation (American Psychiatric Society, 2013; Basson et al., 2001; 
McCabe et al., 2016; World Health Organisation, 2012). The Arizona Sexuality 
Experience Scale (ASEX) had a similar sensitivity (82%) and specificity (90%) and 
was also considered as the measure of choice for the final questionnaire (McGahuey 
et al., 2000). The main drawback with ASEX is that it was developed for use in 
people on psychotropic medicines and has not been validated outside of this 
population.   
STEFFI-5 and ASEX were both discussed with a patient and public involvement and 
engagement (PPIE) group and it was felt that both would be acceptable measures 
from a participant’s point of view (see section 8.11). STEFFI was chosen as it asks 
about sexual function overall as well as specific symptoms, and it provides a more 
comprehensive assessment of sexual function (12 questions vs. 5). This is important 
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as FSD is the primary outcome of the study. Another positive factor for using the 
STEFFI-5 was that it looks at sexual function over the previous six months which is in 
line with the identification of participants for the study (opioid use within the previous 
six months and a painful musculoskeletal condition). STEFFI-5 consists of five 
questions. Each question scores either one or zero depending on response and adds 
to a total between zero and five. Scores of three or more should be considered 
positive for FSD whereas scores of two or less should be considered as a negative 
test. No license is required for use of STEFFI-5 and it is freely available for use if 
cited (Kriston et al., 2010).  
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Table 8-1 Tools to assess female sexual function  
Tool Population Time scale Administration 
and time to 
complete 
Requires 
partner 
Scale Validation  Is distress 
assessed? 
Arizona 
Sexuality 
Experience 
Scale (ASEX) 
(McGahuey et 
al., 2000) 
Developed for 
patients taking 
psychotropic 
drugs 
Past week Self or 
clinician 
administered 
 5 item 
scale to 
assess five 
major 
aspects of 
FSD 
Cronbach’s alpha = 
0.9055. ROC AUC 
0.9292 +/- 0.29. 
Sensitivity 82%, 
specificity 90%, 
PPV 88%, NPV 
85%. 
No 
Brief index of 
sexual 
function for 
women (BISF-
W) (Mazer et 
al., 2000) 
Partner status 
strongly affects 
results 
Past month Self-
administered 
15-20 minutes 
No but 
affects 
results 
22 item 
scale to 
assess 7 
domains 
Cronbach’s alpha 
overall = 0.70 
Domains 1=0.72, 
2=0.39, 4=0.45, 
5=0.72, 6=0.61, 
7=0.08 
No, asks about 
satisfaction 
rather than 
distress 
Brief profile of 
female sexual 
function (B-
PFSF) (Rust 
et al., 2007) 
Postmenopausal 
women who are 
experiencing low 
sexual desire 
2-3 months Self-
administered 
 7 item  Cronbach’s alpha 
0.8, ROC AUC 0.99 
Yes 
Deragotis 
Sexual 
Function 
Inventory 
(Derogatis, 
1997) 
All women  4 weeks Self-
administered 
45 minutes 
 245 items Cronbach’s alpha 
0.8, PPV 75%. 
Yes 
Decreased 
Sexual Desire 
Screener 
Any age  No time 
frame given 
Non expert 
administration 
5 minutes 
 4 or 5 item 
scale  
4 item scale 
sensitivity 88.4, 
specificity 77.5 
Yes 
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Tool Population Time scale Administration 
and time to 
complete 
Requires 
partner 
Scale Validation  Is distress 
assessed? 
(DSDS) 
(Clayton et al., 
2009) 
5 item scale 
sensitivity 83.6, 
specificity 87.8 
Female 
Sexual 
Dysfunction 
Scale (FSDS) 
(Derogatis et 
al., 2002) 
Any age for 
measuring 
distress in 
women with 
FSD 
No time 
frame 
 
Self-
administered 
5-10 minutes 
No 12 items Sensitivity 88%, 
Specificity 93%  
No 
Female 
Sexual 
Function 
Index (FSFI) 
(Rosen et al., 
2000) 
Heterosexual 
women with 
FSD to establish 
severity 
4 weeks Self-
administered 
15 minutes 
Yes 19 item 
scale 6 
domains  
Cronbach’s alpha 
0.85-0.95 
No, measures 
satisfaction 
Keele Sexual 
Relationships 
Questionnaire 
(SeRQ) (Dunn 
et al., 1998) 
Women 3 months Self-
administered 
No 15 item 
scale 
Not given No, measures 
satisfaction 
Natsal-SF: A 
Measure of 
sexual 
function for 
community 
surveys 
(Mitchell et al., 
2012) 
Women of any 
age who have 
had sex in the 
past year  
Past year Interviewer 
administered 
Yes 17 items Comparative fit 
index = 0.963. 
Developed so that 
male and female 
sexual function 
could be tested with 
the same model. 
Yes 
Profile of Post- 4 weeks  Self- Yes 37 item Cronbach’s alpha Yes 
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Tool Population Time scale Administration 
and time to 
complete 
Requires 
partner 
Scale Validation  Is distress 
assessed? 
Female 
Sexual 
Function 
(PFSF) 
(McHorney et 
al., 2004) 
menopausal 
females 
administered 
?time to 
complete as 
not reported 
scale 7 
domains  
0.74-0.96 
Sexual 
interest and 
desire 
inventory 
female (SIDI-
F) (Clayton et 
al., 2006) 
Pre-menopausal 
women with 
hypoactive 
sexual desire 
dysfunction 
(HSDD) to 
measure 
response to 
treatment 
4 weeks Clinician 
administered 
tool  
Time to 
administer not 
reported 
Yes 13 item 
scale 5 
domains  
Cronbach’s alpha 
0.79 in European 
women 
Yes 
Sexual 
function 
questionnaire 
(SFQ) (Quirk 
et al., 2002) 
For use in 
pharmacological 
clinical trials  
4 weeks 20 minutes  Yes 26 items 7 
domains 
Cronbach’s alpha 
0.70-0.91 
No satisfaction 
assessed 
STEFFI (not 
an 
abbreviation) 
(Kriston et al., 
2010) 
Any age women 6 months 1 minute- 10 
minutes 
No 1 item, 2 
items, 5 
items and 
12 items 
respectively  
4 versions: STEFFI-
1 (sensitivity 76.4, 
specificity 76.5), 
STEFFI-2 
(sensitivity 93.5, 
specificity 60.1), 
STEFFI-5 
(sensitivity 83.1%, 
specificity 81.2%) 
Yes 
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Tool Population Time scale Administration 
and time to 
complete 
Requires 
partner 
Scale Validation  Is distress 
assessed? 
and STEFFI  
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8.7.2 Medicine use 
There is a lack of validated questionnaires for self-reported medicine use. The 
majority of measures focus on adherence to prescribed medicine rather than 
identifying medicines currently in use (Garfield et al., 2011; Svarstad et al., 1999). 
Willeboordse et al developed a medicine use questionnaire for use in patients over 
65 years old to aid in medicine reviews, which they compared to a medicine history 
gained through non clinician interview (Willeboordse et al., 2016). Reported 
medicines were compared between the self-completed questionnaire and the 
interview and this found an 87.6% (95% CI 84.7, 90.5%) agreement. Agreement was 
affected by health literacy, with agreement in those with low health literacy being 83.5 
% (95% CI 76.7, 90.4%), and by number of medicines, with those taking more than 
10 medicines agreeing between the two methods for 78.4% (95% CI 71.9, 84.9%) of 
medicines. Agreement for the entire medicine list was much lower at 45.4% (95% CI 
35.8, 55.3%) and this was similarly affected by health literacy and number of 
medicines (Willeboordse et al., 2016). The first section of this tool asks questions 
around specific medicines and then about adherence to medicines. These tools were 
used as a basis for developing the medicine use section of the current questionnaire 
and this development process received input and final approval from PPIE. It was 
important that the tool included enough information to be able to calculate the daily 
oral morphine equivalent dose in order for this to be used in the analysis of this data. 
Where the participant consented to records review, this was used to replace any 
missing items from the questionnaire for medicine use. This was particularly 
important for the dose and name of opioid prescribed. The information was used in a 
sensitivity analysis. It was also important to determine which analgesics participants 
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might have used within the past six months, including any opioids. The question in 
the survey asked specifically about any medicine used for pain within the last six 
months but not currently being used, including the reasons for stopping these 
medicines.  
Comparison measures were undertaken comparing total daily morphine equivalent 
doses with ≥20mg/day as the cut off between high and low doses within current 
opioids users, this cut off has been used in previous studies investigating opioid use 
so should keep the results in line with data on adverse effects that is already 
available (the method for calculating morphine equivalent dose is explained in 
section 8.13) (Dunn et al., 2010). Duration of opioid use was also collected for those 
currently using opioids.  
Data on analgesics other than opioids was collected. Non-opioid analgesics were 
split during data analysis by ER into NSAIDs, Paracetamol, Gabapentoids 
(pregabalin and gabapentin both recommended by NICE for neuropathic pain) and 
antidepressants used for pain. Antidepressants for pain included any antidepressant 
the patient indicated was used for pain relief and the specific antidepressants 
amitriptyline and duloxetine were included if they were recorded in the current 
medicine section rather than the analgesics section of the questionnaire. Amitriptyline 
and duloxetine are the only antidepressants recommend for neuropathic pain in 
primary care by NICE (National Institute for Health Care and Exellence, 2013). 
Contraception was addressed separately to other medicines, as this can be delivered 
in many ways other than a tablet form. This may mean that an implant for instance 
would not be reported as a medicine. A recent study comparing self-report to 
objective assessment found that asking the simple questions “are you using a 
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contraception method” and “what method are you using” produced 100% sensitivity 
and specificity (Smith et al., 2018). A single question was used to assess 
contraception based on this, with a tick box list for methods of contraception, 
including no contraception. This method allowed for the participant to indicate they 
were using either no contraception or more than one method since it was important 
to get accurate information on hormonal contraceptives currently being used to 
include within the analysis.  
Information was also collected from patients on all other medicines they had used 
within the previous four weeks, this included prescription and over-the-counter 
medicine. The dose of these medicines or the frequency of use was not requested as 
this information was not needed to calculate a daily dose and this decreased 
respondent burden from the survey.  
8.7.3 Pain 
The presence or absence of chronic pain was important to assess as part of the 
questionnaire, so it could be included in analysis as a confounding factor. Pain can 
be assessed in a wide variety of ways. The particular tool used depends on several 
factors, including if a measure of change is needed or a single time point, and the 
specific condition being investigated (Hawker et al., 2011). The SF-12 contains a 
single item for assessing pain, but this does not assess level of pain or frequency of 
pain, and therefore was inadequate to assess current pain (Jenkinson and Layte, 
1997). The chronic pain grade questionnaire was developed by Von Korff et al (1992) 
and has been validated for use in UK postal questionnaires (Von Korff et al., 1992; 
Smith et al., 1997). The positive features of the chronic pain grade questionnaire are 
that it assesses current pain and over the previous six months, which for this study 
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was useful given that women will have been identified as having a painful condition 
within the last six months and this may not still be present. The tool gives a grade 
from zero to four based on pain intensity (from questions one to three) and disability 
points (disability score from questions five to seven plus the answer from question 
four). A zero grading equates to no pain, and grade four indicates the highest 
disability possible due to pain (see Table 8-2). The chronic pain grade has been 
validated for use in UK postal questionnaires through comparison with the SF-36, 
has a Cronbach’s alpha of >0.9, and item-total correlations of >0.68 for all items 
indicating good internal consistency and reliability (Smith et al., 1997). No license is 
needed for use of the Chronic Pain Grade questionnaire. 
Table 8-2 Chronic pain grade classification (Von Korff et al., 1992) 
Grade Pain intensity (0-100) Disability points 
0 0 0 
1 <50 <3 
2 ≥50 <3 
3 Any 3 or 4 
4 Any 5 or 6 
 
8.7.4 Psychological wellbeing 
PHQ-2 has been validated for use in primary care settings for identifying depression 
(Arroll et al., 2010; Löwe et al., 2005). PHQ-2 is a two question item with a four point 
Likert scale for response for each item (Löwe et al., 2005). The participant was also 
asked if they have ever been diagnosed with depression or anxiety in the medical 
conditions section of the questionnaire. The short form health survey (SF-12) also 
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calculates a mental component score (MCS) that is a measure of psychological 
wellbeing; this is discussed fully in section 8.7.5.  
8.7.5 Health and wellbeing 
There are many validated measures for health related wellbeing (Busija et al., 2011). 
The SF-36 is a widely used tool to assess health related quality of life (HRQoL), 
which aims to measure “general health concepts not specific to any age, disease or 
treatment groups” (Ware and Sherbourne, 1992). The SF-36 assesses eight 
domains, with four measuring physical functioning and four measuring mental 
functioning. The eight domains are as follows i) limitations in physical activities 
because of health problems, ii) limitations in social activities because of physical or 
emotional problems, iii) limitations in usual role activities because of physical health 
problems, iv) bodily pain, v) general mental health (psychological distress and well-
being) vi) limitations in usual role activities because of emotional problems, vii) vitality 
(energy and fatigue) and viii) general health perceptions (Ware and Sherbourne, 
1992). The SF36v2 takes around ten minutes to complete. The SF12v2 assesses the 
same eight domains but has one or two questions only per domain and this 
decreases the time burden in completing it to under three minutes. Both of these 
measures are suitable for use in the general population as well as in patients with 
clinical diagnoses (Busija et al., 2011). The SF-36 is more accurate for considering 
individual domains whereas the SF-12 and SF-36 are comparable if physical 
component summary (PCS) and mental component summary (MCS) are the main 
outcomes (Busija et al., 2011). Both have been validated internationally and shown to 
be comparable (Gandek et al., 1998). They are available in four week recall and one 
week recall forms. In studies the SF-12 often contains less missing data than the SF-
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36 with the SF-12 having at least one missing item in 9.6% of responses and the SF-
36 in 26% of responses (Loge et al., 1998; Perneger and Burnand, 2005). The SF-12 
was chosen in preference to the SF-36 due to the lower number of responses 
affected by missing items, and decreased respondent burden, despite the decreased 
accuracy for assessing individual domains. When the SF-12 calculates PCS and 
MCS domain scores even a single missing value in each domain will return an invalid 
score, although imputation techniques can be used to overcome this (Liu et al., 
2005). The SF-36 has been assessed for readability using Flesch-Kincaid Grade 
Level and found to have a mean grade level of 6.4 or median level of 4.8 consistent 
with easy and very easy reading levels. However, 36% of items scored above 9.5 
indicating the participants need reading levels equivalent to those in high school 
(Calderón et al., 2006). The required license agreement (#CT184958 OP059432) has 
been agreed for use of the SF-12 in this study (see appendix 14). 
8.7.6 Physical health 
BMI was calculated from self-reported height and weight if provided preferentially 
over BMI recorded in the notes, as it was more likely to be up to date (there is 
evidence that BMI within CPRD which is analogous to GP records is often out of 
date) (Bhaskaran et al., 2013). There was an option for the participant to report their 
height and weight in metric, or imperial units and the database was built to 
accommodate this. Where there was missing data and consent for medical records 
review, the most recent height, weight and BMI were used from the participant’s 
medical records in the sensitivity analysis.  
Smoking status (five options: never smoked, ex-smoker, and current smoker split into 
≤10, 11-20 and ≥21 cigarettes/day), alcohol use (split by frequency of alcohol use 
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daily, once or twice a week, once or twice a month, once or twice a year and never) 
and illicit drug use (yes or no response, with a free text box for which illicit drugs if 
answering yes) were included within the demographics section as simple tick box 
questions.  
The participants were also asked for specific self-reported health conditions, 
including anxiety, chronic pain, depression, menopause, joint pain, endometriosis, 
chronic pelvic pain. Menopause and pregnancy were excluded from the study during 
identification of participants, but menopause was included in the questionnaire, as 
women may not have presented to their GP with menopausal symptoms, so may still 
have been included in the study at the search stage, whereas pregnancy is likely to 
be recorded on the GP system so was not included in the questionnaire (Last, 1963). 
Endometriosis and chronic pelvic pain were important as these are both possible 
confounders that can affect a woman’s sexual function and also indications for 
analgesic use (Pluchino et al., 2016).  
8.7.7 Demographics 
In order to describe the sample demographics questions on age, ethnicity, marital 
status, children and whether the participant lived alone were included. Age was self-
reported. However data from the original search which includes date of birth allowed 
us to compare the ages of responders and non-responders. Index of multiple 
deprivation for each participant based on the practice postcode they were registered 
with was also calculated. This gives a rating on a scale of 1 (most deprived) to 
32,844 (least deprived) and takes into account income, employment, education and 
skills, health, crime, barriers to housing and living environment and is based on 
census data (Department for Communities and Local Government, 2015a, 2015b). 
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Index of multiple deprivation for responders and non-responders was calculated and 
compared. 
The composition of the full survey instrument in shown in Table 8-3. 
8.7.8 Reading age  
As discussed in Section 4.4.5, it is important when designing a self-report 
questionnaire to aim for a reading level of between 8 and 10 years-old, or five years 
of education. Certain parts of the questionnaire are made up of pre-validated 
measures and as such the reading age of these sections could not be altered. The 
three sections that were designed specifically for this questionnaire (Sections 2, 3 
and 6) all have a reading ease of less than 10 years old (see Table 8-4) if using 
Flesch-Kincaid which is appropriate based on the guidelines for medical information. 
Readability was calculated using Word 2013 (Microsoft, 2013a). 
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Table 8-3 Sections within the postal questionnaire and the instruments used to assess each area 
Section Measure/tool Categories Number of items  
1 - Pain Chronic pain grade (Von Korff 
et al., 1992) 
• Pain 7 
2 – Medicines for pain Adapted from Willebordse et 
al (2016) medicine review 
questionnaire 
• Current analgesics 
• Previous analgesics 
• Reasons for stopping 
8 
3 – Medical conditions and 
other medicine 
Medicine questions 
Contraception 
Medical conditions 
 
• Medicine use 
 
• Contraception use 
 
• Specific medical conditions 
• Depression 
5 
4 – Health and wellbeing SF-12 (Gandek et al., 1998) 
PHQ-2 (Löwe et al., 2005) 
• Physical limitations 
• Social limitations  
• Limitations due to physical health 
problems 
• Pain 
• Mental health  
• Limitations due to emotional 
problems 
• Vitality  
12 
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Section Measure/tool Categories Number of items  
General health perceptions   
5- Sexual health STEFFI-5 (Kriston et al., 2010) • Sexual satisfaction 
• Sexual function 
• Frequency of sexual intercourse 
17 
6 – About you Demographic questions • Age 
• Marital status 
• Living situation 
• Children 
• Height/weight 
• Smoking status 
• Alcohol 
• Illegal drug use 
• Employment 
• Ethnic origin 
13 
7 – Consent form Consent form Consent to review medical record 1 
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Table 8-4 Reading age for each section of the self-report questionnaire.  
Questionnaire Tool Flesch-Kincaid grade 
level 
Age 
Section 1 PAIN grade* 11.3 16-17 
Section 2 Medicines for pain 4.7 9-10 
Section 3 Medical conditions and 
other medicines 4.8 
 
9-10 
Section 4 SF-12* 8.8 13-14 
Section 5 STEFFI* 5.6 10-11 
Section 6 About you  3.1 8-9 
Overall 6.4 11-12 
Those sections marked with a * are pre-validated measures. 
8.7.9 Format of the survey questionnaire  
When designing a questionnaire there should be an appropriate flow of questions, so 
that it is not off-putting to those completing it. The first question must seem relevant 
to the topic being investigated, and should not be a sensitive question, as this may 
discourage the participant from completing the rest of the questionnaire (2005). The 
questionnaire was ordered so that sensitive questions surrounding FSD were not the 
first questions the participant was asked. Questions on pain and analgesics were 
placed first to ensure that the questions seemed relevant to the description of the 
study from the patient information leaflet.  
The questionnaire was kept as short as possible whilst asking for information that is 
necessary for the study. A Cochrane review found a 64% increase in response rate 
when short questionnaires were used compared to long questionnaires (Edwards et 
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al., 2009). It is important to note however that there was no definition of what 
constituted either short or long questionnaires in the review.  
The overall formatting of the questionnaire was led by the SF-12, which is licensed 
and the formatting of this could not be changed. The remainder of the questionnaire 
was formatted in the same style, as it was important that the questionnaire remained 
consistent throughout. Questions were not split over pages in order to minimise the 
chance of questions being misread and thereby leading to participants reporting 
answers they did not intend (Bowling, 2014c). Options that are ordinal have been laid 
out horizontally throughout the questionnaire to also help respondents avoid the 
misreading of questions and an unintended answer being given.  
8.8 Recruitment process 
A retrospective medical records search was conducted on a single occasion in each 
practice, examining the previous six months to identify eligible participants. The 
search identified women with an opioid prescription (group three to five, moderate to 
very potent opioids as defined by Bedson et al.2010) and a coded potentially painful 
musculoskeletal condition within the previous six months (Bedson et al., 2010). The 
codes used were from the KAPS and STAMP trial as described in section 8.6.3, 
these were developed to identify painful musculoskeletal conditions, this is not the 
same code list that was used for the CPRD cohort study (Bedson et al., 2019b; 
Campbell et al., 2016) A database query produced a list of names and addresses for 
potentially eligible participants. GPs screened this list against study exclusion criteria 
and for suitability. Those women identified from the initial search and deemed to be 
appropriate were mailed the study pack from the practice. Each participant was given 
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a unique study identifier; this was used to target reminders and for medical record 
review linkage. The study pack included a covering letter from the GP, a patient 
information leaflet, the questionnaire itself and a consent form. The questionnaire 
and consent form were marked with the participant’s unique study identifier. The 
patient information leaflet contained all relevant information relating to the study in 
order to allow the participant to give informed consent for medical records review. If 
there was no response, a postcard reminder was sent at two weeks, and a further 
study pack was sent two weeks later as per research centre standards, see Figure 8-
1 (Keele University, 2017). When a further copy of the questionnaire is included with 
reminder mailings the response rate has been shown to increase 46%, but using a 
postcard for the initial reminder is a more cost effective approach (Edwards et al., 
2009; Roberts et al., 1993). Reminders were coordinated by the research team 
sending a list of unique study identifiers of those that had already replied with a 
completed questionnaire to WM:CRN, who then sent out reminders from the practice. 
Consent for completion of the questionnaire was assumed if a completed 
questionnaire was returned. Consent for medical records review and future contact 
was through written consent only (Lacey et al., 2015).  
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Figure 8-1 Flow diagram of recruitment process for cross-sectional study 
and data collection 
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8.9 Baseline assessment 
The participant was mailed a study pack that included the questionnaire, which took 
approximately 20 minutes to complete. An overview of data collection is provided in 
Table 8-5. The questionnaire included: 
• Sociodemographic variables: age, work status, relationship status, ethnicity 
• Lifestyle factors: alcohol, smoking, illegal drug use 
• Height and weight (for BMI) 
• Pain status (chronic pain grade questionnaire) 
• Medicine use (including current and recent opioid use, reasons for stopping 
medicine and current contraception use)  
• Sexual function assessed through the use of STEFFI-5 which is described 
below 
• General mental and physical health assessed through the use of SF-12 
• Past medical history including important conditions that are associated with 
FSD (anaemia, hypertension, depression, hysterectomy, diabetes, pelvic pain) 
8.10 Medical record review 
For patients who consented to medical record review, data was extracted by practice 
staff regarding prescribed medicines (including pain medicine), recorded sexual 
dysfunction, age, height, weight, BMI, existing chronic diseases (for instance thyroid 
disease and pelvic pain). The medical records were anonymised and assigned the 
unique study identifier that links with the corresponding questionnaire response. 
Medical records data was used to undertake a sensitivity analysis for logistic 
regression of opioid dose and FSD, this allowed a larger number of women to be 
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included in the analysis. Medical records data was not used in preference of self-
reported data. The medical records data was also used for a comparison of self-
reported FSD with coded FSD within the notes.  
Table 8-5: Overview of data collection for cross-sectional study 
 Questionnaire Medical record review 
Socio-demographic variables: 
age, work status, ethnicity  
  
Lifestyle factors: smoking, 
alcohol, drug use, height, weight 
  
Relationship status   
Contraception   
General health (SF-12)   
Opioid use (including previous 
use and reasons for stopping) 
  
Medicine history   
Sexual health: 5 items (STEFFI-
5) 
  (coded diagnosis not 
based on STEFFI-5) 
Pain status (chronic pain grade 
questionnaire)  
 
 
Current medical conditions   
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8.11 Patient and public involvement and engagement (PPIE) 
PPIE is an important part of developing any research study, as it helps to ensure that 
not only are the research aims relevant and of interest to patients but also that the 
research methods are considered appropriate by patients and the public. The 
Research Institute for Primary Care and Health Sciences has an active research user 
group (RUG) which advises and provides feedback on research projects. The RUG 
unfortunately does not have any female members between 18 and 45 years old so it 
was necessary to independently recruit age appropriate women to be involved in a 
PPIE group for this study.  
An initial leaflet was developed by ER to recruit women to participate in the PPIE 
group. The development was based upon previous leaflets used by the PPIE group. 
This leaflet was then amended by the Research Institute for Primary Care and Health 
Sciences PPIE administrative team (Laura Campbell and Adele Higginbottom) to fit 
with current branding and leaflet style that the PPIE team were using (see Appendix 
10). The leaflet was distributed within the Haywood hospital where the local 
musculoskeletal clinics and IMPACT (chronic pain) clinics are undertaken; 
unfortunately this did not generate any interest. Consequently, more innovative ways 
were developed to engage this younger age group who are not traditionally involved 
in PPIE. Steps were taken to engage women in the appropriate age group through 
posting on UK pain support websites (painsupport.co.uk and painconcern.org.uk). 
Those women that responded were included and helped to support the study via 
either email or an online forum (closed Facebook group). Three women (28-42 years 
old) responded and they all wished to be included via email only. The women 
provided feedback on the study pack including the covering letter, tools included in 
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the questionnaire and the final questionnaire. The women were particularly helpful 
during the development of the medicine section and completed early drafts, pointing 
out ways that these could be improved to make them more user friendly. The women 
reviewed the final version of the questionnaire for face validity (see section 8.7) prior 
to use within the study.  
8.12 Data management 
Questionnaire data was entered into a specially designed database, which was 
tested a priori for reliability. The database was developed by ER within Microsoft 
excel 2013 (Microsoft, 2013b). The database was piloted by an independent reviewer 
who would be undertaking secondary data input for quality control and suggestions 
for changes made prior to using the database (Laurna Bullock LB). The changes to 
the database following review included adding a third column for entering 
contraception data (so a participant could report three different methods), changing 
the weight and height section of the database to ensure that these responses could 
only be entered in one format (either metric or imperial with metric being used 
preferentially if both were present), If imperial data was entered, this was converted 
within the database to metric data and used by the database to calculate BMI. 
Coding of questionnaire responses was determined with input from the study 
statistician in accordance with the standard procedures within the Research Institute 
for Primary Care and Health Sciences to facilitate data entry. During data entry the 
coder only needed to input the answer from the questionnaire and this was then 
automatically coded by the database. A code book was developed to accompany the 
database with the possible responses to each question and how to code them 
explained within this, including when an answer was unable to be coded or there was 
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a missing response (see Appendix 8). The data was entered from paper 
questionnaires and there were cross checks (1 in 20) where a second member of the 
team checked the coding (LB). Checks also took place if there was any data outside 
the expected range. This ensured reliability and quality assessment throughout the 
data input process. SF-12 results were calculated through use of software provided 
as part of the license agreement (Quality Metric Health Outcomes Scoring Software 
5.0), data was transferred to the scoring system from the input database 
(QualityMetric Incorporated, 2016). 
8.13 Statistical analysis 
The data were entered by ER (with cross checks by LB) into a database developed 
for the study and was analysed using SPSS 24 by ER (IBM Corp, 2017). The primary 
comparison was between women currently receiving opioids (with comparison 
groups of 0mg/day, <20mg/day (low dose opioids) and ≥20mg/day high dose opioids, 
which have been used as cut off doses in previous research) and previous opioid 
users (Dunn et al., 2010; Saunders et al., 2009). The demographics of the groups 
were described using means and standard deviations if normally distributed, and 
medians and interquartile ranges if non–parametric; categorical items are described 
using numbers with proportions. The demographics were compared using basic 
statistical tests. Where data was non-normally distributed a Kruksal-Wallis test was 
used for significance tests and if the data was continuous ANOVA was used and 
Fisher’s exact test for categorical values. The type (e.g. morphine, codeine) of opioid 
and duration of opioid use was also compared based on morphine equivalent dose; 
comparison was undertaken using Chi-squared for duration of opioid use and 
Fischer’s exact test for type of opioid. The numbers of people who stopped different 
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types of analgesics were presented in a table. The exposure (independent variable) 
of interest was opioid use and this was split into three groups: previous opioid use, 
and current opioid use split into <20mg and ≥20mg oral morphine equivalent per day. 
The outcome (dependent variable) was FSD. The prevalence of women reporting 
FSD was calculated using proportions and this was compared to the number of 
women with a diagnosis of FSD on medical records review. Comparison of the 
proportions of women reporting FSD between current (split by dose) and previous 
opioids users was undertaken through logistic regression. The effect of opioid use on 
FSD was expressed as an odds ratios with 95% CIs. Adjustment for potential 
confounders (SF-12 physical component, SF-12 mental component, age, BMI, PHQ-
2, smoking status, alcohol use, NSAID use, contraception and antidepressant use) 
was done through logistic regression which provided adjusted odds ratios. P values 
of less than 0.05 (two sided tests) were taken as significant. Due to low response 
rate it was only possible to undertake univariate analysis and analysis including a 
second variable rather than multivariable analysis which was initially planned.  
Morphine daily equivalent doses were calculated based on the patients reported 
usage and then converted into morphine equivalents (the corresponding dose of 
different opioids to morphine) using predefined conversion tables developed by Von 
Korff et al. for the CONSORT study (Von Korff et al., 2008). MRR data was used for 
a sensitivity analysis where the dose of prescribed opioids was taken from the notes 
if the participant did not report a dose, this allowed more women to be split into 
groups based on daily morphine equivalent dosage.  
Survey responders and non-responders were compared using age and level of social 
deprivation. Social deprivation was calculated based on the postcode of the general 
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practice each participant was registered with and the index of social deprivation 
(IMD) which is based on census information and ranks areas within England for 1 
(most deprived) to 32,844 (least deprived) (Department for Communities and Local 
Government, 2015a). 
Item non-response was assessed during the data cleaning stage and missing data 
was dealt with in several different ways. Where data was missing from the self-
completion questionnaire, if the participant had agreed to medical records review, 
appropriate data was taken from this in order to undertake a sensitivity analysis and 
include further participants. Data was sourced from the medical records for any 
missing data in relation to comorbidities, medicine names, and doses, MRR data was 
only used in the case of missing data from the questionnaire in order to undertake a 
sensitivity analysis. Missing data in SF-12 was dealt with through the software 
provided with the license for use of the questionnaire. The software employs a 
method called maximum data recovery to deal with missing data. This is an 
automatic process where a value is assigned to missing data so long as at least one 
item in the scale has a response. In order for a PCS and MCS to be calculated 
certain items must be present within the response (Quality Metric Helth Outcomes, 
2016).  
A sensitivity analysis was undertaken using STEFFI-2 (instead of STEFFI-5) for the 
outcome, this increased the number of valid responses and allowed for a larger 
sample size. A second sensitivity analysis was undertaken using MRR data for opioid 
dose, this increased the number of women who could be split by total morphine 
equivalent daily dose and also allowed for a larger sample size to be included.  
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8.14 Conclusion 
This chapter has described the methods of the cross-sectional study including the 
development of the questionnaire. The following chapter will present the results of 
the study.  
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9 Cross-sectional study results 
This chapter presents the results of the cross-sectional study undertaken to 
investigate opioid use and potential associated FSD. The chapter describes the 
included population first, then compare responders and non-responders, and then by 
splitting into different opioid user groups. Medicines and comorbidities will be 
described and compared. FSD will be compared between opioid groups using logistic 
regression. Finally the results of two sensitivity analyses will be presented. 
9.1 Population  
Invitations to take part in the study were sent to 1020 women from 29 GPs. The 
practices included within the study ranged in size from 958 registered patients (with 5 
women invited to take part) up to 43838 registered patients (249 women invited to 
take part). These practices include a wide range of practice types from small single-
handed practices to large multi-site practices. See Table 9-1 for information on list 
size, level of deprivation, number of participants invited per practice and the 
response rate. As can be seen in Table 9-1 there is a range in proportion (0.12 to 
0.92%) of practice list who were invited to participate. All patients who met the 
inclusion criteria were included in the study, so this represents the difference in 
prevalence of women with musculoskeletal pain who are prescribed opioids between 
the different practices. There was also a wide range of index of deprivation (IMD) 
(described in section 8.7.7 and 8.13) from 1,007 to 30,964 (full range of deprivation in 
the English population 1 (most deprived)-32,844 (least deprived).  
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Table 9-1 Characteristics of practices included in the study, with 
participants invited and response rates 
Number of 
Practices 
List size Index of 
multiple 
deprivation 
Number of 
participants 
invited (%) 
Response 
rate n (%) 
29 958 14001 5 (0.52%) 0 (0%) 
2812 1007 26 (0.92%) 7 (27%) 
3974 6975 17 (0.43%) 2 (12%) 
4247 27795 10 (0.24%) 1 (10%) 
4466 20341 10 (0.22%) 2 (20%) 
5164 5840 34 (0.67%) 2 (6%) 
5473 2066 14 (0.26%) 0 (0%) 
5845 25304 17 (0.29%) 5 (29%) 
6292 17311 31 (0.49%) 2 (7%) 
6468 11669 21 (0.32%) 5 (24%) 
6546 28110 9 (0.14%) 3 (33%) 
7121 28579 50 (0.70%) 8 (16%) 
7184 28093 25 (0.35%) 3 (12%) 
7301 22857 9 (0.12%) 3 (33%) 
7427 13694 19 (0.26%) 5 (26%) 
7893 7902 25 (0.32%) 2 (8%) 
7925 21294 15 (0.19%) 2(14%) 
8300 19039 27 (0.33%) 4 (15%) 
8503 30964 21 (0.25%) 2 (10%) 
8980 21792 35 (0.39%) 7 (20%) 
10944 13970 54 (0.49%) 8 (15%) 
11287 22896 52 (0.46%) 13 (25%) 
11852 4759 67 (0.57%) 18 (27%) 
12822 3248 17 (0.13%) 3 (18%) 
13006 15893 44 (0.34%) 8 (18%) 
13202 4423 34 (0.26%) 8 (24%) 
13584 17666 20 (0.15%) 1 (5%) 
16782 1834 63 (0.38%) 3 (5%) 
43838 2444 249 (0.57%) 26 (10%) 
Total 
270196  
1020 
(0.38%) 153 (15%) 
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9.2 Response rate 
1020 women were invited to participate in the study. The overall response rate was 
15% (153/1020). The response rate ranged from 0% to 33% between practices (see 
Table 9-1). Six responders were excluded from analysis as they met the exclusion 
criteria (three were pregnant and three reported being menopausal). All respondents 
were female. The age range was 18-45 years old. A comparison of responders and 
non-responders, found responders were statistically significantly older and from 
practices in less deprived areas, however this was only a small difference with 
responders being 36 years old and non-responder 35 years old when compared 
using the mean age (see Table 9-2). The difference in response rate between 
practices was not statistically significant when compared for practice list size (p=0.84) 
and index of multiple deprivation (p=0.27). Within responders there was no difference 
between those who consented for MRR and those who didn’t when comparing age 
and deprivation (see Table 9-3). 
Table 9-2 Comparison of age and IMD of responders and non-responders 
 Responders Non-Responders P 
N 153 867  
Age (mean) 36.0  34.6  0.03* 
Age (median, IQR) 38 (31-42) 35 (29-41) 
IMD (mean, standard 
deviation (SD) 
12797 (11251-14358) 11208 (10572-11850) 0.02* 
IMD (median, IQR) 13694 (3248-22324) 5840 (2444-19039) 
Significance is calculated using Wilcoxon-Mann-Whitney as both Age and Deprivation are 
non-normally distributed. * indicates significant results. 
Table 9-3 Comparison of consent status for MRR within responders 
 MRR consent MRR consent 
withheld 
P 
N (147) 115 31  
Age (median) 37 (32-42) 37 (31-42) 0.58 
Deprivation 
(median) 
11669 (2444-
22857) 
13694 (4423-
20341) 
0.82 
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9.3 Opioid use 
146 participants responded and were split into three groups based on opioid dose. 11 
(7.5%) current opioid users could not be assigned to a group as there was specific 
item missing data for the dose of opioids. Of those who could be split into opoid 
groups 41 (30.2%) participants were not current opioid users (defined in this case as 
a participant who did not report using opioids at the time of questionnaire), 46 
(36.0%) were using a daily morphine equivalent dose of <20mg/day and 48 (33.8%) 
were using a daily morphine equivalent dose of ≥20mg/day (see Figure 9-1).  
Figure 9-1 Pie chart showing the proportion of the sample in each opioid 
group based on daily morphine equivalent dose 
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The highest number of different opioids any one person was taking was 4. This 
participant was an outlier with the next 4 highest participants taking only 2 different 
opioids. The majority of opioid users reported using only one opioid, with those in the 
≥20mg group being more likely to be using 2 different opioids (p<0.001) (see Table 9-
4).  
Table 9-4 Number of different opioids being used split by opioid group 
based on daily morphine equivalent dose.  
 Whole 
group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 (28.1%) 46 (31.5%) 48 (32.9%)  
Number opioids~ 
0 opioid 41 (28.1%) 41 
(100.0%) 
0 (0.0%) 0 (0.0%) <0.001* 
1 opioid 86 (58.9%)  42 (91.3%) 35 (72.9%) 
2 opioids 18 (12.3%)  4 (8.7%) 12 (25.0%) 
3 opioids 0 (0.0%)  0 (0.0%) 0 (0.0%) 
4 opioids 1 (0.7%)  0 (0.0%) 1 (2.1%) 
Where data is non-normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~, normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. 
Statistical tests do not include comparison to the whole group but are between the three 
types of opioid use. * indicates statistically significant results 
Within those using opioids, the length of use (split into short-term and long-term 
opioid use) did not vary dependent on the daily dose of opioid used. 91.3% those 
using ≥20mg/day of morphine were taking opioids long-term (three months of opioid 
use or longer), compared with 82.2% in the <20mg/day group but this difference was 
not statistically significant (see Table 9-5). The maximum dose of opioids being used 
was 900mg/day, the next highest dose was 357mg/day, the third highest dose was 
240mg/day with the remaining participants all taking less than 100mg/day of opioids, 
all three of the women taking the highest doses were in the high disability, severely 
limiting pain group.  
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Table 9-5 Length of opioid use and the daily morphine equivalent dose 
within each group split by opioid dose.  
 Opioid Use P 
<20mg/day ≥20mg/day  
Total  45 46  
Opioid use 
Long-term 37 (82.2%) 42 (91.3%) 0.23 
Short-term 8 (17.8%) 4 (8.7%) 
Dose 
Range 0.34-19.00 20.00 – 900.00 0.02 
Median (IQR) 9.0 (2.9-18.0) 38.0 (36.0 – 45.3) 
Comparison using Chi-squared. 
 
The most frequent opioid prescribed was codeine (58.5%, including combination 
preparations), followed by tramadol (15.4%), dihydrocodeine (13.0%) and then 
morphine (7.3%). In those taking ≥20mg/day the proportion of codeine fell to 44.1% 
(compared to 78.8% in the <20mg/day users), and the proportion of those prescribed 
tramadol, dihydrocodeine and morphine increased. In those receiving <20mg/day of 
daily morphine equivalent dose no participants reported using morphine whereas 
11.9% of those on higher doses reported using morphine. The difference in type of 
opioid was statistically significant (p<0.001) see Table 9-6. 
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Table 9-6 Types of analgesia prescribed dependent on strength of opioid.  
Opioid Type N (%) Opioid use P 
  <20mg/day ≥20mg/day  
All 123 52 59  
Morphine 9 (7.3%) 0 (0%) 7 (11.9%) <0.001* 
Codeine 72 (58.5%) 41 (78.8%) 26 (44.1%) 
Tramadol 19 (15.4%) 4 (7.7%) 14 (23.7%) 
Dihydrocodeine 16 (13.0%) 4 (7.7%) 9 (15.3%) 
Oxycodone 3 (2.4%) 1 (1.9%) 2 (3.4%) 
Transdermal 
Fentanyl 
1 (0.8%) 0 (0%) 0 (0%) 
Buprenorphine  3 (2.4%) 2 (3.8%) 1 (1.7%) 
NB total numbers when adding <20mg group to ≥ 20mg will not equal the total numbers in N 
as some participants were unable to be split within groups as they did not provide doses for 
medicines. * indicates that the result is statistically significant. Fishers exact test undertaken 
for comparison. 
 
When comparing type of opioid used based on the duration of opioid use, there was 
no statistically significant differences (p=0.61), however there were low numbers in 
the short-term/previous user group (see Table 9-7).  
 
Table 9-7 Types of analgesia prescribed dependent on length of opioid 
use.  
Opioid Type N (%) Opioid use P 
  Short-term 
and previous 
Long-term  
All 123 15 99  
Morphine 9 (7.3%) 0 (0%) 8 (8.1%) 0.61 
Codeine 72 (58.5%) 8 (53.3%) 60 (60.6%) 
Tramadol 19 (15.4%) 4 (26.7%) 13 (13.1%) 
Dihydrocodeine 16 (13.0%) 3 (20.0%) 11 (11.1%) 
Oxycodone 3 (2.4%) 0 (0.0%) 3 (3.0%) 
Transdermal 
Fentanyl 
1 (0.8%) 0 (0.0%) 1 (1.0%) 
Buprenorphine  3 (2.4%) 0 (0.0%) 3 (3.0%) 
NB total numbers when adding long-term and short-term will not equal the total numbers in N 
due to missing data. 
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9.4 Demographics  
The demographics for the groups are described below with figures for all responders 
and then split by opioid use into previous opioid users, current users taking 
<20mg/day total morphine equivalent dose, and current users taking ≥20mg/day total 
morphine equivalent dose (see Table 9-8). Doses throughout the chapter represent 
total morphine equivalent.  
146 women responded. The majority of respondents were White (132/146, 90.4%). 
The median age of responders was 37 (31-42), More than half of respondents were 
currently in paid employment (84/146, 57.5%) with only 9/146 (6.2%) reporting being 
off work on sick leave currently. The median IMD was 12682 (IQR 3248 to 21792). 
The above factors were also compared between different daily total morphine 
equivalent doses. The proportion of Asian respondents was higher in those who had 
previously used opioids than in the whole group and current opioid users (see Figure 
9-2), however this was not statistically significant (see Table 9-8). Women in the 
≥20mg/day category had a higher median age (39.5 years (33-43)), when compared 
to other opioid groups, this was not statistically significant. There was a statistically 
significant difference between groups of opioid use with regards to employment 
(p<0.001 see Table 9-8), with the proportion in paid employment decreasing with 
increasing opioid dose (see Figure 9-3). Level of deprivation was not normally 
distributed. Level of deprivation showed a trend towards increasing deprivation with 
increasing daily morphine equivalent dose, this was not statistically significant 
(p=0.48).  
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Table 9-8 Characteristics of the cross-sectional study, overall and split by 
opioid category.  
 Whole group Opioid Category P  
 No Opioid <20mg/day ≥20mg/day  
N 146 41 (28.1%) 46 (31.5%) 48 (32.9%)  
Ethnicity 
White 132 (90.4%) 34 (82.9%) 42 (91.3%) 45 (93.8%) 0.27 
Other 14 (9.6%) 7 (17.1%) 4 (8.7%) 3 (6.3%) 
Age 
(years)~ 
37 (31, 42) 36 (32, 41) 36.5 (29, 42) 39.5 (33, 43) 0.24 
Employment  
Paid job 84 (57.5%) 33 (80.5%) 27 (58.7%) 19 (39.6%) <0.001
* Voluntary 
job 
2 (1.4%) 0 (0.0%) 2 (4.3%) 0 (0.0%) 
Employed 
but off sick 
9 (6.2%) 1 (2.4%) 0 (0.0%) 6 (12.5%) 
Looking 
after home 
24 (16.4%) 4 (9.8%) 9 (19.6%) 9 (18.8%) 
Retired 0 (0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Student 4 (2.7%) 1 (2.4%) 1 (2.2%) 1 (2.1%) 
Other 23 (15.8%) 2 (4.9%) 7 (15.2%) 22 (16.3%) 
IMD~ 12682 (3248, 
21792) 
13694 (3248, 
22896) 
11669 (2444, 
19039) 
5299.5 (2444, 
21792) 
0.48 
Where data is non-normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~. Normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. 
Tests are for differences between opioid use groups. * indicates statistically significant 
results. 
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Figure 9-2 Ethnicity split by group based on daily morphine equivalent 
dose 
 
Figure 9-3 Employment status of respondents split by group based on daily 
morphine equivalent dose 
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70/146 (48.0%) of the sample overall were married with a further 32/146 (21.9%) co-
habiting. There was no statistically significant difference seen with regards to home 
life between opioid groups including, relationship status (p=0.63), having children 
(p=0.69) and the number of children (p=0.16) see Table 9-9. Around half of the 
respondents were married and this was steady across all three groups. Less than 
30% of women reported being single see Figure 9-4. 74.0% of the respondents 
reported having children with a median number of children of 2 (IQR 0, 3) and a 
range of 0, 5 see Figure 9-5. 
Table 9-9 Relationship and child status of the sample overall and split by 
opioid category 
 Whole group Opioid Category P  
 No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Relationship status 
Married 70 (48.0%) 19 (46.3%) 21 (45.7%) 26 (54.2%) 0.63 
Separated 3 (2.1%) 0 (0.0%) 2 (4.3%) 1 (2.1%) 
Divorced 4 (2.7%) 0 (0.0%) 1 (2.2%) 2 (4.2%) 
Widowed 34 (23.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Co-habiting 32 (21.9%) 13 (31.7%) 9 (19.6%) 10 (20.8%) 
Single 32 (21.9%) 8 (19.5%) 13 (28.3%) 8 (16.7%) 
Missing 2 (2.1%) 1 (2.4%) 0 (0.0%) 1 (2.1%) 
Children 
Yes 108 (74.0%) 31 (75.6%) 32 (69.6%) 37 (77.1%) 0.69 
No 38 (26.0%) 10 (24.4%) 14 (30.4%) 11 (22.9%) 
Number of 
children~ 
2 (0-3) 2 (1-2) 1 (0 – 2) 2 (0.5 – 3) 0.16 
Fishers exact test has been used to compare categorical values, Kruskal-Wallis test for non-
normally distributed continuous data indicated by ~ and median and IQR presented. 
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Figure 9-4 Marital status of respondents split by group based on daily 
morphine equivalent dose 
 
Figure 9-5 Number of children of respondents split by group based on daily 
morphine equivalent dose 
 
  
 257 
 
9.5 Smoking, alcohol and illegal drug use 
Smoking, alcohol and illegal drug use in the sample are presented in Table 9-10. 
There appeared to be a trend towards participants being more likely to smoke if they 
were using opioids, this was not statistically significant (p=0.15) see Figure 9-6. 
Around one quarter of the participants reported never drinking alcohol (26.0%) and 
the proportion of non-drinkers seemed to be higher in opioid users but this was not 
statistically significant (p=0.53) (see Table 9-10). Less than 5% of the respondents 
reported using illegal drugs and this was seen across all three groups of opioid use 
(p=1.00). 
Table 9-10 Smoking, alcohol and drug use, for the whole group and split 
by daily morphine equivalent dose.  
 Whole group Opioid Category P 
 No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Smoking 
Current 
smoker 
34 (23.3%) 5 (12.2%) 10 (21.7%) 14 (29.2%) 0.15 
Non smoker 112 (76.7%) 36 (87.8%) 36 (78.3%) 34 (70.8%) 
Alcohol 
Daily 5 (3.4%) 3 (7.3%) 1 (2.2%) 1 (2.1%) 0.53 
Once or 
twice a 
week 
28 (19.2%) 10 (24.4%) 10 (21.7%) 6 (12.5%) 
Once or 
twice a 
month 
44 (30.1%) 13 (31.7%) 10 (21.7%) 15 (31.3%) 
Once or 
twice a year 
31 (21.2%) 7 (17.1%) 13 (28.3%) 11 (22.9%) 
Never 38 (26.0%) 8 (19.5%) 12 (26.1%) 15 (31.3%) 
Illegal drug use 
Yes 7 (4.8%) 2 (4.9%) 2 (4.3%) 3 (6.3%) 1.00 
No 139 (95.2%) 39 (95.1%) 44 (95.7%) 45 (93.8%) 
Fisher’s exact test has been used to compare categorical values. 
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Figure 9-6 Smoking status split by group based on daily morphine 
equivalent dose 
 
 
9.6 Physical health 
43.8% of the whole group scored 4 (which is the highest grade) on the chronic pain 
grade, with 28.8% self-reporting chronic pain. The median number of days that 
participants across the whole group were kept from their usual activities over the 
preceding 6 months by pain was 23.0 (IQR 7.0, 90.0). The median BMI for the group 
overall was 28.3 (IQR 23.6, 34.5) and the mean SF-12 physical component score 
was 42.01 ±11.67 (see Table 9-11).  
Higher daily morphine equivalent daily doses were associated with higher pain grade 
scores, with 62.5% of those in the ≥20mg/day opioid group scoring 4 on the chronic 
pain grade score compared with only 31.7% in the 0mg group, this was a statistically 
significant relationship (p=0.01) (see Figure 9-7). Self-reported chronic pain 
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increased with opioid use (60.4% in the ≥20mg/day opioid group, compared with 
4.9% in the 0mg/day group) and this relationship was statistically significant 
(p=<0.001). Higher opioid dose was associated with participants being kept from 
daily activities by pain more frequently 69.5 days (IQR 14.75, 160.00) in the 
≥20mg/day opioid group compared with 15 days (IQR 2.00, 60.00) in the no current 
opioid use group and this was also statistically significant (p<0.001) (see Figure 9-8).  
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Table 9-11 Physical health including pain status, SF-12 physical 
component and BMI, for the whole group and split by daily morphine 
equivalent dose. 
 Whole 
Group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Pain Grade  
1 (low disability 
low intensity) 
14 (9.6%) 6 (14.6%) 7 (15.2%) 1 (2.1%) 0.01 
2 (low disability 
high intensity) 
19 (13.01%) 7 (17.1%) 8 (17.4%) 4 (8.3%) 
3 (high 
disability 
moderately 
limiting) 
41 (28.1%) 13 (31.7%) 16 (34.8%) 9 (18.8%) 
4 (high 
disability 
severely 
limiting) 
64 (43.8%) 13 (31.7%) 14 (30.4%) 30 (62.5%) 
Missing data 8 (5.5%) 2 (4.9%) 1 (2.2%) 4 (8.3%) 
Chronic Pain (self-report)  
Yes 42 (28.8%) 2 (4.9%) 7 (15.2%) 29 (60.4%) <0.001* 
No 98 (67.1%) 33 (80.5%) 39 (84.8%) 19 (39.6%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Number of 
days pain has 
kept them from 
usual activities 
in 6 months~ 
23.0 (7.0, 
90.0) 
15.0 (2.00, 
60.00) 
14.00 (4.00, 
37.50) 
69.50 
(14.75, 
160.00) 
<0.001* 
SF-12 physical 
component 
42.01 
±11.67 
49.45 ±10.58 43.95 ± 
10.48  
33.96 ± 8.4 <0.001* 
BMI~ 28.3 (23.6, 
34.5) 
24.4 (21.4, 
29.6) 
28.9 (24.6, 
35.4) 
32.7 (26.6, 
37.3) 
<0.001* 
Where data is non-normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~, normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. 
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Figure 9-7 Pain grade split by group based on daily morphine equivalent 
dose. 
 
Figure 9-8 Number of days kept from normal activities by pain split by 
group based on daily morphine equivalent dose. 
  
        0mg/day            <20mg/day   ≥20mg/day 
Daily oral morphine equivalent dose 
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The SF-12 physical component score decreased (the lower the SF-12 physical 
component score, the worse the participants self-reported physical health) with 
increasing opioid use, with those in the ≥20mg/day group having the lowest score 
(33.96 ± 8.4), this was a statistically significant difference between opioid groups 
(p<0.001) see Figure 9-9. 
Figure 9-9 SF-12 physical component score split by group based on daily 
morphine equivalent dose. 
 
Increasing opioid dose was associated with increasing BMI, participants in the 
≥20mg/day group had a median BMI of 32.7 (IQR 26.6, 37.3), whereas those in the 
0mg/day group had a BMI of 24.4 (IQR 21.4, 29.6) and this was a statistically 
significant difference (see Figure 9-10).   
        0mg/day                   <20mg/day                    ≥20mg/day 
Daily oral morphine equivalent dose 
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Figure 9-10 BMI split by group based on daily morphine equivalent dose.  
 
The most common specific physical problem was joint pain, which was reported by 
39.7% of the participants. There was a statistically significant difference between 
opioid groups for joint pain, with the proportion reporting joint pain increasing with 
daily opioid dose see Table 9-12. No other specific conditions showed a statistically 
significant difference between groups. Women in the no current opioid group were 
significantly more likely to report that they had no current medical problems and this 
decreased with increasing opioid dose.  
  
        0mg/day                      <20mg/day             ≥20mg/day 
Daily oral morphine equivalent dose 
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Table 9-12 Current specific medical conditions described for the whole 
group and split by group based on daily morphine equivalent dose.  
 Whole 
Group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Anaemia 
Yes 7 (4.8%) 1 (2.4%) 3 (6.5%) 3 (6.3%) 0.79 
No 133 (91.1%) 34 (82.9%) 43 (93.5%) 45 (93.8%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Hypertension 
Yes 6 (4.1%) 0 (0.0%) 1 (2.2%) 5 (10.4%) 0.07 
No 134 (91.8%) 35 (85.4%) 45 (97.8%) 43 (89.6%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Hysterectomy 
Yes 4 (2.7%) 0 (0.0%) 1 (2.2%) 3 (6.3%) 0.45 
No 136 (93.2%) 35 (85.4%) 45 (97.8%) 45 (93.8%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Thyroid disease 
Yes 11 (7.5%) 1 (2.4%) 3(6.5%) 7 (14.6%) 0.19 
No 129 (88.4%) 34 (82.9%) 43 (93.5%) 41 (85.4%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Joint Pain 
Yes 58 (39.7%) 5 (12.2%) 18 (39.1%) 29 (60.4%) <0.001* 
No 82 (56.2%) 30 (73.2%) 28 (60.9%) 19 (39.6%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Urinary Incontinence 
Yes 6 (4.1%) 0 (0.0%) 4 (8.7%) 2 (4.2%) 0.20 
No 134 (91.8%) 35 (85.4%) 42 (91.3%) 46 (95.8%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.00%) 0 (0.00%) 
Endometriosis 
Yes 6 (4.1%) 1 (2.4%) 1 (2.2%) 4 (8.3%) 0.45 
No 133 (91.1%) 33 (80.5%) 45 (97.8%) 44 (91.7%) 
Missing 7 (4.8%) 7 (17.1%) 0 (0.0%) 0 (0.0%) 
Chronic Pelvic Pain 
Yes 9 (6.2%) 2 (4.9%) 2 (4.3%) 4 (8.3%) 0.90 
No 131 (89.7%) 33 (80.5%) 44 (95.7%) 44 (91.7%) 
Missing 6 (4.1%) 6(14.6%) 0 (0.0%) 0 (0.0%) 
No conditions 
Yes 100 (68.5%) 21 (51.2%) 13 (28.3%) 4 (8.3%) <0.001* 
No 40 (27.4%) 14 (34.1%) 33 (71.7%) 44 (91.7%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Comparison using fishers exact test. * indicates statistically significant results. 
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9.7 Psychological health  
Higher doses of opioids were associated with worsening mental health both self-
reported and through use of screening tools (see Table 9-13). There was a 
statistically significant relationship between opioid use and positive PHQ-2 screening 
(with a cut off score of 3, p<0.001)), SF-12 mental health component (p<0.001), self-
reported depression (p<0.001) and self-reported anxiety (p=0.02). Figure 9-11 shows 
the SF-12 mental health score for each group of opioid users (lower scores represent 
poorer mental health), this illustrates the decreasing median for the SF-12 with 
increasing daily dose of opioid. 
Table 9-13 Psychological health described for the whole group and 
different categories of opioid use based on daily morphine equivalent dose 
Where data is non-normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~, normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. * 
indicates a statistically significant relationship. 
  
 Whole 
group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
PHQ-2 (cut off ≥3) 
Positive 90 (61.6%) 14 (34.1%) 27 (58.7%) 38 (79.2%) <0.001* 
Negative 52 (35.6%) 25 (61.0%) 17 (37.0%) 10 (20.8%) 
Missing 4 (2.7%) 2 (4.9%) 2 (4.3%) 0 (0.0%) 
SF-12 (Mental 
health 
component) ~ 
40.51 
(31.9, 48.8) 
49.1 (38.3, 
54.4) 
39.3 (32.2, 
49.5) 
36.3 (27.5, 
45.8) 
<0.001* 
Patient reported depression 
Present 50 (34.3%) 5 (12.2%) 15 (32.6%) 26 (54.2%) <0.001* 
Absent 90 (61.6%) 30 (73.2%) 31 (67.4%) 22 (45.8%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
Patient reported anxiety 
Present  46 (31.5%) 5 (12.2%) 15 (32.6%) 21 (43.8%) 0.02* 
Absent  94 (64.4%) 30 973.2%) 31 (67.4%) 27 (56.3%) 
Missing 6 (4.1%) 6 (14.6%) 0 (0.0%) 0 (0.0%) 
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Figure 9-11 SF-12 mental health score split by group based on daily 
morphine equivalent dose. 
 
 
 
PHQ-2 was used as a marker of mental health disorders within the analysis and this 
appeared to be reasonable see Table 9-14. A positive PHQ-2 was correlated with 
self-reported depression and anxiety and worsening SF-12 mental health component 
score.  
  
        0mg/day                  <20mg/day                 ≥20mg/day 
Daily oral morphine equivalent dose 
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Table 9-14 PHQ-2 score compared to pain grade, SF-12 mental component 
and self-reported anxiety and depression. 
 PHQ-2 P 
Negative Positive 
Pain Grade 
1 8 (15.4%) 5 (5.6%) 0.03* 
2 10 (19.2%) 9 (10.0%) 
3 17 (32.7%) 24 (26.7%) 
4 15 (28.8%) 46 (51.1%) 
Missing 2 (3.8%) 6 (6.7%) 
Self-reported depression 
Present 7 (13.5%) 42 (46.7%) <0.001* 
Absent 41 (78.8%) 46 (51.1%) 
Missing 4 (7.7%) 6 (4.2%) 
Self-reported anxiety 
Present 7 (13.5%) 38 (42.2%) <0.001* 
Absent 41 (79.9%) 50 (55.6%) 
Missing 4 (7.7%) 2 (2.2%) 
SF-12 (mental component) 50.4 ± 8.5 34.2 ± 9.4 <0.001* 
 
9.8 Prescribed medicine  
9.8.1 Analgesics 
Those receiving opioids used a higher number of analgesics overall (see Figure 9-
12), were more likely to take paracetamol (p<0.001), gabapentoids (p<0.001) and 
antidepressants that can be used for pain (p<0.001) (see Table 9-15), these 
relationships were all statistically significant. There was no statistically significant 
difference for NSAID use between the three groups of opioid use (see Table 9-15). 
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Figure 9-12 Number of analgesics taken split by group based on daily 
morphine equivalent dose 
 
  
        0mg/day                   <20mg/day                  ≥20mg/day 
Daily oral morphine equivalent dose 
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Table 9-15 Analgesic use split by group of opioid use based on daily 
morphine equivalent dose.  
 Whole 
group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Number of 
Analgesics~ 
2 (1, 3) 1 (0, 1) 2 (2, 3) 3 (2, 4) <0.001* 
Range of 
analgesics 
0, 4 0, 4 1, 4 1, 4  
Paracetamol (alone or in combination form) 
Yes 95 (65.1%) 14 (34.1%) 37 9 
(80.4%) 
36 (75.0%) <0.001* 
No 51 (34.9%) 27 (65.9%) 9 (19.6%) 12 (25.0%) 
NSAIDs~ 
0 77 (52.7%) 25 (61.0%) 23 (50.0%) 26 (54.2%) 0.87 
1 63 (43.2%) 14 (34.1%) 21 (45.7%) 20 (41.7%) 
2 6 (4.1%) 2 (4.9%) 2 (4.3%) 2 (4.2%) 
Gabapentoids 
0 127 
(87.0%) 
41 
(100.0%) 
40 (87.0%) 37 (77.1%) <0.001* 
1 19 (13.0%) 0 (0.0%) 6 (13.0%) 11 (22.9%) 
Pain Antidepressants 
0 121 
(82.9%) 
40 (97.6%) 40 (87.0%) 31 (64.6%) <0.001* 
1 25 (17.1%) 1 (2.4%) 6 (13.0%) 17 (35.4%) 
Where data is not normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~, normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. 
Statistical tests do not include comparison to the whole group but are between the three 
types of opioid use. * indicates statistically significant results 
9.8.2 Reasons for stopping analgesics 
When women indicated that they had stopped taking an analgesic medicine they 
were asked the reasons for this (see Table 9-16). The most common reason for 
stopping an analgesic was that it didn’t help the participant’s pain (31.1%). This was 
highest amongst antidepressant medicines used for pain (50.0%) and NSAIDs 
(50.0%) and was much lower in those reporting stopping opioids (14.8%). 28.1% of 
participants who reported stopping medicines said that they did so as they were no 
longer required. 20.7% of medicines were stopped due to the medicine causing 
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adverse effects, this was the most common reason for gabapentoids being stopped 
(54.5% of cases). Focusing on opioids the most common causes for stopping these 
was that the opioid was no longer needed (35.2%), followed by adverse effects 
(25.9%) and then by the opioid not helping the participants pain (14.8%).  
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Table 9-16 Reasons for stopping medicine split by medicine type. 
Medicine (n) Reason for stopping analgesics 
 It didn’t help my 
pain 
No longer 
needed 
The medicine 
made me feel 
unwell 
I was worried 
about using the 
medicine 
I preferred to try 
something else 
Unable to code 
NSAID (40) 20 (50.0%) 9 (22.5%) 6 (15.0%) 4 (10.0%) 0 (0.0%) 1 (2.5%) 
Opioid (54) 8 (14.8%) 19 (35.2%) 14 (25.9%) 6 (11.1%) 6 (11.1%) 1 (1.9%) 
Paracetamol 
(10) 
4 (40.0%) 4 (40.0%) 0 (0.0%) 1 (10.0%) 0 (0.0%) 1 (10.0%) 
Gabapentoids 
(11) 
3 (27.3%) 1 (9.1%) 6 (54.5%) 0 (0.0%) 0 (0.0%) 1 (9.1%) 
Benzodiazepines 
(4) 
0 (0.0%) 3 (75.0%) 0 (0.0%) 1 (25.0%) 0 (0.0%) 0 (0.0%) 
Antidepressants 
for pain (6) 
3 (50.0%) 0 (0.0%) 1 (16.7%) 0 (0.0%) 0 (0.0%) 2 (33.3%) 
Other (9) 4 (44.4%) 1 (11.1%) 1 (11.1%) 1 (11.1%) 2 (22.2%) 0 (0.0%) 
Overall (135) 42 (31.1%) 38 (28.1%) 28 (20.7%) 13 (9.6%) 8 (5.9%) 6 (4.4%) 
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9.8.3 Non-analgesic medicines 
The median number of medicines used (including analgesics) was 4 (IQR 2, 6) 
across the whole group, with those not currently taking opioids using less than this 
(2, IQR 1, 3) and those in the ≥20mg opioid using more (5, IQR 4, 8.5), This was a 
statistically significant difference (p<0.001) (see Figure 9-13 and Table 9-17) The 
most medicines any participant was receiving was 16 and the minimum 0. Those 
receiving opioids were more likely to report taking antidepressants that are 
traditionally not used as analgesics (p=0.01) and were more likely to be receiving an 
anti-acid medicine (0.00).  
Figure 9-13 Number of medicines taken split by group based on daily 
morphine equivalent dose 
 
        0mg/day                      <20mg/day          ≥20mg/day 
Daily oral morphine equivalent dose 
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Table 9-17 Non analgesic medicine use for the whole group and split by 
group based on daily morphine equivalent dose.  
 Whole 
group 
Opioid Category P 
No Opioid <20mg/day ≥20mg/day  
N 146 41 46 48  
Total number of 
medicine~ 
4 (2, 6) 2 (1, 3) 4 (3, 5) 5 (4, 8.5) <0.001* 
Range of 
medicine 
0, 15 0, 10 1, 16 1, 15  
Benzodiazepine/Zopiclone type drugs 
0 136 
(93.2%) 
40 (97.6%) 41 (89.1%) 46 (95.8%) 0.22 
1 10 (6.8%) 1 (2.4%) 5 (10.9%) 2 (4.2%) 
Antidepressants not for pain 
0 111 
(76.0%) 
38 (92.7%) 34 (73.9%) 32 (66.7%) 0.01* 
1 35 (24.0%) 3 (7.3%) 12 (26.1%) 16 (33.3%) 
Contraception 
Hormonal 55 (37.6%) 16 (39.0%) 20 (43.5%) 15 (31.3%) 0.62 
Non hormonal  31 (21.2%) 10 (24.4%) 9 (19.6%) 10 (20.8%) 
No contraception 54 (37.0%) 12 (29.3%) 17 (37.0%) 22 (45.8%) 
Missing 6 (4.1%) 3 (7.3%) 0 (0.0%) 1 (2.1%) 
Anti-hypertensives 
0 139 
(95.2%) 
41 
(100.0%) 
44 (95.7%) 43(89.6%) 0.12 
1 7 (4.8%) 0 (0.0%) 2 (4.3%) 5 (10.4%) 
Anti-acid medicine (Proton pump inhibitors/Histamine 2 blocker) 
0 124 
(84.9%) 
40 (97.6%) 42 (91.3%) 33 (68.8%) <0.001* 
1 22 (15.1%) 1 (2.4%) 4 (8.7%) 15 (31.3%) 
Where data is non-normally distributed Kruskal-Wallis test has been used for significance 
tests and medians and IQR have been displayed, indicated with a ~, normally distributed 
continuous data is compared using ANOVA and fishers exact test for categorical values. 
Statistical tests do not include comparison to the whole group but are between the three 
types of opioid use.* indicates statistically significant results.  
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Just under 60% of the whole cohort reported using contraception of some kind. The 
proportion of women who report using no contraception appeared to increase with 
increasing opioid dose but this was not statistically significant (p=0.62) (see Table 9-
17). Figure 9-14 shows the specific type of contraception used within each group of 
opioid use, use of the mirena coil (progesterone intrauterine device) was the second 
most common category after no contraception use. 
Figure 9-14 Contraception use split by group based on daily morphine 
equivalent dose 
 
 
 
 
  
 275 
 
9.9 Sexual function 
9.9.1 Frequency of sexual intercourse 
Frequency of reported sexual intercourse ranged from 0-520 per year, with a median 
of 48 (IQR 5, 104) per year. The participant with the highest frequency was an outlier 
and the next closest participant reported having sexual intercourse 364 times each 
year. 25 women reported that they had 0 episodes of sexual intercourse over the 
course of a year. There appeared to be a decrease in frequency of sexual 
intercourse with increasing dose of opioid, but this was not statistically significant. 
There was no relationship between frequency of sexual intercourse, and marital 
status or type of contraception. The women in the high disability severely limiting 
group based on pain grade, appeared to have a lower frequency of sexual 
intercourse, but this again was not statistically significant. The only relationship that 
appeared to be significant was between FSD (based on STEFFI questionnaire) and 
frequency of sexual intercourse, with those participants reporting FSD having sexual 
intercourse less often and this was statistically significant (see Table 9-18 for full 
details). There is no statistically significant difference between the frequency of 
sexual intercourse when comparing women receiving different types of contraception 
dependent on group of opioid use (p = 0.98). The data shows that some women are 
taking opioids and having sexual intercourse without using any form of contraception 
(see Figure 9-15).  
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Table 9-18 Frequency of sexual intercourse (number/year) dependent on 
pain, opioid use, FSD and relationship status.  
 N Sexual intercourse 
(median, IQR) 
P 
Whole group 138 48 (5 – 104)  
Opioid use 
No opioid 40 52 (24 – 124) 0.22 
Opioid < 20mg/day 42 42 (4 – 120) 
Opioid ≥ 20mg/day 45 24 (4 – 52) 
Marital status 
Married 68 36 (12 – 100) 0.12 
separated 3 1 (0-60) 
Divorced 4 24 (12.5 – 38) 
Co-habiting 33 52 (24 – 156) 
Single 28 24 (0-150) 
FSD 
Present 57 24 (0-52) <0.001* 
Absent  74 52 (36-156) 
Pain grade 
1 (low disability low intensity) 14 52 (34-60) 0.14 
2 (low disability high intensity) 17 52 (24 – 120) 
3 (high disability moderately limiting) 41 52 (24-104) 
4 (high disability severely limiting) 58 24 (4-52) 
Contraception 
Hormonal 50 48 (5 – 104) 0.66 
Non-hormonal 30 50 (24 – 104) 
No contraception 52 42 (4 – 112) 
Tests of significance are Kruskal-Wallis as frequency of sexual intercourse is a non-normally 
distributed outcome. * indicates significant results 
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Figure 9-15 Frequency of sexual intercourse split by type of contraception 
and group based on daily morphine equivalent dose 
 
 
9.9.2 FSD and medical records review 
116 women consented to medical records review. Of these women. 50 of these 
women had a positive result for FSD based on their response to the STEFFI-5 
questionnaire and 8 women did not give enough data for a result for STEFFI-5 to be 
calculated. None of the women who consented to medical records review had coded 
sexual dysfunction in the medical notes. 
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9.9.3 Opioid use and female sexual dysfunction (FSD) 
FSD was present in increasing numbers as opioid use increases. 31.7% of those not 
using opioids report FSD, rising to 50.0% in those using ≥20mg morphine equivalent 
per day. The difference was not statistically significant but there is increased odds of 
FSD with those taking increasing doses of opioids. The <20mg group had an OR of 
1.28 (0.51, 3.20) and in the ≥20mg 2.29 (0.94, 5.55), which is more than double the 
odds of FSD than those not currently taking opioids see Table 9-19. A test for trend 
was not statistically significant (p = 0.09). The logistic regression was restricted to 
univariate analysis (including just a single covariate or confounder) due to small 
numbers within the study. The logistic regression was adjusted for clinically important 
variables individually, to see if they confounded the observed relationship see Table 
9-20. There was a consistent relationship across all the outcomes for FSD with 
increasing daily morphine equivalent dose of opioids associated with increasing odds 
of FSD, and this pattern remains after adjustment. However none of the OR were 
statistically significant and the 95% CI were wide.  
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Table 9-19 FSD including both the overall results of STEFFI-5 and the 
 Opioid Category 
No Opioid <20mg/day ≥20mg/day 
N 41 46 48 
FSD 
Present 13 (31.7%) 16 (35.8%) 24 (50.0%) 
Absent 26 (63.4%) 25 (54.3%) 21 (43.8%) 
Missing 2 (4.9%) 5 (10.9%) 3 (6.3%) 
OR (95% CI) Reference 
Category 
1.28 (0.51, 3.20) 2.29 (0.94, 5.55) 
P 0.60 0.07 
Satisfied with sex life 
Yes 25 (61.0%) 24 (52.2%) 25 (52.1%) 
No 15 (36.6%) 19 (41.3%) 23 (47.9%) 
Missing 1 (2.4%) 3 (6.5%) 0 (0.0%) 
OR (95% CI) Reference 
Category 
1.32 (0.55, 3.18) 1.53 (0.65, 3.60) 
P 0.54 0.33 
Partner satisfied with sex life 
Yes 13 (31.7%) 22 (47.8%) 22 (45.8%) 
No 27 (65.9%) 19 (41.3%) 26 (54.2%) 
Missing 1 (2.4%) 5 (10.9%) 0 (0.0%) 
OR (95% CI) Reference 
Category 
0.416 (0.17, 1.03) 0.57 (0.24, 1.36) 
P 0.06 0.57 
Difficulty Orgasming 
Yes 12 (29.3%) 16 (34.8%) 22 (46.8%) 
No 28 (68.3%) 26 (56.5%) 24 (51.1%) 
Missing 1 (2.4%) 4 (8.7%) 1 (2.1%) 
OR (95% CI) Reference 
Category 
1.44 (0.57, 3.60) 2.14 (0.88, 5.21) 
P 0.44 0.09 
Pain during sexual intercourse 
Yes 18 (43.9%) 25 (54.3%) 31 (64.6%) 
No 22 (53.7%) 18 (39.1%) 17 (35.4%) 
Missing 1 (2.4%) 3 (6.5%) 0 (0.0%) 
OR (95% CI) Reference 
Category 
1.70 (0.71, 4.05) 2.23 (0.94, 5.26) 
P 0.23 0.07 
Satisfied with level of sexual desire  
Yes 23 (56.1%) 24 (52.2%) 22 (45.8%) 
No 17 (41.5%) 19 (41.3%) 26 (54.2%) 
Missing 1 (2.4%) 3 (6.5%) 0 (0.0%) 
OR (95% CI) Reference 
Category 
1.07 (0.45, 2.55) 1.60 (0.69, 3.73) 
P 0.88 0.28 
Reports problems with sex life  
Yes 12 (29.3%) 16 (34.8%) 19(39.6%) 
No 27 (65.9%) 26 (56.5%) 28 (58.3%) 
Missing 2 (4.9%) 4 (8.7%) 1 (2.1%) 
OR (95% CI) Reference 
Category 
1.39 (0.55, 3.48) 1.53 (0.62, 3.74) 
P 0.49 0.35 
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individual components split by daily morphine equivalent dose. 
Table 9-20 Odds Ratio for FSD with adjustment for a single covariate or 
confounder comparing groups based on daily morphine equivalent dose 
OR adjusted for Adjusted OR (95% CI) P 
Pain grade 
<20mg/day 1.30 (0.52, 3.28) 0.58 
≥20mg/day 2.22 (0.88, 5.59) 0.09 
SF-12 physical component 
<20mg/day 1.27 (0.50, 3.21) 0.62 
≥20mg/day 2.24 (0.77, 6.34) 0.14 
SF-12 mental component 
<20mg/day 1.03 (0.39, 2.69) 0.95 
≥20mg/day 1.77 (0.69, 4.52) 0.23 
Age 
<20mg/day 1.28 (0.51, 3.19) 0.60 
≥20mg/day 2.30 (0.94, 5.62) 0.07 
BMI 
<20mg/day 1.29 (0.50, 3.37) 0.60 
≥20mg/day 2.28 (0.83, 6.24) 0.11 
PHQ-2  
<20mg/day 1.21 (0.47, 3.08) 0.69 
≥20mg/day 2.01 (0.78, 5.18) 0.15 
Smoker (2 categories smoker vs non-smoker) 
<20mg/day 1.28 (0.51, 3.21) 0.59 
≥20mg/day 2.30 (0.94, 5.63) 0.07 
Alcohol 
<20mg/day 1.20 (0.48, 3.05) 0.70 
≥20mg/day 2.12 (0.86, 5.26) 0.10 
NSAID 
<20mg/day 1.22 (0.48, 3.07) 0.68 
≥20mg/day 2.23 (0.91, 5.43) 0.08 
Contraception (2 categories hormonal vs non-hormonal/no contraception) 
<20mg/day 1.15 (0.45, 2.92) 0.77 
≥20mg/day 1.97 (0.79, 4.94) 0.15 
Antidepressants   
<20mg/day 1.21 (0.48, 3.07) 0.69 
≥20mg/day 1.99 (0.75, 3.05) 0.17 
No opioid use (0mg/day morphine equivalent dose) is used as the reference group and each 
analysis is adjusted for the factor shown in the left hand column. 
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9.10 Sensitivity analysis 
9.10.1 FSD measure 
The first sensitivity analysis was undertaken by using STEFFI-2 rather than STEFFI-
5 to define FSD. This increased the sample size by four women. Undertaking this 
sensitivity analysis returned a statistically significant odds ratio for those taking 
≥20mg/day of oral morphine equivalent dose when compared to those receiving no 
current opioids (OR 2.39, 95% CI 1.01, 5.67) see Table 9-21 for full details. This 
relationship became non-significant when adjusted except when adjusted for age and 
PHQ-2. The largest changes with adjustment were for SF-12 mental component and 
antidepressants (for any reason). 
Table 9-21 Sensitivity analysis using STEFFI-2 as the measure for FSD 
comparing groups based on daily morphine equivalent dose 
 Opioid Category 
No Opioid <20mg/day ≥20mg/day 
N 41 46 48 
FSD 
Present 17 (41.5%) 21 (45.7%) 30 (62.5%) 
Absent 23 (56.1%) 21 (45.7%) 17 (35.4%) 
Missing 1 (2.4%) 4 (8.7%) 1 (2.1%) 
OR (95% CI)  1.35 (0.57, 3.23) 2.39 (1.01, 5.67) 
Adjusted OR 
Pain Grade  1.38 (0.57, 3.30) 2.30 (0.95, 5.53) 
SF-12 physical  1.32 (0.54, 3.22) 2.22 (0.80, 6.19) 
SF-12 mental  0.96 (0.37, 2.44) 1.59 (0.63, 4.02) 
Age  1.35 (0.57, 3.24) 2.38 (1.00, 5.67) 
BMI  1.55 (0.62, 3.89) 2.65 (0.98, 7.17) 
PHQ-2  1.33 (0.56, 3.20) 2.38 (1.00, 5.66) 
Smoker (2 
categories) 
 1.35 (0.56, 3.24) 2.38 (0.99, 5.71) 
Alcohol  1.31 (0.54, 3.16) 2.28 (0.95, 5.51) 
NSAIDs  1.29 (0.54, 3.12) 2.31 (0.97, 5.52) 
Contraception 
(2 categories) 
 1.30 (0.53, 3.19) 2.35 (0.96, 5.78) 
Antidepressants  1.22 (0.50, 2.97) 1.87 (0.73, 4.83) 
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9.10.2 Opioid dose including medical records review data 
The second sensitivity analysis was undertaken by including daily morphine 
equivalent dose calculated with medical records review data replacing missing data 
from the questionnaire. This increased the number of participants that could be split 
by opioid group from 135 to 144. Logistic regression for the sensitivity analysis 
returned an odds ratio of 2.57 (95% CI 1.07, 6.18) for FSD in those who used ≥20mg 
morphine equivalent daily compared with no opioid use. Pain during intercourse was 
also more likely in the highest dose opioid group (p=0.04). Univariate analysis was 
undertaken for FSD and opioid use, the odds ratio remained significant when 
adjusted for pain grade, age, BMI and NSAID use. Adjustment for SF-12 physical 
component, SF-12 mental component, PHQ-2, smoking status, alcohol, 
contraception and antidepressant use (all indications) decreased the odds ratio and 
caused the relationship to become non-significant (see Table 9-22).  
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Table 9-22 Sensitivity analysis using medical records review data 
comparing groups based on daily morphine equivalent dose 
 Opioid Category 
No Opioid <20mg/day ≥20mg/day 
N 41  51 52 
FSD 
Present 13 (31.7%) 16 (31.4%) 27 (51.9%) 
Absent 26 (63.4%) 30 (58.8%) 21 (40.4%) 
Missing 2 (4.9%) 5 (9.8%) 4 (7.7%) 
OR (95% CI)  1.07 (0.43, 2.63) 2.57(1.07, 6.18) 
Adjusted OR 
Pain Grade  1.06 (0.43, 2.61) 2.63 (1.05, 6.57) 
SF-12 physical  1.05 (0.42, 2.64) 2.44 (0.87, 6.84) 
SF-12 mental  0.90 (0.35, 2.30) 2.07 (0.81, 5.24) 
Age  1.07 (0.44, 2.64) 2.55 (1.06, 6.15) 
BMI  1.14 (0.45, 2.91) 2.76 (1.05, 7.26) 
PHQ-2  1.14 (0.44, 2.94) 2.50 (0.96, 6.50) 
Smoker (2 
categories) 
 1.10 (0.44, 2.71) 2.66 (1.10, 6.44) 
Alcohol  1.01 (0.40, 2.51) 2.38 (0.97, 5.83) 
NSAIDs  1.02 (0.41, 2.54) 2.54 (1.05, 6.12) 
Contraception 
(2 categories) 
 0.95 (0.38, 2.38) 2.18 (0.88, 5.42) 
Antidepressants  1.01 (0.41, 2.54) 2.27 (0.87, 5.94) 
 
9.11 Conclusion 
This chapter has presented the results of the cross-sectional study undertaken for 
this thesis which investigates the relationship between opioids and FSD. The results 
will be summarised in the next chapter and the strengths and limitations of the study 
will be discussed.  
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10 Cross-sectional study discussion 
This chapter summarises the main findings from the cross-sectional study, and then 
puts these results in the context of the current literature. The strengths and limitations 
of the study will be discussed and what the results mean in terms of the population of 
interest. Finally the unanswered questions from this study and the conclusions that 
can be drawn from the results will be presented.  
10.1 Summary of main findings 
The study response rate was 15%; responders were older and more often from less 
deprived areas when compared with non-responders.  
Opioid users were split into three groups, those taking a morphine equivalent dose of 
≥20mg/day, those taking a daily dose of <20mg/day and those not currently taking 
opioids. The majority (79/91, 87%) of those taking opioids were long-term users 
(three months or longer), with no difference in length of use dependent on opioid 
dose. The opioid most commonly taken was codeine (58.5% either alone or in 
combination) followed by tramadol (15.4%), dihydrocodeine (13.0%) and morphine 
(7.3%). The order of type of opioid use was the same across the groups split by 
opioid dose, however stronger opioids accounted for a higher proportion of overall 
use in the ≥20mg/day opioid group. Current opioid use was associated with 
increased use of other analgesics (paracetamol either in combination or alone, 
gabapentoids and antidepressants) and total number of medicines used. There was 
no significant difference in the type of contraception used based on opioid use. 
The three groups of opioid use, had statistically significant differences for 
employment (higher opioid doses were associated with decreased numbers in 
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employment), physical health (higher opioid doses associated with increased pain 
grade, increased self-reported chronic pain, increased number of days pain kept 
them from normal activities, decreased SF-12 physical component, increased BMI, 
increased joint pain and increased participants self-reported health conditions). 
Increasing opioid dose was also associated with worsening mental health, with more 
positive PHQ-2 screening, worsening SF-12 mental health score, use of a prescribed 
antidepressant (for low mood rather than pain) and patient self-reported depression 
and anxiety. 
FSD affected 31.7% of previous opioid users, 35.8% of those receiving <20mg/day of 
opioids and 50.0% of those receiving ≥20mg/day of opioids. There was increasing 
odds ratio of FSD with increasing opioid dose when compared with no opioid use but 
this was not statistically significant (<20mg, unadjusted OR 1.28 (95% CI 0.51, 2.30), 
≥20mg, unadjusted OR 2.29 (95% CI 0.94, 5.55)).  
Two sensitivity analyses were undertaken that increased the available sample size, 
the first used STEFFI-2 to identify FSD and the second used medical records data for 
opioid dose. These returned statistically significant odds ratios for FSD in those 
taking ≥20mg morphine equivalent dose compared to no opioid use, but this 
relationship did not remain significant after adjustment with confounders, but the 
direction of relationship remained with increasing odds of FSD with increasing opioid 
dose.  
10.2 Comparison with other studies 
The currently available evidence was synthesised in chapter 3 as part of the 
systematic review. This included three studies in premenopausal women that 
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investigated libido. Low libido was found to affect 61-100% of women taking opioids, 
one paper undertook significance tests but no significant differences were seen 
between opioid users and controls. These papers all had small numbers of 
participants (Finch et al., 2000; Roberts et al., 2001; Wong et al., 2011). The cohort 
study undertaken for this thesis (see chapter 6) found coded low libido in 0.9% (95% 
CI 0.7, 1.0) of long-term opioid users and 0.7% (95% CI 0.6, 0.8) of short-term users. 
Cox regression revealed a trend towards an increased risk of low libido with long-
term opioid use when compared to short-term opioid use, with an adjusted hazard 
over 5 years of follow-up of 1.19 (95% CI 0.96, 1.48). None of these analyses were 
statistically significant. 
The most important comparison to draw between the studies is how FSD was 
defined, as this underpins the remaining comparisons. The studies all used different 
definitions for FSD, with the cross-sectional study for the thesis being the only one to 
use a validated measure, and to follow guidelines where distress must be present for 
symptoms to be classified as FSD (American Psychiatric Society, 2013; Basson et 
al., 2001; Kriston et al., 2010; McCabe et al., 2016; World Health Organisation, 
2012). Wong et al (2011) asked a single question, about whether participants felt 
their sexual desire had decreased, compared to before their chronic pain or opioid 
use. Finch et al (2000) report use of a standardised protocol which asked about libido 
and sexual function, but there was no mention of this being validated and Roberts et 
al (2001) report using a self-administered questionnaire that asked about adverse 
effects to opioids, but it is not clear if any of these meet the diagnostic criteria for 
FSD. The cohort study was based on symptoms of low libido reported by a patient 
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and recorded in the notes, so will not have followed a validated measure, but if they 
have been reported are likely to be causing distress.   
The cross-sectional study had a prevalence of FSD of 50.0% in opioid users 
receiving an oral morphine equivalent dose of ≥20mg/day, 35.8% in <20mg/day 
users and 31.7% in previous opioid users, in comparison with prevalence of low 
libido of 61-100% in the studies within the systematic review and 0.6-1.0% in the 
cohort study (Finch et al., 2000; Roberts et al., 2001; Wong et al., 2011). The 
differences in prevalence between the studies, reinforces the perception that the 
cohort study underestimated the number of women affected by FSD, and that 
medical records may not the best way to investigate this area; this is reinforced by 
results from the medical records review for the cross-sectional study which found no 
women with a coded diagnosis of low libido in the notes, compared with 50/116 who 
consented to medical records review who had a positive STEFFI-5 result. The cross-
sectional study results are closer to the results of the studies included in the 
systematic review, particularly the one study that investigated oral opioids and 
reported a prevalence of FSD of 61% in current opioid users, the remaining studies 
were using intrathecal opioids and had higher prevalence of 71-100% (Finch et al., 
2000; Roberts et al., 2001; Wong et al., 2011). The cross-sectional study may have a 
lower prevalence of FSD compared to the systematic review papers as the definition 
for FSD used required symptoms to be accompanied by distress (American 
Psychiatric Society, 2013; Basson et al., 2001; McCabe et al., 2016; World Health 
Organisation, 2012). None of the studies included in the systematic review or the 
thesis (cross-sectional study and cohort study), were able to show a statistically 
significant difference in FSD between types of opioid use, but with increased 
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numbers in the sensitivity analysis for the cross-sectional study, a significant result 
was seen, this indicates that in a well-designed study with larger numbers, the results 
may have been significant. 
Three different methods were used to collect data on FSD across the studies, self-
report questionnaire (Roberts et al 2001 and the cross-sectional study), interview 
(Finch et al 2000 and Wong et al 2011) and database research (cohort study). Asking 
women about symptoms directly in the cross-sectional study meant that FSD 
identification was not subject to the clinical iceberg (Last, 1963). It also meant that 
actual opioid use rather than prescribed dose could be used to calculate daily 
morphine equivalent dose. However self-report measures are more prone to non-
response, the studies included within the systematic review did not report any non-
response as the patients were recruited directly from clinic and consent was gained 
prior to enrolling the participant, so there may have been those who refused to 
participate in the study but this was not reported. The cohort study was also not 
subject to non-response as it was based on electronic medical records. The effect of 
non-response is discussed in depth later within this section. Interviews are more at 
risk of social desirability bias (where the respondent alters their response based on 
what they feel the interviewer wants to hear or what they consider to be the expected 
answer). The risk of this is lower with self-report questionnaires and this was an 
advantage of the cross-sectional study when compared with the two related studies 
included in the systematic review. 
The cross-sectional study was set within primary care, whereas the papers included 
within the systematic review were all set in secondary care pain clinics (Finch et al., 
2000; Roberts et al., 2001; Wong et al., 2011). This difference in the setting of the 
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study is important, as only 16% of those suffering from chronic pain in the UK are 
referred to a secondary care pain clinics, with the remainder managed in primary 
care (Breivik et al., 2006). The cross-sectional study is therefore more likely to be 
generalisable to other women prescribed opioids. Additionally, the papers within the 
systematic review may represent a subgroup of patients, with potentially more severe 
pain. The cross-sectional study also focused on oral opioids, whereas two of the 
papers in the cohort study investigated intrathecal opioids. Intrathecal pumps for 
chronic pain are not routinely commissioned within England, and this further 
suggests that the results from the cross-sectional study are likely to be more 
generalisable to the population of interest (opioid users within the UK) than the 
results from the systematic review (NHS England, 2012). 
A recent population based survey in Denmark in 2014 (administered by the National 
Institute of Public Health) and had a 56% completion rate, compared with a 
completion rate of 15% for this cross-sectional study (Birke et al., 2018). The 
response rate for the Danish survey is likely to have been higher than the cross-
sectional study response rate as it is a national health and morbidity study 
undertaken by the National Institute for Public Health. Sexual health constitutes just a 
small proportion of the survey. Data was collected via face to face interviews and 
self-report questionnaires which may have increased the response rate further. This 
study is a long running national study and has itself seen decreasing response rates 
in young women (Ekholm et al., 2009). Despite the differences, the Danish study 
found the odds of reporting dissatisfaction with sexual life was increased in all 
chronic pain patients, and increased further in those patients reporting chronic pain 
and receiving opioids (OR 1.81, 95% CI 1.23, 2.68) which was of a similar magnitude 
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as seen in the cross-sectional study reported here (≥20mg/day opioids compared 
with no opioids OR 2.29, 95% CI 0.94, 5.55) (Birke et al., 2018). Birke et al (2018) did 
not report on data split by gender, so it was not included in the systematic review. 
The Danish study did not use a validated questionnaire for identifying sexual 
dysfunction, whereas the cross-sectional study did use a validated measure. The 
Danish study used automatically recorded prescription records for opioid use, opioid 
use was split by duration of use and did not take into account the daily dose of 
opioids, whereas the cross-sectional study was able to take into account daily opioid 
dose during the analysis. Including daily opioid dose does appear to be important 
from the results of the cross-sectional study with an apparent increase in odds ratio 
for FSD as the daily morphine equivalent dose increased, dose related responses 
have been seen in previous work on other adverse effects of opioids (Bedson et al., 
2019a; Dunn et al., 2010; Saunders et al., 2009).  
10.3 Strengths and limitations of the study 
One advantage of the cross-sectional study was that it could enquire directly about 
sexual function, and this was important as the cohort study used medical records and 
did not identify the expected number of women with FSD. Therefore the cross-
sectional study was not affected by the clinical iceberg effect that was likely to have 
affected the CPRD cohort study (Last, 1963). This resulted in a higher proportion of 
women appearing to be affected by FSD in the cross-sectional study when compared 
to the cohort study. Another strength of the cross-sectional study is that the tool for 
assessing FSD was previously validated, and could be used for all women regardless 
of whether they were currently in a relationship, or had been sexually active within 
the preceding year. Including all women was important as women may be excluded 
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from completing some tools based on lack of recent sexual activity (some tools 
require women to either be currently in a relationship, sexually active or be 
heterosexual, which restricts their use), but this lack of sexual activity, could be 
secondary to FSD, so could potentially affect results (see Table 8-2 for further 
information on alternative tools) (Kriston et al., 2010).  
In order to take advantage of the self-report questionnaire, questions designed for 
the study had as low a reading age as possible, and this hopefully improved the 
quality of the responses as the questions were easily understandable and this was 
checked with a PPIE group prior to sending the questionnaire. Low reading age for 
the questionnaire was important, as the participants’ ability to understand and 
respond to a question is dependent on their level of health literacy. Any 
misunderstanding can affect the validity of the data collected (Paz et al., 2009). 
Previous studies into health literacy have found that 43% of those studied fell below 
the competency for understanding health related texts, see Section 4.4.5 for further 
information on health literacy (Paz et al., 2009; Rowlands et al., 2015). Postal 
questionnaires have a high cognitive burden, and are not usually the preferred 
method of survey for respondents (they mainly prefer face to face interviews), but 
postal questionnaires are more likely to yield answers to sensitive questions when 
compared with face to face interviews (Bowling, 2005). 
Another strength of the study was that it was able to assess chronic pain through the 
use of the chronic pain grade, which has been shown to be comparable to pain 
diaries (Von Korff and Dunn, 2008). It was then possible to take pain severity into 
account when assessing the relationship between FSD and opioid use, which was 
not possible in the CPRD cohort study introducing potential for confounding by 
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severity. The ≥20mg/day opioid group had the highest proportion of patients affected 
by the highest chronic pain grade (high disability and severely limiting pain), this is a 
pattern that has been seen in previous work with those receiving the highest doses of 
opioids having the severest pain, poor health related quality of life and poor physical 
function (Sjøgren et al., 2010; Turner et al., 2015). Opioid prescriptions would be 
expected to be correlated to pain at baseline but if they were helping with pain and 
function you would expect pain grade to decrease, this fits with previous evidence 
that has not found evidence for opioids effectiveness in long-term pain. Those 
women receiving the highest doses of opioids reported the highest amount of pain. 
Physical health was also taken into consideration during analysis, which was a 
strength of the study given that increasing opioid dose was associated with 
worsening physical health (e.g. increasing opioid dose associated with decreased 
SF-12 physical health score and increasing BMI). However these confounders could 
only be included as a single confounder at a time rather than building a full 
multivariate model for the logistic regression due to low response rate. 
Another strength of this study was having direct information about daily dose of 
opioids, but this also meant that there was the potential for missing data when 
patients did not complete these sections. Indeed, this item had the largest amount of 
missing data, which was a limitation introduced through using a self-report measure. 
However it was possible to categorise 135 (of 146) into either no opioid use, <20mg, 
or ≥20mg/day morphine equivalent dose of opioids based on the information 
provided (and a further nine participants could be assigned to a group following 
medical records review and this was able to be used as a sensitivity analysis). Self-
reported information on medicines (particularly analgesics) was important, as 
 293 
 
prescription records may not reflect actual usage, due to over-ordering, diversion of 
medicine (opioids in particular have the potential for abuse), or because a medicine 
was not used as prescribed. Analgesics are particularly prone to these issues as they 
are variably used according to pain level. All of this means that it was an advantage 
to have information on actual usage of opioids, as daily morphine equivalent dose 
was able to be confidently calculated and used in analysis.  
In order to create a homogenous group for analysis, and for the cross-sectional study 
to be comparable to the cohort study, women with musculoskeletal conditions and an 
opioid prescription within the preceding six months were identified for inclusion. Of 
those who responded, only 39.7% indicated joint pain (all locations), with this rising to 
60.4% in ≥20mg/day opioid users, and dropping to 12.2% in previous opioid users 
(this was a statistically significant difference). This is a limitation as not everyone 
identified as having painful joints, even in the highest dose opioid group, so the 
sample may not represent the population of interest, however it could indicate that 
the treatment was effective and the pain had resolved with treatment. This lower 
prevalence of joint pain is likely due to women with a musculoskeletal problem being 
identified over the preceding six months (as pain may have resolved particularly in 
those currently not using opioids), however those using opioids currently who do not 
self-report joint pain, must either have missing data for this item, currently be having 
a period where their joints are not causing a problem, the opioid is working to control 
their pain, or be using analgesics for a different reason. 
Another advantage of the cross-sectional study was the ability to take into account 
contraception. Women were separated into two groups based on contraception use 
into hormonal contraception and non-hormonal contraception/no contraception use 
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and this was adjusted for during analysis. This was an important step as hormonal 
contraception can affect sexual function, and the study population included only 
women of childbearing age. In 2008/9 74% of women under 50 years were using at 
least one form of contraception and 12% of women were using no contraception and 
were sexually active (Lader, 2009). Adjustment for hormonal contraception use 
decreased the odds ratio for FSD but did not change the direction of relationship with 
increasing odds of FSD with increasing opioid dose.  
Despite the overall unit response being low, the item response was good, which was 
a strength since it meant that of those that responded, the data for the majority could 
be included in the analysis and preserved the sample size achieved. Importantly only 
two women did not complete the sexual function tool and only 12 had item missing 
data for this tool that affected the result of STEFFI-5. One strength to using the 
STEFFI-5 tool, was that STEFFI-2 is embedded within it, and when this was used 
only seven women had not given enough data, this could then be used for a 
sensitivity analysis, this increased the sample size and results became significant. 
This good item response was likely to be due to the mode of delivery of the survey, 
with high item response for sensitive topics often seen in postal self-report 
questionnaires likely to be due to the pseudo-anonymity offered (the practices had 
lists linking the participant to their study number but did not have access to any of the 
completed questionnaires and the study team did not have access to patient 
identifiable data) by this method study (Bowling, 2005).  
11 responders did not provide enough medicine information to be put into an opioid 
group for analysis which was a weakness as it decreased the sample size available 
for analysis and therefore the statistical power. However, nine of these women could 
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be put into a group following medical records review and this was used for a 
sensitivity analysis. Item non-response was higher in those who did not report current 
opioid use and could be related to how pertinent they felt the study was to them. Six 
(14.6%) previous opioid users did not complete information on medical history, this 
might be due to skipping the question, or that they did not have any conditions but 
did not choose the ‘none of the above option’. 
A further strength of the survey was that mental health of the participants could be 
taken into account. This was important as mental health is related to sexual function 
(Ambler et al., 2001; Gracia et al., 2004; Hayes et al., 2008). Pain, mood and 
disability have all been shown to be related to sexual function in patients with chronic 
pain (Ambler et al., 2001). Mental health was assessed through PHQ-2, SF-12 
mental health component and participant self-report, therefore mental health could be 
assessed without the need for the participant to have a diagnosed mental health 
condition. Worsening mental health (PHQ-2 screen, SF-12 mental health score, use 
of an antidepressant and self-reported anxiety or depression) was associated with 
increasing opioid dose and this was statistically significant. It appeared from the 
analysis, that the SF-12 mental health component had the largest effect on the 
relationship seen between opioids and FSD, but this did not completely change the 
direction of relationship just decrease the magnitude. PHQ-2 scores correlated well 
with those participants who self-reported depression and anxiety but not with 
antidepressant usage.  
Another strength of the study was the ability to use the information on all of the above 
factors (mental health, chronic pain grade, contraception) and compare the groups 
within the study and take these into account as possible confounders which improved 
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the internal validity of the study. Unfortunately due to the low numbers multiple 
regression with all relevant factors could not be undertaken and this was a limitation 
of the study.  
A final strength of the study was that important confounders, including medicine use 
and demographics were also taken into account. It was important to include other 
medicines in the analysis as increasing opioid use was associated with 
polypharmacy and increased use of non-opioid analgesics (including gabapentoids 
and antidepressants) and these factors could potentially act as confounders. The 
opioid groups were also comparable in terms of their demographics, including 
ethnicity, and were only statistically significantly different for employment  
The main limitation with the cross-sectional study was the low response rate with 
only 15% of those invited responding to the survey. This can affect results in several 
ways, for instance decreased sample size increases the risk of non-response bias, 
which therefore affects the external validity and generalisability of the results 
(Bowling, 2005). The target response rate was 31.6%, so the achieved sample size is 
less than half the response rate that was expected.  
As discussed above only univariate analysis could be performed rather than 
multivariate analysis where opioid use was controlled for with only one other 
important factor. This was to a certain degree reassuring, as the direction of 
relationship remained constant when adjusted for individual confounders. However, 
the complex relationships between multiple variables was not accounted for, and 
residual confounding remains a potential issue within the study. In this way, the low 
response rate has affected the ability to draw conclusions from the survey. The 
decreased power has also meant that even though there is a visible direction of 
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relationship and an apparent dose response, this was not statistically significant and 
it is not possible to say whether this is because the relationship between opioid use 
and FSD is not significant or if it is due to the low numbers included in the analysis. 
The sensitivity analysis suggests that the lack of relationship seen was more likely 
due to decreased sample size and power, rather than due to an absence of 
relationship.  
Non-response bias is the next concern introduced through the low response rate. 
Previous work has shown that the participation rate does not determine the extent of 
non-response bias, and that participation rate is only weakly associated with 
presence of bias (Galea and Tracy, 2007). Non-response bias is introduced when 
those who respond are systematically different to those who do not respond, 
particularly if these characteristics are important to the study outcome. That said the 
lower the response rate, the higher the risk that responders and non-responders will 
differ systematically (Bowling, 2005). The responders and non-responders could only 
be compared for age and deprivation (based on practice postcode), and they were 
statistically significantly different for both factors, with responders being older, and 
from less deprived areas. The limitation with this comparison is that social deprivation 
was based on postcode of the practice, and there is evidence that this method 
underestimates level of deprivation in less deprived areas and overestimates 
deprivation in more deprived areas (Strong et al., 2007). This may have particularly 
affected participants from the largest practice, which had over 40000 registered 
patients, and therefore a single postcode is unlikely to reflect the diversity of these 
participants. The fact that respondents were from less deprived areas may have 
introduced bias, as from the responses it appears that responders from practices in 
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more deprived areas, were more likely to be prescribed opioids than those in less 
deprived areas, which could introduce a systematic difference in the sample for 
instance lower socioeconomic status in childhood has been shown to be related to 
obesity in adulthood (Bann et al., 2017).  
This study is consistent with previous studies into sexual health that have found 
those from areas with lower levels of deprivation are more likely to respond (Malavige 
et al., 2015). Health literacy is often associated with level of deprivation, so this may 
reflect why those from higher areas with less deprivation were more likely to respond, 
as postal questionnaires place a high burden on the respondents ability to read and 
understand the questions (Bowling, 2005; Rowlands et al., 2014). The difference in 
age between responders was statistically significant, but it represented a small 
difference in actual age with the median age in responders being 38 years old (IQR 
31-42) and non-responders 35 years old (29-41). This difference in age is unlikely to 
have affected the results, and previous studies in premenopausal women have not 
found age to be significantly associated with low libido (Gracia et al., 2004). These 
differences between responders and non-responders may also have affected the 
generalisability of the results as the population of interest may not be represented by 
those who responded and this in turn affects the external validity of the study 
(Bowling, 2005; Galea and Tracy, 2007). 
Another factor that may have introduced non-response bias is that the response rate 
can be affected by salience (relevance of the subject to those invited to participate) 
(Galea and Tracy, 2007). In the case of the cross-sectional survey this could be a 
drawback, and may have affected the results in several ways. Women who have 
FSD may have been more likely to respond, which could inflate the prevalence of 
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FSD in the study group, however this is likely to have a similar effect across the 
whole group and not just one group of opioid users. Women who were not currently 
sexually active, or not in a relationship may have chosen not to participate, which 
could be a systematic difference between responders and non-responders. There is 
no data on the marital status of non-responders but responders can be compared to 
the data from the 2011 census (the census does not include co-habiting in its 
relationship types whereas the cross-sectional study does). In the census 46.6% of 
adults in England were married compared with 48.0% within the survey. 34.6% of 
those within the census identified as being single compared with 21.9% within the 
study, however a further 21.9% identified as cohabiting and this would be included 
within the single category for the census data (Smith, 2014). This comparison seems 
to show that it is unlikely there was a systematic difference between responders and 
non-responders based on relationship status, which suggests that this was not a 
factor that affected response and therefore there is unlikely to be bias secondary to 
relationship status. There was also no statistically significant difference between the 
opioid groups or when the participants were split by FSD in terms of relationship 
status, which is reassuring and suggests this did not limit the study.  
It is important to consider the possible reasons for the low response rate. The 
estimated response rate was 31.6%, but this was based on historical data from 1998 
and this study was also completely anonymous whereas this study was only pseudo-
anonymised (Dunn et al., 1998). The reason for using this data was because it 
represented a local population (geographically similar to the recruiting area for the 
cross-sectional study), receiving a completely unsolicited population survey with a 
focus on sexual health. In comparison to this, the overall response rate to the cross-
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sectional study was 15%, with some practices having no responses and some having 
a response rate of over 30% approaching the original estimate. It is likely that this 
response rate (15-30%) actually reflects a more realistic view of the response rate 
that should have been expected, given the decrease in response rate since this 
questionnaire was sent and the personal nature of the questions (Galea and Tracy, 
2007; Morton et al., 2006). A more recent study in men examining sexual health, that 
requested consent prior to sending questionnaires had a recruitment rate of only 
8.8% and of those recruited 71.5% responded to the questionnaire, which is an 
overall 6% (544/9100) response rate (Malavige et al., 2015). If the response rate to 
the cross-sectional study is compared to the response rate of Malavige et al. (2015) 
then it seems to be a reasonable response rate, however when compared to the 
Danish study discussed earlier in this chapter with a response rate of 56% it would 
seem very low, the differences for this were discussed earlier (Birke et al., 2018; 
Malavige et al., 2015). It is clear that if the participants had been contacted about the 
study first there would have been a lower amount of non-response to the survey 
itself, however patients would then have consented to be included so selection bias 
may have been introduced.  
Factors that could have affected the response rate are the increasing number of 
surveys that patients are sent, decrease in volunteerism, request for medical records 
review, requesting future contact as part of the study, age of the population of 
interest and mode of the survey (Bowling, 2005; Dunn et al., 2004; Galea and Tracy, 
2007; Green et al., 2018). Requesting consent for medical records review and future 
contact can decrease response rate, perhaps due to the perception that this will 
increase the burden of the research. It has been found in general that those who 
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consent to medical records review are likely to be younger (reaching a peak at 40-49 
years old) and more likely to have the condition of interest (Dunn et al., 2004). There 
were no significant differences between those who consented for medical records 
review, and those who did not consent for medical records review in terms of social 
deprivation or age. A recent population face to face survey on a non-sensitive subject 
found that response rate increased in women up to 67 years old then began to 
decrease again (Green et al., 2018). The response rate in this study ranged from 
28% in 18-27 year olds up to 37% in 38-47 year olds and this was undertaken in 
2011, so it appears that the response rate could have been increased if the study 
had been undertaken as face to face interviews rather than a postal questionnaire 
(Green et al., 2018). Responses to sensitive questions may have been affected by 
altering the mode of survey, as the interviews would have had an increased risk of 
social desirability bias (as participants are in direct contact with the interviewer and 
are more likely to take into account social expectations when responding to a 
sensitive question), which can particularly affect research into sensitive subjects 
(Bowling, 2005). 
10.4 Meaning of the study 
As in all cross-sectional studies associations can be reported but characterising the 
direction of relationship is more difficult. Bradford-Hill (1965) developed a set of rules 
for determining whether a relationship is likely to be an association or causation. 
Bradford-Hill’s rules include considering the following factors that characterise the 
relationship; strength, consistency, specificity, temporality, biological gradient, 
plausibility, coherence, experiment and analogy, these factors do not demonstrate 
causality but they are a useful guideline for when considering an association 
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(Bradford-Hill, 1965). The relationship seen in the results from the cross-sectional 
survey did not reach statistical significance (except in the sensitivity analysis), but it 
still meets some of the above criteria for a causal relationship, suggesting further 
investigation is required.  
The logistic regression appeared to show a dose response relationship, with the odds 
of FSD increasing with increasing daily morphine equivalent dose. Previous work has 
found significant relationships between increasing daily morphine equivalent dose 
and adverse effects (Bedson et al., 2019a; Dunn et al., 2010; Saunders et al., 2009). 
The relationship between opioids and FSD appears to be consistent with recent 
studies observing similar relationships between opioids and sexual function in 
different populations (Birke et al., 2018). The strength of the relationship seen is the 
next criteria to consider whether the relationship is plausible. The results of the cross-
sectional study show that women taking a morphine equivalent dose of ≥20mg/day 
had around double the odds of FSD when compared with those not currently taking 
opioids. This relationship remained in the same direction even when adjusted for 
individual confounders. The relationship seems to be consistent and has been seen 
in different CNCP populations receiving opioids, most recently in a whole population 
study in Denmark (Birke et al., 2018).  
The specificity of the relationship is more difficult to assess. FSD appears to affect a 
large proportion of the population, and as discussed previously there are many 
factors that appear to contribute to this, since CNCP, opioid use, mood and FSD 
appear to be closely interlinked (Arunakumari and Walker, 2009; Hayes et al., 2008). 
It is difficult to determine whether the relationship seen is specific to opioid use rather 
than one of the other factors, as multiple logistic regression was impractical due to 
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low numbers. The relationship between FSD and opioids appears to remain following 
adjustment for CNCP and this has also been seen in previous research where both 
CNCP and opioid use have effects on sexual dysfunction independently (Birke et al., 
2018).  
Temporality is difficult to assess in this case due to the cross-sectional nature of the 
study. The relationship appears to be biologically plausible and related to the affect 
that opioids have on HPG axis, where decreased hormone levels can lead to sexual 
dysfunction and affect menstrual cycle (Vuong et al., 2010). Coherence is important 
and the results do not conflict with any widely received scientific wisdom and is in fact 
in keeping with the available literature even though this is currently sparse (Wersocki 
et al., 2017).  
Following an analysis of the relationship seen with Hill’s criteria, it would seem that it 
would be acceptable to cautiously suggest that there is a potentially causal 
relationship between opioids and FSD. Clearly, however, it is necessary that further 
investigation to elucidate the direction of relationship is required, and it is likely that 
this would need to be part of a wider RCT into opioid effectiveness and adverse 
effects, or alternatively a cohort study examining the benefits of withdrawing opioid 
therapy in a structured and supported manner. 
Pain grade and opioid use were associated with one another (increasing pain grade 
was associated with increasing opioid dose), this could potentially mean that there is 
confounding due to chronic pain itself (confounding by indication, see section 4.7.3). 
The adjusted odds ratio, adjusting for pain grade, showed the same direction of 
relationship between opioid use and FSD, and only a small change in the odds ratio 
for FSD, and in the sensitivity analysis using medical records data the odds ratio 
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remained statistically significant when adjusted for chronic pain grade. With 
increasing dose of opioid pain grade would be expected to decrease, however this is 
not the case in the cross-sectional study and previous work has shown, that 
increasing opioid dose is associated with increased pain and decreasing physical 
function (Green et al., 2013). There is also evidence for a particular adverse effect 
known as opioid induced hyperalgesia, which can cause the patient to become more 
sensitive to certain painful stimuli, thereby worsening pain, the prevalence of this is 
unknown but it could be playing a role in the increased pain seen in those using more 
opioids (Lee et al., 2011). 
There was a range in proportion of those included in the study from each practice 
(0.12-0.92% of the practice list), there is no way to interpret this further without more 
information on the demographics of the patients registered at each practice. This 
difference in proportion may reflect different proportions of women in the age group 
on the practice lists, number of those registered who have a musculoskeletal 
condition or the differential prescribing of opioids in each practice. There is an 8 fold 
difference in the numbers meeting the inclusion criteria between different practices, it 
is unlikely that the numbers in the age groups vary by this amount, so the difference 
is likely to reflect somewhat different prescribing practices between clinicians and 
practices.   
90.4% of the population reported their ethnicity as being White. This is higher than 
the proportion in the general population, with 86% of those in the 2011 census in 
England and Wales reporting they were White (Office for National Statistics, 2012). In 
Staffordshire Moorlands (one of the recruiting areas), the proportion of those 
reporting they were White rose to 97.5% (one of the top three areas within England 
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and Wales). The sample has a slightly higher proportion of women reporting their 
ethnicity as White when compared to the general population, but lower than the rates 
than in Staffordshire Moorlands. The sample overall appears to be representative in 
terms of the UK populations ethnicity.  
Finally there was a group of women on opioids, using no contraception but having 
sexual intercourse. There is no data on whether this is with partners of the same or 
opposite sex, so it is not clear if these women are at risk of pregnancy. Opioids are 
not recommended during pregnancy, unless the benefits outweigh the risks (and they 
should be prescribed at the lowest possible dose if used), and this is particularly 
important in this group of women as they are all of childbearing age (BNF, 2018a). 
The British Pain Society (2010) recommends changing opioids to an alternative prior 
to conception if this is possible due to the risks of withdrawal symptoms in the baby 
at birth (The British Pain Society, 2010). It is worthwhile considering whether 
contraception is important to discuss with these women when commencing opioids, 
and at medicine reviews and indeed whether it is appropriate to start opioids in the 
first place.  
This study adds further evidence for adverse effects related to opioid use and 
supports that this relationship appears to be dose dependent as found in previous 
studies (Bedson et al., 2019a; Dunn et al., 2010; Saunders et al., 2009). As 
discussed previously opioid use has increased over the last 20 years (Bedson et al., 
2016; Foy et al., 2016). With the growing body of evidence to show that opioids have 
significant adverse effects this needs to be taken into account and careful 
consideration taken prior to prescribing opioids and in those who are already 
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receiving opioids, escalation should be avoided if possible and opioid dose de-
escalated (British Medical Association, 2017).  
10.5 Further research 
The cross-sectional study was unable to show statistically significant results, but did 
show a direction of relationship, with increasing dose of opioids associated with 
increased odds of FSD, and these results became significant when sensitivity 
analyses were undertaken which included up to nine more women. The study would 
ideally be repeated with larger numbers. One way to increase the response rate 
would be to include sexual function questions within a larger study, where the 
questionnaire is not the first contact with the participant. Previous studies that have 
included sexual function questions within larger questionnaires seem to have better 
response rates (Birke et al., 2018). Due to low numbers it was not possible to adjust 
for multiple factors in logistic regression so there is a chance that results are actually 
secondary to a confounder. This means that the study needs replicating with larger 
numbers. 
There may be a safe level of daily opioid dose for these adverse effects; future 
research should include daily dose as well as current opioid use. If a safe daily 
morphine equivalent dose was identified then treatment trials of opioids in patients 
could be undertaken with doses only escalated up to this safe level. This would mean 
that opioids could be trialled safely and only continued if effective for pain with less 
risk of adverse effects. 
This study intended to investigate whether there was any difference in risks of FSD 
dependent on the mode of delivery for the opioid. However this was not possible as 
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only two participants were receiving transdermal opioids. It would be important to 
study this further in the future to assess whether any specific opioids or modes of 
delivery are safer than others. Previous work on cardiovascular risk associated with 
opioids found that some opioids were associated with different levels of risk 
(hydrocodone was shown to have lower all-cause mortality at 30 days when 
compared to codeine and oxycodone) (Solomon et al., 2010a).  
This study did not investigate levels of hormones as it was a non-experimental study. 
It would be interesting in the future to investigate levels of HPG axis hormones (LH, 
FSH, oestrodiol, progesterone and testosterone) and how they change in relation to 
opioid use to determine whether these can be used as early markers for FSD.  
10.6 Key messages  
There is a high prevalence of FSD, within the cross-sectional study. This highlights 
the importance of women being asked about sexual function during medicine 
reviews, and this being discussed with women as a potential adverse effect prior to 
prescribing opioids. There was no statistically significant difference between groups 
of opioid users for FSD but there did appear to be a direction of change, with the 
odds of FSD increasing with opioid dose. The lack of statistically significant results is 
more likely to reflect the low numbers, rather than a lack of relationship, which is 
supported by the sensitivity analyses which included more women and found a 
statistically significant relationship. Given the relationship appears to be dose related, 
there may be a safe dose level at which these medicines can be prescribed. Further 
work would be required to delineate a safe dose of opioids and this may be different 
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between patients. For current use it would seem that if opioids need to be used they 
should be used in the lowest possible dose and only if effective.  
Increasing doses of opioids were associated with worsening pain, physical and 
mental health. It is impossible to say whether this was due to opioids, but women 
receiving the highest doses appear to have the worst overall health. 
It is important to discuss contraception with women when they are being prescribed 
opioids, as they are not recommended during pregnancy unless the benefits 
outweigh the risks.  
10.7 Conclusion 
The cross-sectional study has shown a much higher prevalence of FSD than the 
CPRD cohort study. FSD affects a large proportion of women with musculoskeletal 
pain who have been prescribed opioids. The study did not show a statistically 
significant relationship between daily opioid dose and FSD, there was an increase in 
the odds of FSD with increasing daily dose of opioids, with women taking ≥20mg/day 
morphine equivalent dose having double the odds of FSD when compared to those 
not currently using opioids. Despite no statistically significant relationship, since FSD 
was reported in 44% of women, it is important that this is discussed when 
considering prescribing opioids to women with musculoskeletal pain.  
The study was limited by the low response rate, and this has affected the ability to 
draw a strong conclusion. The cross-sectional study has, however, added useful 
information to the current body of evidence in this area.   
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11 Discussion 
11.1 Thesis summary and main findings 
This thesis has focused on investigating the possible relationship between opioid use 
in women with chronic non-cancer pain (CNCP), and female sexual and reproductive 
dysfunction. The main focus of the thesis has been investigating patients with 
musculoskeletal pain as the cause for CNCP. Chapter 1 introduced the subject and 
set out the aims and objectives for the thesis. 
Chapter 2 focused on the background to the studies included within this thesis, this 
included definitions of pain, opioids and the relevant parts of the endocrine system 
and the epidemiology of CNCP, opioid use and opioid adverse effects. The rationale 
for investigating female reproductive and sexual dysfunction further is outlined. It was 
concluded that this was an area that required further investigation, and additionally 
this had been highlighted as such by the British Pain Society (The British Pain 
Society, 2010). 
Chapter 3 investigated the currently available evidence using a comprehensive 
systematic review of the literature. The systematic review included 12 papers with 
165 cases and 35 controls. The review supported the hypothesis that there is a link 
between opioid use and reproductive and sexual dysfunction but did not provide any 
definitive evidence. The results of the systematic review, therefore, established the 
need for further investigation of this area. 
Chapter 4 discussed the methodology underlying the studies undertaken throughout 
the remainder of the thesis, highlighting both the strengths and weaknesses of each 
approach.  
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Chapters 5, 6 and 7 described and discussed the database cohort study that was 
undertaken for this thesis. The cohort study compared long-term to short-term opioid 
use for four outcomes: menopausal symptoms/menopause, abnormal menstruation, 
low libido and infertility. The cohort study included a large number of women (over 
40,000), split evenly between short-term and long-term opioid users and found an 
increased risk of menopausal symptoms/menopause (HR 1.16, 95% CI 1.10, 1.23) 
and abnormal menstruation (HR 1.13, 95% CI 1.05, 1.21) in women prescribed long-
term opioids when compared with short-term opioids. The results relating to low libido 
and infertility were non-significant. Low libido appeared to affect more women in the 
long-term opioid group, compared to the short-term opioid group but the total number 
affected (0.8%) was lower than expected when compared to population estimates 
(25-41%) (Dunn et al., 1998; Laumann et al., 2005). Given this discrepancy in the 
number of women affected by low libido between the cohort study and general 
population estimates, it was determined that an alternative method was needed to 
investigate this area. 
Chapters 8, 9 and 10 describe and discuss the cross-sectional postal survey that was 
undertaken for the thesis which investigated female sexual dysfunction (FSD) further. 
An invitation and postal questionnaire were sent to over 1000 women with a 
response rate of 15%. Responders were split by daily morphine equivalent dose 
(0mg/day, <20mg/day and ≥20mg/day) and compared for FSD (assessed using 
STEFFI-5 tool) and other factors (including age, chronic pain grade and medicine 
use). The prevalence of FSD within the cross-sectional study was 39.3% overall; 
31.7% in those not currently taking opioids, and 50.0% in those receiving a morphine 
equivalent daily dose of ≥20mg/day. There was increasing odds of FSD with 
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increasing opioid dose (0mg/day (reference group), <20mg/day (1.28, 95% CI 0.51, 
3.20) and ≥20mg/day (2.29, 95% CI 0.94, 5.55)) but the results were not statistically 
significant. Two sensitivity analyses were undertaken and the odds ratio for women 
taking ≥20mg/day morphine equivalent today became statistically significant in both. 
This thesis adds to the current literature as it was able to confidently identify the lack 
of current evidence in this area through the systematic review. The cohort study was, 
the first large scale cohort study investigating this area and found increased hazards 
for two of the outcomes included (menopause and abnormal menstruation) in those 
women prescribed long-term opioids. The cross-sectional study adds to the literature 
as it indicated that there is a potential dose dependent relationship between FSD and 
opioid use, which may stimulate future research to investigate whether there is a safe 
dose at which opioids might be prescribed in pre-menopausal women.  
11.2 Strengths and limitations  
11.2.1 Strengths of the thesis 
The work undertaken for this thesis fills a clear gap identified in the evidence for 
sexual and reproductive dysfunction in women prescribed opioids and was the first to 
undertake a large cohort study in this area. A major strength of this thesis is that the 
investigation of the overall aim was undertaken using three different study designs. 
This allowed for comparison of the results and triangulation to assess if the results 
converged with one another. The systematic review supported the hypothesis, that 
there was a relationship between opioids and reproductive and sexual dysfunction in 
women under 55 years old but did not provide the depth of evidence to draw a firm 
conclusion. The results of the subsequent studies undertaken for the thesis 
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strengthen the conclusions drawn from the systematic review, adding detail and 
estimates of effect. The results from the three studies converged to indicate that 
there is a relationship between opioid use and reproductive and sexual dysfunction 
and thereby increases the confidence in the results of each individual study (Heale 
and Forbes, 2013). The use of multiple methods was particularly a strength for 
investigating FSD which was exemplified by the difference in prevalence of low libido 
between the cohort study (<1%) and the cross-sectional study (39.3%). The results of 
the cross-sectional study were more in keeping with previous studies included within 
the systematic review and of the general population where a recent meta-analysis 
estimated a prevalence of 41% (Dunn et al., 1998; Laumann et al., 2005; McCool et 
al., 2016). This highlights the strength of using a cross-sectional self-completed study 
for investigating FSD, and the limitations of investigating FSD in a database, which is 
discussed in further depth in the next section and the importance of using more than 
one study design to answer the questions within this thesis. 
A further strength of the cohort study, and cross-sectional study, was that they were 
undertaken in a primary care setting. This is important because the majority of 
opioids within the UK are prescribed by GP’s in primary care, with only a small 
number of people referred to specialist pain clinics (Breivik et al., 2006). It is 
significant that the studies are set in primary care, as they are more likely to provide 
results that are generalisable to the population of interest from within the UK since 
over 98% of the UK population is registered with a GP (Herrett et al., 2015). Within 
this thesis the population of interest (those prescribed opioids) would have all been 
registered at a GP, as this is the only way in the UK to access regularly prescribed 
medicine. Consequently, this means the sampling frame should be appropriate. The 
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full benefits and disadvantages of CPRD have been discussed previously in the 
thesis (see sections 4.6 and 5.4 for full details) and importantly it has been shown to 
be comparable to the UK population (Herrett et al., 2010).The identification of the 
participants was undertaken using a comprehensive list of Read Codes (including 
symptoms and diagnostic codes) that were developed within the research centre by 
experts (including primary care clinicians) in musculoskeletal research. It is therefore 
unlikely that any women presenting with musculoskeletal conditions will have been 
omitted from the studies. The Read Code lists were also checked by ER who is a 
primary care clinician prior to undertaking the searches for the cross-sectional study. 
This also strengthens the generalisability of the results as all relevant women are 
likely to have been identified.  
An additional strength of the studies was that all women who met the inclusion 
criteria were included in both the cohort study (from CPRD population) and the cross-
sectional study (from 29 GP Practices).The advantage of this is that there was a 
reduced risk of selection bias at the initial stage of the studies.  
Another strength of the studies is that they split opioid use based on definitions 
already in use within the literature, which enables to results to be comparable to the 
evidence already available for other opioid adverse effects. The cohort study split 
opioids by duration using definitions employed by Von Korff et al (2010), and the 
cross-sectional study split opioid dose at 20mg, which has also been previously used 
(Dunn et al., 2010; Von Korff et al., 2008). Using predefined opioid groups means 
that the results are more directly comparable with the existing body of evidence 
relating to opioid use and adverse events. If the studies were to be repeated again it 
would be interesting to split opioids in both studies based on duration and daily 
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morphine equivalent dose particularly in the cohort study which only considered 
duration of use.  
Research into FSD often only includes women who have been sexually active within 
the preceding year. This can artificially lower the prevalence of FSD through 
selection bias, as those women who are not sexually active may have avoided sexual 
intercourse due to sexual problems (Laumann et al., 1999). A strength of the cross-
sectional study is that all women receiving opioids for musculoskeletal pain were 
included within the target populations regardless of their current sexual activity, and 
therefore this particular form of selection bias is avoided. 
11.2.2 Limitations of the thesis  
As discussed within section 11.2.1 there were limitations associated with 
investigating FSD in the cohort study. The prevalence of FSD was much lower than 
expected when compared to population estimates and the results from the cross-
sectional study. This comparison supports the view from the cohort study discussion 
(Chapter 7), that the low prevalence in the cohort study was likely to be due to the 
clinical iceberg (where women might be suffering from these symptoms but did not 
present to medical services) (Last, 1963). This can be a limitation of database 
research, as the absence of a coded diagnosis is taken as the absence of a 
condition. This is interesting as the women in the cross-sectional study who were 
identified as having FSD experienced distress secondary to the symptoms, which 
would lead to the assumption that they would be more likely to seek help. Previously 
the  possible reasons why women may not seek medical attention for reproductive 
and sexual symptoms have been discussed (section 7.3), this may be due to the 
perception that they are a private matter, or embarrassment from either the patient or 
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the clinician about discussing these conditions (Delgado-Rodriguez and Llorca, 2004; 
Montgomery, 2008). It also seems clear from this comparison that database research 
is not the ideal way to investigate FSD currently. The low prevalence of low libido in 
the cohort study, may also have been due to detection bias, where libido may have 
been one of many complaints, so it was either not coded, or was added within the 
free text comments, and therefore could not be identified within database searches 
based on Read Codes. Symptoms that are part of the presenting complaint, but not 
what the GP considered to be the main issue are often not coded, and even if low 
libido was coded this may not have followed diagnostic criteria (Jordan and Croft, 
2008). Use of databases may be appropriate in the future for investigating low libido 
if free text information is also included in the search. Previous research around 
presenting symptoms of bladder and pancreatic cancer found that restricting 
searches to Read Codes underestimated symptom frequency and potentially 
introduced detection bias (Price et al., 2016). 
An important potential limitation of the studies was the question of hormonal 
contraception and whether it was included as a confounder within analysis. The 
cross-sectional study was able to gather information on contraception use, whereas 
the cohort study was not, due to the nature of how contraception is provided in the 
UK (this was previously discussed in chapter 7). It was assumed that contraception 
use would not be different between the two opioid groups when analysing the cohort 
study. The results of the cross-sectional study found no statistically significant 
difference between the comparison groups and which type of contraception (if any) 
they were using. The samples for the two studies were drawn from slightly different 
populations, with the cohort study coming from CPRD which covers the whole of 
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England, and the cross-sectional study population deriving from the West Midlands 
only. Additionally, the comparison groups were different (split by duration in the 
cohort study and total morphine equivalent dose in the cross-sectional study). The 
difference in the two populations’ means, that the cross-sectional study results 
cannot confirm that there was no difference in contraception use between opioid 
groups in the cohort study, but it does provide supporting evidence, that this 
assumption seems to have been appropriate. However the cross-sectional study was 
unable to include contraceptive use as a confounder within multiple logistic 
regression due to low response rate, so it cannot be definitely said that it would have 
no effect on the results. There were women within the cross-sectional study, who 
were receiving opioids that were sexually active and not using any form of 
contraception. This may indicate that women are not aware that opioids are 
potentially harmful in pregnancy and therefore supports the notion that it is important 
to discuss contraception with women during prescribing and when reviewing the use 
of opioids.  
Ethnicity was important to consider within the studies as there is conflicting evidence 
that ethnicity can have an effect on FSD. Unfortunately, 29% of the ethnicity data 
was missing in the cohort study and this was not adjusted for within the analysis. In 
the cross-sectional study there was no missing data for ethnicity, but multiple 
regression could not be undertaken due to the low response rate to the survey 
overall, which decreased the power available for analysis therefore making this a 
potential limitation. The cross-sectional study did not find any statistically significant 
difference in ethnicity between the opioid groups, but a slightly higher proportion 
identified as White when compared to census data for England and Wales (see 
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section 10.4) (Office for National Statistics, 2012). As ethnicity was not included 
within the statistical analysis and was not the same in the cross-sectional study as in 
the general population, it is not possible to determine whether this is likely to have 
affected the generalisability of the results. Additionally it brings into question whether 
the results are applicable to other populations with different ethnicities. Previous work 
has not reached consensus regarding ethnicity and FSD with some studies finding no 
difference in odds of FSD occurring in different ethnic groups, whereas others have 
found increased odds of FSD in those of Black ethnicity and decreased odds in 
Hispanics when compared to those of White ethnicity (Gracia et al., 2004; Laumann 
et al., 1999, 2005).  
The question then arises as to whether this potential difference in FSD between 
ethnicities is due to a biological difference or a societal difference. Gracia et al (2004) 
undertook a study set in the US comparing ethnicity and found no differences in FSD, 
whereas Laumann et al (2005) undertook a multinational study and compared people 
from different countries (but did not explicitly include ethnicity in the analysis) and 
found the highest prevalence of FSD in women from Southeast Asia, East Asia and 
the Middle East (Gracia et al., 2004; Laumann et al., 2005). There is evidence from 
previous studies that Hispanic women reproducibly underreport FSD, so there 
appears to be potential for women from different cultures and ethnic backgrounds to 
answer questions around FSD differently (Laumann et al., 1999). Research has 
investigated if cultural issues can affect the reporting of FSD, and whether the gender 
balance of a culture can have an effect. The lowest rate of FSD was in the non-
European West (32.1% 95% CI 21.1, 44.4), and the highest rates in Africa (61.7%, 
95% CI 48.6, 74.0) (McCool et al., 2016). There is no clear biological evidence to 
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suggest that those from different ethnicities have different levels of adverse effects 
related to opioids, but there is evidence that drug metabolism varies with ethnicity 
and this may have implications for adverse effects. The clearest evidence for 
differences in metabolism are related to codeine, which is metabolised by CYP2D6 
(an enzyme primarily expressed by the liver) to the active metabolite morphine. 
CYP2D6 broadly has two different phenotypes split into poor metabolisers and 
extensive (normal) metabolisers. The level of poor metabolisers varies dependent on 
ethnicity with 7.2% (3.2, 10.7) of White people in studies identified as poor 
metabolisers falling as low as 0.5% (0, 2.1) in those of Asian descent. Those who are 
poor metabolisers will not be able to convert codeine to its active metabolite, and 
therefore will gain no benefit from codeine, and also appear to have less adverse 
effects (Burroughs et al., 2002). There is therefore evidence that potentially ethnicity 
might affect the rates of adverse events, particularly for codeine (which was used by 
the highest proportion of the cross-sectional study), and with those of White ethnicity 
being less likely to have adverse events. This is therefore a potential weakness of the 
studies, and may limit the applicability of the results in other populations with different 
ethnicities, perhaps overestimating the prevalence of adverse effects. The results 
should, however, be generalisable to the general population within the UK.  
One difficulty with investigating FSD is the multiple definitions used and consequently 
determining a single definition and assessment tool to evaluate this (discussed in 
Section 2.5 and 8.7.1). This means that the three sections of the thesis have used 
different definitions of FSD which are therefore not directly comparable, thereby 
introducing some limitations when comparing the results. The systematic review 
included studies that identified FSD based on symptoms, none of the papers 
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reported using validated measures to diagnose FSD. The cohort study only identified 
women who a GP had coded with low libido (this is unlikely to have followed any 
diagnostic criteria), and the cross-sectional study used a pre-validated measure that 
considered the diagnostic guidelines for FSD. This is a problem not just for this thesis 
but for all research relating to FSD as there are multiple definitions and validated 
measures in current use. The cross-sectional study used the most robust method for 
identifying FSD therefore the other results should be interpreted in light of this. There 
is unfortunately no current gold standard for diagnosing and identifying FSD, but an 
appropriate tool for the study was selected through careful consideration of the 
assessment tools.  
The most obvious limitation within the thesis was the low response rate to the cross-
sectional study which has been discussed at depth in Chapter 10. It is important to 
reflect that this low response rate has affected the ability to draw an overall 
conclusion from the thesis regarding FSD, as the cross-sectional study was the only 
part of the thesis to use a validated measure for identifying FSD. If the cross-
sectional study were to be repeated it would be important to attempt to maximise 
both item and unit response rate. Unit non-response could possibly have been 
increased, for instance, with a telephone contact either prior to sending the 
questionnaire or following non-response. Telephone contacts were not included 
within the protocol, due to both economic and logistic reasons, however using this 
method in future studies would be appropriate. In terms of item non-response there 
are also specific changes that it would be sensible to make to the questionnaire 
following having examined the pattern of responses to individual items. The first 
changes would be to the medicine section where having two separate response lines 
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for the name and dose of drug, rather than one for both, would make it more explicit 
that both are required, additionally, including space for five analgesics rather than 
four, and including space for double the amount of other medicines (participants still 
reported all their medicines in two lines in the provided space, but it would be better if 
this were formalised) would have improved data collection. In the other conditions 
section, one question asked if the participants suffered chronic pain, and there was a 
poor correlation between the answers to this and the responses to the chronic pain 
grade results. The reason for this difference is likely to be due to a misunderstanding 
with respect to the word ‘chronic’, which means a long-term illness to doctors. 
However ‘chronic” can mean a severe illness to patients (Rowlands et al., 2014). In 
retrospect it would have been better to change this option to an alternative such as 
long-term pain (although this would need to be defined), or persistent pain. The 
difference between those who indicated chronic pain, and those with a high chronic 
pain grade score may also reflect that some participants simply do not consider 
themselves to have chronic pain even though they score as such on the validated 
tool. The final change to the questionnaire that would be adding a further option in 
the question surrounding current employment status whereby the option “employed 
but currently off sick” would be altered to encompass those on disability benefits, this 
is due to the number of women who ticked other in the questionnaire and in the 
description wrote that they were currently on disability benefits. The participants were 
also asked to consent for medical records review and this may have affected 
response rate as this has been previously shown to decrease response rate (Dunn et 
al., 2004). The medical records review did provide valuable information with regards 
to opioid dose and meant that only two women were unable to be categorised into an 
opioid category following its use compared to 11 women prior to this.  
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A further limitation of the studies was that mental health was unable to take into 
account during either Cox regression (cohort study) or multiple logistic regression 
(cross-sectional study). The cohort study did not include depression or anxiety as a 
possible confounders (as this data was not available for the cohort), and this is a 
limitation as mental health has been shown to be closely interlinked with pain, opioid 
use and sexual function (Gracia et al., 2004; Gureje et al., 1998; Scherrer et al., 
2014). In retrospect, it would have been helpful to have included depression and 
anxiety within analysis of the cohort study, and this would have been particularly 
useful in relation to the low libido outcome (however due to low rates of low libido this 
would not have altered the results significantly). The cross-sectional study did include 
items to assess mental health, unfortunately due to the low response rate, there was 
insufficient statistical power to undertake multiple logistic regression. 
Another potential limitation is how representative the sampling frames (GP practices 
contributing to CPRD and actively involved in research) are of the wider UK 
population. Practices that contribute to CPRD and participate in research have self-
selected from a wider pool of practices. Previous work set in the West Midlands has 
shown that active research practices are from more deprived areas, more likely to 
undertake postgraduate GP training, have larger practice areas (and patient lists) 
and achieve higher QoF points (explained in section 4.6.1). However, despite these 
differences being statistically significant, the absolute difference was small, and these 
differences were felt to be unlikely to have an impact clinically (Mcmanus et al., 
2008). A further study in the Trent region found similar results but also added that 
there was no difference in standardised mortality ratios (Hammersley et al., 2002). It 
is likely, therefore, that the practices included in the cross-sectional study are 
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representative of the general population and the results are generalisable to other 
GP practices within the UK. CPRD has also been shown to be representative of the 
UK population when compared with census data, however there is some concern 
that the participating practices may be high achieving when compared with other 
practices (Campbell et al., 2013; Herrett et al., 2010). Despite these differences, it is 
likely that both CPRD and the practices included in the cross-sectional research were 
representative of GP’s within England which therefore improves the external validity 
of the results through avoiding systematic differences between the study population 
and the population of interest. 
Overall considering the strengths and limitations of the thesis as discussed above, 
the results are likely to be generalisable to primary care in the UK (and other 
populations with similar healthcare systems for accessing opioids), however the low 
response rate to the cross-sectional study has decreased the confidence with which 
a conclusion for FSD can be drawn. 
11.3 Implications for clinical practice and research 
The comparison between the results for sexual dysfunction in the systematic review, 
other research examining sexual issues, the cross-sectional study and the cohort 
study suggest that CPRD is not the most appropriate way to research FSD. This is 
important for future research, as other methods of investigating this area should be 
considered, or if database research is undertaken then thought should be given to 
including data from free text within the records as well as Read Codes. However the 
postal survey was subject to a poor response rate, so potentially future research 
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might be embedded within larger studies, such that participants have already been 
recruited for the study and the focus is not purely on sexual problems.  
Future research should continue to use definitions of long-term opioids and opioid 
dose stratification as exemplified in this thesis and previous research (Dunn et al., 
2010; Von Korff et al., 2008; Saunders et al., 2009). In this way it will ensure that 
future examination of this area is comparable, particularly when the same adverse 
effect is being investigated using different methods. Recent guidelines suggest that 
there is a research gap in those using opioids for six months or longer, and therefore 
this research could be reproduced to reflect this duration of opioid use (British 
Medical Association, 2017). The cross-sectional study investigated daily opioid dose 
and how this was related to adverse effects. There appeared to be a dose response 
with increasing doses of opioids associated with increasing odds of FSD (not 
statistically significant, except in the sensitivity analysis). The results from this thesis 
appear to show that both duration of opioid use and dose are related to adverse 
effects, and if possible, then both of these should be taken into account in the design 
of future studies.  
This research did not investigate specific opioid type. There is a need to investigate if 
there are any specific opioids that are associated with a higher risk of adverse 
effects, independent of daily morphine equivalent dose, as previous work appears to 
have shown different safety profiles when comparing specific opioids (Solomon et al., 
2010a). The mode of delivery of opioid (oral vs. transdermal) would benefit from 
further research to investigate whether this modifies the risk of adverse effects. This 
could be investigated this within the thesis, as the cross-sectional study had 
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insufficient numbers of women reporting the use of transdermal opioids, and 
information on individual opioid type was not available in the cohort study.  
There is also an under investigated area relating to the persistence of adverse effects 
after stopping regular opioid use. The cohort study did not allow participants to move 
between exposure groups, so determining if the effect disappears once opioids are 
stopped is an area that warrants further investigation. The cross-sectional study, by 
its very nature, only investigated a single period in time. This could be achieved by 
using patients as their own controls (case–crossover control study) and re-analysing 
if the participants become a non-opioid user, however this would be difficult to do 
within a database as symptoms are not often marked as resolved within primary care 
systems. 
A further implication for research is the potential effect that opioids might have on 
oestrogen levels through disruption of the HPG axis (symptoms of menopause and 
amenorrhoea). Oestrogen has been identified as a key modulator of pain in humans 
(Craft, 2007; Hassan et al., 2014; Paller et al., 2009). In post-menopausal women, 
HRT has been associated with improvement in some types of pain and worsening in 
some specific conditions such as migraines (Aloisi and Bonifazi, 2006; Craft, 2007). 
This is a complex relationship, but if opioids have an effect in increasing menopausal 
symptoms and amenorrhoea (both low oestrogen states), could this then have a 
further effect on pain. Further hormonal assay studies in women, pre and post long-
term opioid therapy might add further evidence to the part played by HPG hormones 
to determine if there is an absolute difference and how this relates to changes in 
pain.  
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This thesis has highlighted the link between opioid use and reproductive and sexual 
dysfunction in women. It is important that this is considered by GP’s when 
considering prescribing opioids in the short-term, and during review of prescribed 
long-term opioids. This thesis adds to the growing evidence for the burden of adverse 
effects associated with long-term opioids and highlights an area of adverse effects 
that are less well known (Bedson et al., 2019a; Dunn et al., 2010; Saunders et al., 
2009). Guidelines currently suggest that prior to prescribing opioids, the full risks and 
benefits should be discussed with the patient, and this includes the risks of 
reproductive and sexual dysfunction (British Medical Association, 2017). The same 
guidance recommends that opioids should be reviewed soon after starting to assess 
effectiveness and for adverse effects and that regular monitoring should be 
undertaken. Guidance around opioid use in the UK now suggests avoiding using 
opioids if they are not necessary, avoiding escalating dose of opioids that are already 
in use and finally de-escalating those on long-term opioids to lower doses, all of this 
is important to prevent the increase that has been seen in opioid use over the past 20 
years from increasing further (Bedson et al., 2016; British Medical Association, 2017; 
Foy et al., 2016). This means that introducing a discussion around sexual and 
reproductive health would be considered part of the process of initial and ongoing 
prescribing of opioids based on the current evidence. This should not create an extra 
burden on GP’s as reviews of opioids should already be occurring regularly.  
This thesis adds to the growing evidence for adverse effects associated with opioid 
use for CNCP, and this should be considered by clinicians when considering initiating 
opioids or increasing dose of opioids for CNCP, and when undertaking medicine 
reviews for continuation of use or considering dose de-escalation. 
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11.4 Conclusion 
The overall aim of this thesis was to investigate sexual and reproductive dysfunction 
and whether this was associated with opioid use for CNCP. This thesis has 
investigated this question with three separate studies; a systematic review, a 
database cohort study and a cross-sectional survey. The thesis identified this as an 
area with limited relevant research and then investigated this further. The results 
from the cohort study support the hypothesis that opioid use is associated with 
reproductive dysfunction. The cross-sectional study added to this body of evidence 
indicating a relationship between increasing daily morphine equivalent opioid dose 
and FSD, however this was not statistically significant. The work from this thesis has 
increased the knowledge around sexual and reproductive dysfunction associated 
with opioid use in women of reproductive age, and should be used to further develop 
the discussion around risks and benefits of opioid use in CNCP, particularly 
musculoskeletal pain.  
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Appendix 1 Systematic review protocol 
Arthritis Research UK Primary Care Centre  
Systematic Review Protocol & Support Template 
 
This template is primarily intended to help you plan your review in a systematic way. 
A copy of this completed form will be available via the intranet to help others carrying 
out reviews in the future and to avoid duplicating work already undertaken in the 
Centre. Keeping a record of all the reviews will also assist in planning the work of the 
Centre and ensuring adequate methodological support. Not all the information will be 
relevant to every review. However, items can be adapted to fit the type of review that 
is being undertaken. 
Please complete the form in as much detail as possible for your review and email to Jo Jordan, 
j.jordan@keele.ac.uk  
 
Title of the review 
The risk of adverse effects on endocrine function in 
female patients with chronic non-cancer pain (CNCP) 
prescribed long-term opioid analgesia. 
First reviewer Emily Wersocki 
Team of reviewers 
Emily Wersocki 
John Bedson 
Ying Chen 
Kate Dunn 
Supervisor/Project PI  John Bedson 
 
Clinical Portfolio Group  
Project title (if different 
from review title) 
 
 
Support – please state if advice/training or personnel required at each stage 
SR overview Yes 
Protocol development Yes 
Literature searching Yes 
Quality appraisal No EW  
Data Extraction Support with data extraction and training. 
 370 
 
Synthesis No EW 
Writing up No EW 
 
Background to review   
Brief introduction to the subject of the review, including rationale for undertaking the review 
and overall aim 
With age, and particularly in females, there is an increased susceptibility to the 
chronic pain conditions for which treatment according to current guidelines may 
involve the use of opioids. Though much is known about the effects of using long-
term opioids in males and the adverse consequences of so doing, there has been 
very little work relating to their effect on females. However this is an important area 
for clinicians and female long-term opioid users to understand better. Theoretically, 
opioids can interfere with the normal hormonal pathways in humans and therefore 
disrupt the normal function of hormones which regulate the menstrual cycle, the 
menopause and consequently fertility. This has previously been demonstrated in 
methadone users, although there are obvious demographic differences between this 
group and the general population that could potentially account for this. 
Consequently, if opioid analgesics have some form of adverse effect on fertility, and 
if this is combined with an aging population susceptible to MSK pain, that also may 
choose to have children later in life, the combined effect may be to limit a woman’s 
choice to do so because of the analgesic she is prescribed. Determining if long-term 
opioid use is associated with menstrual disturbance and potentially fertility problems 
will help inform guidelines and prescribing that can be tailored to individual needs 
without compromising a patient’s reproductive capacity. 
 
 
 
2. Specific objectives 
To review the literature around the endocrinological effects of taking long term 
opiates for CNCP in females. 
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3. a) Criteria for including studies in the review  
If the PICOS format does not fit the research question of interest, please split up the 
question into separate concepts and put one under each heading 
Population, or 
participants and 
conditions of interest 
 
Female 18-55 years old. CNCP taking opioids (including 
neuropathic pain) 
Studies including men and women will be included if data 
is available separately for women.  
Papers with age ranges outside 18-55 will be included if 
stratified data is available for appropriate age groups.  
If the paper focuses on CNCP in a specific group this will 
be included if the control group is matched. 
Interventions or 
exposures 
Exposure: Long term opioid use (>1 month prescriptions 
for opioids) for chronic non-cancer pain. Each paper will 
be reviewed for how they define long term and included if 
this is >1month. 
Comparisons or control 
groups 
No control/comparison group required for inclusion but if 
study includes comparison group it will be included. 
Outcomes of interest 
 
Primary Outcome - Endocrinological side effects – 
premature menopause, infertility, fertility treatment, IVF 
treatment, irregular menstrual cycle, hypogonadism, libido. 
Setting 
Any 
Study designs 
Cohort studies 
RCTs 
Diagnostic studies, treatment based studies 
Case-control studies 
Case studies 
Case series 
Cross sectional studies 
 
3. b) Criteria for excluding studies not covered in inclusion criteria  
Any specific populations excluded, date range, language, whether abstracts or full 
text available, etc 
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methadone users for rehabilitation from illegal drug use and no chronic pain usage 
illegal opiate use 
cancer pain 
palliative care 
non pain conditions e.g. opiates for breathlessness 
papers not in English where translations are not available 
non- human subjects 
full text unavailable 
systematic reviews 
editorials 
letters 
 
 
4. Search methods 
Electronic databases 
Please list all 
databases that are to 
be searched and 
include the interface 
(eg NHS, EBSCO, etc) 
and date ranges 
searched for each 
 
AMED, MEDLINE, PsychINFO, CINAHL  
 
Embase,Toxline 
 
 
Web of Science:  
 
Citation Index  
 
 
 
Other methods used 
for identifying relevant 
research  
ie contacting experts 
and reference 
checking 
Cochrane library - Reference checking from any systematic reviews found. 
Citation tracking. Contact any relevant experts in the area.  
 
Journals hand searched 
If any are to be hand 
searched, please list 
which journals and 
date searched from, 
including a rationale.  
No 
 
5. Methods of review 
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Details of methods 
Number of reviewers, 
how agreements to be 
reached and 
disagreements dealt with, 
etc. 
Selected databases to be searched with predefined 
criteria. 
Results to be downloaded onto RefWorks and duplicates 
excluded 
Titles screened and inclusion/exclusion criteria applied by 
EW 
Abstracts screened and inclusion/exclusion criteria applied 
by EW, YC and JB (EW and one other reviewer, third 
reviewer if disagreement) 
Assess full-text articles for eligibility by EW, YC and JB. 
(EW and one other reviewer, third reviewed if 
disagreement) 
Disagreements regarding inclusion to be settled by KD 
Papers to be included will be assessed for quality using 
CASP check lists. 
Data will be extracted using a standardised proforma. 
 
Quality assessment 
Tools or checklists 
used with references 
or URLs 
http://www.casp-uk.net/ CASP checklists appropriate for 
each study design.  
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Data extraction  
What information is to 
be collected on each 
included study. If 
databases or forms on 
Word or Excel are 
used and how this is 
recorded and by how 
many reviewers 
Using Word proforma if <20 papers to be included are 
identified.  
First 3 papers the proforma will be completed by EW and 
JB to ensure reproducibility then EW will review the 
remaining papers independently.  
Author 
Title 
Year 
Journal/Source/Country 
Aim of study 
Study design 
type of study 
recruitment method 
non responders? 
Drop outs?  
Length of follow up? 
Measurement bias? 
Recall bias? 
Classification bias? 
Blinded? 
Population –  
number included in study, sampling method 
target population – age/sex 
setting 
Type of pain condition 
Baseline endocrine function 
Confounding factors? Any special characteristics of study 
population? 
Comparison 
Population comparison how were they selected?  
Matched groups? 
Intervention –  
Length of opioid use – How is long term opioid use 
defined? 
Route of administration 
Outcome – 
Endocrine side effects recorded (clinical, biochemical or 
both) 
Valid/reliable results? (using CASP checklist for quality of 
paper by EW) 
Statistically significant? Specific data extracted p values, 
confidence intervals. 
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Narrative synthesis 
Details of what and how 
synthesis will be done 
 
Synthesis to be done by EW following review of the 
literature. It will most likely be thematic and discuss 
individual effects and the papers that discussed these 
effects. 
Meta-analysis  
Details of what and 
how analysis and 
testing will be done. If 
no meta-analysis is to 
be conducted, please 
give reason. 
Unlikely to yield data that can be inputted into a meta-
analysis.  
Grading evidence 
System used, if any, 
such as GRADE 
Not applicable 
 
 
6. Presentation of results 
Additional material  
Summary tables, 
flowcharts, etc, to be 
included in the final 
paper 
Summary tables for papers included which show methods 
and results. Flowchart to show papers identified at each 
stage and how many were excluded (PRISMA flow 
diagram as the model for this) 
Outputs from review  
Papers and target 
journals, conference 
presentations, reports, 
etc 
Presentation at a conference. Potentially a publication 
dependent on findings. 
 
7. Timeline for review – when do you aim to complete each stage of the review 
Protocol  16/10/14 
Literature searching 9/11/14 
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Quality appraisal 20/12/14 
Data extraction 20/12/14  
Synthesis 23/01/14 
Writing up 26/1/15 
 
 
Please send your completed protocol to Jo Jordan (see email below) as we would 
like to put these on the Intranet.  
 
The systematic review team are available to answer any queries or give advice on 
completing your review. Systematic review workshops are run at least once a year, 
or can be arranged on an ad hoc basis if needed by a group. Presentations from 
previous workshops can be found on the Centre’s Intranet. 
 
Jo Jordan – j.jordan@keele.ac.uk 
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Appendix 2: Systematic review data collection form 
Reference number  
Author (year) 
 
 
Title 
 
 
Journal/source country  
Aim  
Study Design  
CASP checklist: Are the 
results of the trial valid? 
 
Recruitment method  
Intervention group: size 
Sampling method 
Characteristics 
 
Control group: size 
sampling method 
characteristics 
matched sample? 
 
Target population (inc type 
of pain) 
 
Inclusion criteria  
Exclusion criteria  
Population characteristics 
at baseline 
Including baseline 
endocrine function 
 
Special characteristics of 
group in study 
 
Intervention - opiate type, 
route  
definition of chronic use 
 
Blinded?  
Setting  
Outcome measures 
used/measurement tools 
 
Validitiy/reliability of  
measures. Measurement, 
recall, 
classification bias? 
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Outcomes – results and 
statistical significance 
(include p values/ 
confidence interval) 
 
Statistical techniques 
 
 
Implementation measures – 
non responders,  
drop outs, 
length of follow up 
 
Overall conclusion 
 
 
Further research questions  
Reviewers comments 
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Appendix 3: Systematic review search strategies 
Medline 
 
Database: Ovid MEDLINE(R) <1946 to October Week 1 2014> on 14/10/14 
Rerun database: NHS HDAS 2014-2016 
Search Strategy: 
-------------------------------------------------------------------------------- 
 Ovid 1946 – 
October 2014 
2014-2016 
1     exp Analgesics, Opioid/  95669 5751 
2     analgesic opioid.mp.  45 0 
3     exp Narcotics/  103046 5903 
4     narcotic.mp.  37290 0 
5     exp Opiate Alkaloids/  77926 2936 
6     opiate.mp.  18330 0 
7     opioid.mp.  77340 0 
8     narcotic analgesic agent.mp.  18 0 
9     acemethadone.mp.  0 0 
10     acetylmethadol.mp.  277 0 
11     alfenta.mp.  3 0 
12     Alfentanil/  1630 19 
13     alfentanil.mp.  2240 0 
14     amidone.mp.  28 0 
15     anileridine.mp.  59 0 
16     ardinex.mp.  0 0 
17     exp Benzomorphans/  3369 27 
18     benzomorphan*.mp.  967 0 
19     Buprenorphine/  4003 398 
20     buprenorphine.mp.  4859 0 
21     buprenex.mp.  2 0 
22     Butorphanol/  963 54 
23     butorphanol.mp.  1252 0 
24     carfentanil.mp.  208 0 
25     exp Codeine/  5621 451 
26     codeine.mp.  5679 0 
27     codinovo.mp.  0 0 
28     delsym.mp.  0 0 
29     demerol.mp.  191 0 
30     Dextromoramide/  252 0 
31     dextromoramide.mp.  332 0 
32     dezocine.mp.  77 0 
33     diacetyl morphine.mp.  5 0 
34     diamorphine.mp.  395 0 
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35     dicodid.mp.  5 0 
36     dihydrocodeinone.mp.  35 0 
37     dihydrocodeine.mp.  413 0 
38     dihydroetorphine.mp.  69 0 
39     dihydrohyroxycodeinone.mp. 
[mp=title, abstract, original title, name 
of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
0 0 
40     Dihydromorphine/  218 0 
41     dihydromorphine.mp.  412 0 
42     dihydrone.mp. 12 0 
43     dilaudid.mp.  61 0 
44     dimepheptanol.mp.  0 0 
45     dinarkon.mp.  0 0 
46     dionine.mp.  24 0 
47     Diprenorphine/  543 5 
48     diprenorphine.mp.  760 0 
49     dolantin.mp.  77 0 
50     dolargan.mp.  2 0 
51     dolcontral.mp.  7 0 
52     dolophine.mp.  10 0 
53     dolosal.mp.  21 0 
54     dolsin.mp.  13 0 
55     duragesic.mp.  35 0 
56     duramorph.mp.  13 0 
57     dyhydromorphinone.mp. 
[mp=title, abstract, original title, name 
of substance word, subject heading 
word, keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
58     exp Dynorphins/  2890 82 
59     dynorphin.mp.  3786 0 
60     endomorphin.mp.  645 0 
61     eseroline.mp.  46 0 
62     Ethylketocyclazocine/  557 0 
63     ethylketocyclazocine.mp.  803 0 
64     eucodal.mp.  2 0 
65     fenoperidine.mp.  0 0 
66     exp Fentanyl/  13735 615 
67     fentanyl.mp.  17353 0 
68     fioricet.mp.  3 0 
69     fortral.mp.  46 0 
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70     hycodan.mp.  3 0 
71     hycon.mp.  4 0 
72     Hydrocodone/  389 81 
73     hydrocodon*.mp.  659 0 
74     hydrocon.mp.  0 0 
75     Hydromorphone/  1056 61 
76     hydromorphon*.mp.  1484 0 
77     hydroxycodeinon.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
78     isocodeine.mp.  5 0 
79     isonipecain.mp.  0 0 
80     isopromedol.mp.  5 0 
81     kaolin-pectin.mp.  30 0 
82     ketobemidone.mp.  159 0 
83     laudacon.mp.  0 0 
84     lealgin.mp.  0 0 
85     Levallorphan/  339 0 
86     levallorphan.mp.  483 0 
87     levamethadyl.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
88     levodroman.mp.  0 0 
89     levomethadryl.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
90     Levorphanol/  575 0 
91     levorphan*.mp.  811 0 
92     lexir.mp.  8 0 
93     lidol.mp. 8 0 
94     lorfan.mp.  18 0 
95     lofentain.mp. [mp=title, abstract, 
original title, name of substance word, 
subject heading word, keyword 
heading word, protocol supplementary 
concept word, rare disease 
0 0 
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supplementary concept word, unique 
identifier]  
96     lydol.mp.  4 0 
97     exp Meperidine/  5512 61 
98     meperidine.mp.  6309 0 
99     Meptazinol/  184 0 
100     meptazinol.mp.  219 0 
101     methadol.mp.  65 0 
102     exp Methadone/  11037 475 
103     methadone.mp.  13377 0 
104     Methadyl Acetate/  417 0 
105     methadyl acetate.mp.  427 0 
106     moradol.mp.  32 0 
107     morphia.mp.  9 0 
108     exp Morphine/  35395 1108 
109     morphine.mp.  49071 0 
110     exp Morphine Derivatives/  46054 1743 
111     morphine derivatives.mp.  2059 0 
112     Ms contin.mp.  73 0 
113     methylnaloxone.mp.  140 0 
114     Nalbuphine/  647 16 
115     nalbuphine.mp.  864 0 
116     naloxiphan.mp.  0 0 
117     nocistatin.mp.  100 0 
118     nubain.mp.  47 0 
119     numorphan.mp.  11 0 
120     omnopon.mp.  32 0 
121     operidine.mp.  0 0 
122     exp Opium/  1897 36 
123     opium.mp.  2662 0 
124     oramorph.mp.  17 0 
125     oxycodein*.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
126     Oxycodone/  1420 244 
127     oxycodone.mp.  2066 0 
128     oxycone.mp. 2 0 
129     oxyconum.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
0 0 
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unique identifier]  
130     oxycontin.mp.  161 0 
131     Oxymorphone/  414 29 
132     oxymorph*.mp.  616 0 
133     pancodiene.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
134     pantopon.mp.  9 0 
135     papaveretum.mp.  137 0 
136     paracymethadol.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
137     paramorfan.mp.  0 0 
138     paramorphan.mp.  0 0 
139     paregoric.mp.  53 0 
140     Pentazocine/  2264 25 
141     pentazocine.mp.  2938 0 
142     percocet.mp.  40 0 
143     pethidine.mp.  2095 0 
144     phenadone.mp.  2 0 
145     Phenazocine/  485 1 
146     phenazocine.mp.  528 0 
147     phenbenzorphan.mp.  0 0 
148     phenethylazocine.mp.  0 0 
149     Phenoperidine/  214 0 
150     phenoperidine.mp.  265 0 
151     physeptone.mp.  3 0 
152     Promedol/  113 3 
153     promedol.mp.  245 0 
154     propoxyphene.mp.  925 0 
155     proptopine.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier]  
0 0 
156     pyrrolamidol.mp.  17 0 
157     rapifen.mp.  15 0 
158     remifentanil.mp.  3198 0 
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159     revivon.mp.  13 0 
160     robidone.mp.  0 0 
161     stadol.mp.  43 0 
162     Sufentanil/  1584 82 
163     sufentanil.mp.  2207 0 
164     sufentanyl.mp.  47 0 
165     talwin.mp.  57 0 
166     tamgesic.mp.  1 13 
167     Thebaine/  328 0 
168     thebaine.mp.  455 0 
169     theocodin.mp.  0 0 
170     Tilidine/  138 2 
171     tilidine.mp.  170 0 
172     Tramadol/  2265 275 
173     tramadol.mp.  3074 0 
174     trimeperidine.mp.  21 0 
175     valoron.mp.  47 0 
176     valerone.mp.  0 0 
177     vicodin.mp.  40 0 
178     1 or 2 or 3 or 4 or 5 or 6 or 7 or 
8 or 9 or 10 or 11 or 12 or 13 or 14 or 
15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 or 24 or 25 or 26 or 27 or 
28 or 29 or 30 or 31 or 32 or 33 or 34 
or 35 or 36 or 37 or 38 or 39 or 40 or 
41 or 42 or 43 or 44 or 45 or 46 or 47 
or 48 or 49 or 50 or 51 or 52 or 53 or 
54 or 55 or 56 or 57 or 58 or 59 or 60 
or 61 or 62 or 63 or 64 or 65 or 66 or 
67 or 68 or 69 or 70 or 71 or 72 or 73 
or 74 or 75 or 76 or 77 or 78 or 79 or 
80 or 81 or 82 or 83 or 84 or 85 or 86 
or 87 or 88 or 89 or 90 or 91 or 92 or 
93 or 94 or 95 or 96 or 97 or 98 or 99 
or 100 or 101 or 102 or 103 or 104 or 
105 or 106 or 107 or 108 or 109 or 110 
or 111 or 112 or 113 or 114 or 115 or 
116 or 117 or 118 or 119 or 120 or 121 
or 122 or 123 or 124 or 125 or 126 or 
127 or 128 or 129 or 130 or 131 or 132 
or 133 or 134 or 135 or 136 or 137 or 
138 or 139 or 140 or 141 or 142 or 143 
or 144 or 145 or 146 or 147 or 148 or 
149 or 150 or 151 or 152 or 153 or 154 
or 155 or 156 or 157 or 158 or 159 or 
160 or 161 or 162 or 163 or 164 or 165 
or 166 or 167 or 168 or 169 or 170 or 
171 or 172 or 173 or 174 or 175 or 176 
185980 128357 
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or 177  
179     exp Hypogonadism/   576 
180     hypogonadism.mp.   0 
181     endocrin*.mp.   0 
182     exp Menstruation Disturbances/   655 
183     menstrual disturbance.mp.   0 
184     Amenorrhea/   147 
185     amenorrhoea.mp.   0 
186     Oligomenorrhea/   20 
187     oligomenorrhoea.mp.   0 
188     Menorrhagia/   149 
189     menorrhagia.mp.   0 
190     Metrorrhagia/   57 
191     dysfunctional uterine 
bleeding.mp.  
 0 
192     DUB.mp.   0 
193     heavy menstrual bleed*.mp.   0 
194     Polycystic Ovary Syndrome/   1011 
195     polycystic ovary syndrome.mp.   0 
196     PCOS.mp.   0 
197     PCOD.mp.   0 
198     Infertility, Female/   1272 
199     Infertility, female.mp.   0 
200     Primary Ovarian Insufficiency/   245 
201     ovarian insufficiency.mp.   0 
202     Anovulation/   61 
203     anovulation.mp.   0 
204     exp Reproductive Techniques, 
Assisted/  
 4131 
205     assisted reproductive 
techniques.mp.  
 0 
206     Libido/   192 
207     libido.mp.   0 
208     exp Sexual Dysfunction, 
Physiological/  
 1702 
209     sexual dysfunction.mp.  11393 0 
210     Menopause/  23851 879 
211     menopause.mp.  35040 0 
212     Menopause, Premature/ 814 60 
213     premature menopause.mp.  514 0 
214     Climacteric/  4689 18 
215     climacteric.mp.  6359 0 
216     Perimenopause/  849 139 
217     perimenopause.mp.  1379 0 
218     metrorrhagia.mp.  2685 0 
219     opioid induced 
endocrinopathy.mp.  
2 0 
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220     opioid induced androgen 
deficiency.mp. [mp=title, abstract, 
original title, name of substance word, 
subject heading word, keyword 
heading word, protocol supplementary 
concept word, rare disease 
supplementary concept word, unique 
identifier]  
7 0 
221     179 or 180 or 181 or 182 or 183 
or 184 or 185 or 186 or 187 or 188 or 
189 or 190 or 191 or 192 or 193 or 194 
or 195 or 196 or 197 or 198 or 199 or 
200 or 201 or 202 or 203 or 204 or 205 
or 206 or 207 or 208 or 209 or 210 or 
211 or 212 or 213 or 214 or 215 or 216 
or 217 or 218 or 219 or 220  
303896 175368 
222     (ae or co or de).fs.  5108792 0 
223     (safe or safety or side effect* or 
undesirable effect* or treatment 
emergent or tolerability or toxicity or 
adrs).ti,ab.  
806543 152685 
224     (adverse adj2 (effect or effects 
or reaction or reactions or event or 
events or outcome or outcomes)).ti,ab.  
239759 20006 
225     222 or 223 or 224  5589493 172691 
226     178 and 221 and 225  1664 20 
 
Re-run via NHS HDAS on 7/4/16 
 
EMBASE 
 
Database: Embase <1974 to 2014 Week 41> Searched on 13/10/14 Ovid Embase 
Re-run via NHS HDAS 2014-2016 on 7/4/16 
Search Strategy: 
-------------------------------------------------------------------------------- 
 13/10/14 Re run 7/4/16 
1     opioid analgesic.mp.  1624 3203 
2     exp narcotic analgesic agent/  252551 26857 
3     narcotic analgesic agent.mp.  15398 2597 
4     exp opiate/  52694 8210 
5     opiate.mp.  105726 12734 
6     narcotic*.mp.  39202 4445 
7     opioid.mp. or opiate/  98099 14248 
8     acemethadone.mp.  0 0 
9     exp acetylmethadol/  442 4 
10     acetylmethadol.mp.  574 5 
11     alfenta.mp.  59 1 
12     exp alfentanil( 6053 251 
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13     alfentanil.mp.  6231 258 
14     amidone.mp.  19 2 
15     exp anileridine/  135 1 
16     anileridine.mp.  144 1 
17     ardinex.mp.  3 0 
18     exp benzomorphan derivative/  12092 316 
19     exp benzomorphan/  88 2 
20     benzomorphan*.mp.  1084 9 
21     exp buprenorphine/  11466 1634 
22     buprenorphine.mp.  12134 1869 
23     buprenex.mp.  181 101 
24     exp butorphanol/  2596 139 
25     butorphanol.mp.  3114 173 
26     exp carfentanil/  377 32 
27     carfentanil.mp.  463 49 
28     exp codeine/  17527 1255 
29     exp codeine phosphate/  1070 94 
30     codeine.mp.  19490 1481 
31     codeine phosphate.mp.  1294 134 
32     codinovo.mp.  2 0 
33     delsym.mp.  35 2 
34     demerol.mp.  1462 23 
35     exp dextromoramide/  946 1 
36     dextromoramide.mp.  959 2 
37     exp dezocine/  213 34 
38     dezocine.mp.  217 37 
39     diacetyl morphine.mp.  12 0 
40     exp diamorphine/  19181 1845 
41     diamorphine.mp.  19248 1850 
42     dicodid.mp.  64 1 
43     dihydrocodeinone.mp.  47 1 
44     exp dihydrocodeine/  2090 118 
45     dihydrocodeine.mp.  2173 125 
46     exp dihydroetorphine/  103 0 
47     dihydroetorphine.mp.  117 0 
48     dihydrohyroxycodeinone.mp. 
[mp=title, abstract, subject headings, 
heading word, drug trade name, 
original title, device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
49     exp dihydromorphine/  675 11 
50     dihydromorphine.mp.  1267 12 
51     dihydrone.mp.  9 0 
52     dilaudid.mp.  781 35 
53     dimepheptanol.mp.  88 0 
54     dinarkon.mp.  1 1 
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55     dionine.mp.  40 1 
56     exp diprenorphine/  973 15 
57     diprenorphine.mp.  1249 20 
58     dolantin.mp.  634 2 
59     dolargan.mp.  47 0 
60     dolcontral.mp.  83 0 
61     dolophine.mp.  278 6 
62     dolosal.mp.  316 2 
63     dolsin.mp.  39 0 
64     duragesic.mp.  473 34 
65     duramorph.mp.  128 7 
66     dyhydromorphinone.mp. 
[mp=title, abstract, subject headings, 
heading word, drug trade name, 
original title, device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
67     exp dynorphin/  5508 365 
68     dynorphin.mp.  5691 387 
69     endomorphin.mp.  848 101 
70     exp eseroline/  58 2 
71     eseroline.mp.  81 2 
72     exp ethylketazocine/  1165 2 
73     ethylketocyclazocine.mp.  555 1 
74     eucodal.mp.  11 0 
75     fenoperidine.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
76     fentanyl/  46955 5198 
77     fentanyl.mp.  50786 5494 
78     fioricet.mp.  87 10 
79     fortral.mp.  609 0 
80     hycodan.mp.  98 2 
81     hycon.mp.  7 1 
82     hydrocodone/  3509 776 
83     hydrocodon*.mp.  4576 962 
84     hydrocon.mp.  0 0 
85     hydromorphone/  6531 992 
86     hydromorphon*.mp.  6706 1027 
87     hydroxycodeinon.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
1 0 
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88     isocodeine.mp.  12 0 
89     isonipecain.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
90     isopromedol.mp.  4 0 
91     kaolin-pectin.mp.  275 3 
92     exp ketobemidone/  542 27 
93     ketobemidone.mp.  567 28 
94     laudacon.mp. [mp=title, abstract, 
subject headings, heading word, drug 
trade name, original title, device 
manufacturer, drug manufacturer, 
device trade name, keyword]  
0 0 
95     lealgin.mp.  6 0 
96     exp levallorphan/  1012 1 
97     levamethadyl.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
98     levodroman.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
99     levomethadryl.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
100     levorphanol/  2196 28 
101     levorphan*.mp.  2291 33 
102     lexir.mp.  18 0 
103     lidol.mp.  10 0 
104     lorfan.mp.  139 0 
105     lofentain.mp. [mp=title, abstract, 
subject headings, heading word, drug 
trade name, original title, device 
manufacturer, drug manufacturer, 
device trade name, keyword]  
0 0 
106     lydol.mp.  14 0 
107     meperidine.mp.  3331 174 
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108     meptazinol/  401 12 
109     meptazinol.mp.  420 15 
110     methadol.mp.  85 0 
111     methadone/  25244 2325 
112     methadone.mp.  27068 2595 
113     methadyl acetate.mp.  30 0 
114     moradol.mp.  32 0 
115     morphia.mp.  26 2 
116     morphine/  85227 6675 
117     exp morphine derivative/  160505 14277 
118     morphine.mp.  98239 7891 
119     morphine derivative.mp.  1721 779 
120     morphine sulfate/  6399 640 
121     morphine sulfate.mp.  7391 764 
122     MS contin.mp.  505 25 
123     methynaloxone.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
124     nalbuphine/  2653 134 
125     nalbuphine.mp.  2712 140 
126     naloxiphan.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
127     nocistatin/  108 8 
128     nocistatin.mp.  118 8 
129     nubain.mp.  439 5 
130     numorphan.mp.  175 2 
131     omnopon.mp.  128 0 
132     operidine.mp.  8 0 
133     opium.mp.  2338 221 
134     oramorph.mp.  226 27 
135     oxycodeine.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
136     oxycodone/  10813 2073 
137     oxycone.mp.  2 0 
138     oxyconum.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
0 0 
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device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
139     oxycontin.mp.  1100 162 
140     oxymorphone/  1640 232 
141     oxymorph*.mp.  1840 248 
142     pancodiene.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
143     pantopon.mp.  76 0 
144     papaveretum.mp.  169 1 
145     paracymethadol.mp. 2 0 
146     paramorfan.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
147     paramorphan.mp.  0 0 
148     paregoric/  213 3 
149     paregoric.mp.  234 3 
150     pentazocine/  8456 295 
151     pentazocine.mp.  8709 316 
152     percocet/  688 57 
153     percocet.mp.  704 71 
154     pethidine/  21308 835 
155     pethidine.mp.  21646 858 
156     phenadone.mp.  4 2 
157     phenazocine/  272 0 
158     phenazocine.mp.  281 1 
159     phenbenzorphan.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
160     phenethylazocine.mp.  0 0 
161     phenoperidine/  689 2 
162     phenoperidine.mp.  723 1 
163     physeptone.mp.  56 1 
164     promedol.mp.  182 7 
165     propoxyphene.mp.  1045 39 
166     protopine/  372 48 
167     protopine.mp.  437 57 
168     pyrrolamidol.mp. [mp=title, 0 0 
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abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
169     rapifen.mp.  255 7 
170     remifentanil/  8500 1713 
171     remifentanil.mp.  8714 1795 
172     revivon.mp.  47 0 
173     robidone.mp.  1 0 
174     stadol.mp.  376 6 
175     sufentanil/  7034 657 
176     sufentanil.mp.  7387 681 
177     sufentanyl.mp.  132 18 
178     talwin.mp.  588 5 
179     tamgesic.mp.  8 1 
180     thebaine/  768 30 
181     thebaine.mp.  884 36 
182     theocodin.mp. [mp=title, 
abstract, subject headings, heading 
word, drug trade name, original title, 
device manufacturer, drug 
manufacturer, device trade name, 
keyword]  
0 0 
183     tilidine/  1033 32 
184     tilidine.mp.  1055 33 
185     tramadol/  13442 2380 
186     tramadol.mp.  13900 2527 
187     trimeperidine/  255 10 
188     trimeperidine.mp.  263 12 
189     valoron.mp.  381 2 
190     valerone.mp. [mp=title, abstract, 
subject headings, heading word, drug 
trade name, original title, device 
manufacturer, drug manufacturer, 
device trade name, keyword]  
0 1 
191     vicodin.mp.  503 47 
192     1 or 2 or 3 or 4 or 5 or 6 or 7 or 
8 or 9 or 10 or 11 or 12 or 13 or 14 or 
15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 or 24 or 25 or 26 or 27 or 
28 or 29 or 30 or 31 or 32 or 33 or 34 
or 35 or 36 or 37 or 38 or 39 or 40 or 
41 or 42 or 43 or 44 or 45 or 46 or 47 
or 48 or 49 or 50 or 51 or 52 or 53 or 
54 or 55 or 56 or 57 or 58 or 59 or 60 
or 61 or 62 or 63 or 64 or 65 or 66 or 
67 or 68 or 69 or 70 or 71 or 72 or 73 
324288 33722 
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or 74 or 75 or 76 or 77 or 78 or 79 or 
80 or 81 or 82 or 83 or 84 or 85 or 86 
or 87 or 88 or 89 or 90 or 91 or 92 or 
93 or 94 or 95 or 96 or 97 or 98 or 99 
or 100 or 101 or 102 or 103 or 104 or 
105 or 106 or 107 or 108 or 109 or 110 
or 111 or 112 or 113 or 114 or 115 or 
116 or 117 or 118 or 119 or 120 or 121 
or 122 or 123 or 124 or 125 or 126 or 
127 or 128 or 129 or 130 or 131 or 132 
or 133 or 134 or 135 or 136 or 137 or 
138 or 139 or 140 or 141 or 142 or 143 
or 144 or 145 or 146 or 147 or 148 or 
149 or 150 or 151 or 152 or 153 or 154 
or 155 or 156 or 157 or 158 or 159 or 
160 or 161 or 162 or 163 or 164 or 165 
or 166 or 167 or 168 or 169 or 170 or 
171 or 172 or 173 or 174 or 175 or 176 
or 177 or 178 or 179 or 180 or 181 or 
182 or 183 or 184 or 185 or 186 or 187 
or 188 or 189 or 190 or 191  
193     exp hypogonadism/  12006 1687 
194     hypogonad*.mp.  18699 2659 
195     endocrin*.mp.  355449 26591 
196     exp menstruation disorder/  52077 5808 
197     menstruation disorder.mp.  8078 851 
198     amenorrhea/  17264 1417 
199     amenorrhoea.mp.  3290 242 
200     oligomenorrhea/  2373 357 
201     oligomenorrhoea.mp.  372 36 
202     menorrhagia/  7055 1235 
203     menorrhagia.mp.  7837 1318 
204     metrorrhagia/  4133 428 
205     metrorrhagia.mp.  4498 457 
206     dysfunctional uterine 
bleeding.mp.  
1082 74 
207     DUB.mp.  812 248 
208     ovary polycystic disease/  17737 2943 
209     polycystic ovary syndrome.mp.  10216 2781 
210     PCOS.mp.  9305 2373 
211     PCOD.mp.  332 19 
212     exp female infertility/  36282 3810 
213     female infertility.mp.  25640 7817 
214     anovulation/  4598 370 
215     anovulation.mp.  5779 373 
216     libido/  6629 504 
217     libido disorder/  4529 601 
218     libido.mp.  12554 1207 
 394 
 
219     exp sexual dysfunction/  61883 8318 
220     sexual dysfunction.mp.  26201 5197 
221     exp infertility therapy/  79955 10991 
222     infertility therapy.mp.  13300 3580 
223     heavy menstrual bleed*.mp.  650 332 
224     exp ovary insufficiency/  11028 1571 
225     ovarian insufficiency.mp.  777 805 
226     premature ovarian failure/  2411 675 
227     premature ovarian failure.mp.  3506 830 
228     menopause/  36779 4685 
229     menopause.mp.  54806 6597 
230     early menopause/  1638 345 
231     early menopause.mp.  2164 1034 
232     climacterium/  7106 828 
233     climacteric.mp.  5174 358 
234     perimenopause.mp.  1272 212 
235     opioid induced androgen 
deficiency.mp.  
14 12 
236     opioid induced 
endocrinopathy.mp.  
5 7 
237     193 or 194 or 195 or 196 or 197 
or 198 or 199 or 200 or 201 or 202 or 
203 or 204 or 205 or 206 or 207 or 208 
or 209 or 210 or 211 or 212 or 213 or 
214 or 215 or 216 or 217 or 218 or 219 
or 220 or 221 or 222 or 223 or 224 or 
225 or 226 or 227 or 228 or 229 or 230 
or 231 or 232 or 233 or 234 or 235 or 
236 
626039 64884 
238     (ae or to or po or co).fs.  3119108 107761 
239     (safe or safety).ti,ab.  653763 152336 
240     ((adverse or undesireable or 
harm* or serious or toxic) adj3 (effect* 
or reaction* or event* or 
outcome*)).ti,ab.  
440752 104498 
241     exp postmarketing surveillance/  24257 4921 
242     exp drug surveillance program/  18434 4061 
243     exp "phase 4 clinical trial 
(topic)"/  
465 492 
244     intoxication/  177023 4475 
245     exp drug toxicity/  82044 8998 
246     adverse drug reaction/  161341 12158 
247     exp drug monitoring/  41949 4140 
248     exp drug hypersensitivity/  49903 4250 
249     (toxicity or complication* or 
noxious or tolerability).ti,ab.  
1208746 220560 
250     238 or 239 or 240 or 241 or 242 
or 243 or 244 or 245 or 246 or 247 or 
4590574 493304 
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248 or 249  
251     192 and 237 and 250  4088 234 
 
TOXLINE 
 
Toxline 20/10/2014 
 
‘opioid analgesic or narcotic analgesic agent or opiate or opioid or narcotic* AND 
Hypogonadism or endocrine* of Menstruation Disturbances or Amenorrhea or 
Oligomenorrhea or Menorrhagia or Metrorrhagia or dysfunctional uterine bleeding or 
DUB or heavy menstrual bleed* of Polycystic Ovary Syndrome or PCOS or PCOD or 
Infertility,Female, or Primary Ovarian Insufficiency or Ovarian insufficiency of 
Anovulation or Reproductive Techniques, Assisted of Libido or Sexual Dysfunction or 
Menopause or Menopause, Premature or Climacteric of Perimenopause or opioid 
induced endocrinopathy or opioid induced androgen deficiency’ 
 
PsychINFO 
 
Database: PsycINFO <1806 to October Week 2 2014> Searched 13/10/14 via NHS 
HDAS 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp opiates/ (18725) 
2     exp narcotic agonists/ (1241) 
3     opiates.mp. (11588) 
4     narcotic agonist.mp. (16) 
5     opioid.mp. (13571) 
6     acemethadone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
7     acetylmethadol.mp. (117) 
8     alfenta.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
9     alfentanil.mp. (86) 
10     amidone.mp. (2) 
11     anileridine.mp. (5) 
12     ardinex.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
13     benzomorphan.mp. (25) 
14     buprenorphine.mp. (1772) 
15     buprenex.mp. (3) 
16     buprenex.mp. (3) 
17     butorphanol.mp. (168) 
18     carfentanil.mp. (48) 
19     exp Codeine/ (164) 
20     codeine.mp. (434) 
21     codeine phosphate.mp. (13) 
22     codinovo.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
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23     delsym.mp. (1) 
24     demerol.mp. (9) 
25     dextromoramide.mp. (12) 
26     dezocine.mp. (16) 
27     diacetyl morphine.mp. (1) 
28     diamorphine.mp. (61) 
29     dicodid.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (1) 
30     dihydrocodeinone.mp. (1) 
31     dihydrocodeine.mp. (36) 
32     dihydroetorphine.mp. (4) 
33     dihydroxycodeinone.mp. [mp=title, abstract, heading word, table of contents, 
key concepts, original title, tests & measures] (0) 
34     dihydromorphine.mp. (19) 
35     dihydrone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
36     dilaudid.mp. (15) 
37     dimepheptanol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
38     dimepheptanol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
39     dinarkon.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
40     dionine.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
41     diprenorphine.mp. (81) 
42     dolantin.mp. (3) 
43     dolargan.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
44     dolcontral.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
45     dolophine.mp. (4) 
46     dolosal.mp. (2) 
47     dolsin.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
48     duragesic.mp. (6) 
49     duramoprh.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
50     dihydromorphinone.mp. (5) 
51     exp Dynorphins/ (263) 
52     dynorphin.mp. (594) 
53     endomorphin.mp. (97) 
54     eseroline.mp. (2) 
55     ethylketazocine.mp. (24) 
56     eucodal.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
57     fenoperidine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
58     exp Fentanyl/ (366) 
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59     fentanyl.mp. (802) 
60     fioricet.mp. (2) 
61     fortral.mp. (2) 
62     hycodan.mp. (1) 
63     hycon.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
64     hydrocodone.mp. (121) 
65     hydromorphone.mp. (226) 
66     hydroxycodeinon.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
67     hydroxycodeinon.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
68     hydroxycodeinon.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
69     isonipecain.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
70     isonipecain.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
71     isonipecain.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
72     isopromedol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
73     kaolin-pectin.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
74     ketobemidone.mp. (5) 
75     laudacon.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
76     lealgin.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
77     levallorphan.mp. (50) 
78     levamethadyl.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
79     levodroman.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
80     levomethadryl.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
81     levorphanol.mp. (105) 
82     levorphan*.mp. (106) 
83     lexir.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
84     lexir.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
85     lidol.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
86     lorfan.mp. (4) 
87     lofetain.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
88     lydol.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
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89     exp Meperidine/ or meperidine.mp. (193) 
90     mepatazinol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
91     methadol.mp. (19) 
92     exp Methadone/ (1474) 
93     methadone.mp. (6203) 
94     methadyl acetate.mp. (11) 
95     moradol.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
96     morphia.mp. (10) 
97     exp Morphine/ (6041) 
98     morphine.mp. (9154) 
99     morphine derivative.mp. (2) 
100     morphine sulfate.mp. (432) 
101     morphine sulphate.mp. (78) 
102     MS contin.mp. (9) 
103     methylnaloxone.mp. (3) 
104     nalbuphine.mp. (141) 
105     naloxiphan.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
106     nocistatin.mp. (10) 
107     nubain.mp. (3) 
108     numorphan.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
109     omnopon.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
110     operidine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
111     opium.mp. (532) 
112     oramorph.mp. (1) 
113     oxycodeine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
114     oxycodone.mp. (427) 
115     oxycone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
116     oxyconum.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
117     oxycontin.mp. (94) 
118     oxymorphone.mp. (54) 
119     pancodiene.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
120     pantopon.mp. (3) 
121     papaveretum.mp. (2) 
122     paracymethadol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
123     paramorfan.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
124     paramorphan.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
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125     paregoric.mp. (7) 
126     exp Pentazocine/ (46) 
127     pentazocine.mp. (272) 
128     percocet.mp. (13) 
129     pethidine.mp. (75) 
130     phenadone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
131     phenoazocine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
132     phenbenzorphan.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
133     phenethylazocine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
134     phenoperidine.mp. (4) 
135     physeptone.mp. (2) 
136     promedol.mp. (16) 
137     propoxyphene.mp. (84) 
138     protopine.mp. (1) 
139     pyrrolamidol.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
140     rapifen.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
141     remifentanil.mp. (130) 
142     revivon.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
143     robidone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
144     sufentanil.mp. (62) 
145     sufentanyl.mp. (1) 
146     talwin.mp. (15) 
147     tamgesic.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
148     thebaine.mp. (14) 
149     theocodin.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
150     tilidine.mp. (10) 
151     exp Tramadol/ (193) 
152     exp Tramadol/ (193) 
153     tramadol.mp. (363) 
154     trimeperidine.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
155     valoron.mp. [mp=title, abstract, heading word, table of contents, key concepts, 
original title, tests & measures] (0) 
156     valerone.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (0) 
157     vicodin.mp. (21) 
158     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 
31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
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or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 
60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 
or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 or 88 or 
89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 
103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 
115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 
127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138 or 
139 or 140 or 141 or 142 or 143 or 144 or 145 or 146 or 147 or 148 or 149 or 150 or 
151 or 152 or 153 or 154 or 155 or 156 or 157 (30909) 
159     exp Hypogonadism/ (694) 
160     hypogonadism.mp. (494) 
161     hypogonad*.mp. (593) 
162     endocrin*.mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (9596) 
163     exp menstrual disorders/ (1040) 
164     menstrual disorder.mp. (19) 
165     exp Amenorrhea/ (234) 
166     amenorrhoea.mp. (100) 
167     oligomenorrhoea.mp. (4) 
168     menorrhagia.mp. (71) 
169     metrorrhagia.mp. (3) 
170     dysfunctional uterine bleeding.mp. (19) 
171     DUB.mp. (88) 
172     polycystic ovary syndrome.mp. (176) 
173     exp endocrine sexual disorders/ (941) 
174     PCOS.mp. (163) 
175     PCOD.mp. (6) 
176     infertility/ (1614) 
177     female infertility.mp. (49) 
178     anovulation.mp. (54) 
179     libido/ (573) 
180     libido.mp. (2637) 
181     female sexual dysfunction/ (561) 
182     sexual dysfunction.mp. (4500) 
183     reproductive technology/ (1343) 
184     infertility therapy.mp. (1) 
185     premature ovarian failure.mp. (25) 
186     ovarian insufficiency.mp. (15) 
187     exp Menopause/ (2961) 
188     menopause.mp. (3971) 
189     early menopause.mp. (44) 
190     early menopause.mp. (44) 
191     climacterium.mp. (45) 
192     climacteric.mp. (449) 
193     perimenopause.mp. (222) 
194     opioid induced androgen deficiency.mp. (3) 
195     159 or 160 or 161 or 162 or 163 or 164 or 165 or 166 or 167 or 168 or 169 or 
170 or 171 or 172 or 173 or 174 or 175 or 176 or 177 or 178 or 179 or 180 or 181 or 
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182 or 183 or 184 or 185 or 186 or 187 or 188 or 189 or 190 or 191 or 192 or 193 or 
194 (24711) 
196     exp "side effects (drug)"/ (44471) 
197     exp toxicity/ (5002) 
198     side effects.mp. (38696) 
199     toxicity.mp. (7402) 
200     (safe or safetly).mp. [mp=title, abstract, heading word, table of contents, key 
concepts, original title, tests & measures] (21175) 
201     adverse drug reaction.mp. (191) 
202     ((adverse or undesireable or harm* or serious or toxic) adj3 (effect* or 
reaction* or event* or outcome*)).mp. [mp=title, abstract, heading word, table of 
contents, key concepts, original title, tests & measures] (31416) 
203     drug monitoring.mp. (396) 
204     drug hypersensitivity.mp. (12) 
205     196 or 197 or 198 or 199 or 200 or 201 or 202 or 203 or 204 (111958) 
206     158 and 195 and 205 (59) 
207     158 and 195 (270) 
 
CINAHL 
 
Searched 13/10/14 CINHAL via HDAS. 
 
Search history: 
1. CINAHL; exp ANALGESICS, OPIOID/; 13832 results 
2. CINAHL; exp NARCOTICS/; 16813 results 
3. CINAHL; narcotics.ti,ab; 647 results 
4. CINAHL; opiate.ti,ab; 1195 results 
5. CINAHL; opioid.ti,ab; 5881 results 
6. CINAHL; acemethadone.ti,ab; 0 results 
7. CINAHL; acetylmethadol.ti,ab; 10 results 
8. CINAHL; exp ALFENTANIL/; 200 results 
9. CINAHL; alfenta.ti,ab; 1 results 
10. CINAHL; alfentanil.ti,ab; 161 results 
11. CINAHL; amidone.ti,ab; 0 results 
12. CINAHL; anileridine.ti,ab; 1 results 
13. CINAHL; ardinex.ti,ab; 0 results 
14. CINAHL; benzomorphan.ti,ab; 1 results 
15. CINAHL; buprenorphine.ti,ab; 903 results 
16. CINAHL; exp BUPRENORPHINE/; 1072 results 
17. CINAHL; buprenex.ti,ab; 1 results 
18. CINAHL; exp BUTORPHANOL/; 44 results 
19. CINAHL; butorphanol.ti,ab; 38 results 
20. CINAHL; carfentanil.ti,ab; 2 results 
21. CINAHL; exp CODEINE/; 1096 results 
22. CINAHL; codeine.ti,ab; 346 results 
23. CINAHL; (codeine AND phosphate).ti,ab; 25 results 
24. CINAHL; codinovo.ti,ab; 0 results 
25. CINAHL; delsym.ti,ab; 0 results 
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26. CINAHL; demerol.ti,ab; 23 results 
27. CINAHL; dextromoramide.ti,ab; 1 results 
28. CINAHL; dezocine.ti,ab; 2 results 
29. CINAHL; (diacetyl AND morphine).ti,ab; 0 results 
30. CINAHL; diamorphine.ti,ab; 126 results 
31. CINAHL; dicodid.ti,ab; 0 results 
32. CINAHL; dihydrocodeinone.ti,ab; 1 results 
33. CINAHL; dihydrocodeine.ti,ab; 21 results 
34. CINAHL; dihydroetorphine.ti,ab; 0 results 
35. CINAHL; dihydrohyroxycodeinone.ti,ab; 0 results 
36. CINAHL; dihydromorphine.ti,ab; 0 results 
37. CINAHL; dihydrone.ti,ab; 0 results 
38. CINAHL; dihydrone.ti,ab; 0 results 
39. CINAHL; dilaudid.ti,ab; 15 results 
40. CINAHL; dimepheptanol.ti,ab; 0 results 
41. CINAHL; dinarkon.ti,ab; 0 results 
42. CINAHL; dionine.ti,ab; 0 results 
43. CINAHL; diprenorphine.ti,ab; 6 results 
44. CINAHL; dolantin.ti,ab; 1 results 
45. CINAHL; dolargan.ti,ab; 0 results 
46. CINAHL; dolcontral.ti,ab; 0 results 
47. CINAHL; dolophine.ti,ab; 4 results 
48. CINAHL; dolosal.ti,ab; 0 results 
49. CINAHL; dolsin.ti,ab; 0 results 
50. CINAHL; duragesic.ti,ab; 16 results 
51. CINAHL; duramoprh.ti,ab; 0 results 
52. CINAHL; dyhydromorphinone.ti,ab; 0 results 
53. CINAHL; dynorphin.ti,ab; 28 results 
54. CINAHL; endomorphin.ti,ab; 6 results 
55. CINAHL; eseroline.ti,ab; 0 results 
56. CINAHL; ethylketazocine.ti,ab; 0 results 
57. CINAHL; eucodal.ti,ab; 0 results 
58. CINAHL; fenoperidine.ti,ab; 0 results 
59. CINAHL; exp FENTANYL/; 2008 results 
60. CINAHL; fentanyl.ti,ab; 1443 results 
61. CINAHL; fioricet.ti,ab; 2 results 
62. CINAHL; fortral.ti,ab; 0 results 
63. CINAHL; hycodan.ti,ab; 0 results 
64. CINAHL; hycon.ti,ab; 0 results 
65. CINAHL; hydrocodone.ti,ab; 165 results 
66. CINAHL; hydrocodon*.ti,ab; 165 results 
67. CINAHL; hydrocon.ti,ab; 0 results 
68. CINAHL; hydromorphone.ti,ab; 225 results 
69. CINAHL; hydroxycodeinon.ti,ab; 0 results 
70. CINAHL; isocodeine.ti,ab; 0 results 
71. CINAHL; isonipecain.ti,ab; 0 results 
72. CINAHL; isopromedol.ti,ab; 0 results 
73. CINAHL; kaolin-pectin.ti,ab; 1 results 
74. CINAHL; ketobemidone.ti,ab; 7 results 
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75. CINAHL; laudacon.ti,ab; 0 results 
76. CINAHL; lealgin.ti,ab; 0 results 
77. CINAHL; levallorphan.ti,ab; 0 results 
78. CINAHL; levamethadyl.ti,ab; 0 results 
79. CINAHL; levodroman.ti,ab; 0 results 
80. CINAHL; levomethadryl.ti,ab; 0 results 
81. CINAHL; levorphanol.ti,ab; 16 results 
82. CINAHL; lexir.ti,ab; 0 results 
83. CINAHL; lidol.ti,ab; 0 results 
84. CINAHL; lorfan.ti,ab; 0 results 
85. CINAHL; lofentain.ti,ab; 0 results 
86. CINAHL; lydol.ti,ab; 0 results 
87. CINAHL; exp MEPERIDINE/; 477 results 
88. CINAHL; meperidine.ti,ab; 266 results 
89. CINAHL; meptazinol.ti,ab; 11 results 
90. CINAHL; methadol.ti,ab; 5 results 
91. CINAHL; exp METHADONE/; 2256 results 
92. CINAHL; methadone.ti,ab; 2075 results 
93. CINAHL; (methadyl AND acetate).ti,ab; 0 results 
94. CINAHL; moradol.ti,ab; 0 results 
95. CINAHL; morphia.ti,ab; 2 results 
96. CINAHL; exp MORPHINE/; 6888 results 
97. CINAHL; morphine.ti,ab; 2726 results 
98. CINAHL; (morphine AND derivative).ti,ab; 9 results 
99. CINAHL; (morphine AND sulfate).ti,ab; 164 results 
100. CINAHL; (morphine AND sulphate).ti,ab; 39 results 
101. CINAHL; (MS AND Contin).ti,ab; 16 results 
102. CINAHL; methynaloxone.ti,ab; 0 results 
103. CINAHL; exp NALBUPHINE/; 58 results 
104. CINAHL; nalbuphine.ti,ab; 64 results 
105. CINAHL; naloxiphan.ti,ab; 0 results 
106. CINAHL; nocistatin.ti,ab; 3 results 
107. CINAHL; nubain.ti,ab; 1 results 
108. CINAHL; numorphan.ti,ab; 0 results 
109. CINAHL; omnopon.ti,ab; 1 results 
110. CINAHL; operidine.ti,ab; 0 results 
111. CINAHL; opium.ti,ab; 152 results 
112. CINAHL; exp OPIUM/; 7047 results 
113. CINAHL; oramorph.ti,ab; 6 results 
114. CINAHL; oxycodeine.ti,ab; 0 results 
115. CINAHL; exp OXYCODONE/; 679 results 
116. CINAHL; oxycodone.ti,ab; 466 results 
117. CINAHL; oxycone.ti,ab; 0 results 
118. CINAHL; oxyconum.ti,ab; 0 results 
119. CINAHL; oxycontin.ti,ab; 121 results 
120. CINAHL; oxymorphone.ti,ab; 54 results 
121. CINAHL; pancodiene.ti,ab; 0 results 
122. CINAHL; pantopon.ti,ab; 0 results 
123. CINAHL; papaveretum.ti,ab; 17 results 
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124. CINAHL; paracymethadol.ti,ab; 0 results 
125. CINAHL; paramorfan.ti,ab; 0 results 
126. CINAHL; paramorphan.ti,ab; 0 results 
127. CINAHL; paregoric.ti,ab; 7 results 
128. CINAHL; exp PENTAZOCINE/; 28 results 
129. CINAHL; pentazocine.ti,ab; 43 results 
130. CINAHL; percocet.ti,ab; 16 results 
131. CINAHL; pethidine.ti,ab; 142 results 
132. CINAHL; phenadone.ti,ab; 0 results 
133. CINAHL; phenazocine.ti,ab; 0 results 
134. CINAHL; phenbenzorphan.ti,ab; 0 results 
135. CINAHL; phenethylazocine.ti,ab; 0 results 
136. CINAHL; phenoperidine.ti,ab; 4 results 
137. CINAHL; physeptone.ti,ab; 1 results 
138. CINAHL; promedol.ti,ab; 0 results 
139. CINAHL; exp PROPOXYPHENE/; 98 results 
140. CINAHL; propoxyphene.ti,ab; 68 results 
141. CINAHL; protopine.ti,ab; 8 results 
142. CINAHL; pyrrolamidol.ti,ab; 0 results 
143. CINAHL; rapifen.ti,ab; 0 results 
144. CINAHL; remifentanil.ti,ab; 354 results 
145. CINAHL; revivon.ti,ab; 0 results 
146. CINAHL; robidone.ti,ab; 0 results 
147. CINAHL; stadol.ti,ab; 14 results 
148. CINAHL; exp SUFENTANIL/; 165 results 
149. CINAHL; sufentanil.ti,ab; 169 results 
150. CINAHL; sufentanyl.ti,ab; 5 results 
151. CINAHL; talwin.ti,ab; 5 results 
152. CINAHL; tamgesic.ti,ab; 0 results 
153. CINAHL; thebaine.ti,ab; 3 results 
154. CINAHL; theocodin.ti,ab; 0 results 
155. CINAHL; tilidine.ti,ab; 5 results 
156. CINAHL; exp TRAMADOL/; 424 results 
157. CINAHL; tramadol.ti,ab; 418 results 
158. CINAHL; trimeperidine.ti,ab; 0 results 
159. CINAHL; valoron.ti,ab; 0 results 
160. CINAHL; valerone.ti,ab; 0 results 
161. CINAHL; vicodin.ti,ab; 15 results 
162. CINAHL; 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 
OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 
OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 
OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 
OR 49 OR 50 OR 51 OR 52 OR 53 OR 54 OR 55 OR 56 OR 57 OR 58 OR 59 OR 60 
OR 61 OR 62 OR 63 OR 64 OR 65 OR 66 OR 67 OR 68 OR 69 OR 70 OR 71 OR 72 
OR 73 OR 74 OR 75 OR 76 OR 77 OR 78 OR 79 OR 80 OR 81 OR 82 OR 83 OR 84 
OR 85 OR 86 OR 87 OR 88 OR 89 OR 90 OR 91 OR 92 OR 93 OR 94 OR 95 OR 96 
OR 97 OR 98 OR 99 OR 100 OR 101 OR 102 OR 103 OR 104 OR 105 OR 106 OR 
107 OR 108 OR 109 OR 110 OR 111 OR 112 OR 113 OR 114 OR 115 OR 116 OR 
117 OR 118 OR 119 OR 120 OR 121 OR 122 OR 123 OR 124 OR 125 OR 126 OR 
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127 OR 128 OR 129 OR 130 OR 131 OR 132 OR 133 OR 134 OR 135 OR 136 OR 
137 OR 138 OR 139 OR 140 OR 141 OR 142 OR 143 OR 144 OR 145 OR 146 OR 
147 OR 148 OR 149 OR 150 OR 151 OR 152 OR 153 OR 154 OR 155 OR 156 OR 
157 OR 158 OR 159 OR 160 OR 161; 24482 results 
163. CINAHL; exp HYPOGONADISM/; 525 results 
164. CINAHL; hypogonadism.ti,ab; 342 results 
165. CINAHL; endocrin*.ti,ab; 4183 results 
166. CINAHL; exp MENSTRUATION DISORDERS/; 3493 results 
167. CINAHL; (menstruation AND disorder).ti,ab; 41 results 
168. CINAHL; amenorrhoea.ti,ab; 118 results 
169. CINAHL; oligomenorrhoea.ti,ab; 10 results 
170. CINAHL; exp MENORRHAGIA/; 551 results 
171. CINAHL; menorrhagia.ti,ab; 265 results 
172. CINAHL; exp METRORRHAGIA/; 143 results 
173. CINAHL; metrorrhagia.ti,ab; 22 results 
174. CINAHL; (dysfunctional AND uterine AND bleeding).ti,ab; 84 results 
175. CINAHL; DUB.ti,ab; 22 results 
176. CINAHL; exp POLYCYSTIC OVARY SYNDROME/; 1020 results 
177. CINAHL; (polycystic AND ovary AND syndrome).ti,ab; 623 results 
178. CINAHL; PCOS.ti,ab; 396 results 
179. CINAHL; PCOD.ti,ab; 9 results 
180. CINAHL; (female AND infertility).ti,ab; 238 results 
181. CINAHL; exp ANOVULATION/; 136 results 
182. CINAHL; anovulation.ti,ab; 106 results 
183. CINAHL; libido.ti,ab; 323 results 
184. CINAHL; exp SEXUAL DYSFUNCTION, FEMALE/; 1787 results 
185. CINAHL; (sexual AND dysfunction).ti,ab; 1509 results 
186. CINAHL; (infertility AND therapy).ti,ab; 157 results 
187. CINAHL; (heavy AND menstrual AND bleed).ti,ab; 1 results 
188. CINAHL; (ovarian AND insufficiency).ti,ab; 41 results 
189. CINAHL; (premature AND ovarian AND failure).ti,ab; 122 results 
190. CINAHL; exp MENOPAUSE/; 9676 results 
191. CINAHL; menopause.ti,ab; 3818 results 
192. CINAHL; exp MENOPAUSE, PREMATURE/; 168 results 
193. CINAHL; (premature AND menopause).ti,ab; 110 results 
194. CINAHL; exp CLIMACTERIC/; 10741 results 
195. CINAHL; climacteric.ti,ab; 260 results 
196. CINAHL; exp PERIMENOPAUSE/; 181 results 
197. CINAHL; perimenopause.ti,ab; 253 results 
198. CINAHL; (opioid AND induced AND androgen AND deficiency).ti,ab; 6 results 
199. CINAHL; (opioid AND induced AND endocrinopathy).ti,ab; 2 results 
200. CINAHL; 163 OR 164 OR 165 OR 166 OR 167 OR 168 OR 169 OR 170 OR 
171 OR 172 OR 173 OR 174 OR 175 OR 176 OR 177 OR 178 OR 179 OR 180 OR 
181 OR 182 OR 183 OR 184 OR 185 OR 186 OR 187 OR 188 OR 189 OR 190 OR 
191 OR 192 OR 193 OR 194 OR 195 OR 196 OR 197 OR 198 OR 199; 23697 
results 
201. CINAHL; 162 AND 200; 110 results 
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AMED 
Database: AMED (Allied and Complementary Medicine) <1985 to October 2014> 
Searched 13/10/14 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp analgesics opioid/ (230) 
2     exp Narcotics/ (176) 
3     opioids.mp. (570) 
4     opiate.mp. (79) 
5     alfentanil.mp. (13) 
6     Buprenorphine/ (14) 
7     buprenorphine.mp. (39) 
8     butorphanol.mp. (1) 
9     Codeine/ (9) 
10     codeine.mp. (52) 
11     codeine phosphate.mp. (7) 
12     diamorphine.mp. (18) 
13     dihydrocodeine.mp. (5) 
14     dilaudid.mp. (1) 
15     dolantin.mp. (2) 
16     duragesic.mp. (3) 
17     Dihydromorphinone/ (6) 
18     dihydromorphinone.mp. (10) 
19     dynorphin.mp. (5) 
20     endomorphin.mp. (1) 
21     Fentanyl/ (41) 
22     fentanyl.mp. (147) 
23     hydrocodone.mp. (15) 
24     hydromorphone.mp. (47) 
25     ketobemidone.mp. (1) 
26     levorphanol.mp. (4) 
27     meperidine.mp. (18) 
28     Methadone/ (52) 
29     methadone.mp. (116) 
30     morphia.mp. (0) 
31     morphine/ (249) 
32     morphine.mp. (617) 
33     morphine derivative.mp. (0) 
34     morphine sulfate.mp. (17) 
35     morphine sulphate.mp. (14) 
36     MS contin.mp. (4) 
37     nalbuphine.mp. (5) 
38     Opium/ (42) 
39     opium.mp. (76) 
40     oramorph.mp. (2) 
41     oxycodone.mp. (51) 
42     oxycontin.mp. (6) 
43     oxymorphone.mp. (5) 
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44     paregoric.mp. (1) 
45     pentazocine.mp. (8) 
46     percocet.mp. (1) 
47     pethidine.mp. (7) 
48     propoxyphene.mp. (6) 
49     protopine.mp. (14) 
50     remifentanil.mp. (4) 
51     thebaine.mp. (4) 
52     tilidine.mp. (2) 
53     tramadol.mp. (50) 
54     1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 
31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 
or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 (1576) 
55     ovarian insufficiency.mp. (1) 
56     premature ovarian failure.mp. (6) 
57     hypogonadism.mp. (18) 
58     gonadal disorders/ (14) 
59     endocrin*.mp. (511) 
60     endocrin*.mp. (511) 
61     exp menstruation disorders/ (423) 
62     Amenorrhea/ (34) 
63     amenorrhoea.mp. (22) 
64     menorrhagia.mp. (19) 
65     metrorrhagia.mp. (10) 
66     dysfunctional uterine bleeding.mp. (11) 
67     Ovary polycystic disease.mp. (0) 
68     polycystic ovary syndrome/ (9) 
69     polycystic ovary syndrome.mp. (41) 
70     PCOS.mp. (27) 
71     PCOD.mp. (14) 
72     exp infertility female/ (166) 
73     female infertility.mp. (19) 
74     anovulation.mp. (10) 
75     libido.mp. (39) 
76     exp sexual dysfunctions/ (193) 
77     sexual dysfunction.mp. (106) 
78     infertility therapy.mp. (0) 
79     exp Menopause/ (520) 
80     menopause.mp. (582) 
81     early menopause.mp. (3) 
82     exp climacteric/ (540) 
83     climacteric.mp. (52) 
84     perimenopause.mp. (11) 
85     opioid induced endocrinopathy.mp. (1) 
86     opioid induced androgen deficiency.mp. [mp=abstract, heading words, title] (0) 
87     55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 
or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 
83 or 84 or 85 or 86 (2098) 
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88     54 and 87 (10) 
 
Web of Science 
 
Web of Science 20/10/2014 
 
TOPIC: (“opioid analgesic” or “narcotic analgesic agent” or opiate or opioid or 
narcotic*) AND TOPIC: ((safe or safety or side effect* or undesireable effect” or 
treatment emergent or tolerability or toxicity or adrs) or (ae or co or de) or (adverse 
adj2 (effect or effects or reaction or reactions or event or events or outcome or 
outcomes))) AND TOPIC: (Hypogonadism or endocrine* or “Menstruation 
Disturbances” or Amenorrhea or Oligomenorrhea or Menorrhagia or Metrorrhagia or 
“dysfunction uterine bleeding” or “DUB” or “heavy menstrual bleed*” of “Polycystic 
Ovary Syndrome” or PCOS or PCOD or “Infertility, Female” or “Primary Ovarian 
Insufficiency” or “ovarian insufficiency” of Anovulation or “Reproductive Techniques, 
Assisted” of Libido or “Sexual Dysfunction” or Menopause or “Menopause, 
Premature” or Climacteric or Perimenopause of “opioid induced endocrinopathy or 
“opioid induced androgen deficiency”) 
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Appendix 4: Systematic review sensitivity analysis 
 Opioid  Menstrual disturbance Libido Hormone 
Age ≤ 45 
Finch et 
al., 2000 
[17]  
Intrathecal 71% amenorrhoea 100% 
opioid 
users 
affected 
Low LH 
Njee et 
al., 2004 
[28]  
Intrathecal 31% amenorrhoea N/A N/A 
Kim et al., 
2004 [28] 
(1 patient) 
Intrathecal N/A N/A Low DHEA termed 
androgen deficient 
by author 
Mussig et 
al., 2007 
[27]  
Oral Amenorrhoea with 
hydromorphone which 
resolved with 
conversion to tramadol 
(1/1) 
N/A Oestrodiol low, LH 
and FSH normal  
Fraser et 
al., 2009 
[18]  
Oral Oliogo/amenorrhoea 
23% (3/13) 
N/A Hormones within 
normal range (LH, 
FSH, SHBG, 
oestrodiol, 
progesterone) 
Reddy et 
al., 2010 
[32]  
Oral Amenorrhoea (1/1) N/A Low LH and 
oestrodiol 
Summary  Oligo/amenorrhoea in 
23-71% with 2 case 
studies with 
amenorrhoea 
100% low 
libido in 
one study 
Low hormone 
levels in 4/5 and 
normal in 1/5 
Age < 55 
Kim et al., 
2004 [28] 
(1 patient) 
Intrathecal N/A N/A Low DHEA termed 
androgen deficient 
by author 
Daniell, 
2008 [16]  
Oral 52% opioid users non-
surgical amenorrhoea, 
20% controls p <0.05 
N/A Statistically 
significantly lower 
TT, fT, oestrodiol 
and DHEAS in 
cases compared to 
controls 
Rhodin et 
al., 2010 
[33]  
Oral 81% (13/16) cases and 
0% (0/6) controls  
N/A Statistically 
significantly lower 
oestrodiol, FSH, 
LH, post GnRH 
stimulation LH and 
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FSH in cases 
compared to 
controls 
Summary  52-81% amenorrhoea  2 studies with 
statistically 
significantly lower 
hormone levels in 
cases compared to 
controls 
Premenopausal 
Abs et al., 
2000 [1]  
Intrathecal 67% (14/21) 
amenorrhoeic 
7/21 irregular 
menstruation 
Controls – normal 
menstrual cycle (3/3) 
N/A Low LH (42.9% 
(9/21) of opioid 
users and 0% 
controls) and FSH 
(23.8% (5/21) of 
opioid users and 
0% of controls). 
Non-significant 
difference 
Roberts et 
al., 2001 
[34]  
Intrathecal 47% amenorrhoea Low libido 
71% 
affected 
N/A 
Wong et 
al., 2011 
[44]  
Oral N/A 61% of 
opioid 
users and 
70% of 
controls p 
= 0.62 
Statistically 
significantly lower 
TT in cases 
compared to 
controls in those 
with low libido 
Aurilio et 
al., 2011 
[3]  
Transdermal 0% (0/8) amenorrhoea N/A No statistically 
significant change 
in hormone levels 
(LH, FSH, TT, fT) 
Summary  Oral/Intrathecal 47-
67% amenorrhoea 
Transdermal 
buprenorphine 0% 
61-71% 
low libido 
One statistically 
significant study, 
one showing lower 
levels in cases 
compared to 
controls.  
Transdermal 
buprenorphine no 
change in 
hormones. 
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Appendix 5: Screenshot of systematic review publication 
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Appendix 6: CPRD study Read Code List for Outcomes and 
Confounders 
Outcomes 
Menstrual Cycle 
 
Readterm Read Code Med Code ICD-10 
Secondary amenorrhoea                                                                                                        K5901 2086 N91.1
Amenorrhoea NOS                                                                                                                                                     K590z 33769 N91.2
Scanty or infrequent menstruation                                                                                              K591. 18527 N91.5
Hypomenorrhoea   K5910 15438 N91.5 
Oligomenorrhoea       K5911 1153 N91.5 
Secondary oligomenorrhoea                                                                                                    K5913 12100 N91.4 
Scanty or infrequent menstruation NOS                                                                                        K591z 25358 N91.5
Irregular menstrual cycle                                                                                                                                       K594. 1065 N92.6 
Irregular menstrual cycle NOS                                             K594z 25355 N92.6 
Other menstruation disorder NOS                                                                                              K59yz 29803 N92.6
Menstruation disorder NOS                                                                                                    K59z. 27829 N92.6
Amenorrhoea K590.11 757 N91.2 
Infrequent Menstruation K591.11 21729 N91.5 
Other menstruation disorders K59y.00 15000 N92.5 
Absence of menstruation                                                                                                      K590. 9632 N91.2
 
Libido 
 
Readterm Read Code Med Code ICD-10 
Psychosexual dysfunction E227.00 15649 no code 
Lack of libido                                                                                                               E227.11 6362 no code
Unspecified psychosexual dysfunction E227000 23534 no code 
Inhibited sexual desire                                                                                                      E2271 2259 no code
Psychsexual dysfunction NOS E227z00 20133 no code 
[X] Lack of libido                                                                                                           Eu52013 21122 F52.0
[X] Lack of or loss of sexual desire Eu52000 28283 F52.0 
[V]Problem with sexual function                                                                                              ZV417 16060 F52.9
 
 
Infertility 
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Readterm Read Code Med Code ICD-10 
Infertility - female                                                                                                                       K5B.. 1808 N97.9 
Female infertility of anovulatory origin                                                                                     K5B0. 4977 N97.0
Primary anovulatory infertility                                                                                              K5B00 52132 N97.0 
Secondary anovulatory infertility                                                                                                                                  K5B01 50116 N97.0
Female infertility of anovulatory origin 
NOS                                                                                                                                                          
K5B0z 63421 N97.0 
Female infertility of pituitary - 
hypothalamic origin                                                                                                          
  K5B1. 69884 E23.0 
Primary pituitary - hypothalamic 
infertility                                                                                                                     
K5B10 94448 E23.0 
Secondary pituitary - hypothalamic 
infertility                                                                                                                                                        
K5B11 99535 E23.0 
Female infertility of pituitary - 
hypothalamic cause NOS                                                        
K5B1z 62084 E23.0 
Other female infertility                                                                                                     K5By. 36458 N97.8
Primary infertility unspecified                                                                                                                                    K5By0 2014 N97.9
Secondary infertility unspecified                                            K5By1 1943 N97.9 
Other female infertility NOS                                                                                                 K5Byz 53018 N97.9
Female infertility NOS                                                                                                                                             K5Bz. 30392 N97.9
Introduction of gamete into uterine 
cavity                                                                                                                                                            
7E0A. 45538 no code 
Implantation of fertilised egg into 
uterus                                                                      
7E0A0 6024 no code 
Intracervical artificial insemination                                                                                        7E0A1 11305 no code
Intrauterine artificial insemination                                                                                                                             7E0A2 11428 no code 
Intrauterine insemination with 
superovulation using partner sperm                                                                                                                                    
7E0A3 91652 no code 
Intrauterine insemination with 
superovulation using donor sperm                                                                                             
7E0A4 88271 no code 
Intrauterine insemination without 
superovulation using donor sperm                                                                                             
7E0A6 89588 no code 
Transfer of embryo to uterus                                                                                                                                     7E0A7 57381 no code 
Intrauterine insemination without 
superovulation using partner sperm                                                                                                                                 
7E0A5 no code no code 
Other specified introduction of gamete 
into uterine cavity                                                                                                          
7E0Ay no code no code 
Introduction of gamete into uterine 
cavity NOS                                                                                                                   
7E0Az 50360 no code 
[V]Infertility management                                             ZV26. 9938 Z31 
[V]Artificial insemination NOS                                                                                               ZV261 33401 Z31.1 
[V]Infertility investigation and testing                                                                                      ZV262 26088 Z31.4
[V]Infertility general advice and 
counselling                                                                                                                     ZV264 
39295 
Z31.6 
[V]Artificial insemination from husband                                                                                      ZV265 30597 Z31.1
[V]In vitro fertilization                                                                                                                                          ZV267 30046 Z31.2
[V]Other assisted fertilization methods                                     ZV268 8981 Z31.3 
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[V]Other specified infertility 
management                                                                                                                   ZV26y
26150 
Z31.8 
[V]Unspecified infertility management                                                                                                                              ZV26z 69751 Z31.9
Artificial insemination                                                   8C81 28455 no code 
Treatment for infertility                                                                                                    8C8.. 1810 no code
Female infertility therapy                                                                                                   8C82. 33458 no code
IVF 8C84.11 10238 no code 
Treatment for infertility NOS                                                                                                          8C8Z. 9983 no code 
In-vitro fertilisation 8C8Z.11 1938 no code 
In vitro fertilisation (IVF)                                                                                                 7M0h. 52626 no code
IVF with donor sperm                                                                                                                                             7M0h0 89966 no code
In vitro fertilisation with donor sperm 7M0h011 91910 no code 
IVF with donor eggs                                                                                                          7M0h1 64063 no code
In vitro fertilisation with done eggs 7M0h111 94632 no code 
IVF with intracytoplasmic sperm 
injection (ICSI)                                                                                                             
7M0h2 57000 no code 
In vitro fertilisation with 
intracytoplasmic sperm injection (ICSI)    
7M0h211 86010 no code 
IVF with intracytoplasmic sperm 
injection (ICSI) and donor egg                                                                                               
7M0h3 97981 no code 
In vitro fertilisation with 
intracytoplasmic sperm injection (ICSI) 
and donor egg        
7M0h311 97044 no code 
IVF with surrogacy                                                                   7M0h5 89716 no code 
In vitro fertilisation with surrogacy 7M0h511 91845 no code 
Other specified in vitro fertilisation 
(IVF)                                                                                                                        
7M0hy 93810 no code 
In vitro fertilisation (IVF) NOS 7M0hz00 90936 no code 
 
Menopause 
 
Readterm Read Code Med Code ICD-10 
Menopause   1512 4383 no code 
Postmenopausal state                                                                                                         151K. 30590 no code 
Ovarian dysfunction                                                                                                          C16.. 6352 E28.9
Primary ovarian failure                                                                                                                                             C1630 31030 E28.3 
Ovarian dysfunction NOS                                                      C16z. 44854 E28.9 
Other ovarian dysfunction C16y.00 58028 E28.8 
Other ovarian failure    C163.00 3686 E28.8 
Ovarian hypogonadism                                                                                                         C163.11 23802 E28.8 
Secondary ovarian failure                                                                                                                                        C1631 15992 E28.3
Premature Menopause NOS C163111 2087 E28.3 
Ovarian hypogonadism                                                                                                         C1633 22836 E28.3 
Early menopause                                                                                                              C1634 94499 E28.8 
Other specified other ovarian failure                                                                                                                              C163y 40672 E28.8 
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Other ovarian failure NOS                                                   C163z 15075 E28.8 
[X]Other ovarian dysfunction                                                                                      Cyu4B 100934 E28.8
Menopausal and postmenopausal 
disorders                                                                                                                    K5A.. 9171 N95
Postmenopausal disorders K5A..11 17628 N95 
Premenopausal menorrhagia                                                                                                    K5A0. 15022 N92.4 
Climacteric menorrhagia K5A0.11 20795 N92.4 
Postmenopausal Bleeding K5A1.00 1583 N95.0 
Menopausal or female climacteric state                                                                                       K5A2. 4043 N95.1 
Menopausal flushing                                                                                                          K5A20 9547 N95.1
Hot Flushes - Menopausal K5A2011 814 N95.1 
Menopausal sleeplessness                                                                                                     K5A21 15283 N95.1 
Menopausal headache                                                                                                                  K5A22 18730 N95.1 
Menopausal concentration lack                 K5A23 25549 N95.1 
Menopausal symptoms NOS                                                                                                      K5A2z 828 N95.1
Postmenopausal atrophic vaginitis K5A3.00 707 N95.2 
Senile (atrophic) vaginitis K5A3.11 1944 N95.2 
Atrophy of vagina K5A3000 16960 N95.2 
Perimenopausal atrophic vaginitis                                                                                            K5A5. 30359 N95.2
Perimenopausal menorrhagia                                                                                                                                         K5A6. 93526 N92.4 
Other menopausal and 
postmenopausal states                               K5Ay. 28046 N95.8 
Menopausal and postmenopausal 
disorder NOS                                                                                                                 K5Az. 45409 N95.9
Confounders 
Thyroid 
 
Readterm Read Code Med Code ICD-10 
Disorders of thyroid gland                                                                                                   C0... 1882 E00-E07
Simple and unspecified goitre                                                                                                C00.. 20311 E04.9 
Simple goitre                                                                                                                C000. 2518 E04.0 
Goitre NOS                                                                                                                   C00z. 7911 E04.9
Nontoxic nodular goitre                                                                                                      C01.. 1348 E041-E049
Nontoxic uninodular goitre                                                                                                                                      C010. 26700 E04.1
Nontoxic multinodular goitre                                             C011. 11743 E04.2 
Nontoxic nodular goitre NOS                                                                                    C01z. 34491 E04.9
Thyroiditis     C05.. 1346 E060-E069 
Acute thyroiditis                                                                                                            C050. 4898 E06.0
Acute nonsuppurative thyroiditis                                                                                                                                    C0500 67972 E06.0 
Acute suppurative thyroiditis                                                C0501 70773 E06.0 
Acute thyroiditis NOS                                                                                                        C050z 42323 E06.0 
Chronic lymphocytic thyroiditis                                                                                              C052. 26833 E06.3
Chronic fibrous thyroiditis                                                                                                                                        C053. 70244 E06.5
Iatrogenic thyroiditis                                                                                                       C054. 61026 E06.4 
Other and unspecified chronic C05y. 65444 E06.9 
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thyroiditis                                                                                                                          
Retrosternal thyroid goitre C000.11 3655 E04.0 
Thyroid enlargement C00z.11 1881 E04.9 
Substernal thyroid goitre C000.12 60288 E04.0 
Thyroiditis NOS                                                                                                              C05z. 20909 E06.9 
Other disorders of thyroid                                                                                                                                         C06.. 43871 E070-E079 
Thyroid-binding globulin abnormality                                    C06y0 41014 E07.8 
Thyroid disorder NOS                                                                                                         C06z. 35957 E07.9
[X]Disorders of thyroid gland                                                                                                Cyu1. 65175 E00-E07
Iodine-deficiency-related diffuse 
(endemic) goitre                                                                                                               
C0A3. 37518 E01.0 
[X]Other specified nontoxic goitre                                        Cyu12 72610 E04.8 
[X]Other specified disorders of thyroid                                                                         Cyu15 73096 E07.8 
[X]Iodine-deficiency-related (endemic) 
goitre, unspecified                                                                                                          
Cyu16 101555 E01.2 
Iodine-deficiency-related multinodular 
(endemic) goitre                                                                                                             
C0A4.00 44459 E01.1 
De Quervain's thyroiditis C051.11 21747 E06.1 
Subacute thyroiditis                                                                                                         C051. 30799 E06.1
Chronic thyroiditis with transient 
thyrotoxicosis                                                                                                                  
C05y4 65907 E06.2 
[X]Other chronic thyroiditis                                                                                                 Cyu14 95335 E06.5 
Autoimmune thyroiditis C052.11 3857 E06.3 
Hashimoto disease C052.12 3436 E06.3 
Other specified thyroid disorder NOS C06yz00 27996 E07.8 
Iodine-deficiency-related diffuse 
(endemic) goitre NOS 
C0AX.00 54511 E01.2 
[X]Other iodine-deficiency related 
thyroid disorders and allied conditions                                                                                      
Cyu10 26833 E01.8 
 
 
Hypothyroid 
 
Readterm Read Code Med Code ICD-10 
Congenital hypothyroidism NOS                                                                                                C03z.00 51481 E03.1 
Acquired hypothyroidism                                                                                                      C04.. 3290 E03.9
Postsurgical hypothyroidism                                                                                                                                         C040. 28852 E89.0
Other postablative hypothyroidism                                                                                            C041. 50275 E89.0
Irradiation hypothyroidism                                                                                                                                         C0410 11322 E89.0 
Postablative hypothyroidism NOS                                             C041z 51706 E89.0 
Iodine hypothyroidism                                                                                                        C042. 34221 E01.8 
Other iatrogenic hypothyroidism                                                                                                                                    C043. 25913 E03.2
Hypothyroidism resulting from para-
aminosalicylic acid                                                                                                                                                
C0430 15743 E03.2 
Hypothyroidism resulting from C0431 97090 E03.2 
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phenylbutazone                                                                      
Hypothyroidism resulting from 
resorcinol                                                                                                                   
C0432 94915 E03.2 
Iatrogenic hypothyroidism NOS                                                                                                                                      C043z 38976 E03.2
Postinfectious hypothyroidism                                               C044. 50860 E03.3 
Acquired atrophy of thyroid                                                                                                  C045. 46345 E03.4 
Autoimmune myxoedema                                                                                                         C046. 31971 E03.8
Other acquired hypothyroidism                                                                                                                                      C04y. 24748 E03.8 
Hypothyroidism NOS                                                          C04z. 3941 E03.9 
Myxoedema coma                                                                                                               C04z1 59702 E03.5
Myxoedema coma                                                                                                                                                     C04..11 1619 E03.9
thyroid deficiency C04..12 14704 E03.9 
hypothyroidism C04..13 273 E03.9 
Post ablative hypothyroidism C040.11 47521 E89.0 
Subclinical hypothyroidism C047.00 95830 no code 
Pretibial myxoedema hypothyroid C04z.11 20310 E03.9 
thyroid insufficiency C04z.12 23014 E03.9 
hypothyroid goitre acquired C04z.13 18282 E03.9 
TSH - thyroid-stimulating hormone 
deficiency                                                                                                                   
C1343 11146 E23.0 
[X]Other specified hypothyroidism                                                                                                                                  Cyu11 73107 E03.8
Subclinical iodine-deficiency-related 
hypothyroidism 
C0A5.00 718 E02.X 
 
Hyperthyroid 
 
Readterm Read Code Med Code ICD-10 
Thyrotoxicosis C02.. 677 E05 
Toxic diffuse goitre                                                                                                         C020. 23315 E05.0 
Toxic diffuse goitre with no crisis                                                                                          C0200 26702 E05.0
Toxic diffuse goitre with crisis                                                                                             C0201 57011 E05.0
Thyroid-associated dermopathy                                                                                                                                      C0202 100476 E05.0
Toxic diffuse goitre NOS                                                   C020z 49334 E05.0 
Toxic uninodular goitre                                                                                                      C021. 53280 E05.1
Toxic uninodular goite with crisis C0211 no code E05.1 
Toxic uninodular goitre with no crisis                                                                                       C0210 26869 E05.1 
Toxic uninodular goitre NOS                                                                                                  C021z 61498 E05.1 
Toxic multinodular goitre                                                                                                                                          C022. 11426 E05.2 
Toxic multinodular goitre with crisis                                       C0221 No code E05.2 
Toxic multinodular goitre with no crisis                                                                                     C0220 46985 E05.2
Toxic multinodular goitre NOS                                                                                                C022z 53981 E05.2 
Toxic nodular goitre unspecified                                                                                             C023. 15790 E05.2
Toxic nodular goitre unspecified with no 
crisis                                                                                                                       
C0230 68512 E05.2 
Toxic nodular goitre unspecified with c C0231 100004 E05.2 
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Toxic nodular goitre NOS                                                                                                                     C023z 49361 E05.2
Thyrotoxicosis from ectopic thyroid 
nodule                                                                                                                       
C024. 49508 E05.3 
Thyrotoxicosis from ectopic thyroid 
nodule with no crisis                                                                                                          
C0240 64656 E05.3 
Thyrotoxicosis from ectopic thyroid 
nodule NOS                                                                                                                                                        
C024z 56270 E05.3 
Subclinical hyperthyroidism                                                                                       C025. 106640 no code 
Thyrotoxicosis of other specified origin 
with no crisis                                                                                                               
C02y0 51273 E05.8 
Thyrotoxicosis of other specified origin 
with crisis                                                                                                                  
C02y1 106532 E05.8 
Thyrotoxicosis factitia                                                                                                                                           C02y2 64856 E05.4
Thyroid crisis                                                             C02y3 19205 E05.5 
Thyrotoxicosis of other specified origin 
NOS                                                                                                                          
C02yz 34220 E05.8 
Thyrotoxicosis without mention of goitre 
or other cause with no crisis                                                                                                
C02z0 26701 E05.9 
Thyrotoxicosis without mention of goitre 
or other cause with crisis                                                                                                                                   
C02z1 3194 E05.9 
Thyrotoxicosis NOS                                                                                                           C02zz 26699 E05.9
Thyrotoxicosis of other specified origin C02y.00 43136 E05.8 
Hyperthyroidism C02..11 1472 E05 
Toxic Goitre C02.12 10760 E05 
[X]Other thyrotoxicosis                                                                                                      Cyu13 72690 E05.8 
Graves' disease C020.12 5257 E05.0 
Thyrotoxicosis from ectopic thyroid 
nodule with crisis                                                                                                           
C0241 no code E05.3 
 
Pituitary disorders 
 
Readterm Read Code Med Code ICD-10 
Hyperprolactinaemia   C1310 6732 E22.1 
Panhypopituitarism    C132. 5026 E23.0 
Idiopathic panhypopituitarism                                                                                                C1320 48590 E23.0
Post-birth injury panhypopituitarism                                                                                              C1321 101601 E23.0 
Postinfarction panhypopituitarism                                                                                                                                 C1322 70695 E23.0 
Postinfective panhypopituitarism                                           C1323 44873 E23.0 
Other specified panhypopituitarism                                                                                           C132y 67154 E23.0
Panhypopituitarism NOS                                                                                                       C132z 33653 E23.0
Isolated ACTH deficiency                                                                                                                                           C1344 41193 E23.0
Iatrogenic pituitary disorders                                              C137. 56983 E23.1 
Post-hypophysectomy hypopituitarism                                                                                               C1371 44881 E89.3
Post-radiotherapy hypopituitarism                                                                                                                                  C1372 44247 E89.3
Iatrogenic pituitary disorder NOS                                           C137z 34459 E89.3 
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Empty sella syndrome                                                                                              C138. 10071 R93.0 
Pituitary apoplexy                                                                                                           C13A. 105321 no code
Pituitary disorders NOS                                                                                                                                         C13z. 12449 E23.7
Hypopituitarism NOS C132.11 8552 E23.0 
Hypoprolactinaemia C134011 16004 E23.0 
ACTH deficiency C134411 11147 E23.0 
Other anterior pituitary disorder NOS C134z00 15488 E23.0 
Anterior pituitary hormone deficiency 
NEC 
C134z11 43908 E23.0 
Iatrogenic hypopituitarism C137.11 50958 E23.1 
Hormone-induced hypopituitarism C137000 105672 E23.1 
 
Adrenal disorders 
 
Readterm Read Code Med Code ICD-10 
Disorders of adrenal glands                                                                                                  C15.. 12876 E24-E27
Adrenogenital disorders                                                                                                      C152. 20085 E25 
Congenital adrenogenital syndrome                                                                                            C1520 29640 E25.0
Acquired adrenogenital syndrome                                                                                              C1521 69916 E25.9
Defective synthesis of 21 hydroxylase                                                                                                                              C1522 29852 E25.0 
Defective synthesis of 11B 
hydroxylase                                                                                                                                                                
C1523 12762 E25.0 
Defective synthesis of 3B 
hydroxysteroid dehydrogenase                                                                                                 
C1524 61615 E25.0 
Defective synthesis of 17-20 
desmolase                                                                                                                             
C1525 71483 E25.0 
Defective synthesis of 17 alpha 
hydroxylase                                                                                                                                                           
C1526 43371 E25.0 
Other adrenogenital syndrome with 
salt loss                                                                       C1527 
67273 E25.0 
Other adrenogenital syndrome without 
mention of salt loss                                                                                                         
C1528 69764 E25.0 
Other specified adrenogenital disorder                                                                                                                             C152y 69134 E25.8 
Adrenogenital disorder NOS                                                                                                   C152z 57321 E25.9 
Adrenal gland disorder NOS                                                                                                                                         C15z. 41542 E27.9 
[X]Other and unspecified primary 
adrenocortical insufficiency                                                                                                                                         
Cyu49 48120 E27.3 
 
Hypothalmic disorders 
Readterm Read Code Med Code ICD-10 
Hypogonadotropic hypogonadism C139. 98210 no code 
Hypothalamic dysfunction, not C13X. 36881 no code 
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elsewhere classified 
 
Obesity 
Readterm Read Code Med Code ICD-10 
Obesity and other hyperalimentation                                                                                          C38.. 66406 no code
Obesity   C380. 430 E66.9 
Obesity due to excess calories                                                                                               C3800 38799 E66.0
Drug-induced obesity                                                                                                                                               C3801 49250 E66.1 
Extreme obesity with alveolar 
hypoventilation                                                                                                              
C3802 38059 E66.2 
Morbid obesity                                                                                                               C3803 8854 E66.8
Central obesity                                                                                                                                                     C3804 22695 E66.9 
Generalised obesity                                                          C3805 25968 E66.9 
Adult-onset obesity                                                                                                C3806 104129 no code 
Lifelong obesity                                                                                                             C3807 104421 no code
Childhood obesity                                                                                                                                               C3808 106771 no code 
Simple obesity NOS                                                    C38z0 11401 E66.9 
[X]Obesity and other hyperalimentation                                                                                          Cyu7. 52782 E65-E68
[X]Other obesity                                                                                                                                              Cyu70 69757 E66.8
 
Low BMI 
Readterm Read Code Med Code ICD-10 
[X]Malnutrition                                                                                                              Cyu5. 72615 E40-E46
[X]Eating disorders                                                                                                                                              Eu50. 6159 F50
[X]Anorexia nervosa                                                                                                          Eu500 30570 F50.0
[X]Atypical anorexia nervosa                                                                                                                                       Eu501 34929 F50.1
[X]Bulimia nervosa                                                          Eu502 9581 F50.2 
[X]Atypical bulimia nervosa                                                                                                  Eu503 33863 F50.3
[X]Eating disorder, unspecified                                                                                                                                    Eu50z 36946 F50.9 
[X]Bulimia NOS                                                              Eu50211 6583 F50.2 
 
Structural Gynaecological disorders 
 
Readterm Read Code Med Code ICD-10 
Ovarian dysfunction                                                                                                          C16.. 6352 E28.9
Hyperoestrogenism   C160. 63226 E28.0 
Other ovarian hyperfunction                                                                                                  C161. 70689 E28.8
Hypersecretion of ovarian androgen                                                                                           C1610 27824 E28.1 
Hypersecretion of ovarian 
progesterone                                                                                                                             
C1611 63795 E28.8 
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Other specified other ovarian 
hyperfunction                                                                                                                                                           
C161y 100812 E28.8 
Other ovarian hyperfunction NOS                                                                                              C161z 71737 E28.8 
Postablative ovarian failure                                                                                                                                       C162. 73041 E89.4 
Postsurgical ovarian failure                                                C1620 102275 E89.4 
Postirradiation ovarian failure                                                                                  C1621 50462 E89.4
Other iatrogenic postablative ovarian 
failure                                                                                                                      
C1622 93791 E89.4 
Other ovarian dysfunction                                                                                                                                          C16y. 58028 E28.8 
Ovarian dysfunction NOS                                                                                                      C16z. 44854 E28.9
Polycystic ovaries                                                                                                                                                 C164.00 1466 E28.2
Suppression of menstruation                                                                                                  K59y1 12792 N94.8
Supression of ovulation                                                                                                                                            K59y2 17826 N94.8 
Artificial menopause state                                                  K5A4. 19954 N95.3 
H/O: hysterectomy                                                                                                            1599 6231 no code
H/O: bilateral oophorectomy                                                                                                                                        159B. 25199 no code
Androgen resistance syndrome                                              C1z5. 52001 E34.5 
Polycystic ovarian syndrome                                                                                     C165. 11347 E28.2
Androgen insensitivity syndrome C1z5.11 49161 E34.5 
 
Opioid misuse 
 
Readterm Read Code Med Code ICD-10 
uses heroin on top of substitution 
therapy 
1TE..00 86041 no code 
Does not use heroin on top of 
substitution therapy                                                                                                         
1TF.. 85953 no code 
Heroin misuse                                                                                                                1V65. 96925 no code
Drug addictn therap-methadone 8B23.11 6111 no code 
Drug addiction detoxification therapy - 
methadone 
8B2N.00 28976 no code 
Drug addiction maintenance therapy - 
methadone 
8B2P.00 30694 no code 
Drug addiction maintenance therapy - 
buprenorphine 
8B2Q.00 43487 no code 
Drug addiction detoxification therapy - 
buprenorphine 
8B2R.00 51052 no code 
Opioid type drug dependence                                                                                                  E240. 16243 no code
Heroin dependence E240.11 689 no code 
Methadone dependence E240.12 16374 no code 
Morphine dependence E240.13 22059 no code 
Opium dependence E240.14 32804 no code 
Unspecified opioid dependence E240000 38034 no code 
Continuous opioid dependence                                                                                                 E2401 43075 no code 
Episodic opioid dependence                                                                                                                                       E2402 20962 no code
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Opioid dependences in remission E2403 27960 no code 
Opioid drug dependence NOS                                                                                                   E240z 24441 no code
Combined opioid with other drug 
dependence                                                                                                                       
E248. 26061 no code 
Combined opioid with other drug 
dependence, unspecified                                                                                                                                              
E2480 56194 no code 
Combined opioid with other drug 
dependence, continuous                                                      
E2481 64265 no code 
Combined opioid with other drug 
dependence, episodic                                                                                                         
E2482 64277 no code 
Combined opioid with other drug 
dependence NOS                                                                                                                   
E248z 73737 no code 
Nondependent opioid abuse                                               E255. 26831 no code 
Nondependent opioid abuse, 
unspecified                                                                                                                  
E2550 40536 no code 
Nondependent opioid abuse, 
continuous                                                                                                                            
E2551 58731 no code 
Nondependent opioid abuse, episodic                                     E2552 64382 no code 
Nondependent opioid abuse NOS                                                                                                E255z 69508 no code
[X]Mental and behavioural disorders 
due to use of opioids 
Eu11.00 47335 no code 
[X]Mental & behav dis due to use 
opioids: acute intoxication 
Eu11000 42456 no code 
X]Mental and behav dis due to use of 
opioids: harmful use 
Eu11100 37568 
no code 
[X]Mental and behav dis due to use 
opioids: dependence syndrome 
Eu11200 34249 no code 
[X]Drug addiction - opioids Eu11211 10538 no code 
[X]Heroin addiction Eu11212 4564 no code 
[X]Mental and behav dis due to use 
opioids: withdrawal state 
Eu11300 36241 no code 
[X]Cold turkey, opiate withdrawal Eu11311 25527 no code 
[X]Men & behav dis due opioid: 
withdrawl state with delirium 
Eu11400 97488 no code 
[X]Mental & behav dis due to use 
opioids: psychotic disorder 
Eu11500 50964 no code 
[X]Mental and behav dis due to use 
opioids: amnesic syndrome 
Eu11600 103991 no code 
[X]Men & beh dis due opioids: resid & 
late-onset psychotic disease 
Eu11700 29652 no code 
[X]Men & behav dis due to use opioids: 
oth men & behav dis 
Eu11y00 52739 no code 
[X]Ment & behav dis due use opioids: 
unsp ment & behav dis 
Eu11z00 91801 no code 
Buprenorphine maintenance therapy 8B2M.00 47083 no code 
Opioid agonist substitution therapy 8B2S.00 93980 no code 
Opioid antagonist therapy 8B2T.00 93979 no code 
Opioid drug dependence NOS                                                                                                   E240z 24441 no code
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Appendix 7: Example STATA do files for CPRD cohort study 
STATA Do Files 
 
Demographics comparison 
by case_status, sort: summarize yc_age, detail 
ranksum yc_age, by (case_status) 
tabulate ethnos_3cats case_status, chi2 
tabulate yc_region case_status, chi2 
tabulate yc_NSAIDs case_status, chi2 
by case_status, sort: summarize yc_comorbidity_bnf, detail 
ranksum yc_comorbidity_bnf, by (case_status) 
proportion ethnos_3cats, over(case_status) 
proportion yc_region_4cats , over(case_status) 
proportion yc_NSAIDs , over(case_status) 
proportion ever_smoking , over(case_status) 
proportion ever_smoking 
tabulate  ever_smoking case_status,  chi2 
proportion ever_alcohol_use , over(case_status) 
tabulate  ever_alcohol_use case_status, chi2 
by case_status, sort : summarize BMIrecorded, detail 
proportion bmi_cats 
proportion bmi_overweight, over (case_status) 
ranksum BMIrecorded, by (case_status) 
 
Number of comorbid conditions and statistical comparison of groups 
tabulate pre_menstruation 
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by case_status, sort: tabulate pre_menstruation 
proportion pre_menstruation , over(case_status) 
proportion pre_menstruation 
by case_status, sort: tabulate thyroid 
proportion thyroid , over(case_status) 
tabulate thyroid case_status, cchi2 chi2 
proportion thyroid 
by case_status, sort: tabulate hypothyroid  
proportion  hypothyroid  , over(case_status) 
tabulate  hypothyroid  case_status, cchi2 chi2 
proportion hypothyroid 
by case_status, sort: tabulate hyperthyroid  
proportion  hyperthyroid  , over(case_status) 
tabulate  hyperthyroid  case_status, cchi2 chi2 
proportion hyperthyroid 
proportion  pituitary , over(case_status) 
tabulate  pituitary case_status, cchi2 chi2 
proportion  pituitary 
proportion  adrenal , over(case_status) 
tabulate  adrenal case_status, cchi2 chi2 
proportion   adrenal 
proportion  hypothalamic , over(case_status) 
tabulate  hypothalamic case_status, cchi2 chi2 
proportion   hypothalamic 
proportion  obesity , over(case_status) 
tabulate  obesity case_status, cchi2 chi2 
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proportion   obesity 
proportion  lowBMI , over(case_status) 
tabulate  lowBMI case_status, cchi2 chi2 
proportion   lowBMI 
proportion  structuralgynae , over(case_status) 
tabulate  structuralgynae case_status, cchi2 chi2 
proportion   structuralgynae 
proportion  illegalopioid , over(case_status) 
tabulate  illegalopioid case_status, cchi2 chi2 
proportion   illegalopioid 
 
Splitting BMI 
egen bmi_overweight = cut (BMIrecorded), at (0,25,51) 
recode bmi_overweight (0=0) 
recode bmi_overweight (25=1) 
recode bmi_overweight (.=2) [missing data] 
proportion bmi_overweight , over(case_status) 
tabulate  bmi_overweight case_status, cchi2 chi2 
 
Creating Age groups 
egen age_cats = cut (yc_age), at (18,26,36,46,56) 
recode age_cats (18=1) 
recode age_cats (26=2) 
recode age_cats (36=3) 
recode age_cats (46=4) 
proportion  age_cats , over(case_status) 
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tabulate  age_cats case_status, cchi2 chi2 
proportion  age_cats 
 
Number of Practices included 
sort pracid 
gen long order=_n 
by pracid (order), sort: gen y=_n==1 
sort order 
replace y=sum(y) 
sum y 
 
Proportion of outcomes five year follow up 
generate outcome_5years=1 if post_menstruation==1 & time<=1825 
recode outcome_5years (.=0) 
tab outcome_5years 
by case_status, sort: tabulate outcome_5years 
proportion outcome_5years 
proportion outcome_5years, over(case_status) 
generate outcome_5years=1 if postlibido==1 & time<=1825 
recode outcome_5years (.=0) 
tab outcome_5years 
by case_status, sort: tabulate outcome_5years 
proportion outcome_5years 
proportion outcome_5years, over(case_status) 
generate outcome_5years=1 if postinfertility==1 & time<=1825 
recode outcome_5years (.=0) 
 427 
 
tab outcome_5years 
by case_status, sort: tabulate outcome_5years 
proportion outcome_5years 
proportion outcome_5years, over(case_status) 
generate outcome_5years=1 if postmenopause==1 & time<=1825 
recode outcome_5years (.=0) 
tab outcome_5years 
by case_status, sort: tabulate outcome_5years 
proportion outcome_5years 
proportion outcome_5years, over(case_status) 
 
 
Calculating rates/10000 person years (database time is in days) 
stset time, id(patid) failure( post_menstruation ==1) exit(time 1825) scale(1) 
by case_status, sort : stptime, by(age_cats) per (3650000) 
stptime, by(age_cats) per (3650000) 
 
Calculating number of people leaving cohort before 5 years for other reasons than 
outcomes 
gen death_noevent = 1 if (deathstatus==1 & post_menstruation==0) 
recode death_noevent (.=0) 
tabulate death_noevent 
gen leave_noevent = 1 if (post_menstruation==0 & fu_time <1825 ) 
recode leave_noevent (.=0) 
tabulate leave_noevent 
gen leave_noevent = 1 if (post_menstruation==0 & fu_time <1825 & 
death_noevent==0 ) 
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Menstruation Cox Regression 
stset time, id(patid) failure(post_menstruation==1) scale(1) 
stsplit split, at (365,730,1835) 
stcox case_status if split == 0 | split == 365 | split == 730 
stcox case_status if split == 0 
stcox case_status if split == 365 
stcox case_status if split == 730 
stcox case_status i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.illegalopioid, tvc (c.yc_age 
i.yc_NSAIDs_3cats i.structuralgynae i.pre_menstruation) 
stcox case_status i.pre_menstruation i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
stcox case_status i. pre_menstruation  i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
stcox case_status i.pre_menstruation  i.thyroid i.hypothyroid i.hyperthyroid  
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
stcox case_status i.pre_menstruation i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
sort age_cats 
by age_cats, sort : stcox case_status i.pre_menstruation i.thyroid i.hypothyroid 
i.hyperthyroid i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI 
i.structuralgynae i.illegalopioid c.yc_age i.ethnos_3cats if  split == 0 | split == 365 | 
split == 730 
by age_cats, sort : stcox case_status i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI  i.illegalopioid, tvc 
(c.yc_age i.yc_NSAIDs_3cats i.pre_menstruation i.structuralgynae) 
by age_cats, sort : stcox case_status if  split == 0 | split == 365 | split == 730 
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stcox case_status 
estat phtest 
stphplot, by(case_status) 
sts graph, by(case_status) 
 
Libido Cox Regression 
stset time, id(patid) failure(postlibido==1) scale(1) 
stsplit split, at (365,730,1835) 
stcox case_status if split == 0 | split == 365 | split == 730 
stcox case_status if split == 0 
stcox case_status if split == 365 
stcox case_status if split == 730 
stcox case_status if split == 0 | split == 365 | split == 730, strata(obesity) 
stcox case_status if split == 0, strata(obesity)  
stcox case_status if split == 365, strata(obesity) 
stcox case_status if split == 730, strata(obesity) 
stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats, tvc (c.yc_age) 
stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if split ==0  
stcox case_status i. prelibido  i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if split == 365 
stcox case_status i.prelibido  i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if split == 730 
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stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
sort age_cats 
by age_cats : stcox case_status if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status if split == 0  
by age_cats : stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
by age_cats : stcox case_status split == 365  
by age_cats : stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
by age_cats : stcox case_status if split == 730 
by age_cats : stcox case_status i.prelibido i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
 
stcox case_status 
estat phtest 
stphplot, by(case_status) 
sts graph, by(case_status) 
 
Cox Regression Infertility 
stset time, id(patid) failure(postinfertility==1) scale(1) 
stsplit split, at (365,730,1835) 
stcox case_status if split == 0 | split == 365 | split == 730 
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stcox case_status if split == 0 
stcox case_status if split == 365 
stcox case_status if split == 730 
stcox case_status if split == 0 | split == 365 | split == 730, strata(obesity) 
stcox case_status if split == 0, strata(obesity) 
stcox case_status if split == 365, strata(obesity) 
stcox case_status if split == 730, strata(obesity) 
 
stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid c.yc_age, tvc (i.yc_NSAIDs_3cats) 
stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
stcox case_status i. preinfertility  i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
stcox case_status i.preinfertility  i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
stcox case_status i.preinfertility i.ever_alcohol_use i.ever_smoking i.bmi_overweight  
i.thyroid i.hypothyroid i.hyperthyroid i.lowBMI i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
age_cats, sort 
by age_cats : stcox case_status if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status i.preinfertility  i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status if split == 0  
by age_cats : stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
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by age_cats : stcox case_status if split == 365  
by age_cats : stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
by age_cats : stcox case_status if split == 730 
by age_cats : stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
stcox case_status  i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid 
i.bmi_overweight i.lowBMI i.ever_alcohol_use i.ever_smoking i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if age_cats==3 & split == 0  
 
stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid i.bmi_overweight 
i.lowBMI i.ever_alcohol_use i.ever_smoking i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if age_cats==3 & split == 365 
stcox case_status i.preinfertility i.thyroid i.hypothyroid i.hyperthyroid i.bmi_overweight 
i.lowBMI i.ever_alcohol_use i.ever_smoking i.structuralgynae i.illegalopioid 
i.yc_NSAIDs_3cats c.yc_age if age_cats==3 & split == 730 
stcox case_status 
estat phtest 
stphplot, by(case_status) 
sts graph, by(case_status) 
 
Cox Regression Menopause 
stset time, id(patid) failure(postmenopause==1) scale(1) 
stsplit split, at (365,730,1835) 
stcox case_status if split == 0  
stcox case_status if split == 365 
stcox case_status if split == 730 
stcox case_status if split == 0 | split == 365 | split == 730 
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stcox case_status if end_date <= INDEXDATE + 1826, strata(obesity) 
stcox case_status if split == 0, strata(obesity) 
stcox case_status if split == 365, strata(obesity) 
stcox case_status if split == 730, strata(obesity) 
stcox case_status i.thyroid i.hypothyroid i.hyperthyroid i.ever_alcohol_use 
i.ever_smoking i.bmi_overweight  i.lowBMI i.illegalopioid, tvc (i.yc_NSAIDs_3cats 
i.premenopause c.yc_age i.structuralgynae) 
 
stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split ==730 
 
sort age_cats 
by age_cats : stcox case_status if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 | split == 365 | split == 730 
by age_cats : stcox case_status if split == 0  
by age_cats : stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 0 
by age_cats : stcox case_status split == 365  
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by age_cats : stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 365 
by age_cats : stcox case_status if split == 730 
by age_cats : stcox case_status i.premenopause i.thyroid i.hypothyroid i.hyperthyroid 
i.ever_alcohol_use i.ever_smoking i.bmi_overweight  i.lowBMI i.structuralgynae 
i.illegalopioid i.yc_NSAIDs_3cats c.yc_age if split == 730 
 
estat phtest 
stphplot, by(case_status) 
sts graph, by(case_status) 
proportion   postmenopause 
proportion postmenopause, over(case_status) 
 
SENSITIVITY ANALYSIS  
FOR COMPLETE DATA ONLY 
drop if ever_smoking==3 
drop if ever_alcohol_use==3 
drop if ethnos_3cats==3 
drop if BMIaverage==. 
drop if imd2010_5==. 
duplicates tag match_pair , gen(tag) 
drop if tag == 0 
and repeat cox regression 
 
FOR THOSE WITHOUT PRE_EXISTING CONDITIONS 
Drop if prelibido==1 
Drop if premenopause==1 
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Drop if premenstruation ==1 
Drop if preinfertility==1 
Duplicates tag match_pair, gen(tag) 
Drop if tag == 0  
 
Redo cox regression 
 
FOR THOSE WITHOUT MENOPAUSE for SENSITIVITY ANALYSIS 
drop if postmenopause == 1 
drop if premenopause == 1 
duplicates tag match_pair, gen(tag) 
drop if tag == 0  
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Appendix 8: Screenshot of cohort study publication 
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Appendix 9 Cross-sectional study protocol
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Opioids, Women and Libido 
 
This protocol has regard for HRA guidance 
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Summary 
Title: Sexual dysfunction in women receiving opioids for potentially painful 
musculoskeletal (MSK) conditions.  
Short Title: Opioids, Women and Libido (OWL) Study 
Protocol Version Number and Date: Protocol 1.0, 25/7/17 
IRAS Project ID: 210681 
Key Words: Opioids, Female Sexual Dysfunction, Libido, Adverse Events 
Background: 22% of primary care attendees suffer chronic non-cancer pain (CNCP), 12-
13% of these are prescribed opioids. Up to 20% of people consult with their GP each 
year with MSK conditions and opioids are often prescribed for the treatment of these 
conditions, in line with guidelines. Since the 1980s there has been a significant increase 
in opioid prescribing. Adverse effects are common in people taking opioids with up to 
80% affected by at least one adverse effect. Long-term prescription opioid use in men 
and illegal opioid use in women can lead to reproductive and sexual problems (low 
libido, impotence), but there is a lack of evidence in women taking prescribed opioids. A 
comprehensive literature review found limited evidence of a potential relationship 
between opioids and reproductive and sexual dysfunction in women. A study in women 
using information from a primary care consultations database found an increased risk of 
menopausal symptoms and abnormal menstruation in long-term (>90 days) opioid users 
with potentially painful MSK conditions. However, there were low numbers of women 
within the cohort with a recorded diagnosis of infertility or low libido compared with 
what might be expected in the general population. This suggests a different approach is 
needed to investigate this area in future research. 
Aim and objectives: The aim of this study is to investigate associations between opioid 
use and sexual dysfunction in women as characterised by low libido. Specific objectives 
are (1) to investigate the prevalence of low libido in women receiving opioids for MSK 
pain; (2) to compare the prevalence of low libido in women using long-term, and short-
term opioids. Long-term opioid use is defined as 90 days of use if self-reported (or 3 
prescriptions in 90 days identified from medical records) and short-term opioid use is 
anything less than this; (3) within women who are long-term opioid users, to compare 
the number with low libido according to the mode of opioid administration, either orally 
as a tablet or transdermal in the form of a patch; (4) within women who are long-term 
opioid users, to compare the number with low libido according to the total opioid dose 
each day using morphine equivalent dose (conversion of corresponding doses of 
different opioids to morphine doses using predefined conversion tables) with a doses of 
20mg/day and higher representing the threshold between high and low dose opioids 
(defined based on previous epidemiological work of opioid adverse effects); and (5) to 
compare self-reported rates of low libido to those within the medical records.  
Design: Cross-sectional postal survey 
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Study Population:  Primary care consulters (women, aged 18-45 years old) presenting to 
General Practice with a Read Coded potentially painful MSK condition who are 
prescribed an opioid. 
Sample Size: 316 responses required, 1000 participants will be contacted. 
Data Collection: A single self-report postal questionnaire will be sent to eligible patients. 
Consent will be sought to access anonymised medical records for a full medication 
history, including all coded entries for low libido. 
Outcome measures: Sexual dysfunction will be recorded using a previously validated 
measure STEFFI-5 (STEFFI is not an acronym but named after the common German girls 
name). The SF-12 will also be used to measure mental and physical health overall.  
Analysis: Descriptive methods will be used to characterise the population and sub-
groups of opioid users (short-term and long-term opioids). The characteristics will be 
compared using statistical tests (e.g. Chi-squared, Student’s T test, Wilcoxon-Mann-
Whitney). The prevalence of sexual dysfunction will be calculated. Comparison between 
different types of opioid users will be undertaken as logistic regression and produce 
odds ratios, this will be adjusted for confounding factors (e.g. age, depression status) 
and covariates (e.g. comorbidities, smoking and BMI). The comparison groups will be 
long-term vs short-term opioids, then within the long-term opioid user group if possible 
oral vs. transdermal and total morphine daily equivalent dose split at 20mg/day. P 
values of less than 0.05 will be taken as significant. 
 
 
 
Background and Rationale 
Background 
Over 20% of primary care attendees report CNCP, with women affected more often than 
men (Gureje et al., 1998). 12% of all affected patients are prescribed opioids and women are 
more likely than men to start a new episode of opioid use (Bedson et al., 2016). One in five 
of the population attend primary care each year with a MSK condition and this accounts for 
one in seven primary care appointments (Jordan et al., 2006, 2010). Opioids are 
recommended in guidelines for use in MSK pain as part of a stepped approach to care 
(National Institute for Health and Care Excellence, 2014a, 2016). Since the late 1980s there 
has been a trend towards increased opioid prescribing (Caudill-Slosberg et al., 2004; Eriksen 
et al., 2006; Von Korff et al., 2008; Ruscitto et al., 2015; Sullivan et al., 2008; Zin et al., 2014). 
A recent UK observational database study showed a 38% increase in opioid prescribing from 
2002 to 2009, with a prescribing rate of 31.2/10000 (95% CI 29.1-33.4) person years in 
women aged 18-44 years old; this increase is despite a Cochrane review showing only weak 
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evidence for their effectiveness (Bedson et al., 2016; Noble et al., 2010). Adverse effects are 
common among people taking opioids for the first time, with 80% of patients experiencing at 
least one, such as constipation, somnolence, nausea, vomiting, dizziness, itching, 
dependency, tolerance, addiction and opioid induced hyperalgesia (Baldini et al., 2012; 
Grady et al., 2002; Kalso et al., 2004; The British Pain Society, 2010).  
Long-term prescription opioid use in men can cause decreased levels of sex hormones (in 
particular testosterone) leading to reproductive and sexual dysfunction; this is known as 
opioid induced androgen deficiency (OPIAD) (Abs et al., 2000; Aloisi et al., 2009; Benyamin et 
al., 2008; Daniell, 2002; Smith and Elliott, 2012). In women, it is recognised that illegal 
dependent opioid use (for instance heroin) can be associated with hypogonadism and 
reproductive and sexual dysfunction (low libido, sexual dysfunction, menopausal symptoms 
and absent or less frequent menstruation) (Brown and Zueldorff, 2007; Genazzani et al., 
1993; Schmittner et al., 2005). The picture is less clear with respect to any association 
between prescription opioid use and reproductive/sexual dysfunction in women. Guidelines 
from the British Pain Society highlight possible reproductive and sexual adverse effects from 
using opioids in men and women as a concern but concluded that there was insufficient data 
to be able to quantify the risk associated with long-term opioids (The British Pain Society, 
2010). A comprehensive systematic literature review undertaken of long-term opioid use in 
women with CNCP and reproductive and sexual dysfunction found 12 papers (small studies 
with 200 subjects in total). Although the evidence was of low quality and conflicting, the 
majority of studies found a link between opioid use (>30 days) and reproductive and sexual 
dysfunction (Wersocki et al., 2017).   
A matched cohort study has been undertaken comparing women with potentially painful 
MSK conditions taking long-term (patients who receive three or more opioid prescriptions 
over 90 days or more) and short-term opioids (maximum of 2 opioid prescriptions in no 
more than 90 days) in a large electronic database containing information from GP practices, 
the Clinical Practice Research Datalink (CPRD) (Wersocki et al., 2016). The aim of the cohort 
study was to investigate the prevalence of reproductive and sexual dysfunction (altered 
menstruation, menopause, low libido and infertility) in women 18-55 years old taking long-
term opioids for potentially painful MSK conditions. The cohort study also compared the risk 
of developing these conditions between long-term opioids users and short-term opioid 
users. The women all had a potentially painful MSK condition in order to make the cohort 
more homogenous and limit systematic differences between the two groups. This also 
addresses elements of indication bias as all the women were receiving the medication for 
the same indication however it does not address any potential differences in severity of 
disease. An increased risk of menopausal symptoms and altered menstruation (less frequent 
or absent menstruation) in women taking long-term opioids was found compared with 
women who had only received short-term opioids. One limitation of this database study was 
the small numbers of women reporting low libido and infertility, less than 1% of women had 
a coded diagnosis of low libido compared with population estimates of 20-40% (Dunn et al., 
1998). Prevalence of infertility was 0.5% (0.5-0.6) with an expected prevalence in the general 
population of around 2%. However this is a global estimate and includes only women aged 
20-44 years old who are exposed to the risk of pregnancy, so this may be in line with those 
estimates (Mascarenhas et al., 2012). 
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Rationale 
The proposed cross-sectional study aims to investigate the relationship between opioid use 
and sexual dysfunction further. The study will focus on low libido in particular, as within the 
CPRD study prevalence of low libido was low when compared to population estimates, 
suggesting this methodological approach may not be most appropriate way to investigate 
this area. One of the possible reasons for this difference is that both women and clinicians 
find it difficult to discuss sexual health issues and as such they are often ignored 
(Montgomery, 2008). A cross-sectional study offers a straight forward approach for 
investigating low libido as it allows women to answer questions directly, however it will not 
be able to examine the issue of causality.  
The cohort will include women aged 18-45 years old with a coded potentially painful MSK 
condition and a prescribed opioid in their electronic medical records. This upper age was 
selected to minimise the number of women in the perimenopause who were included in the 
study. Including women likely to be premenopausal was important as there is good evidence 
that libido decreases during the peri-menopausal period when compared to premenopausal 
women (Odds Ratio 2.6, 95% CI 0.6-10.8) and also decreases with increasing age (Hayes et 
al., 2008).The median age of the menopause in the UK is 52 years old (Hardy and Kuh, 2005). 
It is believed that hormonal changes characteristic of menopause start at around 45 years of 
age and symptoms of perimenopause start at a median age of 47.5 in white women in 
western countries (Gold, 2011). Potentially painful non-inflammatory MSK conditions were 
chosen to identify women as it is a common presenting complaint in primary care (1 in 7 
consultations) and they represent a more homogenous group than women prescribed 
opioids for any indication (Jordan et al., 2010). This decreases systematic differences 
between different types of opioid use, and helps to limit confounding by indication. 
This project will further investigate an area where there is a lack of evidence in the 
literature.  There has been increasing opioid prescribing despite a lack of evidence for opioid 
effectiveness for CNCP and women are more likely than men to be prescribed opioids. This 
study will raise awareness within researchers and health professionals of the potential 
adverse effects of opioids.  
 
Aims and Objectives 
Aims 
The primary aim of this study is to investigate associations between opioid use and sexual 
dysfunction in women with MSK conditions. Sexual dysfunction in this case will mean 
specifically low libido. 
Objectives 
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5) To investigate the prevalence of low libido in women receiving opioids for MSK pain 
6) To compare the prevalence of low libido in women using long-term, and short-term 
opioids. Long-term opioid use is defined as 90 days of use if self-reported (or 3 
prescriptions in 90 days identified from medical records) and short-term opioid use is 
anything less than this. 
7) Within women who are long-term opioid users, to compare the number with low 
libido according to the mode of opioid administration (tablets compared to patches)  
8) Within women who are long-term opioid users, to compare the number with sexual 
dysfunction according to the total opioid dose each day will be compared, using total 
morphine equivalent dose and a cut-off point of ≥20mg/day between high and low 
dose opioids (Saunders et al., 2009). 
9) To compare self-reported rates of low libido to those recorded within the medical 
records. 
 
Study Methods 
Design 
The OWL study will be undertaken as a cross-sectional survey. Quantitative data will be 
collected using a single self-report postal questionnaire. Further information for comparison 
will be gained from medical records data linkage with patient consent. See Figure 1 for an 
illustration of recruitment and data collection procedures.  
Study Population and Setting 
Participants will be recruited from primary care. The participants will be identified from up 
to 20 UK primary care practices within the National Institute for Health Research Clinical 
Research Network (NIHR CRN) in the West Midlands. Women aged 18-45 years old who have 
a coded potentially painful MSK condition and have been prescribed an opioid within the last 
6 months will be invited to participate.  
Inclusion Criteria 
• Women 
• Aged 18-45 years old at the time of prescription 
• Prescription of an opioid group 3 (e.g. codeine 15mg), group 4 (e.g. codeine 30mg) or 
group 5 (e,g oxycodone, morphine) which represents moderate to very strong 
opioids based on a previously developed consensus model of hierarchically arranged 
equipotent opioids (Bedson et al., 2010) within the 6 months prior to records search 
• Painful MSK condition coded within the 6 months prior to records search 
 
Exclusion Criteria 
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• Symptoms and signs indicating a serious pathology (cancer diagnosis) or red flag 
conditions requiring urgent medical attention (e.g. fractures, cauda equina) 
• Inflammatory joint condition (e.g. rheumatoid arthritis or gout) 
• Inability to read and speak English 
• Vulnerable patients (assessed by GP), including patients on Quality and Outcomes 
Framework mental health or learning disabilities register. 
• Pregnant 
• Current HRT use  
• Menopause 
 
All patient facing material will be written in English (cover letters, questionnaires, reminders, 
and consent forms). It is therefore not possible to include any patients who cannot read or 
write English. All study documents will have contact details for the study coordinator if 
participants have any questions or difficulties completing the questionnaire or consent form. 
 
Recruitment process 
A retrospective notes search will be conducted on a single occasion in each practice looking 
at the previous 6 months to identify patients who are eligible for inclusion in the study. The 
search will identify women with an opioid prescription (group 3-5, moderate to very potent 
opioids as coded by Bedson et al. (Bedson et al., 2010)) and a coded painful MSK condition 
within the previous 6 months. GP Practice staff will identify potential participants and look at 
identifiable data. A database query will produce a list of names and addresses for each 
potentially eligible participant. This personal information will be used for mailing the study 
pack by the practice. GPs will be asked to screen the list of potential participants against 
study exclusion criteria and for suitability. Those women identified from the initial search 
and deemed to be appropriate by the GP will be mailed the study pack from the practice 
(the contact details will not leave the practice site, and will not be available to the study 
team). Each woman identified for participation in the study will be given a unique study 
identifier; this will be used to target reminders and for data linkage, these reminders will be 
sent from the general practice. The study pack will include a covering letter from the GP, a 
patient information leaflet, the questionnaire itself and a consent form for medical record 
review, the questionnaire and consent form will be marked with the participants unique 
study identifier. The patient information leaflet will contain all the relevant information 
required to allow the participant to give informed consent for review of their medical 
records. Following the study pack being mailed initially there will be a reminder system in 
place where a postcard reminder will be sent at 2 weeks if there is no response from the 
study participant, and a further questionnaire 2 weeks later as per research centre 
standards. This will be coordinated by the research team at Keele sending a list of unique 
study identifiers of those that have already replied with a completed questionnaire to the 
CRN and practice team, who will then send out reminders from the practice (Roberts et al., 
1993). The reminders will be sent based on the basis of whether the participant has already 
responded and this will be based on the participant’s unique study identifier which was 
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assigned during the identification stage. Consent for completion of the questionnaire will be 
assumed if a completed questionnaire is returned, however consent for medical records 
review and future contact will be through written consent.  
Figure 1  Flow diagram of recruitment process and data collection 
 
 
Baseline assessment 
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The participant will be mailed a questionnaire with the study pack, which will take 
approximately 20 minutes to complete.  An overview of data collection is provided in Table 
1. The questionnaire will include: 
• Sociodemographic variables: age, work status, relationship status 
• Lifestyle factors: alcohol, smoking, illegal drug use 
• Height and weight (for BMI) 
• Pain status (Chronic Pain Grade Questionnaire) 
• Medication use (including current and recent opioid use, reasons for stopping 
medication and current contraception use)  
• Sexual function assessed through the use of STEFFI-5 which is described below 
• General mental and physical health assessed through the use of SF-12 
• Past medical history including important conditions that are associated with low 
libido (anaemia, hypertension, depression, hysterectomy, diabetes, pelvic pain) 
The primary study outcomes will be assessed via validated measures from previous studies. 
Sexual dysfunction will be assessed using STEFFI-5 which is a 5 question tool that screens for 
sexual dysfunction. STEFFI-5 was compared to the female sexual function index (FSFI) which 
is a widely used tool for those women already identified as having sexual dysfunction and 
had 83.1% sensitivity and 81.2% specificity for identifying women with sexual dysfunction 
(Kriston et al., 2010). The study will produce descriptive data on sexual dysfunction in this 
group and also undertake comparison between long-term and short-term opioid users. 
Comparison measures will also be undertaken within the long-term opioid user groups if 
possible, comparing transdermal and oral opioids and total daily morphine equivalent doses 
with ≥20mg/day as the cut off between high and low doses within the long-term opioids 
users. The study will provide the opportunity to compare self-reported problems to those 
within the medical records for those who consent to medical record review.   
Pain will be assessed using the Chronic Pain Grade Questionnaire, a validated measure that 
assesses pain, currently and in the past 6 months (Von Korff et al., 1992). This has been 
validated for use in UK postal questionnaires through comparison with the SF-36 and had a 
Cronbach’s alpha of >0.9 and item-total correlations of >0.68 for all items indicating good 
internal consistency and reliability (Smith et al., 1997). 
STEFFI-5 and Chronic Pain Grade Questionnaire do not need a license for use as they are 
both freely available but do need to be cited. A license agreement (#CT184958 OP059432) 
has been agreed for use of the SF-12. 
 
Medical Record review 
For patients who have consented to medical record review, data will be extracted by 
practice staff regarding prescribed medication (including pain medication), recorded sexual 
dysfunction, age, height, weight, BMI, existing chronic diseases (for instance thyroid disease 
and pelvic pain) over the preceding 12 months. The medical records will be anonymised and 
assigned the unique study identifier by the practice staff that links with the corresponding 
questionnaire response. Each participant will be assigned a unique study identifier and this 
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will be used to link the questionnaire data to data from the medical record review. The study 
team will not have access to patient identifiable data from the medical records, the records 
will be anonymised prior to them being sent to the study team.  
 
Table 23: Overview of Data Collection 
 Questionnaire Medical Record Review 
Socio-demographic 
variables: age, work status, 
ethnicity  
  
Lifestyle factors: smoking, 
alcohol, drug use, height, 
weight 
  
Relationship status   
Contraception   
General Health (SF-12)   
Opioid Use (including 
previous use and reasons 
for stopping) 
  
Medication history   
Sexual Health: 5 items 
(STEFFI-5) 
  
Pain status (Chronic Pain 
Grade Questionnaire)  
  
Current Medical Conditions   
 
Data Management (entry, coding, cleaning, storage and confidentiality) 
Questionnaire data will be entered into a specifically designed database, which will be tested 
a priori for reliability. The coding of questionnaire responses will be determined with input 
from the study statistician in accordance with the standard procedures within the Research 
Institute for Primary Care and Health Sciences, to facilitate data entry. The data will be 
entered from paper questionnaires and there will be cross checks (1 in 20) where a second 
member of the team will check the coding. Checks will also take place if there is any data 
outside the expected range. This will ensure reliability and quality assessment throughout 
the data input process.  
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Participant personal data (e.g. names and addresses) will be stored at the GP site and the 
study team will not access these, the study team will not have access to medical records 
unless the patient consents to medical records review and then will only receive anonymised 
records. Completed consent forms and questionnaires will be returned to the study team, 
the consent form will be separated from the questionnaire responses immediately on 
receipt by the study team. Consent forms with participant personal data will be stored 
separately to questionnaires. The questionnaire data will be stored in a password protected 
database accessible only to the study team. All paper documents (including consent forms 
and completed questionnaires) will be stored in locked cabinets within an alarmed building. 
Hard copies will be stored for a period of 5 years following completion of the study. All 
confidentiality arrangements adhere to the relevant regulations and guidelines (Data 
Protection Act 1998, Caldicott, GMC, MRC, Research Governance Framework) and Keele 
Clinical Trials Unit standard operating procedures (https://www.keele.ac.uk/kctu/services/). 
The Chief investigator has responsibility to ensure confidentiality procedures are followed 
and the integrity of the data.  
Any future data sharing will follow the Institute’s data sharing procedure 
(https://www.keele.ac.uk/kctu/datasharingresources/). All members of staff included in the 
study have explicit duties of confidentiality written into their employment contracts which 
are equivalent to those of NHS staff members.  
Analysis 
The data will entered into a database developed for the study and will be analysed using 
STATA (StataCorp, 2017). The postal survey will provide information on demographics, 
outcomes and confounding factors. The primary comparison will be between women 
receiving long-term opioids (>90 days opioid use) and women receiving short-term opioids 
to be in line with previous work. The demographics of the short-term and long-term opioid 
users will be described using means and standard deviations if normally distributed, and 
medians and interquartile ranges if non–parametric; where proportions are used, 95% 
Confidence Intervals (CI) will be presented. The demographics will be compared using basic 
statistical tests. Where two categorical variables are compared, a Chi-squared test will be 
used, and if the comparison is between a continuous variable, a student’s t-test will be used 
if the data is parametric. Wilcoxon-Mann-Whitney test will be used for non-parametric data. 
The exposure (independent variable) of interest is opioid use. The outcome (dependent 
variable) will be sexual dysfunction in this case low libido. The prevalence of women 
reporting low libido will be calculated using proportions with 95% CIs. Comparison of the 
proportions of women reporting low libido between long-term and short-term opioids users 
(strength and mode of administration (oral or transdermal) will also be used for 
comparisons) will be done with chi-squared statistics. The association between the 
dependent variable (low libido) and the independent variable (opioid use long-term vs. 
short-term) will be expressed as odds ratios with 95% CIs. As this is a cross-sectional study 
we will not be able to estimate cause and effect but will describe any associations. 
Adjustment for potential confounders will be done through use of logistic regression which 
will provide adjusted odds ratios. Including age in the logistic regression is particularly 
important as there is evidence that libido decreases with age (Hayes et al., 2008). P values of 
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less than 0.05 (two sided tests) will be taken as significant.  If there are sufficient numbers 
the above will be repeated comparing transdermal and oral opioids and also total morphine 
daily equivalent dose divided at a dose of ≥20mg/day for high and low doses (Saunders et 
al., 2009). Morphine daily equivalent doses will be calculated based on the patients reported 
usage and then converted into morphine equivalents (the corresponding dose of different 
opioids to morphine) using predefined conversion tables developed by von Korff et al. for 
the CONSORT study (Von Korff et al., 2008).  
 
Sample size 
A sample size of 1,000 participants has been calculated. The sample size calculation was 
based on unpublished data from a postal questionnaire by Dunn et al (1998) which found an 
odds ratio of sexual dysfunction in those taking opioids compared to those without opioids 
of 2.2 (based on 31% of opioid users an 17% of non-opioid users being affected by sexual 
dysfunction). This is a best estimate based on the available evidence using a two sided 95% 
significance level, a power of 80% and a ratio of 1:1 for comparison groups with primary 
comparison between long-term and short-term opioid users; the calculation estimated a 
sample size of 316 women. The same study asking about sexual problems in the general 
population in 1998 had a response rate of 49% in women of all ages but the response rate in 
those less than 57 years of age was 43% (Dunn et al., 1998). Sensitive topics are widely 
believed to cause a lower response rate; a Cochrane review found an odds ratio of 0.94 (95% 
CI 0.88-1.0) when sensitive questions were included (Edwards et al., 2009). Based purely on 
the sample size calculation of 316 and an expected response rate of 43% a total sample size 
of 735 women would be employed. It is likely that the response rate will be lower in this age 
range of participants. The national census which has excellent response rates had a response 
rate of 10% less in women aged 20-24 years old compared with 98% in women aged 60-64 
years old; if this 10% decrease in response rate is taken into account the study would require 
a sample size of 957, which we adjusted to 1000 to help to ensure adequate response rate 
(Office for National Statistics, 2015).  
User Involvement 
The Research Institute for Primary Care and Health Sciences has an active Research User 
Group (RUG) which advises and provides feedback on research projects. The RUG 
unfortunately does not have any female members between 18 and 45 years old so novel 
methods will need to be used to engage this group of women. Steps have been taken to 
engage women in the appropriate age group through posting on UK pain support websites 
(painsupport.co.uk and painconcern.org.uk). Those women that responded were included 
and helped to support the study via either email, or an online forum (closed Facebook 
group), and if needed by face to face contact via skype. The women provided feedback on 
the study pack including the covering letter and questionnaire. The women reviewed the 
final version of the questionnaire for face validity prior to sending out. Results will be 
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reported to those who have contributed and they will be included in plans for dissemination 
of results if they wish to be.  
Ethical Considerations 
The main ethical consideration is the questionnaire itself as it will contain potentially 
sensitive questions regarding relationships and sexual health. To minimise any potential 
distress, the number of questions will be minimised and they will be introduced in a sensitive 
manner. All study documents will have contact details for the study coordinator if 
participants have any questions regarding the study. Contact details will also be provided in 
the event the questionnaire causes any distress, both MIND’s contact number and advice on 
contacting their own GP. The questionnaire will be confidential and questionnaires will be 
anonymised. The participants will be identified with a unique study identifier in order to 
facilitate data linkage to medical records if participants consent. The study team will not 
have access to patient identifiable data at the identification and mailing stage as this will be 
held at the practice site. The study team will only hold patient identifiable data in the form 
of consent forms, these will be stored in a locked cabinet separately to the questionnaire 
responses. 
Study team and organisation 
Study Team 
Table 2: Study Team 
Role Name 
Lead Supervisor and Data Custodian John Bedson  
Chief Investigator, Keele University  Emily Wersocki  
Study Coordinator, Keele University Emily Wersocki 
Statistical Support Ying Chen 
Co-Applicant  Rosie Lacey  
 
Study Sponsor 
Sponsor Organisation: Keele University 
Contact on behalf of the sponsor:  
Dr Clark Crawford, Head of Research Integrity, Directorate of Engagement and Partnerships, 
IC2 Building, Keele University, Staffs, ST5 5NH  
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Dissemination 
This study represents an opportunity to provide new evidence regarding possible sexual 
adverse effects of opioids. Previous papers by the study team looking at the area of adverse 
effects of opioids have been published in international journals. This area of research is 
topical and is likely to generate interest. The findings of the study will be presented at a 
national conference and published within a peer reviewed academic journal. The 
dissemination will be discussed with the Patient Public Involvement and Engagement group 
(PPIE) established for this project via online contact (either Skype, email or Facebook) to see 
if they have any other important ideas. The results will also support a project being 
undertaken by the evidence based medicine group at Keele to provide a decision making aid 
for opioid prescribing to be used by clinicians and patients.  
Funding Source 
The study is funded by Professor Christian Mallen’s NIHR Professorship. 
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OWL 
Study Information Sheet 
 
Invitation 
We would like to invite you to take part in a research study about painkillers called opioids 
such as codeine and morphine and reproductive and sexual health in women with joint pain.  
The study is entitled OWL (Opioids, Women and Libido).The study is being undertaken by a 
team at the Research Institute for Primary Care and Health Sciences, Keele University.  
Why have I been invited?  
You have been invited because you are registered at a General Practice that is part of the 
West Midlands Clinical Research Network. Within the last 6 months you have seen your GP 
about joint pain and have also been prescribed an opioid pain killer. If you are not currently 
using opioid pain killers we would still like you to take part in the study.  
What is the purpose of the research?  
Opioid painkillers are being prescribed more commonly for long-term pain, for example joint 
pain. The evidence for their use is mainly based on use in cancer pain. We do not know very 
much about the sexual health of women who take opioid painkillers for joint pain, which is 
why we are doing this study. One of the things we are interested in is how libido is related to 
opioids. 
What do I need to do if I choose to take part?  
The study involves a single questionnaire. The questionnaire should take you approximately 
20 minutes to complete. There is also a consent form asking if we may access anonymised 
information from your medical records. If you do not wish to consent to access to your 
medical records please still consider completing the questionnaire, as your answers are still 
important to us. Once completed, please post both the questionnaire and the consent form 
back to us in the enclosed stamped addressed envelope.  
If you consent to being contacted for future research we will store your name and address in 
a password protected database for up to 5 years after the completion of the study. If you 
consent to contact this does not mean you have to take part in future studies and you can 
ask to be removed from the list at any time by contacting us via the methods below.  
Do I have to take part? 
No, your involvement is voluntary and you do not have to take part if you do not want to. 
You may either complete the questionnaire with or without consent for medical record 
review or choose to not complete the questionnaire. Choosing to not take part will not 
affect your usual medical care in anyway. If you do not wish to take part please return the 
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questionnaire blank. If you do not want to take part but do not return the blank 
questionnaire, you will be sent two reminders about the study following this invitation. 
What are the benefits/risks of taking part?  
Taking part will help improve knowledge around use of opioid painkillers for future patients. 
There will be no direct benefit to you. We do not foresee any risks from taking part.  
Who is funding the project? 
The study is funded by Professor Christian Mallen’s National Institute for Health Research 
Professorship.  
Who will have access to information about me?  
Your participation will be kept completely confidential. The paper questionnaires (including 
your signed consent form) will be returned to Keele University, where they will be stored in 
separate locked cabinets with limited access. Other than your consent form, your 
information and data will be anonymised (your name removed) and you will be assigned a 
unique study code so we can link your answers to the information from your medical records 
(if you have agreed to give us access). Digital information will be stored on a secure 
password protected university network computer.  
What will happen to the results of the study? 
The results will be written up for a PhD thesis and publication in a scientific journal.  
Has the research study been ethically approved?  
NHS ethical approval has been granted (IRAS 210681). Approval has also been granted from 
the Health Research Authority to conduct this research. 
What if there is a problem?  
If you have concern about any aspect of the study and wish to speak to the researcher then 
please contact Dr Emily Wersocki by email at e.wersocki@keele.ac.uk or by telephone on 
01782 734889. Alternatively if you do not wish to contact the researcher please write to Dr 
Clark Crawford Head of Research Integrity, Directorate of Engagement and Partnership, IC2 
Building, Keele University, ST5 5NH, or email research.governance@keele.ac.uk , or 
telephone 01782 733371. If this invitation or questionnaire has caused you any distress 
please visit www.fpa.org.uk/your-body/sexual-problems for further information and 
support. 
Further information and contact details 
If you would like further information please contact the OWL study coordinator, Emily 
Wersocki by email at e.wersocki@keele.ac.uk or via phone 01782 734889. 
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Consent Form 
 
 
 
Participant Unique Identifier:…………………………….. 
 
 
Please read the patient information leaflet and then complete the following consent form, 
and sign below.  
 
Consent form  
 
Please answer each statement by putting your INITIALS in one box on each line  
 
             YES         
NO 
 
I give my permission for my medical records to be reviewed………………  
 
I am happy to be contacted again (this does not mean that you must  
take part in future - you are just agreeing to be contacted again)………..  
 
 
Signed……………………………………………………….Date……………………  
 
Only if you have answered yes to being contacted for future studies, please print your name 
and address below, 
………………………………………………………………………………………….  
…………………………………………………………………………………..………  
…………………………………………………………………………………..………  
……………………….………………………………………………………………….  
 
Even if you would prefer us not to review your medical records or contact you in the future 
about linked studies, the answers you have given in this questionnaire will still be very 
important to us.  
 
Please return your questionnaire in the FREEPOST (no stamp needed) envelope provided  
 
Thank you for your help with this research project 
IRAS 210681 
